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Preface 
I have written this thesis as a staff candidate while working full-time in the South East Wales 
Trials Unit (SEWTU). My original intention was to accumulate a sufficient number of 
publications around the theme of medication adherence, with a specific focus on methodological 
challenges, and submit for a PhD by published works. However, I registered to submit via the 
normal thesis route, assuming I could switch pathway later down the line (thus reaping the 
benefits that being a student brings for as long as possible), only to find out that this was something 
against regulations. Thus, following my first year, I had published one paper, was well on my way 
to publishing another, but found myself at risk of lacking a coherent thesis. I took stock, planned 
thesis chapters that coherently linked the work in my planned papers, and while I continued to 
write papers as a priority over my thesis during my second year, I had a much better 
understanding of how it would all fit together. 
During this whole process, I did not stray from who I was as a researcher; an applied statistician 
with a passion for high quality evidence using the best available research methods, and a desire 
to communicate directly with end users. 
As an applied researcher working in a clinical trials unit, I saw (and continue to see) a lot of 
methods and techniques recommended out of convenience and tradition, rather than the most 
rigorous, cutting edge methods that could be used in a given situation. In my opinion, this is often 
due to time constraints – to take a technique that has had its theoretical principles documented 
in a technical journal and translate that into an approach that can be feasibly applied, reported, 
and communicated during the analysis and reporting phase of a trial can take time that an applied 
researcher may not have. It is my intention that this thesis, and the publications that are produced 
from it, will aid the applied researcher to readily adopt the findings and recommendations from 
this work. 
vi 
 
Why write a thesis on the subject of medication adherence? 
In short, I like to tackle problems that are both challenging and yield solutions that are of practical 
use. I have worked on a variety of studies during almost a decade working in SEWTU. Early on, 
I developed a keen interest in missing data and bias arising from nonresponse. To me, 
medication adherence is a missing data problem and more. Measuring adherence presents a 
challenge in itself – I was fortunate to work on a trial early in my career where medication 
adherence was measured in a variety of ways. It was the first time I really had to think about some 
fundamental issues around this topic – “What if participants don’t take their medication as 
prescribed?” “What is the best way of measuring whether or not they are?” “Should several 
measures be used, and if so, what if they don’t agree?” The consequences of poor adherence 
also fascinated me early on. One of the clinical areas in which I specialise is infections treated in 
primary care; an area within which antibiotic prescribing is rife and the consequences of antibiotic 
resistance are a real concern. There is a strong drive to reduce antibiotic use, particularly for self-
limiting infections. However, the theoretical relationship between poor use of antibiotics and 
antibiotic resistance is an area that is, I believe, underappreciated. Through the dissemination of 
the work presented throughout this thesis, particularly through an international network of 
primary care infections researchers (the General Practitioners’ Research in Infections Network, 
or GRIN), I have raised the profile of the problem of adherence to antibiotic treatment, and have 
engaged leading clinicians in discussion around this topic. 
Being awarded with a PhD will allow me to progress onto the next stage of my career, which will 
focus on me developing as an independent researcher. I intend to take the work I have carried 
out here and apply for funding to conduct high quality research, addressing questions of 
importance to clinicians treating patients, policy makers deciding on the value of medication, and 
applied researchers looking to use the most appropriate methods to answer their questions. 
- David Gillespie, Cardiff 2016  
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Summary 
Poor adherence to medication wastes resources and can lead to reduced exposure to and 
effectiveness of pharmacological treatments. Poor adherence to medication in clinical research 
can dilute treatment effects, obscuring the true benefits that medication can provide. The study 
of medication adherence comprises significant methodological challenges. 
The aim of my thesis was to investigate several methodological challenges encountered when 
studying medication adherence in clinical research using data from five clinical studies. 
Several methods for measuring adherence were compared using both correlation and agreement 
approaches. I proposed extensions to data visualisation techniques for comparing agreement. As 
an alternative to reporting summary measures, I explored the use of advanced modelling 
techniques to model adherence data collected via electronic monitors. I also moved beyond 
comparisons of measures and investigated approaches for predicting disagreement and 
calibration techniques. 
I investigated various methods for modelling the determinants of adherence, considering 
determinants according to type of measure used, type of condition being studied, different study 
designs, and different conceptualisations of adherence. I explored, quantitatively, the extent to 
which the treating clinician influenced whether a patient adhered to their treatment. 
I also established the feasibility of calculating randomisation-based efficacy estimators in 
randomised controlled trials with non-adherence, scrutinising the implementation of these 
approaches during placebo-controlled trials and non-inferiority trials involving two active 
treatments. 
My findings emphasise the need for considering the impact of medication adherence when 
designing a study, rather than leaving it as an afterthought, as it would appear to be much of the 
time. Such considerations include selecting an appropriate mode (or modes) of medication 
adherence ascertainment, agreeing adherence definitions of interest, measuring variables that are 
likely to be associated with adherence, and, particularly for trials, determining whether it is 
feasible to adjust findings for non-adherence while maintaining a comparison of groups as 
randomised.  
xvii 
 
Glossary of Abbreviations 
AACTG: Adult Aids Clinical Trials Group ICC: Intracluster Correlation Coefficient 
AAS: Antidepressant Adherence Scale 
ICH: International Conference on 
Harmonisation of Technical Requirements 
for Registration of Pharmaceuticals for 
Human Use 
ADHD: Attention Deficit Hyperactivity 
Disorder 
IQR: Inter-Quartile Range 
AED: Anti-Epileptic Drug ITT: Intention-To-Treat 
AIC: Akaike's Information Criterion IV: Instrumental Variable 
AMSTAR: Assessing the Methodological 
Quality of Systematic Reviews (checklist) 
IZA: Intravenous Zoledronic Acid 
ART: Anti-Retroviral Therapy 
JAMA: Journal of the American Medical 
Association 
BC: Before Christ MARS: Medication Adherence Rating Scale 
BD: Twice daily 
MASRI: Medication Adherence Self-Report 
Inventory 
BMC: BioMed Central 
MEMS: Medication Event Monitoring 
System 
xviii 
 
BMI: Body Mass Index 
MMAS: Morisky Medication Adherence 
Scale 
BMJ: British Medical Journal MPR: Medication Possession Ratio 
BMQ: Brief Medication Questionnaire NEJM: New England Journal of Medicine 
BNF: British National Formulary NHS: National Health Service 
BPI: Brief Pain Inventory 
NICE: National Institute for Clinical 
Excellence 
CACE: Complier Average Causal Effect OD: Once daily 
CA-LRTI: Community-Acquired Lower 
Respiratory Tract Infection 
OIA: Oral Ibandronic Acid 
CI: Confidence Interval OR: Odds Ratio 
CODA: The Colitis Once Daily Asacol 
study 
PP: Per-Protocol 
CONSORT: Consolidated Standards of 
Reporting Trials 
QALY: Quality-Adjusted Life Year 
COPD: Chronic Obstructive Pulmonary 
Disease 
RBEE: Randomisation-Based Efficacy 
Estimator 
CRF: Case Report Form RCT: Randomised Controlled Trial 
DAG: Directed Acyclic Graph SD: Standard Deviation 
xix 
 
DAI: Drug Attitude Inventory SMM: Structural Mean Model 
DDD: Defined Daily Dose SRE: Skeletal Related Event 
EORTC QLQ-C30: European Organisation 
for Research and Treatment of Cancer 
Quality of Life Questionnaire Core version 
TDS: Three times daily 
ESAC: European Surveillance of 
Antimicrobial Consumption Network 
UC: Ulcerative Colitis 
ESPACOMP: European Society for Patient 
Adherence, Compliance, and Persistence 
UK: United Kingdom 
GLMM: Generalised Linear Mixed Model US: United States (of America) 
GP: General Practitioner WHO: World Health Organisation 
GRACE: Genomics to combat Resistance 
against Antibiotics in Community-acquired 
lower respiratory tract infection in Europe 
WP: Work Package 
HIV: Human Immunodeficiency Virus 
ZICE: The Zoledronate versus Ibandronate 
Comparative Evaluation 
HR: Hazard Ratio  
 
1 
 
CHAPTER 1: Background 
1.1 The importance of medication adherence 
The consumption of medication has long been recognised as a topic of great importance, 
concern, and complexity. (Osterberg and Blaschke, 2005) 
It is an issue that was recognised by Hippocrates during the 4th century B.C., when he remarked 
“Keep a watch…on the faults of the patients, which often make them lie about the taking of things 
prescribed. For through not taking disagreeable drinks, purgative or other, they sometimes die.”  
The phenomena has even been documented in religious texts. In one of the first stories in the 
Old Testament, God commanded Adam and Eve not to eat from the tree of knowledge of good 
and evil, for if they did they would most certainly die. However, despite this warning, they still 
ate from the tree. Relating this to the consumption of medication, this illustrates how we (as 
human beings) are susceptible to making decisions that are clearly irrational – such as avoiding 
taking medication that we have been prescribed, even when this medicine has demonstrable 
therapeutic benefits. 
More recently, a report published by the World Health Organization indicated that adherence 
(which they define as the extent to which a person’s behaviour corresponds with agreed 
recommendations from a health care provider) to long-term therapies is around 50% in 
developed countries and much lower in developing countries, where health resources may be 
scarce, and access to health care may not be universal. (Sabaté, 2003) The report also suggested 
that “increasing the effectiveness of adherence interventions may have a far greater impact on the 
health of the population than any improvement in specific medical treatments”, and that 
adherence is a multifaceted problem, with patients requiring support and not blame. These 
aspects demonstrate the importance that is placed on this topic and development of the field. 
2 
 
Poor adherence to medication can lead to reduced exposure to and effectiveness of 
pharmacological treatments. The often quoted observation from US surgeon general C. Everett 
Koop that “drugs don’t work in patients who don’t take them” highlights this issue succinctly. 
The clinical impact of poor adherence varies depending on the extent to which the medicine was 
not taken as recommended, the condition for which the medicine was prescribed, and the 
therapeutic window (or forgivingness) of the medicine.  
For example, early discontinuation and non-adherence to adjuvant hormonal therapy has been 
associated with increased mortality in women with breast cancer. (Hershman et al., 2011) With 
cancer being a common and severe life threatening condition, it often comes as a shock to both 
the public and healthcare professionals alike that non-adherence is an issue for patients with this 
condition. However, as remarked at an international conference on patient adherence, 
compliance, and persistence by a presenter who herself lives with chronic myeloid leukaemia 
“This is cancer. Of course my patient is taking their medicine!” is often a misled assumption. 
(Pelouchova, 2015) 
For patients with the human immunodeficiency virus (HIV), high levels of adherence to 
antiretroviral therapy (e.g. ≥95%) plays a critical role in the long-term suppression of viral load. 
(Paterson et al., 2000) Sub-optimal levels of adherence are associated with the development of 
resistance, which not only affects the therapeutic nature of treatment in the individual, but can 
also be transmitted to others. (Wainberg and Friedland, 1998) Non-adherence is also associated 
with an increased risk of the virus progressing to aids and also mortality. (Bangsberg et al., 2001) 
The consequences of non-adherence to anti-epileptic drugs (AEDs) in people with epilepsy are 
variable. While in some individuals the impact can be to increase seizure frequency, (Cramer et 
al., 2002) with the effects immediate in some instances, there are individuals who do not adhere 
to AEDs and experience no apparent ill effects and also some who adhere perfectly but continue 
to have an increase in seizure frequency. (Shope et al., 1988) 
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Moving to more acute conditions, poor adherence to antibiotics, that are appropriately 
prescribed for common infections in primary care, has the potential to reduce their effectiveness 
(e.g. delay recovery, increase the risk of complications, recurrence, re-consultations). (Daschner 
and Marget, 1975) There is also the theoretical possibility that poor adherence to antibiotics 
could result in infecting bacteria being exposed to sub-optimal levels of treatment; creating an 
environment that promotes antibiotic resistance. (Vrijens and Urquhart, 2005) 
While the link between poor medication adherence and clinical outcomes has been disputed, 
what cannot be disputed is the cost associated with poor adherence. In 2010, a report published 
evaluating the scale, causes, and costs of wasted medicine found that the gross annual cost of 
NHS primary and community care prescription medicines wastage in England was approximately 
£300 million per annum. (Trueman et al., 2010) Combined with the cost borne out of medication 
adherence-related hospital admissions, (McDonnell and Jacobs, 2002) it is evident that improper 
use of medication places a substantial financial burden on healthcare systems. 
1.2 Medication adherence in clinical research 
In clinical research, non-adherence to medication can reduce the perceived impact of treatments. 
For example, in a two-arm randomised placebo-controlled trial, treatment effects estimated by 
comparing outcomes in each of the arms using the intention-to-treat principle (the gold standard 
principle for comparing outcomes in randomised controlled trials) will provide a diluted estimate 
of the true effect of treatment in the presence of non-adherence. (Hernán and Hernández-Díaz, 
2012) While this estimate will still provide useful insight into the effectiveness of treatment at a 
population level, it does not help the individual who might be interested in knowing the likely 
effects they will have, good or bad, should they take their medicine as prescribed. 
Medication non-adherence during the early phase drug trials, where the goal is to demonstrate 
the efficacy of a therapy, has the potential to adversely impact on the drug development process, 
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and consequentially could mean that some medicines that truly are efficacious are not taken 
forward to later phases and given regulatory approval. (McCann et al., 2015) 
The impact of non-adherence to treatment also impacts more than the interpretation of the 
statistical analysis of trial outcomes. It is common for trials to include a health economic 
component, usually to demonstrate that a treatment is not only effective, but is also cost effective 
(that is, the health expected to be gained from a treatment exceeds the health likely to be forfeited 
through the movement of resources of other health service activities). (Drummond et al., 2015) 
In the UK, the National Institute for Clinical Excellence (NICE) threshold for cost effectiveness 
is up to £30,000 per quality-adjusted life year (QALY), which is a measure of health that 
combined length and quality of life. (NICE, 2012) Non-adherence to treatments in clinical 
research has the potential to move a treatment from being cost-effective, and therefore 
recommended by NICE, to not being cost-effective and not recommended. (Brilleman et al., 
2016) This has a direct impact on the care that a patient can receive in the National Health 
Service (NHS), and therefore demonstrates the importance of the study of medication adherence 
in clinical research. 
Interventions aimed at improving adherence to medication is an area of clinical research in itself. 
There exists a plethora of interventions, based on various health and psychological models of 
behaviour change, that have been trialled. (Nieuwlaat et al., 2014) While some have been shown 
to be successful in improving adherence to medication, the majority to date have failed to 
demonstrate that this improvement led to a clinically important improvement in clinical 
outcomes. 
1.3 Methodological challenges in medication adherence 
The study of medication adherence comprises significant methodological challenges.  
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Obtaining an accurate measurement of whether an individual has taken their medication as 
prescribed is difficult. (Farmer, 1999) Several types of measures are commonplace in research 
(for example, self-report, tablet counts, blood monitoring, and electronic monitoring), but all are 
indirect, relying on assumptions of varying strength and plausibility. These measures also vary in 
the quality and wealth of data they can provide, and also the extent to which they can be subject 
to bias. (Norell, 1981, Cramer and Mattson, 1991, Matsui et al., 1994, Vitolins et al., 2000) 
Variation in the literature regarding the quantification and conceptualisation of adherence has 
led to confusion, ambiguity, and inconsistent reporting. (Lehane and McCarthy, 2009) While 
definitions have evolved over time (e.g. from compliance to adherence, concordance, and 
persistence), these terms continue to be broad in scope. More recent developments have moved 
towards defining separate elements of adherence (i.e. initiation, implementation, and persistence) 
that are thought to describe the processes involved in medication taking, treating the term 
“adherence” as an overarching term. (Vrijens et al., 2012) 
Understanding the types of patients and circumstances that heighten the risk of poor adherence 
to medicine can help when it comes to the development of effective interventions, but 
determining these is not a straightforward task. (Vermeire et al., 2001) The determinants of poor 
adherence to medication can be multifaceted, and not purely related to the characteristics of the 
individual who was prescribed the medicine. Therefore, complex statistical analysis using detailed 
data sources are required in order to accurately quantify these influences. 
Randomised controlled trials that are subject to treatment non-adherence tend to provide 
adjusted estimates of treatment efficacy (the effect of taking treatment as prescribed) alongside 
their standard estimate based on the intention-to-treat principle. (Montori and Guyatt, 2001) 
However, traditional approaches to estimating treatment efficacy make implicit assumptions (for 
example, no unmeasured confounding) that are unlikely to be plausible in practice. (Altman, 
1990) Methods of analysis that are more nuanced, and importantly that respect the random 
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allocation of patients, can be used, but to date have largely been restricted to technical journals 
and seldom used in applied clinical research. The practicalities of their implementation remain 
uncertain. 
1.4 Aim of thesis 
The aim of this thesis is to investigate various methodological challenges that are encountered 
when studying medication adherence in clinical research, generating new evidence that will 
advance the field, and indicating areas in which further developments are warranted. 
1.5 Thesis synopsis 
The remainder of this thesis will be structured as follows. Chapter 2 will summarise and appraise 
the published literature on specific methodological issues of medication adherence in clinical 
research. Chapter 3 will provide a description of the data sources used throughout the findings 
chapters of the thesis. Chapter 4 will compare different types of measures of medication 
adherence, their correlation and agreement with one another, and methods for combining or 
calibrating an estimate of medication adherence in the presence of multiple types of disagreeing 
estimates. Chapter 5 will focus on investigating the determinants of medication adherence for a 
variety of conditions, including both long-term chronic conditions and short-term acute 
conditions. This chapter will also explore the impact of different types of measures, and different 
conceptualisations of medication adherence on the determinants that are found. Chapter 6 will 
look at how causal treatment effects can be derived from randomised controlled trials in the 
presence of non-adherence to medication. The concept of randomisation-based efficacy 
estimators will be introduced, and the feasibility of their implementation on real data and for 
different trial designs will be examined. Finally, Chapter 7 will summarise the key findings and 
novel contributions from the thesis, and propose directions of future research in this field. 
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CHAPTER 2: Summary and Appraisal of Key Literature 
on the Methodological Issues of Medication Adherence 
in Clinical Research 
2.1 Introduction 
Understanding the key gaps in knowledge that exist in this field, and the opportunities that exist 
for novel contribution, requires an understanding and appraisal of relevant literature. Therefore, 
the purpose of this Chapter is to summarise and appraise the published literature on several 
methodological issues related to medication adherence in clinical research. The topics of focus 
will be  
1. The measurement of medication adherence;  
2. Understanding risk factors for non-adherence to medication;  
3. Adjusting findings of randomised controlled trials for medication non-adherence using 
randomisation-based efficacy estimators. 
2.2 Type of literature review 
The purpose of these literature reviews is to provide the reader with a broad overview of the 
topics of focus throughout my thesis. Due to their often narrow focus and resource intensity, it is 
not practical to carry out a systematic review of the literature. A rapid review process was 
therefore undertaken. This is a streamlined approach for synthesising evidence in a timely 
manner, and is well suited for reviewing topics that are broad in scope. (Khangura et al., 2012) 
To assess how far my literature review deviates from a high quality systematic review, the 
AMSTAR checklist will be completed and the scores reported. (Shea et al., 2007) I will also 
highlight where these reviews may appear deficient, according to this checklist, highlighting the 
likely implications of these deficiencies, and draw conclusions appropriately. 
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2.3 Search strategies 
Search strategies were created for each topic, with each search initiated in Ovid Medline using 
several terms related to medication (medicine, medication, drug, or medicinal), and adherence 
(adherence, compliance, concordance, persistence, initiation, implementation, or 
discontinuation). From this point, strategies diverged, with Topic 1 aiming to capture common 
methods for measuring adherence (electronic monitoring, tablet count, pill count, or self-report) 
and narrowing the focus down to papers that were interested in comparing measures if possible 
(comparison, agreement, correlation, calibration, or adjustment). Topic 2 considered several 
terms similar to “risk factor” (factors, determinants, or predictors), and aimed to cover both long-
term/chronic and short-term/acute medical conditions (long term condition, long term illness, 
chronic condition, chronic illness, short term condition, short term illness, acute condition, or 
acute illness). Finally, the primary aim of Topic 3 was to capture randomised controlled trials of 
medicinal products that had been published, where findings were adjusted for non-adherence 
using randomisation-based efficacy estimators. Therefore, a wide range of terms were used to 
capture this (causal inference, principal stratification, structural mean model, randomisation 
based efficacy estimator, instrumental variable, instrumental variables, complier average causal 
effect, complier-average causal effect, CACE, SMM, randomisation-based efficacy estimator, 
adherence-adjusted, or RBEE). The purpose of this review was to give an overview of the extent 
to which these methods are being used in practice, rather than describe methods that have been 
proposed in the statistical literature. Finally, an additional search was undertaken, specifically 
looking at all randomised controlled trials of medicinal products that have been published since 
the beginning of 2015 in the highly-ranked medical journals (specifically, The Lancet, The British 
Medical Journal, The New England Journal of Medicine, and The Journal of the American 
Medical Association). The purpose of this search was to identify whether these papers referred 
to medication adherence, and if so, whether/how they described methods for its measurement 
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and whether/how it was modelled/adjusted for. Phase I clinical trials were excluded, as adherence 
to medication would be directly observed in all of these and therefore unlikely to be reported. 
All strategies also limited findings to studies published on humans and written in English. 
Abstracts were initially screened for duplicates. As the purpose of the review was to obtain a 
broad view of the literature, rather than ensure that every paper was reviewed, papers were 
reviewed for relevance in blocks of ten until no new themes were found within an entire block. 
Abstracts were reviewed in alphabetical order (with respect to the lead author). The purpose of 
this was to not focus on reviewing papers from any particular time point (and risk obtaining a 
biased view of the literature), and thus be more likely to obtain a broader view of the literature 
(that is, both past and present methods and techniques). 
To ensure that no key literature was missed using this approach, the search was re-run with a list 
of key authors that have published important works on medication adherence (Bangsberg, 
Claxton, DiMatteo, Farmer, Horne, Hughes, Kane, Kardas, Osterberg, Pechere, Sabate, 
Urquhart, Vermeire, Vrijens, or Weinman). A review of other work published by these authors 
in the field of medication adherence was also undertaken, to ensure that any key literature not 
covered by these searches were read (Figure 2.1).
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Figure 2.1: Flow diagram outlining search strategies* 
 
*Searches for Topics 1 to 3 were re-run with the list of key authors specified. For this search, all abstracts were reviewed. 
Medicine terms
Adherence terms
Topic 1: Measurement Topic 2: Determinants Topic 3: Adjustments Review of RCTs in top medical journals
Ovid Medline
Measuring terms
Comparison terms
Risk factor terms
Condition terms
Adjustment terms
Randomised controlled trials
Medicinal products
Top medical journals
Since 2015
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2.4 Topic 1: The Measurement of Medication Adherence 
2.4.1 Search Results 
The initial search was conducted on 19/04/2016 and yielded 195 papers, six of which were 
duplicates (Table 2.1). From the 189 unique papers that were identified, no new themes emerged 
after reviewing 60. In total, 43 papers were deemed relevant, with the remaining 17 not relevant 
for this review. The search was re-run with the names of key authors included. Nine paper were 
identified. However, four had already been reviewed, and one was deemed not relevant for the 
review. Therefore, this search yielded an additional four relevant papers. Following the review of 
full texts of all 47 papers, two papers were excluded for not being relevant, on closer inspection. 
The section of the Chapter therefore relates to the review of 45 papers (Figure 2.2). 
2.4.2 Findings 
2.4.2.1 Clinical conditions 
The papers found cover a wide range of conditions, including those focused on the respiratory 
tract (e.g. asthma, cystic fibrosis), (Berg et al., 1998, Butz et al., 2005, Daniels et al., 2011, Casey 
et al., 2012) long-term physical conditions such as HIV, (Dlamini et al, 2009, Haberer et al., 
2011, Buscher et al., 2015) cancer, (Escalada and Griffiths, 2006) type 2 diabetes, (Farmer et al., 
2006, Bogner et al., 2013) and hypertension, (Choo et al., 1999, El Zubier, 2000, Horne et al., 
2010) and mental illnesses such as depression (Gabriel and Violato, 2010, De las Cuevas et al., 
2014) and schizophrenia. (Garavan et al., 1998, Frangou et al., 2005, Byerly et al., 2007, Brain 
et al., 2014) There were also studies included in this review looking at adherence to treatment in 
substance abusers (e.g. alcohol, ecstasy, speed, and heroin). (Digiusto et al., 1996, Cooper et al., 
2000, Feinn et al., 2003) 
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Table 2.1: Findings from the initial search for Topic 1 
# Searches (conducted on 19/04/2016) Results 
1 (MEDICINE or MEDICATION or DRUG or MEDICINAL).ab. 992741 
2 
(ADHERENCE or COMPLIANCE or CONCORDANCE or 
PERSISTENCE or INITIATION or IMPLEMENTATION or 
DISCONTINUATION).ab. 
504576 
3 1 and 2 67965 
4 
(ELECTRONIC MONITORING or TABLET COUNT or PILL 
COUNT or SELF REPORT).ab. 
32363 
5 3 and 4 1246 
6 
(COMPARISON or AGREEMENT or CORRELATION or 
CALIBRATION or ADJUSTMENT).ab. 
1254070 
7 5 and 6 199 
8 limit 7 to (English language and humans) 195 
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Figure 2.2: Diagram illustrating the flow of papers from identification to review (Topic 1) 
Topic 1
Papers identified
N = 195
Unique papers
n = 189
Abstracts retained
n = 47
Full papers retained
n = 45
Excluded N = 6
- Duplicates n = 6
Excluded N = 124
- Not reviewed n = 124
Excluded N = 2
- Not relevant for review n = 2
Saturation reached
n = 60
Abstracts retained
n = 43
Excluded N = 17
- Not relevant for review n = 17
Key author papers
n = 9
Abstracts retained
n = 4
Excluded N = 5
- Already retained n = 4
- Not relevant for review n = 1
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2.4.2.2 Types of measures 
A variety of different methods for measuring adherence to medication were found. Indirect 
accounts of medication use/adherence were often used in the papers reviewed, rather than direct 
(observed) measures. These tended to be reported by the patient themselves (self-report), 
(Garber et al., 2004, Jerant et al., 2008, Brask-Lindermann et al., 2011) but in some instances 
were reported by some form of carer and/or a healthcare professional (proxy-report). (Cassidy 
et al., 2010, Daniels et al., 2011) There are several reasons one may choose to measure 
adherence via proxy report rather than self-report, including attempts to assess the quality of 
treatment administration (if the recipient requires correct technique to take the medicine), 
reduction of reporting bias (though this could still be present in some proxy-reports), and 
convenience (for example, if the proxy is responsible for administering medication). The mode 
of data capture also varied between studies, including completion via prospective self-completed 
diaries, (Anastasio et al., 1994) and other means such as face-to-face (Garavan et al., 1998) and 
retrospective telephone administered interviews. (Choo et al., 1999) For these subjective 
measures, the mode of data capture and also nature of data capture (prospective versus 
retrospective) can impact on the level and extent of response bias, and should be considered in 
full by the investigator prior to implementation. (Hood et al., 2012) Some papers also reported 
on the use of validated scales to obtain self/proxy-reported adherence, including scales that could 
be used across conditions, such as the Morisky Medication Adherence Scale (MMAS), (Morisky 
et al., 1986, Butler et al., 2004, Elm et al., 2007, Ayoade and Oladipo, 2012, De las Cuevas et 
al, 2014) the Medication Adherence Rating Scale (MARS), (Horne and Weinman, 1999, Farmer 
et al., 2006, Horne et al., 2010, Mahler et al., 2010) the Medication Adherence Self-Report 
Inventory (MASRI), (Walsh et al., 2002, Andy et al., 2015) the Drug Attitude Inventory (DAI), 
(Hogan et al., 1983, Dolder et al., 2004) and the Brief Medication Questionnaire (BMQ). 
(Svarstad et al., 1999, Choo et al., 1999) Condition-specific measures were also used, such as the 
Adult Aids Clinical Trials Group (AACTG) 4-day self-report measure of missed doses (de Klerk 
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et al., 1999, Chesney et al., 2000, Buscher et al., 2011) and the Antidepressant Adherence Scale 
(AAS). (Gabriel and Violato, 2010) Validated, or standardised scales give the advantage of having 
existing evidence demonstrating the extent to which the scale measures what it is intended to 
measure (validity), can yield consistent responses (reliability), and can discriminate between 
different types of subjects (sensitivity). Without previous investigation of these areas, ad-hoc 
questions risk producing data that are useless (e.g. not sensitive and cannot distinguish between 
people who do and do not adhere, or changes in adherence over time) or worse misleading 
(because the scales measure something different than what was intended). (Streiner and Norman, 
2014) Pill counts also commonly featured in the papers reviewed. (Almeida et al., 2014, Banek 
et al., 2014, Baxi et al., 2015) While the majority of pill counts were scheduled (e.g. occurring 
clinic visits or other known time points), (Elzubier et al., 2000, Feinn et al., 2003, Elm et al., 
2007, Brain et al., 2014) some papers reported the collection of pill count data during 
unannounced home visits. (Haberer et al., 2011) The purpose of the latter being to reduce the 
risk of pill dumping (removing pills from containers without consuming them with the intention 
of appearing more adherent to treatment) and/or white coat adherence (increasing medication 
usage as the time to a scheduled visit neared to appear more adherent) (Rudd et al, 1989, 
Bangsberg et al., 2000) and thus improve the validity of the measure. Indeed, Haberer et al, 
reported better agreement between electronic monitoring and unannounced pill counts 
compared to scheduled pill counts. In some of the papers reviewed, biological assays were used 
as a means of monitoring medication use. (Digiusto et al., 1996, Cooper et al., 2000, Banek et 
al., 2014, Baxi et al., 2015) Various types of samples were used to obtain measure of medication 
use, including samples obtained from blood, urine, and hair. The advantage of these are that 
they can measure the concentration of drug within an individual’s body. However, they are 
resource intensive, invasive, and similar to pill counts, where these are scheduled, patients may 
take medication as prescribed a few days prior (where they had not been doing so previously). 
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In other words, while they can be viewed as a direct measure, in practice they remain indirect in 
all but short-term treatments. Pharmacy refill records were also reported in some papers. (Choo 
et al., 1999, Esposito et al., 2008, Clifford et al., 2014) These are records collected routinely by 
pharmacists which provide an account of a prescription being collected. While there are a 
number of advantages to using pharmacy refill data to monitor adherence (non-invasive, 
participant not overtly aware they are being monitored, etc.), due to the data used during this 
thesis, they will not be considered in any great detail. Electronic monitors were a frequently 
utilised means of obtaining medication adherence data in the papers reviewed. (Chui et al., 2003, 
Boland et al., 2014) The types of monitors varied, depending on the way in which the medication 
was delivered. Examples include the Medication Event Monitoring System (MEMS), (Escalada 
et al., 2006, Buscher et al., 2011, Baxi et al., 2015) that records the date and time of each bottle 
cap opening, a similar micro-switch device housed inside an inhaler, (Berg et al., 1998) and 
electronic nebulizer monitors, that record the date, time, and duration of each nebulizer use 
event. (Butz et al., 2005) Electronic monitors do not rely on patients consciously reporting their 
medication use, and can provide rich detail on patterns in adherence. However, their expense 
(relative to other types of measures) can make them infeasible. The knowledge that a patient’s 
medication taking habits are constantly monitored can also risk influencing adherence itself. 
Where electronic monitoring is commonplace, this is not a problem. However, when an 
intervention to improve adherence is being trialled, and adherence is being monitored 
electronically, it may be difficult to disentangle intervention effects from the effect of the 
electronic monitor due to this reactivity (French and Sutton, 2010, McCambridge et al., 2011). 
Nevertheless, electronic monitors are widely regarded as the best measure of adherence in 
clinical research, with a key study by Sutton et al., (2014) finding that while electronic containers 
may lead to small increases in adherence, this is outweighed by their advantages. Figure 2.3 
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illustrates the different types and subtypes of measures described in this section, as well as 
summaries reported in the literature. 
2.4.2.3 Quantification of adherence 
A range of approaches were used to quantify adherence, both between and within the different 
types of measures described previously. For validated scales, scores or categories were computed 
using the items suggested by the scale developers. (Dlamini et al., 2009, Buscher et al., 2011) 
These, along with un-validated accounts, were often dichotomised into “adhered to medication 
regimen” / “did not adhere to medication regimen”. (Elzubier et al., 2000, Dorz et al., 2003, 
DiMatteo et al., 2004, De las Cuevas et al., 2014) While a categorisation such as this may appear 
more intuitive for a clinical or patient audience, and for defining populations it is sometimes 
needed (for example, when defining an analysis population in a randomised controlled trial), 
dichotomising ordinal or continuous variables results in a loss of information for often very little 
gain. (Senn, 2005) The gain is even smaller if the categorisation is not based on strong evidence 
of a clear dichotomy at the chosen threshold (i.e. the threshold has been arbitrarily chosen, or 
chosen based on weak evidence), as participants categorised as ‘not adhering’ might have taken 
enough of the treatment for a therapeutic benefit.   Indeed, these categorisations varied across 
studies in a fairly arbitrary fashion, with some studies using a cut-off at 100%, (Almeida et al., 
2014) and others using cut-offs ranging from 70% upwards. (Bogner et al., 2013, Brain et al., 
2014) 
Adherence measured using pill counts tended to calculate the difference between the number of 
pills given and the number returned, expressing it as a percentage of the number of pills given. 
(Horne et al., 2010, Haberer et al., 2011) This can provide a measure of consumption within a 
defined period, but gives little understanding of patterns in adherence within the period (other 
than when adherence is 0 or 100%). Calculations from biological assays were based on either the 
amount of drug detected in the sample, or a categorisation of this that indicated whether the 
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amount of drug detected was consistent with someone adhering to their prescribed regimen. 
(Cooper et al., 2000, Brain et al., 2014) Note the latter summary has similar issues to 
dichotomisation elsewhere in that information is lost and may be an overly simplistic 
representation of adherence. (Farmer, 1999) Where adherence data were obtained via pharmacy 
refill records, the Medication Possession Ratio (MPR) was the popular metric of choice. The 
MPR counts the number of days of medication supplied within a time interval and divides this 
by the time interval, with a ratio calculated provided there is at least one refill/repeat prescription.  
(Steiner and Prochazka, 1997, Steiner et al., 1998) Electronic monitors that record the date and 
time of a dosing event have an advantage of providing data on adherence in multiple ways. 
Indeed, from the papers reviewed, data collected via electronic monitors were used to create 
adherence metrics based on the percentage of days that patients adhered to their treatment (e.g. 
had at least the required number of dosing events corresponding to their prescribed regimen), 
(Brain et al., 2014) the amount of times that doses were within a defined time interval, (Boland 
et al., 2014) and the average duration of each dosing event (e.g. average length of time that a 
nebulizer was in use during a dosing event). (Butz et al., 2005) 
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Figure 2.3: Diagram of the different types of indirect adherence measures described during this literature review (with summary measures in green) 
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Knowledge of the treatment being investigated can influence the recommended metric of 
interest. For treatments where time between consumption is vital for achieving or maintaining 
efficacy (or minimising toxicity), analysis based on time intervals is important. Conversely, where 
comparisons are being made between two treatments that are taken a different number of times 
a day, data regarding frequency of openings is important (Figure 2.3). 
2.4.2.4 Comparing different types of measures - correlation 
One of the key aims of this review was to summarise literature that reports comparisons of 
different methods for measuring adherence. Broadly speaking, the literature reviewed reported 
comparisons between methods in two ways – correlation and agreement. The strength of 
correlation between different types of methods was wide ranging. Strong relationships were found 
in some studies comparing self-report to pill counts, (Feinn et al., 2003, Almeida et al., 2014) 
and biological assays to electronic monitoring, (Baxi et al., 2015) but correlations that were weak 
to moderate were also found. (Elm et al., 2007 Esposito et al., 2008, Buscher et al., 2011) For 
example, one study found a moderate correlation between self-reported adherence and pill 
count-derived adherence that weakened over time. (Andy et al., 2015) This could reflect the fact 
that self-report adherence measures aim to measure adherence to treatment (both in terms of 
consumption but also tendencies to consume correct doses at the correct times), whereas pill 
counts are only able to provide a measure of consumption within a defined period. It would 
therefore follow that strength of association between these two types of measures would weaken 
as the observation period widened. Another study of inhaled medications compared different 
adherence metrics derived from electronic monitors to those derived from self-reported diaries 
found that while a moderate correlation was found when using frequency data (percentage of 
days with correct administrations), there was considerably weaker correlation when comparing 
diaries to metrics based on the number of puffs. (Berg et al., 1998) The latter metric yielded a 
lower adherence rating when based on electronic monitors compared to self-reported data (i.e. 
according to self-reports, patients thought they were adhering better than the electronic monitors 
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suggested). This study highlights the advantages of having automated date and time data, as this 
was combined in an algorithm, with the number of puffs at each dosing event, to determine the 
level of adherence of a given patient. Achieving the same detail via self-reported data would rely 
on patients actively recording the date, time, and number of puffs (potentially the time of each 
puff) at each dosing event. This is unlikely to be sustainable in patients on an indefinite basis, or 
even research participants (particularly where a long-term condition is of interest). 
2.4.2.5 Comparing different types of methods - agreement 
Assessing the correlation between two methods can only indicate the strength of the relationship 
between them. It cannot provide an accurate indication of the level of agreement between the 
two methods (for example, it is mathematically possible for two methods that are strongly 
correlated to have poor agreement), which is an important estimand for understanding the 
reliability or bias of a particular method. The papers in this review estimated agreement using a 
diverse range of methods. The observed percentage of agreement was often reported. (Cooper 
et al., 2000, Banek et al., 2014) This was usually accompanied by Cohen’s Kappa, which takes 
into account chance-agreement for categorical variables, (Digiusto et al., 1996) or the intra-class 
correlation coefficient, if a quantitative measurement of adherence was used. (Cassidy et al., 
2010) Some papers reported on the sensitivity and specificity of a particular method, where the 
performance of a particular method (often self-report) was compared to a gold/reference 
standard (often electronic monitoring). (de Klerk et al., 1999) This method relies on a categorical 
definition of adherence, and assumes that the reference standard reflects the true nature of 
adherence. While these approaches can describe the amount of agreement present between two 
types of measures, and to some extent the direction of disagreement (e.g. more adherent people 
according to one approach), they cannot provide information about the extent of disagreement. 
This might be important, as two measures may disagree by a negligible amount, or disagreement 
may be sensitive to how adherence thresholds were chosen (if a continuous measure was available 
but subsequently categorised). Another method for assessing agreement, less frequently reported 
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in the literature reviewed, was Bland-Altman plots and limits of agreement. These involve plotting 
the average and paired-difference across two types of measures that produce quantitative 
summaries of adherence. This plot is then used to compare methods and detect systematic 
disagreement (bias) between them. For example, one study used a Bland-Altman plot to assess 
the agreement between self-report and electronic monitoring in the use of nebulizers, 
demonstrating that self-reports consistently overestimated use of nebulizers, when compared to 
electronic monitoring. (Daniels et al., 2011) Similarly, another study found that electronic 
monitoring and unannounced pill counts yielded lower adherence compared to carer-reported 
adherence and scheduled pill counts. (Haberer et al., 2011) 
2.4.2.6 Calibration and other approaches 
On comparing methods, be that via correlation or agreement, the natural progression might be 
to use this information in an attempt at deriving a more accurate estimate of medication 
adherence. The majority of methods, indeed every method described in this review, provide an 
indirect measure of medication adherence, relying on assumptions in order for their data to be 
used as means for quantifying medicine use. Using information from multiple indirect sources 
to acquire an improved estimate (and hence understanding) of medication would therefore seem 
important. Despite this, there appear to have been few attempts at using the information obtained 
in this way. One study explicitly did this by creating a consensus definition of adherence based 
on pill counts along with patient, clinician, and family accounts of medication use. (Cassidy et al., 
2010) However, it is not clear how this consensus was arrived at, only that all individual measures 
correlated very highly with the consensus measure (as would be expected). Another study, that 
used electronic monitors to study adherence to medication given on a multiple doses per-day 
regimen, added in questions at follow-up visits that took account of multiple doses being removed 
during a single dosing event, stating that this information was then used to add dosing events as 
appropriate. (Byerly et al., 2007) However, further detail of this process was lacking. This 
approach is likely to be unreliable, unless these questions were asked frequently and specific 
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questions were asked (rather than a general question, such as “how often did you remove more 
than one dose at a time?”). Nevertheless, this was an attempt at creating a calibrated adherence 
measure, using multiple sources of data. Finally, one study from those reviewed, that reported 
the concordance between urinalysis and self-reported drug use by applicants for methadone 
maintenance, conducted an analysis that looked at predictors of misreporting drug use. (Digiusto 
et al., 1996) The analyses yielded no strong associations. However, this is type of analysis appears 
to be seldom reported, and may be useful when it comes to informing the reliability of reported 
levels of adherence provided by individuals within a study, or potentially when it comes to 
selecting a suitable method/s for measuring adherence across an entire study (that is, by 
considering the typical characteristics of the population of interest in relation to known factors 
that influence misreporting of treatment adherence). 
2.4.2.7 Summary (Topic 1) 
The review of these papers highlighted both gaps in the literature, and areas in which knowledge 
and understanding could be further strengthened by the work presented in this thesis. The 
majority of papers focused on adherence to medication prescribed for long-term conditions. The 
measurement of adherence to medication prescribed for short-term illnesses appears to be a less 
well researched area. However, non-adherence to these medicines could impact on clinical 
outcomes, potentially leading to complications that have long-lasting consequences. This is an 
area that therefore warrants further investigation. As previously reported, electronic monitors 
used to measure medication adherence have the advantage of providing accounts of dosing 
frequency, timing, and in some instances duration. However, despite there being many studies 
reporting their use, simple summary measures of adherence (e.g. an average adherence score / 
dichotomous indicator averaged across an entire observation period) appear to be the popular 
means of reporting these data. It is my intention to move beyond that during this thesis and 
provide more accurate accounts of adherence, as measured by electronic monitoring, and 
demonstrate how these data can be used to demonstrate the evolution of adherence over time. 
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The investigation of agreement between adherence measures was reported in several studies. 
However, most used dichotomous definition of adherence based on an arbitrary cut-off. Bland-
Altman plots were infrequently used, and this thesis will explore their use further. Agreement 
between adherence measures should never be an end in itself, however. This thesis will therefore 
explore means for estimating risk factors for disagreement between adherence measures, and 
consider different ways in which measures can be combined in order to create a calibrated 
measure that, ideally, provides a more accurate reflection of how well an individual has adhered 
to their prescribed medication regimen. 
2.5 Topic 2: Understanding Risk Factors for Non-Adherence to 
Medication 
2.5.1 Search Results 
The initial search, performed on 19/04/2016, yielded 85 papers (Table 2.2). Three duplicates 
were removed, leaving 82 unique papers. Similar to Topic 1, no new themes emerged after 
reviewing 60 papers. In total, 30 papers were deemed relevant, with the remaining 30 not relevant 
for this review. The search was re-run with the names of key authors included. Two papers were 
identified. However, both had already been identified in the initial search. Therefore, this 
approach yielded no additional papers. On further review of the full texts, four papers were 
subsequently excluded due to their irrelevance for this review. This section therefore relates to 
the review of 26 papers (Figure 2.4). 
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Table 2.2: Findings from the initial search for Topic 2 
# Searches (conducted on 19/04/2016) Results 
1 (MEDICINE or MEDICATION or DRUG or MEDICINAL).ab. 992741 
2 
(ADHERENCE or COMPLIANCE or CONCORDANCE or 
PERSISTENCE or INITIATION or IMPLEMENTATION or 
DISCONTINUATION).ab. 
504576 
3 1 and 2 67965 
4 
(RISK FACTORS or DETERMINANTS or PREDICTORS or 
FACTORS).ab. 
1381410 
5 3 and 4 11798 
6 
(LONG TERM CONDITION or LONG TERM ILLNESS or CHRONIC 
CONDITION or CHRONIC ILLNESS or SHORT TERM CONDITION 
or SHORT TERM ILLNESS or ACUTE CONDITION or ACUTE 
ILLNESS).ab. 
12851 
7 5 and 6 87 
8 limit 7 to (English language and humans) 85 
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Figure 2.4: Diagram illustrating the flow of papers from identification to review (Topic 2) 
 
Topic 2
Papers identified
N = 85
Unique papers
n = 82
Abstracts retained
n = 30
Full papers retained
n = 26
Excluded N = 3
- Duplicates n = 3
Excluded N = 22
- Not reviewed n = 22
Excluded N = 4
- Not relevant for review n = 4
Saturation reached
n = 60
Abstracts retained
n = 30
Excluded N = 30
- Not relevant for review n = 30
Key author papers
n = 2
Abstracts retained
n = 0
Excluded N = 2
- Already retained n = 2
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2.5.2 Findings 
2.5.2.1 Clinical conditions 
In the same way as Topic 1, the papers found for this review covered a wide range of clinical 
conditions. The majority focused on long-term or chronic conditions (e.g. HIV, ADHD, and 
bipolar disorder), (Berk et al., 2004, Harvey et al., 2008, Coletti et al., 2012, Mackey et al., 2012) 
with some papers focusing on risk factors of non-adherence medicines in general, but in a specific 
population (e.g. the elderly). (Henriques et al., 2012, Dharmapuri et al., 2015) 
2.5.2.2 Approaches used to study risk factors 
The papers reviewed used both quantitative and qualitative means of studying risk factors for 
non-adherence. Those that used quantitative means tended to report their findings on the basis 
of regression analyses. (Bagchi et al., 2007, Dean et al., 2011, Gadkari et al., 2012) This is a 
useful approach for measuring the strength of association that these risk factors may have on 
adherence, and how this association is influenced by other factors. Univariable analyses were also 
reported in some papers, though these lack the advantage of being able to be adjusted for any 
confounding relationships that may exist. (Dalbeth et al., 2011, Lin et al., 2014) One paper used 
a stated-preference approach to quantify how certain attributes of medication affected the 
adherence to these treatments. (Johnson et al., 2007) This approach is a systematic method for 
understanding preferences through structured trade-offs. (Thurstone, 1927, Louviere et al., 
2000) Relevant medication attributes were identified using existing literature (for example, 
frequency of mania episode), with participants asked to choose between a series of medicines 
that had varying levels of these attributes (for example, less than once a year; 1-3 times a year; 4-
6 times a year; more than 6 times a year), as well as being asked to compare their current 
medication with hypothetical medication (again, with varying levels of the identified attributes). 
This approach has the key advantage of data being cheap and quick to collect (compared to, for 
example, a cohort study investigating risk factors of adherence to a treatment being taken long-
term). However, as with all stated-preference approaches, it has the disadvantage of yielding data 
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related to decisions and trade-offs for hypothetical scenarios, rather than observed behaviour. 
There is therefore the risk of a lack of external validity. Nevertheless, identifying risk factors for 
non-adherence naturally leads to the development of interventions to improve adherence. These 
risk factors (stated or revealed) will thus be validated externally through this process. Qualitative 
methods that were used to study risk factors for non-adherence included interviews, focus groups, 
and narrative commentaries on existing literature. (Kjellgren et al., 2004, Li et al., 2007, Chen et 
al., 2014) Each of these methods have their benefits, with interviews being particularly useful in 
situations where the issue of non-adherence for a certain medication, or indeed, the condition 
for which the medication is treating, is of a sensitive nature. Interviews are also a valuable method 
for seeking detailed opinions/perspectives on topics from individuals. For example, a study 
exploring the factors facilitating and challenging access and adherence to antiretroviral therapy 
(ART) interviewed patients to explore this topic in depth and found risk factors that would be 
difficult to quantify (for example, loss of earnings due to side effects making them too ill to work, 
and the desire to see their children finish school, rather than leave small orphans). (Grant et al., 
2008) Focus groups allow for the appraisal of multiple perspectives on a topic in an interactive 
group setting, and the acceptance and challenge around ideas that are put forward can be 
documented more easily than from interviews. An example of this is seen in a study investigating 
patient-provider perceptions on engagement of HIV care in Argentina. In this study, both 
patients and providers considered a strong therapeutic alliance as vital to achieving treatment 
adherence. (Bofill et al., 2014) However, while providers suggested that poor communication 
skills and a passive attitude on behalf of the patient were factors influencing adherence, perceiving 
non-adherence as a patient failure, patients expressed frustration over the lack of shared 
responsibility between patient and provider for achieving adequate adherence levels. Narrative 
reviews of the literature are useful when studies have been conducted, and the harmony and 
dissonance of the risk factors identified across studies is required. One such review, investigating 
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the influences of adherence to paediatric asthma treatment, found a variety of different risk 
factors associated with adherence to asthma treatment that were consistent across studies, if of 
varying strength. (Drotar and Bonner, 2009) Some inconsistent findings were also reported, with 
factors positively associated with adherence in some studies, and negatively associated in others. 
(Nischal et al., 2005, Browne and Merighi, 2010) This could reflect differences in the 
characteristics of the samples considered (different cultures or ethnicities, different treatments, 
patients from different socio-economic backgrounds, etc.) 
2.5.2.3 Risk factors 
The risk factors that were found varied across, and even sometimes within, the various clinical 
conditions in which this work has been studied. Factors that were found fairly consistently across 
studies as associated with improved adherence were age (older people are more likely to adhere 
to treatment than younger people), (Horne and Weinman, 1999, Grant et al., 2004) social 
support (for example, being married, having medication administered by a carer), (Berk et al., 
2004, Browne and Merighi, 2010) therapeutic alliance (the relationship the patient has with their 
healthcare provider), (Lin et al., 1995, Nischal et al., 2005, Bofill et al., 2014) improvements in 
health literacy, (Henriques et al., 2012) and educational level. (Kalkan et al., 2013) Factors found 
that were negatively associated with adherence include side effects, (Chesney, 2003) the 
complexity of the regimen, (Beni, 2011) both in terms frequency of treatment and additional 
instructions given with the treatment (e.g. daily fluid restrictions in the use of oral medications 
for haemodialysis patients), (Browne and Merighi, 2010) pill burden in general (e.g. 
polypharmacy), (Chen et al., 2014) and the stigma of the illness for which the medication was 
prescribed. (Bofill et al., 2014) Other factors associated include race and access to healthcare. 
(Nischal et al., 2005, Bagchi et al., 2007) In addition to the risk factors identified, there is a wealth 
of literature suggesting that adherence to medication can be characterised and predicted by 
behavioural models, with several health psychology theories used to describe this phenomenon 
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(e.g. social cognitive theory, self-regulatory theory). (Munro et al., 2007, Holmes et al., 2014, 
Patton et al., 2016)    
These factors show that the ability to take medication as prescribed is a complex phenomenon 
that may rely on a variety of interacting aspects. Nevertheless, many of these factors are likely to 
be modifiable or amenable to targeted interventions. 
2.5.2.4 Summary 
The key gaps and deficiencies identified in the literature during this review can be divided into 
three areas – the conditions in which this work mainly resides; the method of calculation 
primarily used when looking at risk factors of adherence; and the research methods used to 
explore some of the factors related to medication adherence. Papers reviewed for this Topic 
focused on long-term and chronic conditions. While they were not an exhaustive list of 
publications that investigate risk factors of medication adherence, they nevertheless indicate a 
lack of research on adherence to treatments for short-term acute conditions, such as antibiotics 
to treat uncomplicated respiratory tract infections. This is an area that requires investigation, and 
a comparison of the determinants of adherence to those reported in the literature on long-term 
conditions may be of interest. As was also reported for Topic 1, the majority of papers 
conceptualised adherence as a single, all-encompassing and dichotomous trait. Rarely was a 
quantitative measure of adherence used or an attempt made to investigate risk factors related to 
any separate element of adherence (e.g. initiation, implementation, or persistence). Investigating 
risk factors of a quantitative measure or by using different elements of adherence, means the data 
are likely to be better used, as there is generally a reduction in information and statistical power 
when a continuous / quantitative variable is dichotomised. Investigating elements of adherence 
separately also allows for the possibility that there may be different mechanisms influencing 
whether a person initiates, the extent to which they implement their medication correctly, and 
the length of time they persist with their treatment. (Vrijens et al., 2012) These matters will be 
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explored in this thesis. Finally, while qualitative research methods can provide information that 
is often difficult to capture quantitatively, their findings are generally viewed as hypothesis 
generating, rather than hypothesis confirming. Indeed, there appears to be a lack of quantitative 
evidence regarding some of the on the barriers and facilitators of medication adherence reported 
in abundance throughout the qualitative studies – particularly those related to healthcare provider 
(e.g., therapeutic alliance) and healthcare system (e.g. ease of access to healthcare). Some of these 
factors will be explored quantitatively during this thesis. 
2.6 Topic 3: Adjusting Findings of Randomised Controlled Trials 
for Medication Non-Adherence: The Use of Randomisation-Based 
Efficacy Estimators 
2.6.1 Search Results 
The initial search, performed on 18/04/2016, yielded 32 papers (Table 2.3). Two duplicates 
were removed, leaving 30 unique papers. Due to the low number of papers, all abstracts were 
reviewed. One paper was retained, with the other 29 excluded for a variety of reasons (study 
protocol, n = 2; not a trial of a medication, n = 20; trial did not adjust findings for adherence 
using a randomisation-respecting approach; n = 7) (Figure 2.5). 
2.6.2 Findings 
The search led to the retention of one paper. This reported a randomised controlled trial 
comparing the efficacy of two different antidepressants. (Wiles et al., 2014) In this paper, a 
structural mean modelling approach was used to generate adherence-adjusted estimates of the 
efficacy of one antidepressant compared to another, while maintaining a comparison of groups 
as randomised. The paper highlights, during its discussion section, the appropriateness of these 
methods for non-inferiority trials. 
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The implication from this review is clear: there are few randomised controlled trials of medicinal 
products that are adjusting for treatment adherence using randomisation-based efficacy 
estimators. There is a need to investigate the implementation of these approaches using real 
datasets. There is also a specific need to investigate how these approaches can be used for non-
inferiority trials. 
An additional review was undertaken that relaxed the focus on papers describing randomised 
controlled trials of medicinal products, therefore allowing trials of other interventions to be 
considered. This search yielded 34 unique papers from 45 papers initially found, which were 
reduced to 11 following an assessment of the full papers. These studies reported a variety of 
interventions, including music education (Cogo-Moreira et al., 2013), exercise (Mock et al., 2005, 
Jago et al., 2006, Tilbrook et al., 2014), family training programmes (Stanger et al., 2011, Kogan 
et al., 2016), housing-based interventions (Osypuk et al., 2012, Nguyen et al., 2013), and 
psychological interventions (Dunn et al., 2003, Knox et al., 2014, Picardi et al., 2016). These 
papers all used an instrumental variables approach, primarily using the term “complier average 
causal effect”. That these analytical approaches are more frequently used in trials of complex 
interventions is surprising, given some of the assumptions required (to be described in Chapter 
6). 
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Table 2.3: Findings from the initial search for Topic 3 
# Searches (conducted on 18/04/2016) Results 
1 (MEDICINE or MEDICATION or DRUG or MEDICINAL).ab. 1048176 
2 
(ADHERENCE or COMPLIANCE or CONCORDANCE or 
PERSISTENCE or INITIATION or IMPLEMENTATION or 
DISCONTINUATION).ab. 
534564 
3 1 and 2 72854 
4 
(CAUSAL INFERENCE or PRINCIPAL STRATIFICATION or 
STRUCTURAL MEAN MODEL or RANDOMISATION BASED 
EFFICACY ESTIMATOR or INSTRUMENTAL VARIABLE or 
INSTRUMENTAL VARIABLES or COMPLIER AVERAGE CAUSAL 
EFFECT or COMPLIER-AVERAGE CAUSAL EFFECT or CACE or 
SMM or RANDOMISATION-BASED EFFICACY ESTIMATOR or 
ADHERENCE-ADJUSTED or RBEE or STRUCTURAL or 
RANDOMIZATION-BASED EFFICACY ESTIMATOR or 
RANDOMIZATION BASED EFFICACY ESTIMATOR).af. 
487509 
5 3 and 4 1126 
6 limit 5 to (English language and humans and randomized controlled trial) 32 
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Figure 2.5: Diagram illustrating the flow of papers from identification to review (Topic 3) 
 
 
2.7 Review of Top Medical Journals 
2.7.1 Search Results 
Given the single paper retained for the previous topic, a review of all randomised controlled trials 
of medicinal products, published in top medical journals within the past year, provides an 
additional exploration of the extent that randomised controlled trials (and indeed, those 
published in high ranking medical journals) are using these cutting-edge techniques. 
Topic 3
Papers identified
N = 32
Unique papers
n = 30
Abstracts retained
n = 1
Full papers retained
n = 1
Excluded N = 2
- Duplicates n = 2
Excluded N = 29
- Study protocol n = 2
- Not a drug trial n = 20
- Not reporting adherence adjustment with 
a randomisation respecting method n = 7
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A total of 105 papers were identified using the search strategy above, which was run on 
18/04/2016 (Table 2.4). Once duplicates were identified and removed, 68 papers remained. An 
additional 22 papers were excluded, with 18 describing non-drug trials (either trials of surgical or 
behavioural interventions), and four describing Phase I dose-escalation studies. There were 
therefore 46 unique and relevant papers included in this section of the review (Figure 2.6). 
Table 2.4: Findings from the initial search for the review of top medical journals 
# Searches (conducted on 18/04/2016) Results 
1 (MEDICINE or MEDICATION or DRUG or MEDICINAL).ab. 1048176 
2 limit 1 to (english language and humans and yr="2015") 51544 
3 
(The Lancet or The British Medical Journal or The Journal of the American 
Medical Association or The New England Journal of Medicine or Lancet or 
NEJM or BMJ or JAMA or British Medical Journal or The BMJ).jn. 
398974 
4 1 and 2 and 3 264 
5 limit 4 to randomized controlled trial 105 
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Figure 2.6: Diagram illustrating the flow of papers from identification to review (Top Medical 
Journals) 
 
2.7.2 Findings 
From the 46 full papers retained, 18 were from The Lancet, 17 from The New England Journal 
of Medicine, nine from The Journal of the American Medical Association, and two from The 
British Medical Journal.  
2.7.2.1 Papers that mention medication adherence 
Seven papers made no mention of medication adherence in relation to their trial. (Kereiakes et 
al., 2015, Ruff et al., 2015) There was no consistent reason why adherence was not mentioned 
in these papers. For some, treatment was administered directly by a healthcare professional, 
(Langendonk et al., 2015, Rahman et al., 2015, Saver et al., 2015) and it might have been 
assumed (or implied) that all participants therefore received their randomised treatment. Other 
Top Medical Journals
Papers identified
N = 105
Unique papers
n = 68
Full papers retained
n = 46
Excluded N = 37
- Duplicates n = 37
Excluded N = 22
- Non-drug trials n = 18
- Phase I study n = 4
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paper described trials of conditions such as glaucoma and hypertension, conditions for which 
medication adherence is a highly discussed topic, and also for which treatments have to be taken 
long-term and self-administered. (Garway-Heath et al., 2015, Williams et al., 2015) 
2.7.2.2 Description of type of measures 
For the remaining 39 that mentioned medication adherence, 24 papers did not explicitly state 
how it was measured. (Robert et al., 2015, Scott et al., 2015) While the majority of these went on 
to report adherence levels, or report some adherence-adjusted trial analysis, two of these papers 
did not. (Hézode et al., 2015, Kuyken et al., 2015) The remaining 22 papers either reported 
adherence without adjusting any analysis for it (Cannon et al., 2015, Postow et al., 2015, Robert 
et al., 2015, Wyles et al., 2015) or performed some form of adjusted analysis. Fifteen papers 
reported how medication adherence was ascertained, doing so in a variety of ways including direct 
observations (Desai et al., 2015, Krug et al., 2015), self-reports either via diaries (Leder et al., 
2015) or at follow-up visits, (Azizi et al., 2015, Kastelien et al., 2015, Khanna et al., 2015, Tshefu 
et al., 2015), pill counts, (Gagyor et al., 2015, Marrazzo et al., 2015) electronic monitoring, 
(Donny et al., 2015), pharmacy records, (Wechsler et al., 2015), biological samples, (Dawson et 
al., 2015) or using multiple types of measures (Smith et al., 2015) 
2.7.2.3 Use of adjusted analysis 
Twenty-four papers reported statistical analysis that adjusted for non-adherence in some way. 
The terminology used varied substantially between papers, with seven referring to their analysis 
as a “safety” analysis, where six of these excluded participants who had not initiated treatment 
(Dawson et al., 2015, DeVincenzo et al., 2015, Gerding et al., 2015, Gheorghiade et al., 2015, 
Grainger et al., 2015, Robert et al., 2015), and the remaining using their safety analysis to analyse 
participants in the groups corresponding to the treatment received (regardless of the treatment 
to which they were randomised). (Swain et al., 2015) Other studies reported an “efficacy” analysis 
that excluded participants who did not initiate treatment (Davies et al., 2015, Kastelein et al., 
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2015, Raal et al., 2015, Raal et al., 2015) or a “modified intention to treat” analysis. (Gaudet et 
al., 2015, Sax et al., 2015, Wainwright et al., 2015, Zinman et al., 2015) For two studies, no 
specific terminology was used, but the primary analysis excluded participants who did not initiate 
treatment. (Bachelez et al., 2015, Bakris et al., 2015) A “per-protocol” analysis was reported in 
four of the studies, all of which defined their own adherence populations. (Desai et al., 2015, 
Gnat et al., 2015, Lee et al., 2015, Tshefu et al., 2015) Two papers reported “intention-to-treat” 
analyses that excluded participants who did not receive the intervention. (Cung et al., 2015, Scott 
et al., 2015) All of the above analyses make post-randomisation exclusions or adjustments. As I 
will describe in Chapter 6, this risks inducing selection bias unless it is plausible that those 
excluded or switched are equivalent to those who remain. One paper from the 46 reviewed 
(2.2%) adjusted trial findings for non-adherence using a randomisation-respecting approach. 
(Schlumberger et al., 2015) This paper used a rank-preserving structural accelerated failure time 
model to account for treatment switches in a time-to-event analysis. This paper was not found in 
the search in Topic 3.  
While this paper described treatment switching that followed processes in the study protocol, 
and was investigator-led (rather than non-adherence in terms of participants not receiving their 
allocated treatment as intended), it did include a randomisation-respecting analytical approach 
used to circumvent selection bias through departures from randomised treatment. The key term 
used in this paper was “crossover bias”. To ensure that key papers were not missed during topic 
3, I re-ran the search and included this term. Eleven papers were found. However, all but one 
described investigator-led treatment switching. The one paper that was investigating non-
adherence, (Kubo et al., 2015) did so using the same rank-preserving structural accelerated 
failure time model as Schlumberger et al.  
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2.7.2.4 Summary 
This search of all randomised controlled trials of medicinal intervention published in top medical 
journals in the past year demonstrates a lack of consistency with regards to the extent to which 
descriptions of medication adherence are given. Analytical approaches either did not account for 
non-adherence or were not randomisation respecting in 98% of papers reviewed, and in those 
that did account for non-adherence there was a lack of consistency around the description of this 
analysis. The one paper that used a randomisation-respecting approach to adjust for departures 
from randomisation treatment was not strictly accounting for non-adherence, but rather protocol-
approved treatment switching that was instigated by the clinical team. In summary, This search, 
as well as that carried out in the previous section (Topic 3), demonstrate that for randomised 
controlled trials of medicinal products, randomisation-based efficacy estimators are a rare 
feature. More work is needed to investigate the implementation and presentation of these 
analytical approaches to medical researchers.  
2.8 AMSTAR checklist scores and implications 
Using the AMSTAR checklist to score these reviews, scores of 5/11 were obtained (where 11 
was deemed a systematic review of the highest methodological quality). The key areas where 
these rapid reviews were negatively marked were: 
 No duplicate study entry or extraction: no resource was available to have duplicate study 
entry or data extraction for any of the reviews; 
 Comprehensive literature search was not performed (i.e. only one database): while this is 
the case, recent work by Hartling et al., 2016 has demonstrated that the vast majority of 
relevant studies appear within a limited number of databases, and restricting the number 
looked at rarely altered conclusions or resulted in systematic bias; 
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 List of excluded studies were not included: while this is also the case, reasons for 
excluding studies were documented throughout. 
Two items were deemed not applicable, as they appeared focused on a systematic review asking 
a clinical question, rather than methodological literature reviews (assessments of publication bias 
and conflicts of interest). 
Despite this, the literature reviews provide a broad overview of the methodological areas, key 
authors were identified a priori, with searches re-run to screen for their works, and to ensure key 
papers were not missed during Topic 3, I re-ran the search using a term newly discovered during 
my review of randomised controlled trials from top medical journals. 
2.9 Summary 
These literature reviews have identified some key gaps and deficiencies that will be explored 
during this thesis: 
 Adherence to treatments for short-term or acute conditions appears to be an under 
researched area, with literature tending to focus on long-term conditions. During my 
thesis, I intend to explore both, and particularly will aim to see how certain paradigms 
that have been developed for long-term conditions fit with short-term conditions. 
 Electronic monitoring is a popular method for obtaining data on medication adherence. 
Despite this, there seems to be an overreliance on simple summary measure. I plan to 
use advanced statistical modelling techniques to exploit the richness of data obtained 
from electronic monitors. 
 Bland-Altman plots and limits of agreement are seldom used to assess agreement 
between different types of adherence measures. I will investigate their use, as well as the 
use of other agreement techniques and plotting methods during this thesis. 
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 Approaches for determining risk factors for disagreement between measures will be 
considered throughout this thesis, as will methods for deriving calibrated measure of 
adherence when multiple sources are available 
 Determining risk factors for non-adherence will be considered for both short and long-
term conditions. The value of separating adherence out into different processes (rather 
than modelling it as a single summary measure) will be explored. 
 Modelling approaches that aim to quantify the extent of therapeutic alliance, or influence 
that clinicians have on a patient’s adherence, will be investigated. 
 The implementation of randomisation-based efficacy estimators to adjust randomised 
controlled trials will be investigated. This work will consider these approaches for both 
placebo-controlled superiority trials and non-inferiority trials with two active treatments. 
The uses and limitations of these approaches using real world data, as well as effective 
ways of communicating the approaches and their findings, will be of primary focus. 
The following Chapter will describe the data used to address the abovementioned gaps and 
deficiencies.  
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CHAPTER 3: Description of Data Sources 
3.1 Introduction 
The aim of this thesis is to investigate various methodological challenges that are encountered 
when studying medication adherence in clinical research. It therefore follows from this aim that 
data from real clinical research will form the basis of the illustration of these challenges. Datasets 
from five clinical studies, three of which are from the same research project, will be used 
throughout this thesis. It is my intention to exemplify and discuss some of the methodological 
challenges that are common when studying medication adherence and how they differ for various 
study designs, for example randomised controlled trials and observational studies, and for 
different clinical conditions, for example short-term or acute conditions and long-term or chronic 
conditions.  
The remainder of this Chapter will provide an introduction to the different research projects and 
datasets used throughout this thesis. An outline of the studies will be given, the method/s used to 
record adherence to study medication will be described, and the contribution that the dataset 
makes to the thesis will be specified. 
3.2 GRACE 
Acute lower respiratory tract infection (LRTI) is a short-term, largely self-limiting condition that 
accounts for approximately one fifth of all consultations in primary care. (Currie et al., 2014) The 
majority of patients who consult with this condition are prescribed antibiotics, though the 
appropriateness of these prescriptions is often questionable. (Butler et al., 2009) Use (and 
overuse) of antibiotics has been shown to be associated with the development of antibiotic 
resistance, (Goossens et al., 2005, Costelloe et al., 2010) the consequences of which involve 
widespread deaths from common infections and minor illness that were previously treatable. 
(World Health Organization, 2014) However, adherence to antibiotics in primary care is often 
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poor. (Kardas et al., 2005, Francis et al., 2012) Poor adherence to antibiotics, in those who are 
prescribed, them wastes healthcare resources, could negatively impact on clinical outcomes (e.g. 
slow recovery or increase the risk of complications), and for those in whom they are needed 
could also result in the infecting bacteria being exposed to suboptimal levels of antibiotic; creating 
an environment that promotes antibiotic resistance. (Vrijens and Urquhart, 2005) 
Genomics to combat Resistance against Antibiotics in Community-acquired LRTI (CA-LRTI) 
in Europe (GRACE) was a European Union Framework Programme 6 funded network of 
excellence. The project aimed to combat resistance to antibiotics in CA-LRTI by integrating and 
co-ordinating the activities of clinicians and scientists from 15 European countries (Figure 3.1). 
Figure 3.1: Map of Europe indicating primary care networks involved in the GRACE project 
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The project was divided into several work packages (WPs), with three of these containing clinical 
studies. These studies are described in chronological order below. For completeness, Table 3.1 
briefly outlines the 12 different WPs included in the project. 
Table 3.1: Outline of GRACE work packages 
Work package Purpose 
1 Project management 
2 Manage data and outputs from all work packages 
3 
i.) Develop novel rapid genome-based diagnostic tests for the detection of 
pathogens; ii.) Establish a European repository of specimens and strains 
linked to a database including microbial and patient information  
4 
i.) Undertake a large-scale genome wide screen for human susceptibility 
genes affecting severe CA-LRTI; ii.) Use human genomic data to devise 
the potential genetic risk profile; iii.) Determine whether the human 
genetic risk factors identified in GRACE interact with each other or with 
key microbial genetic or other environmental risk factor 
5 
Develop and test novel molecular techniques based on amplification-based 
detection assays 
6 
i.) Correlate antibiotic resistance, virulence characteristics and 
pneumococcal genotype to severity of CA-LRTI; ii.) Perform comparative 
pneumococcal genomics with micro-array technology 
7 
i.) Investigate the distribution, transmission and evolution of antibiotic 
resistance; ii.) Assess risk factors for infection with resistant H. influenza; 
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Work package Purpose 
iii.) Quantify the relationship between the exposure to antibiotics and both 
the distribution of resistance elements and their population structure 
8* 
Describe current presentation, investigation, treatment and outcomes of 
CA-LRTI and analyse the determinants of antibiotic use in 14 primary 
care networks across 12 European countries, using qualitative and 
quantitative approaches 
9* 
Develop models to i.) Differentiate viral from bacterial infections; ii.) 
Detect patients with pneumonia; iii.) Identify patients at risk for adverse 
outcomes including severe and prolonged illness 
10* 
Develop and conduct i.) A randomised placebo-controlled double-blind 
trial with patients as unit of randomisation to study the clinical effectiveness 
of antibiotics in CA-LRTI; ii.) A randomised controlled trial with primary 
care clinicians’ practices as unit of randomisation to study improvements of 
antibiotic prescribing behaviour 
11 
i.) Study the economics of molecular diagnostics in CA-LRTI; ii.) Model 
the macroeconomic impact of resistance and policies to contain it; iii.) 
Model the cost-effectiveness of the management strategies developed in the 
observational studies; iv.) Conduct economic evaluations in parallel with 
the intervention studies 
12 
Spread knowledge, raise professional and public awareness, and provide 
training on the containment of antimicrobial resistance in CA-LRTI 
 *Contained clinical studies used throughout this thesis 
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3.2.1 GRACE WP8 observational study 
This was a prospective observational study, conducted between 2006 and 2007, that aimed to 
describe the presentation, management, and outcomes of patients consulting in primary care with 
an acute cough or signs suggestive of a LRTI. (Butler et al., 2009) 
Patients were eligible for the study if they were aged 18 years or older, consulting with an illness 
where an acute or worsened cough was the main symptom (or their clinical presentation 
suggested a LRTI), had been unwell for no longer than 28 days, were consulting for the first time 
with their particular illness episode, were seen within normal working hours, had not previously 
participated in the study, were able to fill out study materials, had provided written informed 
consent, and were considered immunocompetent. 
Recruited participants had their clinical history, presenting signs and symptoms, and 
management recorded on a case report form (CRF), and were then asked to complete a diary 
for up to 28 days. The diary contained daily information regarding the severity of symptoms and 
the use of medication. Adherence data were therefore obtained via self-report (Figure 3.2). 
A description of the variables considered can be found in Appendix I. 
Figure 3.2: Example of self-report medication use questions taken from the GRACE WP8 diary 
 
The data obtained from GRACE WP8 are from an observational study. They are therefore more 
likely to reflect the behaviour of patients under normal circumstances. Participants in 
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randomised controlled trials tend to receive considerably more information about their 
treatment, are more closely monitored, and tend to have higher motivations for participation. 
Their adherence levels may therefore not reflect that which is seen in routine practice. 
These data will be used to investigate the determinants of adherence to antibiotics for this 
condition, and will be useful in comparing adherence levels and determinants across different 
study types for the same condition, with observational studies likely to more closely reflect 
practice than randomised controlled trials. 
3.2.2 GRACE WP9 observational study 
Similar to WP8, GRACE WP9 was also a prospective observational study. It was conducted 
between 2007 and 2010, and aimed to investigate the aetiology, diagnosis, and prognosis of 
LRTI. (van Vugt et al., 2013) The key difference between this study and the WP8 observational 
study is that participants in this study provided various biological samples alongside being 
observed over time. 
Eligibility was similar to that in GRACE WP8, with the addition of patients having not been on 
antibiotic treatment in the previous month and not pregnant at the point of recruitment. 
Data collection methods were similar to GRACE WP8, and adherence was captured via self-
report. The rationale for including these data in this thesis are therefore the same as for the 
previous study. 
A description of the variables considered can be found in Appendix I. 
While participants in GRACE WP8 and WP9 could be prescribed any treatment for their 
illness, the analysis in this thesis will be restricted to those that were prescribed amoxicillin for 
immediate use. Amoxicillin is the recommended first-line choice of antibiotic for LRTI in the 
European Union, and consequently the most frequently prescribed. By focussing on this 
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treatment, it allows for the investigation of the impact of the dose, frequency, and duration 
without being confounded by type of antibiotic prescribed. This thesis does not consider 
adherence to delayed prescriptions, focussing solely on amoxicillin prescribed for immediate 
use. While a delayed prescription is also a legitimate prescribing strategy, adherence under this 
strategy is ambiguous. Delay instructions can often be vague (for example, “here is a prescription 
if you get any worse”), and delayed prescriptions are often issued with the intention that the 
patient would never actually take their treatment. This is in contrast with a prescription issued 
for immediate use, where the working assumption is that the clinician intended that the treatment 
would be taken as prescribed. 
GRACE WP10a placebo-controlled trial 
The aim of GRACE WP10a was to investigate the benefits and harm of amoxicillin in acute 
uncomplicated community-acquired LRTI. To achieve this, a randomised placebo-controlled 
trial was conducted between 2007 and 2010, nested within GRACE WP9. (Little et al., 2013) 
Patients were eligible to participate in the trial if they met the eligibility criteria for WP9, and in 
addition were not allergic to penicillin (or have a contra-indication for amoxicillin because of a 
major interaction with other medication), and their history/physical examination was not 
suggestive of community-acquired pneumonia (see Table 3.2 for a comparison of eligible 
criteria). 
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Table 3.2: Comparison of eligibility criteria for the GRACE WP8, WP9, and WP10a studies 
Eligibility criteria WP8 WP9 WP10a 
Aged 18 years or over x x x 
An illness where an acute or worsened cough is the main or 
dominant symptom, or a clinical presentation suggesting LRTI, 
< 28 days duration 
x x x 
First consultation for this illness episode x x x 
Seen within normal consulting hours x   
First time in the study x x x 
Able to fill out study materials x x x 
Written consent to participate x x x 
Immunocompetent x x x 
Not been on antibiotic treatment in previous month  x x 
Not pregnant  x x 
Allergic to penicillin or have a contra-indication for amoxicillin 
because of a major interaction with other medication 
  x 
History/physical examination suggestive of community acquired 
pneumonia (CAP)? 
  x 
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Randomised participants received a prescription for amoxicillin, to be taken as two 500mg tablets 
three times a day for seven days, or a placebo identical in appearance, taste and texture. Other 
data collection methods were similar to GRACE WP8 and WP9. 
A description of the variables considered can be found in Appendix I. 
While data collection methods were mostly similar to GRACE WP8 and WP9, adherence to 
trial medication in WP10a was also recorded via tablet counts at the end of the study and during 
telephone follow-ups, with the latter generally conducted in participants who had not returned a 
diary (i.e. after the 28 day follow-up period). 
The data from GRACE WP10a will contribute to this thesis in many ways. Capturing adherence 
using multiple types of measures allows for a comparison of the different types, and levels of 
agreement between types to be estimated. Using other information on the trial participants, 
variables that predict disagreement can also be investigated. The participants allocated to the 
amoxicillin group can be used to explore the determinants of adherence to amoxicillin. Finally, 
data from participants in the whole trial can also be used to investigate the use of randomisation-
based efficacy estimators for adjusting trial findings for treatment non-adherence. 
CODA 
Ulcerative Colitis (UC) is a chronic inflammatory disease that affects the internal lining of the 
colonic mucosa and rectum, with patients exhibiting symptoms such as abdominal pain, blood 
and pus in stools, diarrhoea, fever, rectal pain and weight loss. The estimated prevalence of UC 
is 8 to 246 cases per 100,000 per year, and is most commonly seen in the populations of Northern 
Europe and North America. The disease is often relapse-remitting, with patients experiencing 
few or no symptoms between systematic flare ups. (Ardizzone, 2003) Coated formulations of 
mesalazine (Asacol®) have been demonstrated in many trials to prevent relapses in patients who 
have achieved remission. (Sutherland and MacDonald, 2006) Treatment is often prescribed in 
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divided daily doses (e.g. two or three times daily dosing schedules (BD, TDS)), (BNF Online, 
2013) with adherence and treatment success suffering as a result. (Shale and Riley, 2003, D’IncÀ 
et al., 2008) There has thus been an increasing interest in evaluating once-daily (OD) dosing of 
mesalazine. (Hussain et al., 2001, Kane, 2006, Gandia et al., 2007, Flourie et al., 2013) 
The Colitis Once Daily Asacol (CODA) study assessed the efficacy and safety of OD dosing with 
mesalazine versus TDS dosing over a 12-month period for patients in remission with UC. 
(Hawthorne et al., 2012) Patients were eligible to take part in the study as long as they were in 
remission with UC and on maintenance therapy with mesalazine, sulfasalazine, olsalazine, or 
balsalazide for at least 4 weeks, but who had had at least one relapse within the previous two 
years. Patients had to be aged over 18, if female to be taking adequate contraception (if otherwise 
able to conceive), and able to give informed consent. Patients were excluded if they had Crohn’s 
disease; symptoms of active colitis; a modified Baron score at sigmoidoscopy of 2 or 3; used 
enema or suppository therapy for UC in the past 4 weeks; had started or altered the dose of 
azathioprine or 6-mercaptopurine in the past 3 months (these drugs were permitted if in stable 
dosage over that period of time); had intolerance to mesalazine; known HIV infection; significant 
renal or hepatic impairment; or other medical or psychiatric disorder (including alcohol 
dependence) that in the opinion of the investigator would affect participation in the study; or 
females if pregnant or lactating. 
Randomised participants were given 800mg Asacol tablets and told to take either three tablets 
once daily (OD) or in three divided doses (TDS) for 12-months or until relapse (whichever came 
first). Participants attended trial follow-up visits at six weeks, six months, and 12 months after 
randomisation, or in the event of a suspected relapse. In addition, participants were also 
contacted via telephone at three and nine months. 
A description of the variables considered can be found in Appendix II. 
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The study found that the OD regimen was no worse than TDS in terms of clinical relapse. 
Although this was attributed to better adherence among the participants allocated to the OD 
regimen, the main trial captured adherence using self-report and tablet counts at clinic visits, two 
types of measures with several known limitations. Detailed measures of adherence in this setting 
were also lacking from previous trials of patients in remission with UC. Foreseeing this as a 
problem, a sub study was run alongside the main study. The aim of this sub study was to evaluate 
the impact of an OD dosing regimen on treatment adherence using electronic monitors (namely, 
the Medication Event Monitoring System, or MEMS), a more intensive monitoring process to 
capture adherence than that had been used previously (Figure 3.3). 
Figure 3.3: Example of a MEMS container 
 
The data from the CODA study will contribute to this thesis in several ways. The long-term 
chronic condition of UC will provide a contrast to the short-term nature of acute LRTI. 
Adherence was captured using self-report and tablet counts during the main study, and also 
electronic monitoring for the substudy. Therefore a subgroup of CODA participants will have 
adherence measured in three different ways. 
Capturing adherence using electronic monitoring allows for each dosing event to be recorded. 
This provides very rich data over a 12-month period, and allows for longitudinal modelling and 
the exploration and testing of behavioural aspects of medication taking. 
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The main study was also designed to assess the non-inferiority of the OD regimen over the TDS 
regimen on the rate of relapse over the 12-month follow-up period. The data will therefore be 
used to investigate different approaches to adjusting trial findings for non-adherence – particularly 
in the case of the CODA study exploiting the non-inferiority design, use of an active control 
group, and the similar nature of the treatment groups. 
ZICE 
Bone metastases cause major morbidity in metastatic breast cancer. The introduction of 
bisphosphonate therapy has led to a substantial reduction in the incidence of skeletal-related 
events for this clinical condition, (Wong et al., 2012) and in particular zoledronic acid, which has 
been shown to lower skeletal morbidity rates and risk of skeletal complications compared to 
standard therapies. (Rosen et al., 2003) 
However, zoledronic acid is given by four weekly intravenous infusion, which may be 
inconvenient for patients who may not otherwise need to attend hospital. An alternative 
bisphosphonate, ibandronic acid, is available in both intravenous and oral formulations. 
Alongside the potential for reducing inconvenience, a self-administered oral therapy is likely to 
incur considerably less healthcare costs compared to a therapy administered via intravenous in 
hospital. 
The Zoledronate versus Ibandronate Comparative Evaluation (ZICE) study was a randomised 
phase 3 trial designed to assess the noninferiority of oral ibandronic acid compared with 
intravenous zoledronic acid in preventing skeletal-related events in an unselected UK population 
of patients with breast cancer metastatic to bone. (Barrett-Lee et al., 2014) 
Randomised participants were either assigned to receive intravenous zoledronic acid (4mg over 
a minimum of 15 minutes in at least 100mL of saline) every four weeks for 96 weeks or one 
50mg tablet of ibandronic acid to be taken daily for 96 weeks. Following randomisation, 
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participants were assessed at three to four week intervals up to week 12, and every 12 weeks up 
to 96 weeks thereafter. Following week 96, participants were assessed every year up to five years 
post-randomisation. Adherence to study medication was noted by the treating clinician at interim 
and 12-weekly visits (clinician / self-report). 
The primary outcome in the main ZICE study was based on the time and frequency of skeletal-
related events (SREs) over the first 96 weeks post-randomisation. For illustrative purposes, this 
thesis will focus on a simplified version of this outcome, specifically the proportion of participants 
experiencing a skeletal-related event during the first 12 months of the study. 
A description of the variables considered can be found in Appendix III. 
The original study found that oral ibandronic acid was inferior to intravenous zoledronic acid, 
though side effect profiles were similar in both groups and the oral treatment was generally more 
convenient. 
Like the CODA study, data from the ZICE study allows for the assessment of adherence to a 
long-term condition and was designed to assess non-inferiority. However, unlike CODA, ZICE 
has two very contrasting treatment arms, comparing a four-weekly intravenous therapy 
administered in hospital by a clinician to a daily oral therapy self-administered at home. This 
study will mainly be used during this thesis to investigate different approaches to adjusting trial 
findings for non-adherence. 
Summary 
This Chapter described the data sources that will be used throughout the following three 
Chapters, including a justification for the study, a description of the data flow, and the rationale 
for using these particular studies throughout this thesis.  This concludes the background Chapters 
that have laid out the motivation of the thesis, problems that will be addressed, and data sources 
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that will be used. The next three Chapters will each focus on distinct methodological challenges 
encountered when studying medication adherence in clinical research, providing the reader with 
detail on the methodologies used, and using the data sources to illustrate how the proposed 
methods work on data from real clinical research studies.  
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CHAPTER 4: Measuring Medication Adherence in 
Clinical Research: Correlation, Agreement, and 
Calibration Techniques 
4.1 Introduction 
When clinical research involves determining the safety and efficacy of treatments intended for 
human use, the goal is to conduct this research as rigorously as possible, while balancing this 
within the confines of limited resources. In clinical research aiming to generalise findings to a 
real world setting, there is an additional aspiration of ensuring that considerations have been 
made related to the usefulness and implementation of these findings in practice (e.g. outcomes 
have been selected that are of importance to patients and clinicians). (Loudon et al, 2015) The 
study of medication adherence within clinical research does not escape these restrictions, and as 
such there is a reliance on methods for measuring adherence that are cheap, minimise participant 
burden, and can be replicated in a real world setting, if required. (Lam and Fresco, 2015) The 
consequence of this is that the majority of medication adherence measures used in clinical 
research are indirect. That is, they rely on unverifiable assumptions that vary in their degree of 
plausibility, depending on context, and consequently multiple modes of measurement are often 
used in clinical research. Gaining an understanding of different types of measures of medication 
adherence, their advantages and disadvantages, how to compare them (when multiple modes are 
available), and what to do when disagreement occurs, is therefore an area of great importance in 
this field. 
The aims of this Chapter are to compare several methods commonly used for measuring 
medication adherence in clinical research, using a variety of method-comparison techniques. I 
will demonstrate the potential of advanced statistical modelling techniques for modelling patterns 
in electronically monitored medication adherence over time. Moving beyond method-
comparison, I will also investigate the predictors of disagreement between medication adherence 
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measures, and develop calibration techniques to arrive at summary measures of medication 
adherence that incorporates knowledge and uncertainty from the different types of measures. 
To meet these aims, this Chapter will draw on data from the CODA and GRACE WP10a 
studies, to highlight the differences and similarities between medication given for long-term and 
short-term conditions. 
4.2 Methods 
4.2.1 Adherence definitions, summary measures, and assumptions 
As described during Chapter 3, adherence to medication during the CODA study was monitored 
via self-report and tablet counts at study follow-up visits, and electronically via the MEMs. 
Participants were asked about their adherence levels (i.e. whether or not they thought they had 
taken their study tablets as prescribed at least 90% of the time) and the ease of medication taking 
(very easy, fairly easy, fairly difficult or very difficult to remember to take their medication). These 
provide retrospective accounts of adherence. For analysis purposes, these reports are taken at 
face value (i.e. it was assumed that participants reported their levels of adherence accurately and 
had perfect recall in the time under consideration). Tablet counts were performed by trained 
research nurses at each trial follow-up visit. It was assumed that the difference between the 
number of tablets participants started with and the amount remaining at each follow-up visit 
equated to the amount taken during the time interval. For the purposes of reporting, adherence 
measured using tablet counts was reported as the number of tablets taken expressed as the 
percentage of correct number of tablets taken. The date and time of bottle cap openings were 
electronically recorded using the MEMS, with data uploaded onto the study database at each trial 
follow-up visit. Calculating adherence using the MEMS assumed that the correct number of 
tablets were removed and consumed each time the bottle was opened. Adherence was reported 
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as the percentage of days that a participant adhered to their allocated regimen (i.e. the percentage 
of days that a participant opened their bottle the correct number of times). 
The GRACE WP10a study measured adherence to allocated medication via self-reported 
diaries, tablet counts, and self-reports collected over the telephone. Using their daily symptom 
diary, participants prospectively recorded whether or not they took their study medication on a 
given day, and whether they took their study medication according to the instructions. 
Participants for whom a diary was not returned were asked to (retrospectively) state the number 
of days that they took their study medication. This information was collected via telephone 
interviews. Participants were also instructed to return their study medication bottles, complete 
with any unused medication, at the end of the trial. The number of tablets returned was recorded 
by members of the research team. Participants were given 42 tablets in total (two 500mg tablets, 
to be taken three times a day for seven days). 
Adherence to study medication was defined as the percentage of the correct number of tablets 
taken during the first seven days of the follow-up period (i.e. the period for which the medication 
was prescribed). For each of the three types of measures, a binary definition was also created, 
with a cut-off at 100% (i.e. took all prescribed tablets during the first seven days of the follow-up 
period). 
Where participants indicated that they had taken medication on a particular day, in the absence 
of information to the contrary (e.g. stating that they only took one tablet three times a day instead 
of two tablets), to calculate adherence, an assumption was made that a participant consumed all 
study medication as instructed. Where medication bottles were returned, it was assumed that the 
difference between the number of tablets prescribed and the number returned equated to the 
number of tablets consumed. It was also assumed that all tablets were consumed during the first 
seven days of the follow-up period. Where a short questionnaire or telephone call was 
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conducted, it was assumed that the correct numbers of tablets were taken for the number of days 
medication was reportedly taken. Table 4.1 provides a summary of the types of measures used 
and assumptions made across the two studies. 
Table 4.1: Types of medication adherence measures available across the CODA and GRACE 
studies 
Type of 
measure 
Data collection 
intensity 
Measured 
in CODA 
Measured 
in 
GRACE 
Assumptions 
Self-report at 
clinic visits 
Clinic visits (6 
weeks, 6 
months, 12 
months) 
  
Accurate reporting. Perfect 
recall. Self-reported 
diary 
Daily   
Self-reported 
telephone 
At the end of 
the study 
  
Tablet counts Clinic visits   
All tablets not returned were 
consumed. Consumption was 
in line with prescribed 
regimen. 
Electronic 
monitoring 
Each dosing 
event 
  
Dosing event equates to 
correct number of tablets 
being consumed. 
 
Quantitative measures are reported as means with associated standard deviations, medians, and 
minimum / maximum values. Binary measures are reported as frequencies and percentages. 
4.2.2 Longitudinal modelling of electronic monitoring data 
Using the data obtained from the MEMS caps, medication adherence was modelled over time 
by fitting a two-level generalised linear (logistic) mixed effects model, with daily adherence 
indicators nested within participants. This is an extension to the generalised linear model, 
(McCullagh and Nelder, 1989) and is a useful approach for modelling discrete repeated 
measures. (Verbeke, 2005) The general model formula is given by 𝑦 = 𝑋𝛽 + 𝑍𝛾 + 𝜖, where y 
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is the outcome variable, X represents the predictor variables, Z represents the random effects 
(participants for whom multiple daily adherence indicators are available), and ɛ are the residuals. 
A logit link function (𝑙𝑜𝑔 (
𝑝
1−𝑝
)) is applied to account for the binary nature of the outcome 
variable. Alternatives to this approach would involve summarising adherence over the time 
period, or not accounting for the correlated nature of responses within individuals. For the 
former, information regarding the evolution of adherence over time (and behavioural patterns 
over time) would be lost. For the latter, assuming observations were independent would risk 
calculating standard errors that were artificially narrow, and hence drawing erroneous conclusions 
regarding the width of the confidence intervals around model estimates. For these models, a 
participant was assumed to have adhered to their allocated regimen on a given day if they opened 
their cap the required number of times (once for the OD group and three times for the TDS 
group). Non-linear patterns of adherence over time were accounted for using B-splines. The 
model also accounted for different participant adherence patterns by fitting B-spline estimates of 
a time-varying mean with random coefficients, thereby allowing each participant to have their 
own individual curve that was not restricted by the overall fixed effect curve. B-splines are 
piecewise polynomials with interior knots (or turning points) linking each polynomial function 
via a series of linear combinations. (Marsh and Cormier, 2001) An accessible mathematical 
formulation of B-splines has been presented previously. (Weisstein) B-splines provide a flexible 
and arguably more interpretable approach to accounting for non-linear effects in regression 
models. Alternative approaches involving making linearity assumptions or fitting polynomial 
functions (e.g. modelling time as a quadratic or cubic function, or using fractional polynomial 
functions (Royston and Altman, 1994)). However, the drawback of these is poorer model fit, 
implausibility of assumptions, and difficulties in interpretation. (Tilling et al., 2014) Trial arm 
(dosing regimen) was included in the model as an explanatory variable, in order to describe the 
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difference in adherence patterns between regimens. The interaction between trial arm and time 
was also explored, in order to assess whether adherence trajectories differed for each regimen.  
To explore any potential differences in adherence during the week compared to the weekend, 
the above model was extended by the addition of an indicator that distinguished whether a day 
fell on a weekday or weekend. Its interaction with trial arm was also explored to determine 
whether these differences were larger for participants allocated to a particular dosing regimen. 
Similarly, the model was also extended to explore any potential differences in adherence at clinic 
visit dates (defined as the date of a scheduled clinic visit and one week either side of this date). 
Model fit was assessed using Akaike’s Information Criterion (AIC). (Akaike, 1974) The AIC is 
a relative assessment of model fit (i.e. it compares the fit of a model relative to each of the other 
models fitted) that penalises for the number of parameters included in the model. The AIC value 
is calculated as 𝐴𝐼𝐶 = 2𝑘 − 2 ln(𝐿), where k is the number of parameters and L is the maximum 
value of the likelihood function, and smaller AIC values reflect better model fit. Results are 
presented as odds ratios with associated 95% confidence intervals and p-values. 
4.2.3 Comparing different types of measures 
4.2.3.1 Correlation 
Different types of measures were initially compared using correlational methods. Scatter plots 
were produced to compare different quantitative measures to each other. Each scatter plot 
includes a black dashed line along the line of perfect agreement (y=x). Where multiple data 
points overlapped (i.e. there was over-plotting), jittering and semi-transparency were used to 
highlight this, (Few, 2009) with these modified plots displayed beneath the original. Pearson 
product-moment correlation coefficients were calculated to compare the different types of 
measures, (Pearson, 1895) with mathematically equivalent point biserial correlation coefficients 
used for the binary measures. (Glass and Hopkins, 1970) To provide some qualitative 
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description and visualisation around the correlation coefficients, intervals suggested by Hinkle et 
al. with increasingly darker shades of yellow indicating stronger correlation (Table 4.2). 
Table 4.2: Descriptions and visualisations of correlation coefficients* 
Size of Correlation Interpretation 
Colour code 
indication 
>.90 to 1.00 or −.90 to −1.00 Very high positive or negative correlation  
>.70 to .90 or −.70 to −.90 High positive or negative correlation  
>.50 to .70 or −.50 to −.70 Moderate positive or negative correlation  
>.30 to .50 or −.30 to −.50 Low positive or negative correlation  
.00 to .30 or .00 to −.30 negligible correlation  
*Intervals and interpretation as suggested in Hinkle et al., 2003 
4.2.3.2 Agreement 
Correlation provides an assessment of the linear relationship between two variables. However, 
given the nature of the variables being compared (i.e. different ways of measuring adherence to 
medication), a high degree of correlation would not be surprising. What correlation cannot tell 
you is how well different types of measures agree. High correlation can be found between two 
variables without any agreement whatsoever, as demonstrated in Figure 4.1. 
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Figure 4.1: Scatter plot of two simulated variables showing perfect correlation but no agreement* 
 
*The black dashed line represents the line of perfect agreement (i.e. y = x). 
Throughout this Chapter, agreement between different types of measures is presented in several 
ways. For dichotomous measures of adherence, observed agreement, expressed as a percentage, 
will be presented (e.g. the percentage of times both measures either indicated less than 100% 
adherence or 100% adherence) alongside kappa statistics (a measure of inter-rater agreement for 
categorical items that corrects for chance agreement) (Cohen, 1960) and Bangdiwala observed 
agreement charts. (Bangdiwala, 1988) These charts plot observed agreement between categorical 
measures and provide a graphical illustration of an N x N contingency table. The white rectangles 
represent marginal totals, and the area shaded black within them represents the amount of 
observed agreement (Figure 4.2). 
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Figure 4.2: Example of a Bangdiwala observed agreement chart for two binary measures of 
adherence 
 
In the paper first proposing these charts, it was acknowledged that it was not easy to visualise the 
kappa statistic on the chart. However, in my experience, the components that make up the kappa 
statistic (that is, the relative observed agreement, and the relative agreement that would be 
expected by chance) provide greater information than the statistic itself. I therefore propose an 
extension to these charts that involves overlaying the observed agreement with the expected 
agreement. This chart can provide additional information which would have otherwise been 
lacking. See Figure 4.3 for an illustration of these extended charts. In this Figure, the expected 
agreement (i.e. assuming that adherence for each measure is determined by chance) is 
represented by a blue semi-transparent square that overlays the observed agreement. The 
Adhered (Measure 1)
A
d
h
e
re
d
 (
M
e
a
s
u
re
 2
)
No
N
o
Yes
Y
e
s
20 80
14
86
85 
 
 
interpretation of the black shaded region thus alters slightly, and becomes the amount of 
observed agreement that is in addition to that expected purely by chance. 
Figure 4.3: Example of an extended Bangdiwala agreement chart for two binary measures of 
adherence (with chance agreement also illustrated) 
 
For continuous or interval measures, Bland-Altman plots will be presented. (Bland and Altman, 
1986) These plot the average of two types of measure against the difference. Perfect agreement 
would be illustrated in these plots by all data points lying along the line y = 0, with symmetric 
random scatter above and below the line an indication of no systematic biases in either of the 
measures. The mean difference is calculated, to indicate the degree of systematic bias between 
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the two types of measures (red solid line), with 95% limits of agreement also displayed to indicate 
the extent of disagreement likely to be seen for most participants (red dashed lines). See Figure 
4.4 for an illustration of these plots. 
Figure 4.4: Example of a Bland-Altman plot of the comparison of adherence as measured by 
measure 3 (M3) and measure 4 (M4) 
 
What is not obvious from Figure 4.4, but is clear on plots with more extreme values, is that when 
comparing two measures on the same scale (for example, two measures of adherence that range 
from 0 to 100), data points can only ever be plotted within a restricted space. For the example 
provided in Figure 4.4, the most extreme a data point could be is [50, +/- 100], and in general 
this would be [
𝑚𝑎𝑥(𝑥𝑖)
2
, ± 𝑚𝑎𝑥(𝑥𝑖)], where x is the measure of interest and i=1, 2. The 
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relationship between the difference and the mean imposes this restriction (i.e. as the average of 
the two measures moves away from 1/2 of the maximum, the difference between the two 
measures gets smaller). This has implications for the 95% limits of agreement, and I propose an 
extension to these plots that involves overlaying with a diamond shape that indicates the space in 
which the data points can lie. An example of this is given in Figure 4.5, with the effective space 
being indicated with navy dashed lines. 
Figure 4.5: Example of an extended Bland-Altman plot of the comparison of adherence as 
measured by M3 and M4 (with boundaries marked) 
 
Measuring and examining the comparability of different types of adherence measures is a useful 
way of establishing the quality of the adherence data that has been collected. However, in order 
to maximise the benefits of collecting multiple types of adherence measures, further 
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investigations can be carried out to determine characteristics that predict disagreement between 
measures, and approaches to generate an agreed or calibrated measure of adherence. It is clear 
to see why calibration is worthwhile. In practice, the use of multiple types of adherence measures 
implies a lack of trust in any of the measures used. The aim of calibration, in this instance, is to 
achieve a measure of adherence that is closer to the truth (or at least has less systematic bias). 
Understanding the circumstances and situations that are likely to lead to greater disagreement 
can inform researchers (and potentially practitioners) of adherence measures that are most suited 
to certain populations, and whether certain populations require adherence measured via multiple 
methods (i.e. a risk-adapted approach to adherence monitoring). 
4.2.3.4 Predictors of disagreement between different types of adherence measures 
Three different approaches were taken in this thesis to investigate predictors of disagreement 
between different types of adherence measures. The first approach, and simplest of the three, 
was to treat the comparison as a dichotomous variable (disagreed / agreed) and investigate 
predictors of disagreement using logistic regression. The second approach was to consider the 
difference between types of measures and create a categorical variable that indicated whether 
they were the same (i.e. agreed), one was lower, or higher, investigating predictors of being lower 
or higher compared to being the same using multinomial logistic regression. The third approach 
taken was to consider the direction and extent of disagreement by treating the difference between 
types of measures as a continuous variable and investigating predictors using linear regression. 
The GRACE WP10a data were used to investigate predictors of disagreement using the three 
approaches described above. Adherence according to self-report diaries and tablet counts were 
used, as these two types of measures were most frequently available for participants. When 
considering the direction and extent of disagreement, this was based on self-reported diary minus 
tablet count adherence data, and therefore the “lower” category, or a lower value meant that 
adherence data according to self-reported diaries was lower than tablet count data, and vice versa. 
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The clustered nature of participants within clinicians was accounted for by fitting mixed models 
for approaches 1 and 3 (i.e. two-level logistic and linear regression models), and by calculating 
cluster-robust standard errors for the multinomial logistic regression model. (Williams, 2000) 
The candidate variables considered for inclusion related to participant characteristics (age, 
gender, co-morbidities, use of chronic medication, and smoking status (never/past/current)) and 
characteristics about the illness with which the participant presented (presence/absence of 14 
different symptoms, clinician-rated symptom severity, auscultation abnormality, and days waited 
prior to consulting). Variables were selected into a univariable model and retained if they were 
significant at the p < 0.1 level (it was sufficient to demonstrate an association at the p < 0.1 level 
for at least one of the lower / higher comparisons for the multinomial logistic regression model). 
Variables in the multivariable model that were not significant at the p < 0.05 level were removed 
sequentially, from largest to smallest p-value, until a final multivariable model was attained. 
Findings from the models are presented as odds ratios / relative risk ratios / mean differences, 
for approaches 1, 2, and 3 respectively, with associated 95% confidence intervals and p-values. 
4.2.3.5 Calibrating adherence 
Where multiple types of methods are used to measure adherence, and there are discrepancies 
between them, several approaches could be taken to adjust or agree upon a measure that takes 
into account these discrepancies. The GRACE WP10a data were used throughout this section. 
The approaches considered in this Chapter are described below: 
4.2.3.5.1 Range calibration 
This approach is based on taking the minimum or maximum adherence measure across several 
types of measures. There are several advantages to using an approach such as this. It is easy to 
understand and communicate, it allows for calibration based on more than two methods of 
measurement, and while taking the minimum could be viewed as conservative, also reporting the 
maximum gives a likely range of the level of adherence in a given sample.  
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4.2.3.5.2 Hierarchy calibration 
Calibrating adherence based on a hierarchy involves making a judgement by ranking your 
methods from most to least reliable, and basing your measure on the most reliable method you 
have available. In a similar way to the range calibration, this is easy to understand and 
communicate and calibration can be based on more than two methods of measurement. 
However, the judgement is, to some extent, subjective (though can be based on previous evidence 
and the plausibility of the assumptions each method makes), and can vary depending on the 
context (e.g. the medication and regimen under investigation, the population of interest, etc.) 
Using the GRACE WP10a data, the ordering of the hierarchy was: 
1. Adherence based on tablet count data 
2. Adherence based on self-reported diary data 
3. Adherence based on self-reported telephone data 
4.2.3.5.3 Calibration based on classification 
The final calibration approach presented in this thesis is an adaptation of a technique developed 
by Dukic et al. The original technique used biological assays to measure cotinine, a metabolite 
of nicotine, to calibrate self-reported measures of smoking in pregnant women. While a more 
direct adaptation of this technique would rely on biological assays, the general approach can be 
adapted for other methods of medication adherence measurement. The calibration approach, 
based on having two types of measures, is as follows: 
1. Declare one type of measure as the reference standard (the measure that will be used to 
calibrate) and one as the comparator (the measure that will be calibrated). Using the 
GRACE WP10a data, tablet count data were used to calibrate self-reported diary data. 
Tablet count data were used as the reference standard. While adherence according to 
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self-reported diary allowed for an assessment of whether a participant took their 
medication on a given day, it had to be assumed that if they stated they had taken it, they 
had also taken the correct number of tablets. Calibrating by tablet count data therefore 
provided a way of correcting for instances where this assumption may not have been true. 
2. Calculate adherence according to each measure and compare them 
3. Classify individuals into groups based on the above comparison and some sensibly 
chosen cut-offs: 
a. Extreme over-reporter 
b. Over-reporter 
c. Accurate reporter 
d. Under-reporter 
e. Extreme under-reporter 
Participants were classified as “accurate reporters” if there was perfect agreement between self-
reported diary and tablet count adherence data (i.e. zero difference). A cut-off of 1/7 was used to 
distinguish between over/under-reporters and extreme over/under-reporters. This cut-off was 
chosen as it reflected a discrepancy equivalent to an entire days’ worth of medication. Participants 
were given 42 tablets, to be taken as two tablets, three times a day for seven days. Adherence was 
expressed as a percentage and 6/42 expressed as a percentage is 1/7. Over/under-reporters were 
classified so if the discrepancy between self-reported diary and tablet count adherence was up to 
1/7 percentage points (inclusive), with extreme classifications given when the discrepancy 
exceeded this cut-off. 
4. Calculate the mean in each of the above groups 
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5. Use these means and the group to which an individual belongs and calibrate their 
adherence measure 
4.3 Results 
4.3.1 Available data 
A total of 213 participants were recruited into the main CODA study, with 61 of these also 
included in the sub-study that involved the use of electronic monitoring of medication use. Self-
reported adherence data were available for 187 participants (87.8%), with 164 having tablet count 
data (77.0%). Of those included in the sub-study, 58 had valid electronic monitoring data (95.1%). 
Electronic monitoring data was therefore available for 27.2% of all participants in the CODA 
study. Nineteen participants had no data collected that could be used to assess adherence to 
medication (8.9%). All three types of measures were available for 49 participants (23.0%). 
Participants infrequently only had one type of measure available (21 had self-report only (9.9%), 
five had tablet count only (2.3%), and two had electronic monitoring data only (0.9%)). The most 
frequent combination seem in this study was the collection of valid self-report and tablet count 
data (110 participants (51.6%)) (Figure 4.6). 
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Figure 4.6: Availability of the different types of medication adherence measures for participants 
in the CODA study 
 
The GRACE WP10a study included 2061 participants in total, with self-reported adherence 
data, collected via a self-completed diary, available for 1675 participants, tablet count data 
available for 1266, and self-reported telephone data for 129. Adherence data of at least one type 
were available for 1854 participants (90.0% of those included in the study). Multiple types of 
measures were available for the majority of participants (1214, or 58.9%), with the majority of 
these involving the availability of both self-reported diary and tablet count data. Self-reported 
telephone data was generally collected in circumstances where diaries were not returned, hence 
the low number of participants with both diary and telephone data available (Figure 4.7). The 
small number of participants with both self-reported diaries and telephone adherence measures 
(and all three measures) represents those who were telephoned for their information (as they had 
not returned their diary), and then the research team subsequently receiving their diary. 
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Figure 4.7: Availability of the different types of medication adherence measures for participants 
in the GRACE WP10a study 
 
4.3.2 Summary measures of adherence 
In the CODA study, 170 participants stated that they had taken their medication as prescribed 
(at least 90% of the time), when asked at the end of the study (90.9%). According to tablet counts, 
154 participants had consumed at least 75% of the medication that was prescribed for them 
(93.9%), with 19 consuming all medication that was prescribed for them (11.6%), and a mean 
percentage of medication that was consumed of 92.7% (SD: 11.7). Thirteen participants 
consumed more than 100% of medication than they should have, according to tablet counts. 
This relates to participants who exited the study before the 12-month period (due to withdrawal 
or relapse), but returned fewer tablets than they should have. On average, the percentage of days 
that participants adhered to their regimen, according to electronic monitoring data, was 73.7% 
(SD: 30.2), however the distribution of these data was considerably more skewed than the tablet 
Tablet counts
(n=53)
Self-report telephone
(n=48)
Self-report diary
(n=539) (n=1133)
(n=1) (n=78)
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95 
 
 
count data (Table 4.3). The majority of participants adhered to their treatment regimen on at 
least 75% of days (37 participants, or 63.8%), with no participants adhering on 100% of days. 
Table 4.3: Summary statistics of medication adherence data in the CODA study 
Type of 
measure 
Summary measure 
N 
(%) 
Mean 
(SD) 
Median 
(Min, Max) 
Self-
report 
(n=187) 
Taken their study tablets as prescribed at least 
90% of the time 
170 
(90.9) 
  
Tablet 
count 
(n=164) 
Consumed at least 75% of tablets that they 
should have 
154 
(93.9) 
  
Consumed (at least) 100% of tablets that they 
should have* 
19 
(11.6) 
  
Percentage of tablets consumed  
92.7 
(11.7) 
96.2 
(42.2,133.3) 
Electronic 
monitorin
g 
(n=58) 
Adhered to their regimen at least 75% of the 
time 
37 
(63.8) 
  
Adhered to their regimen 100% of the time 0 (0.0)   
Percentage of days that they adhered to their 
regimen 
 
73.7 
(30.2) 
89.2 
(0.0,99.39) 
*The number of tablets returned by some participants implied they consumed more than 100% 
of the number of tablets they should have consumed. 
For participants in the GRACE WP10a study, 100% adherence was observed in 1342 
participants based on self-reported diary data (80.1%), 934 based on tablet count data (73.8%), 
and 88 based on self-reported telephone data (68.2%). The mean adherence score was 91.2 
based on self-reported diary data (SD: 22.0), 88.5 based on tablet count data (SD: 25.4), and 77.5 
based on self-reported telephone data (SD: 36.9). Due to adherence generally being high, and 
bounded at 100%, the distributions of adherence scores were highly skewed to the left for all 
measures (Table 4.4). 
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Table 4.4: Summary statistics of medication adherence data in the GRACE WP10a study 
Type of 
measure 
Summary 
measure 
n 
(%) 
Mean 
(SD) 
Median 
(Min, Max) 
Self-reported 
diary 
(n=1675) 
100% adherence 1342 (80.1)   
Adherence 
score 
 
91.2 
(22.0) 
100.0 
(0.0,100.0) 
Tablet count 
(n=1266) 
100% adherence 934 (73.8)   
Adherence 
score 
 
88.5 
(25.4) 
100.0 
(0.0,100.0) 
Self-reported 
telephone 
(n=129) 
100% adherence 88 (68.2)   
Adherence 
score 
 
77.5 
(36.9) 
100.0 
(0.0,100.0) 
 
4.3.3 Longitudinal modelling of electronic monitoring data (CODA) 
Electronic monitoring data were available for 14,863 days nested within 58 participants. As 
demonstrated by Figure 4.8 and Table 4.5, there was a small but statistically discernible decrease 
in medication adherence over time. In Figure 4.8, the bold black lines represent the overall 
estimated adherence probabilities derived from the fixed effects of the GLMM, with the greyed 
area representing the 95% confidence bands around these probabilities. All other curves are 
estimated individual adherence probabilities, derived from the random effects of the GLMM, 
for each participant in the study. Colour-coded indicators are attached to each individual curve 
to represent days that a participant adhered to or did not adhere to their medication (blue and 
red respectively). There were two instances of individuals having MEMS caps that malfunctioned 
for a small period during the study, with no data collected during this time. These periods are 
marked as grey on the corresponding individual curves. There was an initial decrease in 
adherence followed by a period of stabilisation, with some further reduction in adherence 
towards the end of the study. There was a marked difference between the two dosing regimens 
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(OR for TDS compared to OD regimen 0.03, 95% CI: 0.01 to 0.08, p < 0.001). As is also evident, 
there was considerably more variation in individual adherence patterns over time for TDS 
participants than for OD participants. There was no evidence of an interaction between dosing 
regimen and time (all p-values ≥ 0.1), indicating that while medication adherence was generally 
higher for participants allocated to the OD regimen, the adherence in both groups decreased 
over time at a similar rate. 
As demonstrated by Figure 4.9, medication adherence was generally lower on weekends than it 
was on weekdays, with the difference larger for participants allocated to the TDS dosing regimen 
than for those allocated to OD. While the absolute difference was small, there was a statistically 
discernible difference in adherence on weekdays compared with adherence at weekends, with 
odds of being adherent 47% higher on weekdays compared to weekends (OR for weekday 1.47, 
95% CI: 1.31 to 1.65, p < 0.001) (Table 4.5). There was no evidence of an interaction between 
time of the week and dosing regimen (p = 0.111), indicating that while the difference was 
descriptively more pronounced for participants allocated to the TDS regimen, this difference 
was not statistically discernible at the 5% level. 
Similarly, there was a small but discernible difference between adherence around (i.e. a week 
either side of) clinic visit times and non-clinic visit times, with the odds of being adherent around 
clinic visit times 43% higher compared to non-clinic visit times (OR for clinic visit times 1.43, 
95% CI: 1.18 to 1.72, p < 0.001). The interaction between time of visit and dosing regimen was 
not discernible at the 5% level (p = 0.429) (Figure 4.10, Table 4.5). 
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Table 4.5: Estimated daily adherence over time from a two-level generalised linear mixed model 
with time modelled as a cubic B-spline (based on 14,863 days nested within 58 participants) 
Variable 
Adherence over time 
and differences between 
dosing regimen  
Differences in adherence 
during weekdays 
Differences in adherence 
at clinic visit times 
Odds ratio  
(95% CI) 
p-value 
Odds ratio  
(95% CI) 
p-value 
Odds ratio  
(95% CI) 
p-value 
Intercept 
121.49  
(56.78 - 
259.93) 
<0.001 
94.65 
(43.95 - 
203.84) 
<0.001 
113.67 
(53.36 - 
242.17) 
<0.001 
Day  
0.07  
(0.02 - 0.26) 
<0.001 
0.07 
(0.02 - 0.26) 
<0.001 
0.07 
(0.02 - 0.27) 
<0.001 
Day
2
  
1.08  
(0.46 - 2.52) 
0.857 
1.09 
(0.46 - 2.54) 
0.851 
1.09 
(0.47 - 2.54) 
0.843 
Day
3
 
0.14  
(0.07 - 0.28) 
<0.001 
0.13 
(0.06 - 0.28) 
<0.001 
0.15 (0.07 - 
0.03) 
<0.001 
Once 
daily 
dosing 
regimen 
Reference category for dosing regimen (trial arm) 
Three 
times 
daily 
dosing 
regimen 
0.03  
(0.01 - 0.08) 
<0.001 
0.03 
(0.01 - 0.08) 
<0.001 
0.03 
(0.01 - 0.08) 
<0.001 
Weekday: 
Yes 
  
1.47 
(1.31 - 1.65) 
<0.001   
Weekday: 
No 
Reference category for weekday indicator 
Clinic 
visit time: 
Yes 
    
1.43 
(1.18 - 1.72) 
<0.001 
Clinic 
visit time: 
No 
Reference category for clinic visit time indicator 
 
99 
 
 
Figure 4.8: Estimated medication adherence probabilities over time (using the MEMS cap data) 
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Figure 4.9: Percentage of days participants adhered to regimen for each day of the week split by 
allocated regimen 
 
Figures 4.10: Percentage of days that participants adhered to regimen during clinic visit periods 
and non-clinic visit periods split by allocated regimen 
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4.3.4 Comparing different types of measures 
4.3.4.1 Correlation 
In the CODA study, there was negligible to low positive correlation between adherence as 
measured using self-report and tablet count data (correlation coefficients, ρ, ranged from 0.111 
to 0.339), and low to moderate positive correlation when compared to electronic monitoring (ρ 
ranged from 0.465 to 0.523). The dichotomous measures of adherence based on tablet count 
data correlated negligibly with both dichotomous and quantitative electronic monitoring 
adherence measures (ρ ranged from 0.141 to 0.300). However, high positive correlation, largely 
driven by a clustering of points at 100%, was observed between adherence as measured 
quantitatively by tablet counts and dichotomous/quantitative electronic monitoring measures (ρ 
= 0.702 and 0.725 respectively) (Figure 4.11, Table 4.6). 
Figure 4.11: Scatter plot comparing medication adherence as measured quantitatively using 
electronic monitoring and tablet counts (dashed line represents the line of perfect agreement) 
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Table 4.6: Correlation coefficients for different types of adherence measures in the CODA study 
 Self-report 
Tablet count Electronic monitoring 
Consumed at 
least 75% of 
tablets that they 
should have 
Consumed (at 
least) 100% of 
tablets that they 
should have 
Percentage of 
tablets consumed 
Adhered to their 
regimen at least 
75% of the time 
Percentage of 
days that they 
adhered to their 
regimen 
Self-report 1.000      
Tablet count 
Consumed at 
least 75% of 
tablets that they 
should have 
0.194 1.000     
Consumed (at 
least) 100% of 
tablets that they 
should have 
0.111 0.092 1.000    
Percentage of 
tablets consumed 
0.339 0.736 0.394 1.000   
Electronic 
monitoring 
Adhered to their 
regimen at least 
75% of the time 
0.465 0.283 0.141 0.702 1.000  
Percentage of 
days that they 
adhered to their 
regimen 
0.523 0.300 0.179 0.725 0.901 1.000 
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In the GRACE WP10a study, correlation between different types of adherence measures was 
moderate to very high (ρ ranged from 0.547 to 1). Moderate correlation was observed when 
comparing binary measures of adherence as measured using self-reported diaries and tablet 
counts to each other (ρ = 0.583) and to their quantitative equivalent (correlations between binary 
self-reported diary and quantitative tablet count = 0.591, and binary tablet count and quantitative 
self-reported diary = 0.547). All other correlation was high or very high. Table 4.7 provides 
correlation coefficients for all comparisons. Figures 4.12a to 4.12e illustrate the relationship 
between the quantitative measures of adherence. What is evident, particularly when observing 
Figures 4.12d and 4.12e, is that there is a high concentration of participants for whom adherence 
was 100% across all types of measures. 
Table 4.7: Correlation coefficients for different types of adherence measures in the GRACE 
WP10a study 
 
Self-reported diary Tablet counts Self-reported telephone 
Adherence 
score 
100% 
adherence 
Adherence 
score 
100% 
adherence 
Adherence 
score 
100% 
adherence 
Self-
reported 
diary 
Adherence 
score 
1.000      
100% 
adherence 
0.803 1.000     
Tablet 
counts 
Adherence 
score 
0.767 0.591 1.000    
100% 
adherence 
0.547 0.583 0.756 1.000   
Self-
reported 
telephone 
Adherence 
score 
1.000* 1.000* 0.949 0.752 1.000  
100% 
adherence 
1.000* 1.000* 0.828 0.855 0.895 1.000 
*NB. These are based on three data points. 
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Figures 4.12a to 4.12e: Scatter plots comparing medication adherence as measured via self-reported diaries, tablet counts, and self-reported telephone 
(plots d and e include identical data to those in a and b respectively, with jittering and semi-transparency used to indicate the extent of over plotting) 
 
d e
a b c
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4.3.4.2 Agreement 
When comparing the observed percentage of agreement between different types of measures in 
the CODA study, it is clear from Table 4.8 and Figures 4.13a to 4.13f that for some comparisons 
there is considerable disagreement. The lowest agreement is observed when comparing across 
measures or within measures and using different cut-points (though the latter is not surprising). 
The Figures 4.13a to 4.13f illustrate that where disagreement occurred it was generally due to 
tablet counts suggesting higher levels of adherence compared to self-report and electronic 
monitoring, with self-report similarly suggesting higher levels of adherence when compared to 
electronic monitoring. Note the highest kappa is for the comparison between electronic 
monitoring and self-report, despite this not having the highest observed agreement. Figures 4.13a 
to 4.13f illustrate that while observed agreement may have been higher for other comparisons 
(e.g. 4.13a), a lot of this agreement was expected by chance. Figure 4.13c displays the greatest 
amount of observed agreement that is in addition to that expected by chance. 
When comparing the agreement between quantitative measures of adherence via tablet counts 
and electronic monitoring, the absolute mean difference of -17.81 suggested that tablet counts 
consistently provided a higher estimate of adherence compared to electronic monitoring. Figure 
4.14 illustrates the agreement between the two types of measures, and highlights that while there 
is a large concentration of data points around [100, 0] (fully adhered according to both types of 
measure), the majority of instances where disagreement occurred was for participants allocated 
to the TDS regimen, where there was a requirement to open the MEMs cap on three separate 
occasions throughout the day. 
  
106 
 
 
Table 4.8: Percentage of observed agreement between dichotomous measures of adherence in 
the CODA study (kappa in brackets) 
 Self-report 
Tablet count 
(75%) 
Tablet count 
(100%) 
Electronic 
monitoring 
(75%) 
Self-report 100%    
Tablet count 
(75%) 
88.7% (0.19) 100%   
Tablet count 
(100%) 
20.1% (0.02) 17.7% (0.02) 100%  
Electronic 
monitoring 
(75%) 
75.0% (0.36) 69.4% (0.15) 42.9% (0.07) 100% 
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Figures 4.13a to 4.13f: Extended observed agreement charts for dichotomous measures of adherence in the CODA study 
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Figure 4.14: Extended Bland-Altman plot investigating the agreement between electronic 
monitoring and tablet count adherence measures in the CODA study* 
 
*The black unbroken line is set at y=0 (i.e. no disagreement). The red unbroken line represents 
the mean difference between the two measures (i.e. the bias [-17.81]), and the red dashed lines 
represent the lower and upper 95% limits of agreement (-63.11 and 27.49 respectively). The blue 
dashed diamond represents the space in which data points can lie. 
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Agreement between different types of measures in the GRACE WP10a study was generally high, 
with the lowest percentage agreement observed when comparing binary measures of self-report 
diary and tablet count adherence (85.6%) (Table 4.9). Disagreement occurred most frequently 
between different types of measures because self-report (both diary and telephone) indicated 
adherence was 100% when tablet counts did not (Figures 4.15a and 4.15b). 
Agreement when comparing different types of measures quantitatively was similarly high. The 
absolute mean difference when comparing tablet counts to self-reported diary and self-reported 
telephone was 1.7 and 2.6 respectively. The limits of agreement when comparing diary and tablet 
count adherence ranged from -26.8 (self-reported diary adherence was calculated as 26.8 
percentage points lower than tablet count adherence) to 30.2 (self-reported diary adherence was 
calculated as 30.2 percentage points higher than tablet count adherence) and when comparing 
telephone and tablet count from -21.8 to 26.9. Figures 4.16a and 4.16b provide an illustration of 
the level of agreement between different types of measures. What is clear from these figures is 
that adherence was high and was generally good (most data points on both plots are clustered 
around the co-ordinate [100, 0], indicating full adherence and no difference between measures). 
For the comparison of diary to tablet count adherence, 7% of participants were outside the limits 
of agreement; for the comparison of telephone to tablet count adherence, 5% of participants 
were outside the limits of agreement. 
Table 4.9: Percentage of observed agreement between dichotomous measures of adherence in 
the GRACE WP10a study (kappa in brackets) 
 Self-report diary Tablet counts Self-report telephone 
Self-report diary 100%   
Tablet counts 85.6% (0.58) 100%  
Self-report telephone 100% (1.00) 92.5% (0.85) 100% 
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Figures 4.15a and 4.15b: Extended observed agreement charts for dichotomous measures of adherence in the GRACE WP10a study 
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Figures 4.16a and 4.16b: Extended Bland-Altman plots investigating the agreement between self-reported diary, tablet count, and self-reported 
telephone adherence measures in the GRACE WP10a study* 
 
*The black unbroken line is set at y=0 (i.e. no disagreement). The red unbroken line represents the mean difference between the two measures (i.e. the bias), and 
the red dashed lines represent the lower and upper 95% limits of agreement. For the comparison of self-reported diary and tablet counts (4.16a), the bias was 1.7, 
and the 95% limits of agreement were -26.8 to 30.2. For the comparison of self-reported telephone and tablet counts (4.16b), the bias was 2.6, and the 95% limits 
of agreement were -21.8 to 26.9. Where data points lie outside the bounded region (blue dashed lines), this is due to the use of jittering.
a ba b
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4.3.4.3 Predictors of disagreement between different types of adherence measures 
4.3.4.3.1 Descriptive statistics for disagreement variables 
As demonstrated in the previous section, agreement between adherence as measured using self-
reported diaries and tablet counts was high. Indeed, for the quantitative measure of adherence, 
disagreement was observed in only one-quarter of cases (Table 4.10).  
Table 4.10: Observed disagreement between adherence as measured using self-reported diaries 
and tablet counts in the GRACE WP10a study 
Binary Disagreement (YES/NO) n (%) 
Yes (disagree) 286 (25.2) 
No (agree) 849 (74.8) 
Total 1135 (100.0) 
 
When calculating the difference between the two types of measures (self-report diary minus tablet 
count), Figure 4.17 demonstrates a fairly symmetric distribution around zero, with Table 4.11 
revealing slightly more instances of participants providing higher measures of adherence 
according to self-reported diary compared to tablet counts (173, or 15.2% of participants), 
compared to instances where self-reported diaries were lower (113, or 10% of participants). That 
is, where different types of measures disagreed, self-report diaries were more likely to produce 
higher adherence than tablet counts. 
Table 4.11: Direction of disagreement between adherence as measured using self-reported 
diaries and tablet counts in the GRACE WP10a study 
Self-report diary versus Tablet Count  
(Lower / Same / Higher) 
n (%) 
Lower 113 (10.0) 
Same 849 (74.8) 
Higher 173 (15.2) 
Total 1135 (100.0) 
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Figure 4.17: Histogram of the difference between adherence as measured using self-reported 
diaries and tablet counts 
 
4.3.4.3.2 Predictors of binary disagreement 
In the univariable analyses, age, gender, presenting with phlegm, feeling generally unwell, or 
diarrhoea, and the number of days waited prior to consulting were all associated with the two 
types of adherence measures disagreeing at the 10% significance level, and were therefore 
retained for the initial multivariable model. The final multivariable model included age, gender, 
presenting with phlegm, and the number of days waited prior to consulting (Table 4.12). 
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Table 4.12: Multivariable two-level logistic regression model of associations between 
participant/illness characteristics and disagreement between self-reported diary and tablet count 
adherence measures* 
Variable 
Odds ratio for 
disagreement 
95% Confidence 
Interval p-value 
Lower Upper 
Age (decades) 0.84 0.77 0.92 <0.001 
Male Reference category 
Female 1.49 1.10 2.01 0.011 
Phlegm (presenting symptom) 1.55 1.06 2.26 0.023 
Waited 7 days or fewer prior to 
consulting 
Reference category 
Waited 8 to 14 days prior to 
consulting 
0.66 0.45 0.96 
0.011 
Waited 15+ days prior to consulting 0.59 0.39 0.88 
Intercept 0.49 0.27 0.91 0.024 
*Based on 1133 participants nested within 183 clinicians. The clinician-level ICC was 0.09 (95% 
CI: 0.04 to 0.19). 
As demonstrated in Table 4.12, the odds of disagreeing were lower in older participants (OR for 
a decade increase = 0.84, 95% CI: 0.77 to 0.92), with a mean age of 46.9 years for those whose 
adherence disagreed, and 51.8 years for those who agreed (SD = 16.2 and 15.9 respectively). For 
those who had waited longer prior to consulting, the odds of disagreeing were lower, with a dose-
response relationship observed (OR for waiting 8 to 14 days compared to 7 days or fewer = 0.66, 
95% CI: 0.45 to 0.96, OR for waiting 15+ days compared to 7 days or fewer = 0.59, 95% CI: 0.39 
to 0.88). The odds of disagreeing were higher for females (OR = 1.49, 95% CI: 1.10 to 2.01), 
and for those presenting with phlegm (OR = 1.55, 95% CI: 1.06 to 2.26). 
4.3.4.3.3 Predictors of the direction of disagreement 
In the univariable analyses, several variables were associated with either self-report diary yielding 
lower adherence than tablet counts (versus the same), or higher at the 10% significance level. The 
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variables, age, gender, use of chronic medication, smoking status, presenting with phlegm, muscle 
aching, feeling generally unwell, confusion / disorientation, or diarrhoea, having an auscultation 
abnormality, and the number of days waited prior to consulting were associated for at least one 
of the directions. Only age was univariably associated in both directions (Table 4.13). 
The final multivariable model included age, gender, presenting with phlegm, diarrhoea, 
auscultation abnormality, and number of days waited prior to consulting. An increase in age was 
associated with a lower risk of disagreeing in either direction (RRR for lower = 0.85, 95% CI: 
0.74 to 0.98, RRR for higher = 0.85, 95% CI: 0.76 to 0.94). The risk of disagreeing in either 
direction was higher for participants presenting with phlegm. Being female or presenting with 
diarrhoea were associated with a higher risk of having an adherence score lower according to self-
report diary (versus tablet count) compared to it being the same. Having an auscultation 
abnormality on presentation was associated with a lower risk of having an adherence score lower 
according to self-report diary compared to it being the same. The longer participants waited 
before consulting, the lower their risk of having an adherence score higher according to self-
report diary compared to it being the same (Table 4.14). 
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Table 4.13: Univariable associations between participant and illness characteristics and the 
direction of disagreement 
Variable 
p-value (lower 
versus same) 
p-value (higher 
versus same) 
Retain for 
multivariable analysis? 
Age 0.005 <0.001 Yes 
Gender 0.003 0.186 Yes 
Comorbidities 0.526 0.872 No 
Use of chronic 
medication 
0.485 0.047 Yes 
Current smoker 0.375 0.204 No 
Smoking status 0.383 0.096 Yes 
Phlegm 0.159 0.084 Yes 
Shortness of breath 0.261 0.464 No 
Wheeze 0.398 0.840 No 
Runny nose 0.275 0.714 No 
Chest pain 0.880 0.401 No 
Fever 0.932 0.602 No 
Muscle aching 0.801 0.066 Yes 
Headache 0.778 0.142 No 
Disturbed sleep 0.202 0.847 No 
Feeling generally 
unwell 
0.704 0.003 Yes 
Interference with 
normal activities 
0.322 0.409 No 
Confusion / 
disorientation 
0.481 0.096 Yes 
Diarrhoea 0.065 0.494 Yes 
Symptom severity 
score 
0.247 0.162 No 
Auscultation 
abnormality 
0.011 0.670 Yes 
Days waited prior to 
consulting 
0.948 0.001 Yes 
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Table 4.14: Multivariable multinomial logistic regression model of associations between participant/illness characteristics and the direction of 
disagreement between self-reported diary and tablet count adherence measures* 
Model Variable Relative Risk Ratio 
95% Confidence Interval 
p-value 
Lower Upper 
Adherence according to 
self-reported diary lower 
than tablet counts  
(versus same) 
Age (per decade increase) 0.85 0.74 0.98 0.020 
Male Reference category 
Female 1.83 1.19 2.82 0.006 
Phlegm (presenting symptom) 1.67 1.04 2.68 0.032 
Diarrhoea (presenting symptom) 2.19 1.05 4.56 0.037 
Auscultation abnormality 0.56 0.35 0.89 0.015 
Waited 7 days or fewer prior to consulting Reference category 
Waited 8 to 14 days prior to consulting 1.03 0.61 1.75 
0.940 
Waited 15+ days prior to consulting 1.10 0.66 1.83 
Intercept 0.14 0.06 0.36 <0.001 
Adherence according to 
self-reported diary higher 
than tablet counts  
(versus same) 
Age (per decade increase) 0.85 0.76 0.94 0.003 
Male Reference category 
Female 1.22 0.87 1.72 0.255 
Phlegm (presenting symptom) 1.61 1.03 2.51 0.037 
Diarrhoea (presenting symptom) 1.19 0.61 2.31 0.603 
Auscultation abnormality 0.95 0.68 1.33 0.772 
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Model Variable Relative Risk Ratio 
95% Confidence Interval 
p-value 
Lower Upper 
Waited 7 days or fewer prior to consulting Reference category 
Waited 8 to 14 days prior to consulting 0.49 0.29 0.83 
0.002 
Waited 15+ days prior to consulting 0.39 0.23 0.69 
Intercept 0.38 0.18 0.80 0.011 
*Based on 1128 participants. Standard errors corrected for clustering of 182 clinicians. 
119 
 
4.3.4.3.4 Predictors of the direction and extent of disagreement 
Perhaps unsurprisingly, given the distribution of the difference between adherence as measured 
using self-reported diaries and tablet counts as shown in Figure 4.17, the assumptions of a linear 
regression were not satisfied, with the distribution of the residuals non-normal but fairly 
symmetric (see Figures 4.18a to 4.18c for the residual plots for the univariable model that 
includes age as a predictor). A linear mixed model was therefore fitted with robust standard errors 
to obtain accurate standard errors (and hence confidence intervals and p-values). 
Figures 4.18a to 4.18c: Residual plots from linear mixed model of difference between self-report 
 
In the univariable analyses, presenting with a headache, feeling generally unwell, the clinician-
rated symptom severity score, and number of days waited prior to consulting were all associated 
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“Symptom severity score” was missing for 385 participants and the final multivariable model 
(including symptom severity) excluded all other variables. When the modelling process excluded 
symptom severity score, the only variable retained was days waited prior to consulting. The 
findings for both of these models are therefore presented separately (Table 4.15 for symptom 
severity score and Table 4.16 for days waited prior to consulting). 
Table 4.15: Association between clinician-rated symptom severity score at baseline and 
differences between adherence as rated via self-reported diaries and tablet counts* 
Variable 
Mean difference 
(self-report 
diary minus 
tablet count) 
95% Confidence 
Interval 
p-value 
Lower Upper 
Symptom severity score 0.10 0.01 0.18 0.026 
Intercept -3.54 -7.63 0.55 0.090 
*Based on 750 participants within 163 clinicians 
Table 4.16: Association between days waited prior to consulting and differences between 
adherence as rated via self-reported diaries and tablet counts* 
Variable 
Mean difference 
(self-report 
diary minus 
tablet count) 
95% Confidence 
Interval 
p-value 
Lower Upper 
Waited 7 days or fewer prior to 
consulting 
Reference category 
Waited 8 to 14 days prior to 
consulting 
-2.00 -3.51 -0.48 
0.003 
Waited 15+ days prior to consulting -2.66 -4.47 -0.84 
Intercept 2.29 0.96 3.62 0.001 
*Based on 1134 participants within 184 clinicians 
As shown in Table 4.15, for each unit increase in symptom severity score (which ranged from 0 
– all 14 symptoms normal / not causing a problem, to 100 – all 14 symptoms as bad as they could 
be) adherence according to self-reported diaries is 0.1 percentage points higher (95% CI: 0.01 to 
0.18). Table 4.16 demonstrates that for participants who waited 8 to 14 days prior to consulting, 
adherence according to self-reported diaries was, on average, 2 percentage points lower than 
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tablet counts (95% CI: 3.51 to 0.48 percentage points lower), compared to those who waited 7 
days or fewer. For those who waited 15+ days, adherence was 2.66 percentage points lower than 
tablet counts (95% CI: 4.47 to 0.84 percentage points lower). 
4.3.4.4 Calibration 
The GRACE WP10a data were used to create calibrated measure of medication adherence using 
several methods. The summary statistics for the different types of measures are presented in 
Table 4.18. 
4.3.4.4.1 Range 
Taking the minimum/maximum value from all available types of adherence measures, adherence 
data in the GRACE WP10a trial were available for 1854 participants (90% of all randomised 
participants).  The average percentage of medication taken was 87.3 when taking the minimum 
value (with an SD of 26.5) and 90.8 when taking the maximum (SD = 23.8). 
4.3.4.4.2 Hierarchy 
Of the 1854 participants with adherence data, adherence was based on tablet counts in 1266 
instances (68.3%), self-reported diaries in 540 instances (29.1%), and self-reported telephone in 
the remaining 48 instances (2.6%). The average percentage of medication taken was 88.5 when 
considering a measure of adherence calibrated and based on treating different types of measures 
in a hierarchy (SD = 25.9). 
4.3.4.4.3 Classification 
As demonstrated in Figure 4.17, while agreement between self-reported diary and tablet count 
adherence was high, there were instances of high levels of disagreement in both directions. When 
comparing the two types of measures, 849 participants were classed as accurate reporters (74.8%). 
Over-reporting of adherence (reporting a higher level of adherence in self-reported diaries than 
in tablet counts) occurred for 173 participants, with 97 classified as over-reporters and 76 as 
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extreme over-reporters (8.5 and 6.7% of all participants for whom both types of measures were 
available respectively). Under-reporting occurred for 113 participants, with 73 classified as under-
reporters and 40 as extreme under-reporters (6.4 and 3.5% respectively) (Table 4.17). 
Table 4.17: Summary of reporter classifications and mean differences within each classification 
Reporter classification Frequency (%) Mean difference* 
Extreme over-reporter 76 (6.7) 41.1 
Over-reporter 97 (8.5) 8.7 
Accurate reporter 849 (74.8) 0.0 
Under-reporter 73 (6.4) -8.6 
Extreme under-reporter 40 (3.5) -36.3 
*Self-reported diary minus Tablet count 
When calibrating self-reported diary adherence using this classification approach, the average 
percentage of medication taken was 90.0 (SD = 23.2). 
Table 4.18 provides summary statistics for the different types of calibrated measures. 
Table 4.18: Summary statistics for different types of calibrated adherence measures 
Calibrated 
adherence measure 
n Mean S.D. Median 
Lower 
quartile 
Upper 
quartile 
Min Max 
Minimum 1854 87.3 26.5 100.0 90.5 100.0 0.0 100.0 
Maximum 1854 90.8 23.8 100.0 100.0 100.0 0.0 100.0 
Hierarchy 1854 88.5 25.9 100.0 100.0 100.0 0.0 100.0 
Self-reported diary 
(calibrated) 
1675 90.0 23.2 100.0 97.2 100.0 0.0 100.0 
 
4.4 Discussion 
4.4.1 Summary 
In this Chapter, several types of methods for measuring adherence to medication were presented 
and compared. Summary statistics were presented, treating adherence as a dichotomous variable 
and also treating it as a continuous variable where this was possible. Moving beyond summary 
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measures, electronic monitoring data were used to model adherence patterns over time, 
considering the clustered nature of daily adherence measures within individuals, non-linear time 
effects, the testing of behavioural hypotheses, and visual means by which the findings can be 
presented. Several methods for comparing different types of measures were presented, including 
frequently-used correlational methods and infrequently-used agreement methods (see Chapter 
2). For the latter, I proposed extensions to observed agreement plots and Bland Altman limits 
of agreement, which were utilised as a way of reporting agreement based on dichotomous and 
continuous measures of adherence respectively. The final part of the Chapter presented various 
methods for investigating predictors of disagreement, and several methods for calibrating 
adherence measures. Disagreement was considered as a dichotomous variable (disagreed / 
agreed), and the direction and extent of disagreement was also considered, with suitable statistical 
models suggested for each. Several methods for arriving at an adherence measure that takes into 
account numerous types of (occasionally discrepant) measures were presented, with some 
methods requiring fewer assumptions than others. 
4.4.2 Learning points 
1. Summary measures of medication adherence provide useful information about the 
sample from which data were collected. Continuous summary measures should be 
reported, where possible, as these can give a better indication of the distribution of the 
data (e.g. the average and variability) than can be provided by dichotomous summary 
measures. However, dichotomous or categorical measures presented alongside can 
provide complementary information, particularly if the categories have some clinically 
important meaning. For example, in the CODA study the average percentage of tablets 
consumed was 92.7, while only 11.6% of participants consumed 100% (or more) of their 
prescribed medication. 
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2. When comparing measures in the CODA (long-term medication for a chronic condition) 
and GRACE (short-term medication for an acute condition) studies, self-report and tablet 
count agreement was considerably higher in the latter. This could be related to the 
duration of monitoring in the CODA study, the fact that self-report data was only 
obtained retrospectively during clinic visits (GRACE had both prospective self-report via 
diaries and retrospective via telephone calls), and that clinic visits were often far apart 
(increasing the likelihood of recall bias). 
3. Measuring adherence to medication electronically allows data to be captured at each 
dosing event in a passive manner (i.e. participants do not have to physically record the 
event, the device records it automatically). Capturing data so frequently, particularly over 
a long time period, provides the opportunity to explore patterns in adherence over time 
and enable detailed insights into patient behaviour to be gained. Mixed models are a 
suitable tool for the statistical analysis of these data, as they can provide estimates about 
the evolution of adherence over time, while accounting for the correlated nature of events 
within individuals. In the CODA study, mixed models were used to demonstrate that 
adherence to mesalazine declined over time, was more variable for participants allocated 
to take medication in divided doses, was better on weekdays than at weekends, and was 
better around clinic visit dates than non-clinic visit dates. 
4. When comparing different types of measures, correlation can provide an indication of 
the strength of association between different types of measures. However, it is usually 
agreement that should be the main parameter of focus. Where adherence is only 
measured in a dichotomous or categorical manner, observed agreement plots provide a 
visual means of representing the extent of agreement between two types of measure. 
Extending these by also including the agreement expected by chance enhanced the 
amount of information that could be obtained from these plots. Bland Altman plots and 
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limits of agreement provide a greater level of detail regarding the extent of agreement and 
direction of disagreement between different types of measures. For example, in the 
CODA study, while high positive correlation was observed between tablet count and 
electronic monitoring, the Bland-Altman plot and limits of agreement suggested that this 
association may belie a lack of agreement, particularly for participants allocated to take 
their medication in divided doses. The plots were enhanced by overlaying them with the 
boundaries within which data points can lie. These provided a more accurate 
representation of the boundaries in which data can lie than that suggested by the limits of 
agreement. 
5. Several statistical models can be used to investigate which patient and illness 
characteristics predict disagreement between different types of adherence measures. If 
the focus is purely on whether there is disagreement (regardless of direction or extent), a 
multivariable binary logistic regression model can be fitted. If the direction is also of 
interest, a multivariable multinomial logistic regression model can be fitted. If direction 
and extent are both of interest, a multivariable linear regression model can be fitted. Each 
of these approaches provides increasingly detailed insights into variables that are 
associated with disagreement, and these can be used to inform the selection of 
appropriate type/s medication adherence measures. For example, in the GRACE 
WP10a study, older patients were less likely to have adherence measured using self-
reported diary and tablet count data that disagreed. This may indicate that an age-
stratified approach to measuring adherence to medication (i.e. tailoring the type of 
measure, or whether multiple types are used, is dependent on the age of a participant) 
may prove useful in subsequent research. 
6. Calibration techniques provide a means of moving beyond merely reporting the 
comparison of different types of measures, and onto an approach to using a more reliable 
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measure of adherence (relative to reliance on a single type of measure), taking into 
account multiple data sources. The approaches presented in this Chapter are 
straightforward to implement, easy to communicate, and require relatively minimal 
assumptions. In the GRACE WP10a study, range calibration was used to maximise the 
amount of adherence data available and provide bounds on the level of medication 
adherence during the study. Hierarchy calibration was used to similarly maximise the 
amount of data available, but then created an agreed measure by making assumptions 
about the reliability of different types of measures. Calibration by classification was then 
used specifically to calibrate self-reported diary data using tablet count data. While these 
different calibration techniques did not result in the mean adherence differing by a large 
amount (the mean adherence was as low as 87.3 when based on the minimum value of 
all available measures and was as high as 90.8 when the maximum was used), the 
recommended approach will depend on the purpose of your calibration. If the purpose 
is to use all available data and provide bounds on the extent that participants adhered to 
treatment (for example, in sensitivity analysis), the range approach is most suitable. 
However, if more formal calibration is required, whereby assumptions are required about 
the reliability of different sources of adherence data, a hierarchy or classification 
approach may be more suitable.  
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CHAPTER 5: Determinants of Non-adherence to 
Medication: A Comparison among Different Clinical 
Conditions and Study Designs 
5.1 Introduction 
As described in earlier Chapters, non-adherence to medication can have severe consequences at 
both an individual and societal level. There exists a plethora of research investigating the 
effectiveness of interventions to improve adherence to medication, (Nieuwlaat et al., 2014) 
though only a minority of studies have reported on interventions that successfully improve both 
adherence and clinical outcomes, the latter arguably being the main goal in research of this kind. 
Interventions with this aim are likely to be most effective if they are informed by theory and 
developed gradually (for example, using a framework such as that proposed for the development 
of complex interventions (Craig, 2008)), and one of the first steps in this process involves 
developing an understanding of the determinants of adherence/non-adherence itself. 
The aims of this Chapter are to investigate the determinants of non-adherence to medication and 
to explore several methodological considerations when investigating these determinants. The 
methodological aspects considered in this Chapter are: 
 How determinants differ depending on type of measure 
 How they differ across different clinical conditions (short-term acute conditions versus 
long-term conditions) 
 How they differ depending on the study design (observational studies versus trials) 
 How different domains of adherence can be appropriately modelled 
 The value of modelling adherence as distinct processes rather than as a single variable 
To meet these aims, this Chapter will draw on data from all studies described in Chapter 3. 
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5.2 Methods 
5.2.1 Description of candidate determinants 
The determinants of non-adherence to medication can be multifaceted. Indeed, the World 
Health Organisation (WHO) has identified five dimensions that all have the potential for 
influencing how medication is taken to treat long-term conditions, which comprise factors related 
to the patient, condition, therapy, social/economic, and healthcare team/system (Figure 5.1). The 
variables collected that were considered potentially influential on an individual’s adherence to 
their medication (the candidate determinants) are described for each study in the following 
Section. All variables considered were collected (or known) prior to any medication being 
prescribed. This is important as it means that the variables may be modifiable or amenable to 
intervention, as they include details that can be known prior to commencing treatment. 
Figure 5.1: The five dimensions of adherence (from Sabaté, 2003) 
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5.2.1.1 CODA 
The candidate baseline determinants used in the CODA study included patient-related factors 
(age study entry (<65, ≥65), age at diagnosis (≤25, 26-45, 46-64, ≥65), gender, and smoking status 
(never smoker, current smoker, ex-smoker)), condition-related factors (length of remission (<12 
months, ≥12 months), calprotectin concentration at study entry (<60mg/kg stool, ≥60 mg/kg 
stool), maximum documented extent of colitis (extensive, left-sided or sigmoid, proctitis), disease 
duration (≤10 years, 11 to 20 years, >20years), and endoscopy findings at study entry (normal, 
not normal)), a therapy-related factor (allocated regimen (once daily/three times daily)), and a 
social/economic factor (employment status (unemployed, employed)). No healthcare team or 
healthcare system factors were collected. 
5.2.1.2 ZICE 
The ZICE study included determinants related to patients (age at study entry, gender, Body Mass 
Index (BMI) at study entry), the condition (the modified Brief Pain Inventory severity score at 
study entry, Quality of Life (EORTC QLQ-C30 score version 3.0) at study entry, SRE within the 
previous three months), and therapy (previous use of bisphosphonates, treatments being received 
at study entry (including painkilling drugs, chemotherapy, hormone therapy, and trastuzumab), 
allocated treatment (oral ibandronic acid or intravenous zoledronic acid)). No social/economic, 
healthcare team, or healthcare system factors were collected. 
5.2.1.3 GRACE 
Participants in the GRACE studies had a substantial amount of data collected about them prior 
to receiving an allocation to or prescription of antibiotic treatment. 
Patient-related determinants included age at study entry, gender, and whether the participant had 
a co-morbidity (at least one of the following: Chronic Obstructive Pulmonary Disease (COPD), 
asthma, other lung disease, heart failure, ischemic heart disease, other heart disease, or diabetes). 
Condition-related determinants included presenting symptoms (cough, phlegm, shortness of 
breath, wheeze, coryza, fever, chest pain, muscle aching, headache, disturbed sleep, feeling 
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generally unwell, interference with normal activities, confusion/disorientation, and diarrhoea), 
clinician-rated symptom severity score (a summation of the severity of the 14 symptoms 
previously described scaled to range from 0 to 100, where 100 represented the maximum severity 
on all 14 symptoms and 0 represented no problems on any of the 14 symptoms), phlegm colour 
(categorised as no phlegm, normal coloured phlegm (white or clear), and discoloured phlegm 
(yellow, green, or bloodstained)), whether an abnormality was found when performing an 
auscultation examination (at least one of the following: diminished vesicular breathing, wheeze, 
crackles, or rhonchi), and the number of days of symptoms prior to consulting (categorised as 
seven days or less, eight to 14 days, or 15 days or more). 
Therapy-related determinants included the dose (categorised as less than 500mg, 500mg, 
between 500 and 1000mg (not inclusive), and 1000mg or more), frequency (categorised as twice 
a day or more than twice a day), and duration (categorised as five days or less, six to seven days, 
or eight or more days) of the amoxicillin prescription. For the participants in the trial, this was 
fixed, as all participants were prescribed 1000mg of amoxicillin, three times a day for seven days. 
While there were no specific healthcare professional-related determinants available consistently 
across all three datasets, responsible clinician identifiers were available and could be used to 
determine whether variation in adherence could be attributed to the influence of individual 
clinicians. 
Participants were recruited from several European countries (Belgium, England, Finland, 
France, Germany, Hungary, Italy, Norway, Poland, Slovakia, Slovenia, Spain, Sweden, The 
Netherlands, and Wales), and healthcare setting-related determinants were established from 
work carried out as part of the GRACE project (GRACE website. Available from: 
http://www.grace-lrti.org/portal/en-gb/), and subsequent surveys among clinicians from countries 
that were not represented in this work (France and Slovenia). These included whether single-
handed (i.e. one clinician running an entire practice) practices were common (i.e. representing 
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at least a quarter of all practices), whether there had been public campaigns related to antibiotic 
use at the time the study was conducted, whether patients had to pay to see a general practitioner, 
whether clinicians were required to certify sickness for less than seven days of absence from work, 
whether amoxicillin was the first-line choice of antibiotic for a respiratory infection in primary 
care, and the country-level antibiotic prescribing rate. The prescribing rate was obtained from 
the European Surveillance of Antimicrobial Consumption Network (ESAC) antimicrobial 
consumption interactive database (ESAC-Net. Available from: http://tinyurl.com/zh233d3), 
defined as the Defined Daily Dose (DDD) per 1000 inhabitants per day, averaged across the 
years 2007 to 2010. 
The figure below illustrates the candidate determinants available across the different domains 
and studies. Note the lack of social / economic factors available. While these factors were clearly 
not measured in as much detail as other factors were (e.g. those related to the patient or 
condition) in the studies considered throughout this thesis, some of the social / economic factors 
reported as being found to be associated with adherence in the WHO report by Sabaté (e.g. 
illiteracy, low level of education, unstable living conditions) may have also been key influencers 
for people not taking part in research (potentially an indicator of sampling bias). What is also 
lacking from all studies, which may have provided useful insight into how patients take their 
medication, are questions related to the patient’s personality and beliefs about their condition 
and treatment. (Horne et al., 2013) As highlighted during Chapter 2, these behavioural influences 
(a patient-related factor) have been demonstrated to be predictive of adherence to medication. 
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Figure 5.2: Candidate determinants available for the CODA, ZICE, and GRACE studies  
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5.2.2 Definitions of adherence 
5.2.2.1 Determinants of adherence depending on type of measure used 
As described in Chapter 4, adherence was captured in the CODA study through self-reports, 
tablet counts, and electronic monitoring. In this Chapter, the determinants of adherence to 
treatment in the CODA study will be assessed and compared across all three types of measure 
in order to investigate the sensitivity of these (specifically, the ability to detect groups who adhered 
better/worse). 
5.2.2.1.1 Self-report 
At the end of the study, participants were asked “whether or not they had taken their study tablets 
as prescribed (e.g. at least 90% of the time)”, hence participants were defined as having adhered 
to their treatment if they gave a response of “yes” and not adhered if “no”.  
5.2.2.1.2 Tablet counts 
Research nurses counted the number of tablets returned at each study visit, and deducting this 
from the number of tablets issued determined the number consumed during the study period. 
Adherence to study medication in the original trial was defined as participants consuming at least 
75% of their issued medication, and due to the skewed nature of the responses, this definition 
will also be used in this Chapter. 
5.2.2.1.3 Electronic monitoring 
The date and time of bottle cap openings were electronically recorded using the MEMS, with 
data uploaded onto the study database at each trial follow-up visit. Adherence was reported as 
the percentage of days that a participant adhered to their allocated regimen. Due to the skewed 
nature of responses, this measure also had to be dichotomised, with a 75% threshold chosen in 
order to be consistent with the tablet count threshold. 
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5.2.2.2 Adherence as a single variable or as distinct processes 
Adherence may be defined as “the process by which patients take their medicine as prescribed. 
Traditionally, this has been represented quantitatively as a single variable (e.g. percentage of 
medicine taken as prescribed, a binary variable of taken as prescribed / not, etc.). However, 
recent work in this field encourages the use of the distinct processes involved in taking medicine; 
namely, initiation (the taking of the first dose), implementation (the extent to which a patient’s 
actual dosing corresponds to the prescribed dosing regimen, from initiation until the last dose), 
and persistence or time to discontinuation (length of time between initiation and the last dose). 
(Vrijens et al., 2012) Each individual process may have its own determinants and influences on 
outcomes. Therefore, different interventions may be required to address each of the adherence 
processes. For the ZICE and GRACE studies, the benefits of modelling the determinants of 
adherence as a single variable and as distinct processes will be considered. ZICE and GRACE 
were considered to provide a comparison between long and short-term conditions. CODA was 
not considered in this section as all participants initiated treatment. 
5.2.2.2.1 ZICE 
Questions about adherence to study medication were asked at three initial interim visits, and then 
subsequently at 12-weekly visits. 
Missing visit patterns were inspected, with the view to calculate adherence levels only in those 
with complete visit data up until the point of an event, withdrawal, death, or the end of the first 
12 months.  
For participants allocated to intravenous zoledronic acid, adherence was based on interim and 
12-weekly visit data, as participants were required to attend to receive intravenous medication. It 
was assumed that participants did not adhere to study medication if they either did not attend a 
scheduled visit, or attended but were noted as not receiving study medication as prescribed 
during at least one visit. Participants in the oral ibandronic acid arm were also invited to attend 
135 
 
interim visits to minimise the likelihood that an increase in clinical contact in one arm could 
impact on trial findings. However, as it was not necessary for participants in this arm to attend 
visits to receive medication, and non-attendance at one or more interim visit was high, adherence 
to oral ibandronic acid was based on 12-weekly visit data only. It was assumed that participants 
did not adhere to study medication if they were noted as not receiving study medication as 
prescribed during at least one visit. 
5.2.2.2.1.1 Combined summary measure 
A single combined summary measure was created that indicated whether or not a participant 
took their treatment as prescribed. Based on the approach described above, a participant was 
considered to have adhered to their treatment if that had reported that they had taken their 
allocated treatment as prescribed when asked at valid clinic visits. This excludes visits that were 
not mandatory to attend, such as the interim visits for participants allocated to the oral ibandronic 
acid treatment, and visits where data were censored due to withdrawal. 
5.2.2.2.1.2 Initiation 
Participants were considered as having initiated their treatment if they reported, on at least one 
occasion/clinic visit, that they had taken their treatment. 
5.2.2.2.1.3 Implementation 
In those who reported initiating their treatment, participants were considered to have fully 
implemented their treatment if that had reported that they had taken their allocated treatment as 
prescribed when asked at all valid clinic visits. 
5.2.2.2.1.4 Discontinuation 
While I considered time from initiation to discontinuation for ZICE, I ultimately concluded it 
inappropriate to define with the type of measure used to capture adherence in this study. 
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Adherence relied on reports at clinic visits, but the interim visits (when treatment generally 
initiated) were not mandatory for one of the treatment arms (and these participants generally did 
not attend interim visits). I therefore considered it inappropriate to define time to discontinuation 
for this treatment group, and determinants of discontinuation will thus not be explored for this 
study. 
5.2.2.2.2 GRACE 
5.2.2.2.2.1 Combined summary measure 
Using participant-completed diaries, a single summary measure was calculated, that indicated 
whether or not a participant took the full amount of medication they were prescribed (Yes/No). 
5.2.2.2.2.2 Initiation 
Participants were defined as having initiated their amoxicillin if they indicated in their diary that 
they took amoxicillin at least once during the 28 day follow-up period. 
5.2.2.2.2.3 Implementation 
In participants who initiated their amoxicillin, implementation describes the extent to which the 
prescription was taken as prescribed. As the focus was on amoxicillin prescribed for immediate 
use, for the purpose of this Chapter, it is defined as the proportion of amoxicillin reportedly 
taken during the prescribed period. For example, if a participant was prescribed amoxicillin for 
five days and only reported taking it for four days during the first five days of the follow-up period, 
their implementation score would be 0.8 (i.e. they initiated their amoxicillin course and took 
80% of it during the prescribing period). A participant was considered to have fully implemented 
their amoxicillin if they reported taking it for the number of days it was prescribed for during the 
prescribing period.  
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5.2.2.2.2.4 Discontinuation 
Participants were defined as having discontinued their amoxicillin prescription if they initiated 
their prescription and subsequently reported a full week of not taking their medicine. A gap of 
one week was deemed appropriate in distinguishing between patients who stopped and restarted 
their medicine, and those who were prescribed a new course of amoxicillin. The first day of that 
one-week gap was defined as the day they discontinued, and the time to discontinuation was 
calculated as the difference in days between the day of discontinuation and the day of initiation. 
For example, if a participant was prescribed a seven day course of amoxicillin for immediate use, 
initiated their amoxicillin on day three, and days 10 to 17 were the first full week where no 
amoxicillin was reportedly taken, they would be defined as having discontinued on day 10, and 
their time from initiation to discontinuation would be seven days (however, their implementation 
score would be 0.7, or 5/7). 
5.2.3 Modelling 
Logistic regression models of the odds of adhering to, initiating, and implementing treatment 
were presented as odds ratios, 95% confidence intervals, and p-values. Cox proportional hazards 
models of the time from initiation to discontinuation of treatment were presented as hazard 
ratios, 95% confidence intervals, and p-values. (Cox, 1972) Variables were entered into a 
univariable model and retained if they were significant at the p < 0.1 level. All retained variables 
were then entered into a multivariable model, with those that were not significant at the p < 0.05 
level (in the multivariable model) removed sequentially, from largest to smallest p-value, until a 
final multivariable model was attained.  
For the GRACE studies, participants recorded the use (or non-use) of amoxicillin on each study 
day. They also presented to clinicians within different countries. Data were available to indicate 
where participants presented to in terms of clinician and country. Variables pertaining to the 
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healthcare setting / country were also available for analysis. To investigate the proportion of 
variation that was attributable to differences between clinicians / countries, and hence may be 
potential influencers in whether someone adheres to their treatment (or initiates / implements it 
as intended), and also to appropriately model these determinants (i.e. calculate standard errors, 
and hence confidence intervals and p-values that are not artificially small), an appropriate 
hierarchy was selected prior to any further analysis taking place. To do this, null models were 
fitted with an increasing number of levels, with the AIC used to establish the best fitting model, 
with a smaller AIC indicating a better model fit. Some clinicians participated in more than one 
of the three studies, and where this was the case their identifier was linked across studies.  
Data from the GRACE studies were also combined in order to increase the precision of the 
estimates. The study from which a participant provided data was used in all models (both 
univariable and multivariable), to ensure that any association was not confounded by the 
characteristics of participants from different studies. 
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5.3 Results 
5.3.1 CODA 
Levels of adherence based on self-report, tablet count, and electronic monitoring data were 
reported in Chapter 4. They are briefly reported again here for consistency throughout this 
Chapter and to assist with interpretation of the findings (Figure 5.3). 
5.3.1.1 Determinants of adherence to mesalazine based on self-report data 
When the candidate determinants were tested in univariable analysis, only the allocated regimen 
could be retained for further investigation (Table 5.1). 
Table 5.1: Univariable analysis of determinants of adherence to mesalazine based on self-report 
data* 
Domain Variable Univariable p-value 
Retain for 
multivariable analysis 
Patient-related 
factors 
Age 0.509 No 
Gender 0.746 No 
Smoking status 0.456 No 
Social / economic-
related factors 
Employment status 0.519 No 
Condition-related 
factors 
Length of remission 0.184 No 
Calprotectin 
concentration 
0.575 No 
Maximum 
documented extent 
of ulcerative colitis 
0.375 No 
Duration of disease 0.215 No 
Endoscopy findings 0.292 No 
Therapy-related 
factor 
Allocated regimen 0.011 Yes 
*Analysis based on up to 187 participants 
The odds of adhering, based on self-report data, were over five times higher for participants 
allocated to the once daily regimen, compared to those allocated to the three times daily regimen 
(Table 5.2). 
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Table 5.2 Logistic regression model of the odds of adhering to mesalazine based on self-report 
data 
Domain Variable Odds ratio* 95% Confidence Interval p-value 
Therapy-related 
factor 
Allocated to three 
times daily regimen 
Reference category 
Allocated to once 
daily regimen 
5.25 1.46 to 18.94 0.011 
*Odds for adhering to prescribed regimen, according to self-report data. Analysis is based on 
187 participants. 
 
5.3.1.2 Determinants of adherence to mesalazine based on tablet count data 
No variables were found to be associated at the p < 0.1 level with adherence according to tablet 
count data (Table 5.3). 
5.3.1.3 Determinants of adherence to mesalazine based on electronic monitoring data 
Two variables were retained for multivariable analysis, when investigating the determinants of 
adherence based on electronic monitoring data – gender and allocated regimen (Table 5.4).  
Both variables were also retained in the final multivariable model, which demonstrated that the 
odds of adhering to treatment, according to tablet count data, was 80% lower in females than in 
males (75% of males adhered, 50% of females adhered), and over 30 times higher for those 
allocated to the once daily regimen (93% of those allocated to once daily adhered compared to 
37% of those allocated to three times daily), compared to those allocated to the three times daily 
regimen (Table 5.5).  
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Table 5.3: Univariable analysis of determinants of adherence to mesalazine based on tablet count 
data* 
Domain Variable Univariable p-value 
Retain for 
multivariable analysis 
Patient-related 
factors 
Age 0.637 No 
Gender 0.492 No 
Smoking status 0.135 No 
Social / economic-
related factors 
Employment status 0.968 No 
Condition-related 
factors 
Length of remission 0.446 No 
Calprotectin 
concentration 
0.955 No 
Maximum 
documented extent 
of ulcerative colitis 
0.260 No 
Duration of disease 0.277 No 
Endoscopy findings 0.163 No 
Therapy-related 
factors 
Allocated regimen 0.467 No 
*Analysis based on up to 164 participants 
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Figure 5.3: Levels of adherence to mesalazine by type of measure and allocated regimen 
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Table 5.4: Univariable analysis of determinants of adherence to mesalazine based on electronic 
monitoring data* 
Domain Variable Univariable p-value 
Retain for 
multivariable analysis 
Patient-related 
factors 
Age 0.254 No 
Gender 0.052 Yes 
Smoking status 0.764 No 
Social / economic-
related factors 
Employment status 0.159 No 
Condition-related 
factors 
Length of remission 0.462 No 
Calprotectin 
concentration 
0.515 No 
Maximum 
documented extent 
of ulcerative colitis 
0.111 No 
Duration of disease 0.194 No 
Endoscopy findings 0.278 No 
Therapy-related 
factors 
Allocated regimen <0.001 Yes 
*Analysis based on up to 58 participants 
 
Table 5.5: Multivariable logistic regression model of the odds of adhering to mesalazine based 
on electronic monitoring data 
Domain Variable Odds ratio* 95% Confidence Interval p-value 
Patient-related 
factor 
Male Reference category 
Female 0.20 0.04 to 0.89 0.035 
Therapy-related 
factor 
Allocated to three 
times daily regimen 
Reference category 
Allocated to once 
daily regimen 
30.47 5.15 to 180.25 <0.001 
*Odds for adhering to prescribed regimen for at least 75% of study days, according to electronic 
monitoring data. Analysis is based on 58 participants. 
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5.3.2 ZICE 
5.3.2.1 Adherence measures in the ZICE trial 
Overall, 66.9% of participants adhered to their treatment in the ZICE trial, based on the 
combined summary measure. More participants allocated to oral ibandronic acid adhered than 
those allocated to intravenous zoledronic acid (76.7% compared to 60.0%). Initiation was 
extremely high in the ZICE trial. Overall, 95.0% of participants initiated treatment. 
Consequently, full implementation provides similar characteristics as the combined summary 
measure (Table 5.6). 
Table 5.6: Adherence to treatment in the ZICE trial based on a combined summary measure 
and separated into different elements (initiation and implementation)* 
 Oral ibandronic acid 
Intravenous 
zoledronic acid 
Overall 
Adhered (based on 
combined summary 
measure) 
76.7 (371/484) 60.0 (408/680) 66.9 (779/1164) 
Initiated treatment 95.6 (614/642) 94.4 (646/684) 95.0 (1260/1326) 
Fully implemented 
treatment 
77.9 (371/476) 63.4 (408/644) 69.6 (779/1120) 
*Numbers are % (n/N) 
5.3.2.2 Determinants of adherence to treatment in the ZICE trial based on a 
combined summary measure 
Univariable analysis led to the retention of two variables: participant age and allocated treatment 
(Table 5.7). However, only allocated treatment was retained in the final model. The odds of 
adhering to treatment in the ZICE trial were 47% lower in those allocated to intravenous 
zoledronic acid compared to those allocated to oral ibandronic acid (95% CI: 0.42 to 0.69, p < 
0.001). 
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Table 5.7: Univariable analysis of determinants of adherence to treatment in the ZICE trial* 
Domain Variable 
Univariable 
p-value 
Retain for 
multivariable analysis 
Patient-related 
factors 
Age 0.095 Yes 
Gender 0.642 No 
BMI 0.630 No 
Condition-related 
factors 
BPI pain severity score 0.980 No 
BPI pain interference score 0.825 No 
QLQ C30 global health 0.272 No 
QLQ C30 physical functioning 0.242 No 
QLQ C30 role functioning 0.729 No 
QLQ C30 emotional functioning 0.870 No 
QLQ C30 cognitive functioning 0.144 No 
QLQ C30 social functioning 0.721 No 
QLQ C30 fatigue symptoms 0.220 No 
QLQ C30 nausea/vomiting 
symptoms 
0.339 No 
QLQ C30 dyspnoea symptoms 0.174 No 
QLQ C30 insomnia symptoms 0.234 No 
QLQ C30 appetite symptoms 0.875 No 
QLQ C30 constipation symptoms 0.650 No 
QLQ C30 diarrhoea symptoms 0.581 No 
QLQ C30 financial symptoms 0.744 No 
Previous SRE (last 3 months) 0.978 No 
Therapy-related 
factors 
Allocated treatment <0.001 Yes 
Previous bisphosphonates use 0.971 No 
Recent use of pain medication 0.121 No 
Current use of chemotherapy  0.489 No 
Current use of hormone therapy 0.258 No 
Current use of trastuzumab therapy 0.352 No 
*Analysis based on up to 1,164 participants 
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5.3.2.3 Determinants of initiation of treatment in the ZICE trial 
Univariable analysis led to the retention of variables related to the condition (global health, 
cognitive functioning, social functioning, and fatigue symptoms) and therapy (current use of 
hormone therapy) (Table 5.8). 
The final model found that the odds of initiating treatment in the ZICE study increased as social 
functioning increased (odds ratio for a unit increase = 1.01, 95% CI: 1.00 to 1.02, p = 0.029).  
5.3.2.4 Determinants of implementation of treatment in the ZICE trial 
Univariable analysis of the determinants of implementation of treatment in the ZICE trial led to 
the retention of similar variables to those retained when using the combined summary measure 
(participant age and allocated treatment), with the addition of another therapy-related factor 
(recent use of pain medication). However, only allocated treatment was retained in the final 
model, which demonstrated that the odds of implementing treatment in the ZICE trial was 51% 
lower for those allocated to intravenous zoledronic acid compared to those allocated to oral 
ibandronic acid (95% CI: 0.37 to 0.64, p < 0.001). 
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Table 5.8: Univariable analysis of determinants of initiation of treatment in the ZICE trial* 
Domain Variable Univariable p-value Retain for multivariable analysis 
Patient-related factors 
Age 0.894 No 
Gender 0.864 No 
BMI 0.884 No 
Condition-related factors 
BPI pain severity score 0.626 No 
BPI pain interference score 0.417 No 
QLQ global health 0.083 Yes 
QLQ physical functioning 0.600 No 
QLQ role functioning 0.737 No 
QLQ emotional functioning 0.308 No 
QLQ cognitive functioning 0.044 Yes 
QLQ social functioning 0.029 Yes 
QLQ fatigue symptoms 0.059 Yes 
QLQ nausea/vomiting symptoms 0.583 No 
QLQ dyspnoea symptoms 0.273 No 
QLQ insomnia symptoms 0.445 No 
QLQ appetite symptoms 0.164 No 
QLQ constipation symptoms 0.869 No 
QLQ diarrhoea symptoms 0.268 No 
148 
 
Domain Variable Univariable p-value Retain for multivariable analysis 
QLQ financial symptoms 0.655 No 
Previous SRE (last 3 months)  0.226 No 
Therapy-related factors 
Allocated treatment 0.319 No 
Previous bisphosphonates use 0.109 No 
Recent use of pain medication 0.854 No 
Current use of chemotherapy  0.851 No 
Current use of hormone therapy 0.099 Yes 
Current use of trastuzumab 
therapy 
0.550 No 
*Analysis based on up to 1,326 participants
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5.3.3 GRACE 
In total, data were available for 1,346 participants prescribed amoxicillin for immediate use and 
for whom self-reported follow-up diary data were available (WP10a, the placebo-controlled trial, 
n = 848; WP8, the prospective observational study, n = 306; and WP9, the observational study 
within which the trial was nested, n = 192). 
Overall, participants were recruited by 322 clinicians who were based in 15 different countries 
across Europe (Figure 5.4). 
Figure 5.4: Flow diagram showing data from all three GRACE studies used in this Chapter 
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5.3.3.1 Characteristics of participants in the GRACE studies 
Participants were aged between 18 and 88 years (median 51, IQR: 38 to 62). While the age 
distributions in WP8 and WP10a were similar, those recruited into WP9 tended to be slightly 
older (median 58, IQR: 45 to 65). Overall, 540 participants were men (40.1%), and 372 
participants had at least one of the listed co-morbidities (27.7%). WP9 contained a higher 
percentage of participants with co-morbidities (36.5%) (Table 5.9). 
5.3.3.2 Illness characteristics of participants in the GRACE studies 
Other than cough, which was part of the inclusion criteria for all three studies, the five most 
frequently reported symptoms were phlegm (81.3%), feeling generally unwell (79.8%), 
interference with normal activities (69.6%), disturbed sleep (64.5%), and shortness of breath 
(59.0%). Fever and headache were most frequently reported by participants in WP8, and coryza 
by participants in WP10a. Phlegm, shortness of breath, wheeze, disturbed sleep, feeling generally 
unwell, and diarrhoea were symptoms most frequently reported by participants in WP9 (Table 
5.9). 
Overall, the median clinician-rated symptom severity score at recruitment was 36 (IQR: 25 to 
46), with participants from WP9 reporting the highest average symptom severity (median = 38, 
IQR: 26 to 48) and those from WP10a the lowest (median = 35, IQR: 25 to 46). Abnormal 
findings on auscultation examination were found in 652 participants (48.5%), with participants in 
WP10a least likely to have abnormal findings (34.3%). Discoloured phlegm was reported by 680 
participants (53.2%) (Table 5.9). 
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Table 5.9: Participant and illness characteristics by study 
Participant / illness characteristic 
WP8 
(n=306) 
WP9 
(n=192) 
WP10a 
(n=848) 
Overall 
(n=1346) 
Age (years)* 49 (37 to 62) 58 (45 to 65) 50 (37 to 61) 51 (38 to 62) 
Male
†
 124 (40.5) 75 (39.1) 341 (40.2) 540 (40.1) 
Female
†
 182 (59.5) 117 (60.9) 507 (59.8) 806 (59.9) 
At least one co-morbidity
†
 77 (25.2) 70 (36.5) 225 (26.6) 372 (27.7) 
Clinician-rated symptom severity* 36 (26 to 48) 38 (26 to 48) 35 (25 to 46) 36 (25 to 46) 
Phlegm 255 (83.6) 173 (90.1) 665 (78.5) 1093 (81.3) 
Shortness of breath 198 (64.7) 143 (74.5) 452 (53.4) 793 (59.0) 
Wheeze 175 (57.2) 125 (65.1) 344 (40.6) 644 (47.9) 
Coryza 204 (66.9) 134 (69.8) 635 (75.0) 973 (72.4) 
Fever 183 (59.8) 79 (41.1) 290 (34.3) 552 (41.1) 
Chest pain 157 (51.3) 100 (52.1) 372 (44.0) 629 (46.8) 
Muscle aching 179 (58.5) 108 (56.2) 421 (49.7) 708 (52.6) 
Headache 199 (65.0) 104 (54.2) 467 (55.1) 770 (57.2) 
Disturbed sleep 213 (69.8) 145 (75.9) 508 (60.0) 866 (64.5) 
Feeling generally unwell 269 (88.2) 174 (90.6) 629 (74.3) 1072 (79.8) 
Interference with normal activities 242 (79.3) 143 (74.5) 551 (65.1) 936 (69.6) 
Confusion/disorientation 23 (7.5) 11 (5.7) 23 (2.7) 57 (4.2) 
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Participant / illness characteristic 
WP8 
(n=306) 
WP9 
(n=192) 
WP10a 
(n=848) 
Overall 
(n=1346) 
Diarrhoea 23 (7.5) 19 (9.9) 53 (6.3) 95 (7.1) 
Abnormal auscultation finding
†‡
 220 (71.9) 142 (74.3) 290 (34.3) 652 (48.5) 
No phlegm
†§ 50 (16.5) 17 (9.1) 133 (16.9) 200 (15.6) 
Normal coloured phlegm
†§ 71 (23.4) 60 (32.1) 268 (34.0) 399 (31.2) 
Discoloured phlegm
†§ 182 (60.1) 110 (58.8) 388 (49.2) 680 (53.2) 
Waited 7 days or fewer prior to consulting
†
  212 (70.4) 123 (65.4) 524 (62.7) 859 (64.8) 
Waited 8 to 14 days prior to consulting
†
 68 (22.6) 43 (22.9) 192 (23.0) 303 (22.9) 
Waited 15 days or more prior to consulting
†
 21 (7.0) 22 (11.7) 120 (14.4) 163 (12.3) 
*Median (IQR); †n (%); ‡ At least one of the following: diminished vesicular breathing, wheeze, crackles, or rhonchi; § Normal coloured phlegm = 
clear or white, discoloured phlegm = yellow, green, or bloodstained. 
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5.3.3.3 Prescription characteristics of participants in the GRACE studies 
While participants in WP10a were prescribed a fixed dose, frequency, and duration of 
amoxicillin, it was not fixed for participants in the other two studies. For these participants, the 
most frequently prescribed dose was 500mg (218, or 44.2% of all participants were prescribed 
this dose), with 393 instructed to take their medication three or more times a day (79.2%), and 
339 prescribed a six or seven day course (68.3%). Participants in WP8 were more likely to be 
prescribed higher doses to be taken less frequently and for a shorter duration, than those in WP9 
(Table 5.10). 
5.3.3.4 Healthcare setting characteristics of participants in the GRACE studies 
Of the 15 countries included, single handed practices were common in six (40.0%), campaigns 
around antibiotic use had recently been conducted in seven (46.7%), patients were required to 
pay to see a GP at the point of delivery of care in seven (46.7%), and a doctor-issued sick 
certificate was required for certifying people off work for less than seven days in three (20.0%). 
Amoxicillin was the first-line choice of antibiotic in the national guidelines of six of the countries 
(40.0%), and antibiotic prescribing rates ranged from 11.2 DDDs per 1000 inhabitants/day (The 
Netherlands) to 28.6 DDDs per 1000 inhabitants/day (France), with six countries categorised as 
low prescribers (The Netherlands, Sweden, Germany, Slovenia, Norway, and Hungary), five as 
moderate (England, Wales, Finland, Spain, and Poland), and four as high prescribers (Slovakia, 
Belgium, Italy, and France) (Table 5.11). 
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Table 5.10: Amoxicillin prescription characteristics by study 
Prescription characteristic* 
WP8 
(n=306) 
WP9 
(n=192) 
WP10a 
(n=848) 
Overall 
(n=1346) 
Dose (mg) 
Less than 
500 
23 (12.3) 52 (17.0) 0 (0.0) 75 (5.6) 
500 99 (52.9) 119 (38.9) 0 (0.0) 218 (16.3) 
500 to 1000 
(not 
inclusive) 
8 (4.3) 34 (11.1) 0 (0.0) 42 (3.1) 
1000 or 
more 
57 (30.5) 101 (33.0) 848 (100.0) 1006 (75.0) 
Frequency 
(times per 
day) 
Twice 13 (6.8) 90 (29.4) 0 (0.0) 103 (7.7) 
More than 
twice 
177 (93.2) 216 (70.6) 848 (100.0) 1241 (92.3) 
Duration 
(days) 
5 or fewer 14 (7.3) 59 (19.3) 0 (0.0) 73 (5.4) 
6 or 7 144 (75.4) 195 (63.9) 848 (100.0) 1187 (88.3) 
8 or more 33 (17.3) 51 (16.7) 0 (0.0) 84 (6.2) 
*n (%) 
 
5.3.3.5 Adherence measures in the GRACE studies 
Full adherence, based on a combined summary measure, was observed in 827 participants 
overall (61.5%), though varied widely between studies, from 26.7% for participants in WP9 to 
87.1% for those in WP10a. 
While overall a high proportion of participants initiated their amoxicillin (1057, or 78.5% of 
participants), this was again largely driven by the almost-complete initiation of amoxicillin seen 
in WP10a, the randomised placebo-controlled trial (97.6%). Initiation in participants from WP8 
and WP9 were considerably lower (51.0 and 38.0% respectively). When initiation occurred, it 
was mostly on the day of prescription (91.5% of participants who initiated did so on day 1). 
In participants who initiated amoxicillin, implementation levels were high and highly skewed 
across all three studies. Full implementation was achieved by 827 participants overall (78.3%), 
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with full implementation across studies ranging from 70.8% of participants in WP9 (51/72) to 
80.0% in WP10a (662/828). 
The median time from initiation to discontinuation of amoxicillin was seven days across all three 
studies (overall IQR: 7 to 8 days). 
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Table 5.11: Healthcare setting characteristics of participants in the GRACE studies* 
Country 
Widespread 
availability 
of single-handed 
practices* 
Recent public 
campaigns 
around 
antibiotic use 
Payment 
required 
to see GP 
Sick certification 
required for less 
than 
7 days off work 
Amoxicillin 
first-line choice 
for a 
respiratory 
infection in 
primary care 
Antibiotic 
prescribing rate
†
 
Belgium      
27.1 (25.2 to 
28.2) 
England      
17.4 (16.5 to 
18.7) 
Finland      
18.1 (17.8 to 
18.5) 
France      
28.6 (28.1 to 
29.6) 
Germany      
14.6 (14.5 to 
14.9) 
Hungary      
15.6 (15.2 to 
16.0) 
Italy      
28.1 (27.6 to 
28.7) 
The 
Netherlands 
     
11.2 (11.1 to 
11.4) 
Norway      
15.5 (15.2 to 
15.8) 
Poland      
21.9 (20.8 to 
23.6) 
Slovakia      
23.9 (23.2 to 
24.8) 
Slovenia      
14.9 (14.3 to 
15.9) 
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Country 
Widespread 
availability 
of single-handed 
practices* 
Recent public 
campaigns 
around 
antibiotic use 
Payment 
required 
to see GP 
Sick certification 
required for less 
than 
7 days off work 
Amoxicillin 
first-line choice 
for a 
respiratory 
infection in 
primary care 
Antibiotic 
prescribing rate
†
 
Spain      
19.9 (19.7 to 
20.3) 
Sweden      
14.6 (14.1 to 
15.5) 
Wales      
17.4 (16.5 to 
18.7) 
*Obtained from interview data as part of the GRACE project. Characteristics relate to the time at which participant data were collected. 
†Obtained from the European Surveillance of Antimicrobial Consumption Network (ESAC) antimicrobial consumption interactive database 
(http://ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/esac-net-database/Pages/overview-country-consumption.aspx), and defined as the 
Defined Daily Dose (DDD) per 1000 inhabitants per day. Rate averaged across years 2007 to 2010 (min and max values in brackets). United Kingdom 
rates used for England and Wales. 
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5.3.3.6 Determinants of adherence to amoxicillin based on combined summary 
measure 
As demonstrated by Table 5.12, the best fitting model according to the AIC was a three-level 
model with participants nested within clinicians nested within countries. All univariable and 
multivariable analyses will therefore be based on this. The clinician-level ICC from this initial 
model was 0.29, and the country-level ICC was 0.06. 
Table 5.12: Hierarchy selection for a logistic regression model of adherence to amoxicillin based 
on a combined summary measure 
Model Description ICCs AIC Decision 
1 Single level N/A 1794.938 
Null model (to 
obtain 
benchmark 
AIC) 
2 
Two-level 
(participant within 
clinician) 
Clinician: 0.29 1701.074 
Better model 
fit 
3 
Three-level 
(participant within 
clinician within 
country) 
Clinician: 0.29 
Country: 0.06 
1677.694 
Better model 
fit 
 
Univariable analysis led to participant age, muscle aching, phlegm colour, clinician-rated 
symptom severity score, duration of prescription, and being from a country where payment is 
required to see a GP being retained (Table 5.13). 
  
159 
 
Table 5.13: Univariable analysis of determinants of adherence to amoxicillin based on a 
combined summary measure* 
Domain Variable 
Univariable  
p-value 
Retain for 
multivariable analysis 
Patient-related 
factors 
Age 0.002 Yes 
Gender 0.135 No 
Smoking status 0.453 No 
Co-morbidities 0.227 No 
Condition-related 
factors 
Phlegm 0.271 No 
Shortness of breath 0.768 No 
Wheeze 0.611 No 
Coryza 0.582 No 
Fever 0.227 No 
Chest pain 0.478 No 
Muscle aching 0.076 Yes 
Headache 0.966 No 
Disturbed sleep 0.158 No 
Feeling generally unwell 0.666 No 
Interference with normal 
activities 
0.374 No 
Confusion / disorientation 0.888 No 
Diarrhoea 0.883 No 
Phlegm colour 0.078 Yes 
Clinician-rated symptom 
severity score 
0.077 Yes 
Auscultation abnormality 0.184 No 
Days waited prior to consulting 0.229 No 
Therapy-related 
factors 
Dose 0.386 No 
Frequency 0.599 No 
Duration 0.099 Yes 
Healthcare setting-
related factors 
Single handed practices 
widespread 
0.268 No 
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Domain Variable 
Univariable  
p-value 
Retain for 
multivariable analysis 
Recent public campaigns on 
antibiotic use 
0.701 No 
Payment required to see GP 0.065 Yes 
Sick certification required for 
missing less than 7 days of work 
0.384 No 
Amoxicillin first line choice of 
antibiotic 
0.952 No 
Country-level prescribing rate 0.545 No 
*Analysis based on up to 1345 participants nested within 332 clinicians within 15 countries 
The only determinant retained in the final model was participant age, with the odds of adhering 
to amoxicillin increasing by 15% per 10-year increase in age (Table 5.14). 
The ICCs from the final model indicated that 15% of the total variation in adherence was 
attributable to clinicians, with 3% attributable to country differences. 
Table 5.14: Three-level logistic regression model of the odds of adhering to amoxicillin based 
on a combined summary measure 
Domain Variable Odds ratio* 95% Confidence Interval p-value 
Patient-related 
factor 
Age (per decade 
increase) 
1.15 1.05 to 1.26 0.002 
N/A 
Participant from 
WP8 
Reference category 
Participant from 
WP9 
0.51 0.31 to 0.83 
<0.001 
Participant from 
WP10a 
7.83 5.22 to 11.74 
*Odds for fully adhering to prescribed treatment, according to self-report diary data. Analysis is 
based on 1345 participants nested within 332 clinicians within 15 countries. 
5.3.3.7 Determinants of initiation of amoxicillin 
Similar to the combined measure, the best fitting model according to the AIC incorporated 
clustering at both the clinician and country levels. The clinician-level ICC from this initial model 
was 0.28, and the country-level ICC was 0.22 (Table 5.15). 
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Table 5.15: Hierarchy selection for a logistic regression model of initiation of amoxicillin 
Model Description ICCs AIC Decision 
1 Single level N/A 1402.192 
Null model (to 
obtain 
benchmark 
AIC) 
2 
Two-level 
(participant within 
clinician) 
Clinician: 0.54  1244.809 
Better model 
fit 
3 
Three-level 
(participant within 
clinician within 
country) 
Clinician: 0.28  
Country: 0.22  
1193.064 
Better model 
fit 
 
Univariable analysis led to the retention of participant age, number of days waited prior to 
consulting, duration of prescription, and being in a country where sick certification is required 
for missing less than seven days of work (Table 5.16). 
Table 5.16: Univariable analysis of determinants of initiation of amoxicillin* 
Domain Variable 
Univariable  
p-value 
Retain for 
multivariable analysis 
Patient-related 
factors 
Age 0.095 Yes 
Gender 0.927 No 
Co-morbidities 0.327 No 
Condition-related 
factors 
Cough 0.950 No 
Phlegm 0.192 No 
Shortness of breath 0.808 No 
Wheeze 0.663 No 
Coryza 0.595 No 
Fever 0.513 No 
Chest pain 0.549 No 
Muscle aching 0.913 No 
Headache 0.100 No 
Disturbed sleep 0.413 No 
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Domain Variable 
Univariable  
p-value 
Retain for 
multivariable analysis 
Feeling generally unwell 0.213 No 
Interference with normal 
activities 
0.144 No 
Confusion/disorientation 0.749 No 
Diarrhoea 0.633 No 
Clinician-rated symptom severity 
score 
0.909 No 
Phlegm colour 0.408 No 
Auscultation abnormality 0.940 No 
Number of days with illness 
prior to consulting 
0.008 Yes 
Therapy-related 
factors 
Dose 0.459 No 
Frequency 0.776 No 
Duration 0.005 Yes 
Healthcare setting-
related factors 
Single handed practices 
widespread 
0.885 No 
Recent public campaigns on 
antibiotic use 
0.325 No 
Payment required to see GP 0.810 No 
Sick certification required for 
missing less than 7 days of work 
0.001 Yes 
Amoxicillin first line choice of 
antibiotic 
0.740 No 
Country-level prescribing rate 0.893 No 
*Analysis based on up to 1346 participants within 332 clinicians within 15 countries. 
Compared to those who had waited seven days or fewer, participants who had waited 15 days or 
more prior to consulting had higher odds of initiating their amoxicillin (OR = 2.77, 95% CI: 1.35 
to 5.67). There was some evidence that the duration of the prescription was also associated with 
amoxicillin initiation. Participants who were prescribed amoxicillin for eight days or more had 
higher odds of initiating their amoxicillin than those prescribed for five days or less, though this 
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was not statistically significant at the 5% level (OR = 2.29, 95% CI: 0.97 to 5.42). Participants in 
countries where a sick certificate was required for taking fewer than seven days off work had 
higher odds of initiating their amoxicillin (OR = 2.15, 95% CI: 1.27 to 3.64) (Table 5.17). 
The ICC from the final multivariable model indicated that 17% of the total variation in initiation 
was attributable to differences between clinicians. The country-level ICC was negligible. 
Table 5.17: Multivariable logistic regression model investigating the determinants of initiation of 
amoxicillin 
Domain Variable* 
Odds 
ratio 
95% CI p-
value Lower Upper 
Condition-
related factor 
Waited 7 days or less prior to 
consulting  
Reference category 
Waited 8 to 14 days prior to 
consulting 
1.47 0.92 2.34 
0.010 
Waited 15+ days prior to consulting 2.77 1.35 5.67 
Therapy-related 
factor 
Prescribed amoxicillin for 5 days or 
fewer 
Reference category 
Prescribed amoxicillin for 6 or 7 days 0.84 0.44 1.62 
0.013 Prescribed amoxicillin for 8 days or 
more 
2.29 0.97 5.42 
Healthcare 
setting-related 
factor 
Sick certification required for missing 
less than 7 days of work 
2.15 1.27 3.64 0.004 
N/A 
Participant from WP8 Reference category 
Participant from WP9 0.46 0.28 0.75 
<0.001 
Participant from WP10a 56.04 27.54 114.03 
* The model is based on 1,323 participants, nested within 330 clinicians, nested within 15 
countries. The AIC for the final model was 814.3369, an improvement over the AIC of the null 
three-level model. The ICCs from the final model were: Clinician: 0.17; Country: 0.00. 
5.3.3.8 Determinants of implementation of amoxicillin 
The AIC indicated that a four-level model was the best fitting for the implementation data, with 
days nested within participants (ICC = 0.64) within clinicians (ICC = 0.06) within countries (ICC 
= 0.01). This approach therefore modelled implementation as the probability of correctly 
implementing on a given day (Table 5.18). 
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Table 5.18: Hierarchy selection for a logistic regression model of implementation of amoxicillin 
Model Description ICCs AIC Decision 
1 Single level N/A 3964.348 
Null model (to 
obtain 
benchmark 
AIC) 
2 
Two-level (day within 
participant) 
Participant: 
0.72 
3005.479 
Better model 
fit 
3 
Three-level (day within 
participant within 
clinician) 
Clinician: 0.07 
Participant: 
0.64 
2996.044 
Better model 
fit 
4 
Four-level (day within 
participant within 
clinician within country) 
Country: 0.01  
Clinician: 0.06 
Participant: 
0.64 
2994.807 
Better model 
fit 
 
The univariable analysis led to the retention of several variables, with variables related to the 
patient (age), condition (fever, muscle aching, clinician-rated symptom severity score, and 
auscultation abnormality), and therapy (duration of prescription) retained for further 
investigation (Table 5.19). 
 
Table 5.19: Univariable analysis of determinants of implementation of amoxicillin* 
Domain Variable 
Univariable  
p-value 
Retain for 
multivariable analysis 
Patient-related 
factors 
Age 0.021 Yes 
Gender 0.179 No 
Co-morbidities 0.370 No 
Condition-related 
factors 
Cough 0.970 No 
Phlegm 0.765 No 
Shortness of breath 0.947 No 
Wheeze 0.405 No 
Coryza 0.520 No 
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Domain Variable 
Univariable  
p-value 
Retain for 
multivariable analysis 
Fever 0.094 Yes 
Chest pain 0.490 No 
Muscle aching 0.055 Yes 
Headache 0.734 No 
Disturbed sleep 0.174 No 
Feeling generally unwell 0.350 No 
Interference with normal 
activities 
0.504 No 
Confusion/disorientation 0.818 No 
Diarrhoea 0.331 No 
Clinician-rated symptom severity 
score 
0.086 Yes 
Phlegm colour 0.137 No 
Auscultation abnormality 0.040 Yes 
Number of days with illness 
prior to consulting 
0.560 No 
Therapy-related 
factors 
Dose 0.369 No 
Frequency 0.585 No 
Duration <0.001 Yes 
Healthcare setting-
related factors 
Single handed practices 
widespread 
0.733 No 
Recent public campaigns on 
antibiotic use 
0.171 No 
Payment required to see GP 0.138 No 
Sick certification required for 
missing less than 7 days of work 
0.462 No 
Amoxicillin first line choice of 
antibiotic 
0.794 No 
Country-level prescribing rate 0.258 No 
*Analysis based on up to 7,463 days within 1,057 participants within 281 clinicians within 15 
countries 
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The final multivariable model found that the odds of implementing amoxicillin on a given day 
were higher among older participants (OR for a decade increase = 1.21, 95% CI: 1.03 to 1.41), 
and there was some evidence that it was higher for participants with abnormal auscultation 
findings at their index consultation, though the 95% CI included 1 (OR = 1.71, 95% CI: 1.00 to 
2.91). The odds were lower for participants prescribed courses of amoxicillin lasting eight days 
or more (OR compared to courses lasting up to five days = 0.07, 95% CI: 0.01 to 0.42) (Table 
5.20). 
Sixty-two percent of the total variation in whether amoxicillin was taken on a given day was 
attributable to differences between participants. The clinician and country-level ICCs were both 
0.04. 
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Table 5.20: Four-level logistic regression model investigating the determinants of implementation 
of amoxicillin 
Variable* Odds ratio 
95% CI 
p-value 
Lower Upper 
Age (per decade increase) 1.21 1.03 1.41 0.019 
Auscultation abnormality† 1.71 1.00 2.91 0.050 
Prescribed amoxicillin for 5 days or less Reference category 
Prescribed amoxicillin for 6 or 7 days 1.18 0.22 6.25 
<0.001 
Prescribed amoxicillin for 8 days or more 0.07 0.01 0.42 
Participant from WP8 Reference category 
Participant from WP9 1.23 0.42 3.64 
0.909 
Participant from WP10a 1.18 0.48 2.88 
* The model is based on 7,421 days nested within 1,054 participants, nested within 281 clinicians, 
nested within 15 countries. The ICCs from the final model were: Participant: 0.62; Clinician: 
0.04; Country: 0.04. † At least one of the following: diminished vesicular breathing, wheeze, 
crackles, or rhonchi. 
 
5.3.3.9 Determinants of time to discontinuation of amoxicillin 
Attempts were made to conduct survival analyses that explicitly modelled the multilevel structure 
of the data (i.e. frailty models). However, these models failed to converge for the majority of 
candidate determinants. These analyses are therefore based on single-level Cox proportional 
hazards models with standard errors corrected for clustering of participants within clinicians. In 
addition, the final model was also fitted correcting for the clustering of participants within 
countries, to explore the robustness of findings to alterations in how the standard errors were 
corrected. 
The univariable analysis led to the retention of determinants related to therapy factors (dose and 
duration of prescription) and healthcare setting factors (participants from countries where single 
handed practices were widespread and where recent public campaigns on antibiotic use had 
taken place) (Table 5.21). 
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Findings from the final multivariable model indicated that longer courses were associated with a 
longer time to discontinuation (HR for six to seven days compared to five days or less = 0.30, 
95% CI: 0.17 to 0.55, HR for 8 days or more compared to five days or less = 0.19, 95% CI: 0.10 
to 0.36). Participants from countries where single-handed practices were widespread were 
associated with a shorter time until discontinuation (HR = 1.15, 95% CI: 1.03 to 1.28) (Table 
5.22). These results persisted when the standard errors were corrected for clustering of 
participants within countries (Table 5.23). 
5.3.3.10 Differences across studies 
As indicated by the forest plots, there was insufficient evidence to suggest that the determinants 
found in the models for initiation, implementation, and discontinuation differed within the 
individual studies (Figures 5.5, 5.6, and 5.7). 
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Table 5.21: Univariable analysis of determinants of time to discontinuation of amoxicillin* 
Domain Variable 
Univariable 
p-value 
Retain for 
multivariable analysis 
Patient-related 
factors 
Age 0.273 No 
Gender 0.331 No 
Smoking status 0.312 No 
Co-morbidities 0.189 No 
Condition-related 
factors 
Phlegm 0.389 No 
Shortness of breath 0.217 No 
Wheeze 0.198 No 
Coryza 0.972 No 
Fever 0.549 No 
Chest pain 0.859 No 
Muscle aching 0.245 No 
Headache 0.497 No 
Disturbed sleep 0.405 No 
Feeling generally unwell 0.244 No 
Interference with normal 
activities 
0.445 No 
Confusion / disorientation 0.147 No 
Diarrhoea 0.365 No 
Phlegm colour 0.689 No 
Clinician-rated symptom 
severity score 
0.761 No 
Auscultation abnormality 0.265 No 
Days waited prior to consulting 0.252 No 
Therapy-related 
factors 
Dose 0.017 Yes 
Frequency 0.432 No 
Duration <0.001 Yes 
Healthcare setting-
related factors 
Single handed practices 
widespread 
0.051 Yes 
Recent public campaigns on 
antibiotic use 
0.044 Yes 
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Domain Variable 
Univariable 
p-value 
Retain for 
multivariable analysis 
Payment required to see GP 0.543 No 
Sick certification required for 
missing less than 7 days of work 
0.286 No 
Amoxicillin first line choice of 
antibiotic 
0.255 No 
Country-level prescribing rate 0.133 No 
*Analysis based on up to 1,057 participants, with standard errors corrected for clustering of 
participants within 274 clinicians. 
 
Table 5.22: Cox proportional hazards model of time from initiation to discontinuation of 
amoxicillin 
Domain Variable Odds ratio* 95% Confidence Interval p-value 
Therapy-related 
factor 
Prescribed or five 
days or fewer 
Reference category 
<0.001 
Prescribed for six 
to seven days 
0.30 0.17 to 0.55 
Prescribed for 
eight+ days 
0.19 0.10 to 0.36 
Healthcare 
setting-related 
factor 
Single handed 
practices 
widespread 
1.15 1.03 to 1.28 0.010 
N/A 
Participant from 
WP8 
Reference category 
0.05 
Participant from 
WP9 
0.77 0.56 to 1.06 
Participant from 
WP10a 
0.78 0.64 to 0.96 
*Odds for fully adhering to prescribed treatment, according to self-report diary data. Analysis is 
based on 1056 participants, with confidence intervals corrected for clustering at the clinician level 
(274 clinicians). 
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Table 5.23: Cox proportional hazards model of time from initiation to discontinuation of 
amoxicillin 
Domain Variable Odds ratio* 95% Confidence Interval p-value 
Therapy-related 
factor 
Prescribed or five 
days or fewer 
Reference category 
<0.001 
Prescribed for six 
to seven days 
0.30 0.17 to 0.55 
Prescribed for 
eight+ days 
0.19 0.09 to 0.42 
Healthcare 
setting-related 
factor 
Single handed 
practices 
widespread 
1.15 1.04 to 1.27 0.005 
N/A 
Participant from 
WP8 
Reference category 
0.06 
Participant from 
WP9 
0.77 0.59 to 0.99 
Participant from 
WP10a 
0.78 0.62 to 0.98 
*Same model as above, but with confidence intervals corrected for clustering at the country level 
(15 countries). 
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Figure 5.5: Forest plot illustrating the odds ratios and 95% confidence intervals for the initiation 
model for each individual study and overall* 
 
*Days waited prior to consulting compared to a reference category of 7 days or fewer. Duration 
of prescription variable compared to a reference category of 5 days or fewer.  
0 1 2 3 4 5 6 7
Sick certification required for missing less than 7
days of work - OVERALL
Sick certification required for missing less than 7
days of work - WP10a
Sick certification required for missing less than 7
days of work - WP9
Sick certification required for missing less than 7
days of work - WP8
Duration of prescription (8+ days) - OVERALL
Duration of prescription (8+ days) - WP9
Duration of prescription (8+ days) - WP8
Duration of prescription (6-7 days) - OVERALL
Duration of prescription (6-7 days) - WP9
Duration of prescription (6-7 days) - WP8
Waited 15+ days prior to consulting - OVERALL
Waited 15+ days prior to consulting - WP10a
Waited 15+ days prior to consulting - WP9
Waited 15+ days prior to consulting - WP8
Waited 8-14 days prior to consulting - OVERALL
Waited 8-14 days prior to consulting - WP10a
Waited 8-14 days prior to consulting - WP9
Waited 8-14 days prior to consulting - WP8
Multivariable odds ratio for amoxicillin initiation
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Figure 5.6: Forest plot illustrating the odds ratios and 95% confidence intervals for the 
implementation model for each individual study and overall* 
 
*Duration of prescription variable compared to a reference category of 5 days or fewer  
0 1 2 3 4 5 6
Duration of prescription (8+ days) - OVERALL
Duration of prescription (8+ days) - WP9
Duration of prescription (8+ days) - WP8
Duration of prescription (6-7 days) - OVERALL
Duration of prescription (6-7 days) - WP9
Duration of prescription (6-7 days) - WP8
Auscultation abnormality - OVERALL
Auscultation abnormality - WP10a
Auscultation abnormality - WP9
Auscultation abnormality - WP8
Age (decades) - OVERALL
Age (decades) - WP10a
Age (decades) - WP9
Age (decades) - WP8
Multivariable odds ratio for implementing amoxicillin on a given day
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Figure 5.7: Forest plot illustrating the hazard ratios and 95% confidence intervals for the 
discontinuation model for each individual study and overall* 
 
*Duration of prescription variable compared to a reference category of 5 days or fewer  
0 0.5 1 1.5
Single-handed practices widespread - OVERALL
Single-handed practices widespread - WP10a
Single-handed practices widespread - WP9
Single-handed practices widespread - WP8
Duration of prescription (8+ days) - OVERALL
Duration of prescription (8+ days) - WP9
Duration of prescription (8+ days) - WP8
Duration of prescription (6-7 days) - OVERALL
Duration of prescription (6-7 days) - WP9
Duration of prescription (6-7 days) - WP8
Multivariable hazard ratio for amoxicillin discontinuation
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5.4 Discussion 
5.4.1 Summary 
In this Chapter, several methods for modelling the determinants of adherence to medication 
were investigated. Data from the CODA study were used to compare the determinants of 
adherence to treatment across self-report, tablet count, and electronic monitoring data. Three 
clinical conditions were considered. One short-term condition (lower-respiratory-tract infection), 
and two long-term conditions (ulcerative colitis and breast cancer with bone metastases). Data 
from three studies, two observational and one trial, were compared and combined in order to 
investigate whether (and how) determinants differed across study designs. Several domains of 
determinants of medication adherence were also considered throughout the Chapter. Where 
domains were included at a healthcare professional or healthcare setting-level, modelling 
approaches were considered that appropriately accounted for this. Finally, for the GRACE and 
ZICE studies, a comparison was made between modelling adherence as a single combined 
variable and modelling it based on distinct processes (e.g. initiation, implementation, and 
discontinuation). 
5.4.2 Learning points 
1. Using the CODA study to compare the determinants of adherence across different types 
of measures highlighted the importance of considering the uses and limitations of the 
choice of measure, and how that should depend on the treatment under consideration. 
Using the CODA data, adherence was found to be strongly associated with allocated 
regimen for both self-report and electronic monitoring data, but not for tablet count data. 
As the regimens were three tablets once daily or three tablets in divided doses (therefore 
both groups are required to take the same number of tablets overall), this is hardly 
surprising. Self-report and electronic monitoring data can inform us about patterns in 
adherence, from which we can infer consumption, but tablet count data can only do the 
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latter. While it still may be useful to record consumption using tablet count data in 
instances such as this, it is inadvisable for such a measure to be the primary adherence 
measure, particularly if the aim is for participants to maintain the regimen to which they 
were allocated. 
2. The complexity of treatment was the one determinant that was consistently associated 
with adherence across all studies. Participants in the CODA study were less likely to 
adhere when allocated to take their medication in divided doses (rather than at one point 
during the day), those in the ZICE study were less likely to adhere when allocated to 
intravenous zoledronic acid that required hospital attendance to maintain (rather than 
daily oral medication that could be consumed at home), and those in the GRACE studies 
were less likely to adhere if they were prescribed long courses of amoxicillin. 
3. While the previous learning point may indicate that treatments should be as simple as 
possible, this needs to be balanced against the consequence of non-adherence and how 
this may be amplified in treatments that are simplified. An example of this can be seen 
in the ZICE study, where despite implementation being worse for those prescribed 
intravenous zoledronic acid (compared to those prescribed oral ibandronic acid), the 
latter was still inferior to the former (as I will describe in the next Chapter).  
4. While the three GRACE studies comprised two observational studies and the active arm 
of a double blind placebo-controlled trial, and it was found that the samples differed 
according to their participant, illness, and prescribing characteristics, and adherence 
differed between studies considerably (ranging from 27% to 87%), the mechanisms by 
which adherence / initiation / implementation / time to discontinuation occurred were 
generally consistent across studies. Indeed, all models controlled for study as a fixed 
effect, and determinants of adherence and each of the elements were found that were 
therefore independent of study/ study type.  
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5. Multilevel analysis enabled determinants related to individual characteristics (e.g. the 
person, their condition, their treatment) to be simultaneously account for with 
determinants related to healthcare professionals and healthcare settings. By appropriately 
accounting for the data hierarchy, correct inferences could be drawn regarding the 
magnitude of the influence that each determinant had. In the GRACE studies, the 
amount of clustering at the clinician-level was high, perhaps a quantitative indication of 
therapeutic alliance so often reported in qualitative research as important for achieving  
high levels of adherence (see Chapter 2). Prescribers, and their relationship and 
interaction with patients, would appear to be an important area for further investigation 
with regards to how this influences adherence to medication. 
6. Separating out adherence into distinct processes enabled different sets of determinants 
to be considered. The processes are distinct, and indeed different determinants were 
associated with each. Such nuances would have been missed, had adherence been 
considered as a single variable. While the analysis of initiation and implementation were 
performed separately, in essence the approach taken can be viewed as a hurdle model 
(Mullahy, 1986), where initiation was considered first as a binary variable, and then in 
those who initiate, implementation was considered consequently. This approach made 
fuller use of the available data, and allowed for a better assessment of where the variability 
in the data lie. The distinction between adherence when considered as a single variable 
and when it was separated out into its elements was clearer for the GRACE study than it 
was for ZICE, as almost all participants in the ZICE study initiated treatment. Clearly, 
the level of adherence and each adherence element needs inspecting before determining 
the necessity of this approach. 
7. Following from the previous point, while I could see the value of investigating the 
determinants of initiation and implementation of amoxicillin (that is, they are elements 
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that are desirable to intervene on), there was arguably less necessity in investigating the 
determinants of time from initiation to discontinuation (regardless of how well the 
amoxicillin was implemented). There needs to be a clear rationale behind the decision 
around which elements are of interest. 
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CHAPTER 6: Adjusting Findings of Randomised 
Controlled Trials for Medication Non-Adherence: The 
Use of Randomisation-Based Efficacy Estimators 
6.1 Introduction 
Chapters 4 and 5 of this thesis focused on the investigation of different modes of medication 
adherence measurement, and methods for modelling the determinants of medication non-
adherence, in clinical research. While these topics are crucial in the study of medication 
adherence, the consumption of the majority of medicine relies on individual decision making, 
and inevitably non-adherence will occur, even in clinical research. When there is interest in the 
relationship between use of medication and clinical outcomes (e.g. use of antidepressants and 
incidents of self-harm, use of antibiotics and time to recovery from pneumonia, etc.), this interest 
generally centres on determining the causative nature of the relationship. Determining the causal 
nature of a treatment is not straightforward even in randomised controlled trials (RCTs), where 
participants are allocated to treatment groups at random, as the choice to consume the allocated 
treatment is unlikely to be determined at random (i.e. independent of both observed and 
unobserved confounders). While this is an issue for all RCTs, the problem is compounded for 
RCTs that are designed to evaluate whether a new treatment is equivalent to (or no worse than) 
an existing treatment. Traditional approaches for investigating these relationships in RCTs make 
implicit assumptions (e.g. medication non-adherence occurs completely at random) which are 
likely implausible in practice. Approaches that are randomisation-respecting exist, and are 
becoming increasingly popular, but are generally only reported in specialist methodological 
journals. 
The aims of this Chapter, therefore, is to explore the use of randomisation-based efficacy 
estimators for adjusting findings of RCTs for medication non-adherence, and the feasibility of 
their implementation for different trial designs. 
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To meet these aims, this Chapter will draw on data from the GRACE WP10a, CODA, and 
ZICE studies. 
6.2 Methods 
6.2.1 Randomised Controlled Trials and their importance for inferring 
causal treatment effects 
One of the key reasons we perform experiments is to determine the effect that a treatment has 
on some outcome of interest, that is, the causal effect. Causal effects in health sciences research 
are generally represented using potential outcomes or graphical models. The former relies on 
counterfactuals, that is, the outcome that would have happened if, contrary to the fact, the 
exposure of interest had been something other than what it actually was. The latter relies on fixing 
conditions. That is, the outcome when physically forcing an exposure on an individual. While 
graphical methods can be useful for displaying assumptions inherent in analytical approaches, 
potential outcomes have been more useful in developing these approaches. See Greenland and 
Brumback 2002 for a more detailed overview of different types of causal models found in health 
sciences research. I have chosen to describe causal effects throughout my thesis using the 
potential outcomes framework because the analytical techniques I implement are based on this 
framework. However, I also illustrate these approaches using graphical methods to give the 
reader a more visual interpretation. Ideally, causal effects would be measured at the level of the 
individual. However, without simultaneously observing the effect of both giving and not giving 
treatment, we will never be able to calculate a true individual-level treatment effect (Figure 6.1). 
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Figure 6.1: Illustration of an individual-level treatment effect 
 
Instead of striving to directly calculate these individual-level effects, we instead calculate 
population-level (or average) treatment effects, where the average outcomes of individuals in the 
treated group are compared to those in the untreated group, and we use this calculation as an 
estimate for the individual-level effects. For this estimate to be valid, the choice to be in the 
treated / untreated group must be made at random (Figure 6.2). If the choice is not made at 
random, the estimate is likely to be biased unless the decision to choose one group over another 
(i.e. the selection mechanism) is measured and adjusted for. This is unlikely in most 
circumstances, where typically some variables that contribute to the selection mechanism will 
remain unmeasured. (Lewis, 1999) 
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Figure 6.2: Illustration of a population-level (average) treatment effect from a randomised 
experiment 
 
RCTs involve the allocation of participants to groups at random, and hence provide unbiased 
estimates of the causal effect of being in one group (e.g. being given a new treatment to take), 
compared to another group (e.g. given a placebo to take, or given a different/standard treatment 
to take). These comparisons are generally then used to test hypotheses regarding the difference 
between groups (also known as “superiority”) (i.e. null hypothesis, 𝐻0, stating that the two groups 
are the same (𝜇1 = 𝜇2), alternative, 𝐻1, stating that they are different (𝜇1 ≠ 𝜇2)) (Moher et al., 
2010). However, for some RCTs, the purpose of the comparison lies in testing different 
hypotheses, such as whether the groups are equivalent (𝐻0: |𝜇1 − 𝜇2| > ∆; 𝐻1: |𝜇1 − 𝜇2| < ∆, 
where ∆ is a margin that represents an acceptable / negligible difference), or whether one (e.g. a 
new treatment) is not inferior to another (e.g. an existing / standard treatment). For these non-
inferiority trials, the hypotheses are 𝐻0: 𝜇1 − 𝜇2 > ∆ and 𝐻1: 𝜇1 − 𝜇2 < ∆  (i.e. the one-sided 
version of the equivalence hypotheses). Commonly, comparisons from these trial designs are 
also interpreted using confidence intervals (Figure 6.3). (Piaggio et al., 2006) 
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Figure 6.3: Confidence intervals illustrating some conclusions drawn from different study 
designs* 
 
*Dashed lines indicate the limit that is not of interest extends to minus infinity. 
The work presented in this Chapter will focus on two-arm RCTs, including superiority trials 
where one treatment is compared to a placebo control, and non-inferiority trials that compare a 
new treatment against an existing / standard treatment (active control). 
6.2.2 Estimating treatment effectiveness in RCTs 
The gold standard approach to estimating treatment effectiveness in RCTs (i.e. the performance 
of a treatment under ‘real-world’ conditions (Singal et al., 2014)) is based on the Intention To 
Treat (ITT) principle, where participants are analysed in the groups to which they were originally 
randomised. (Montori and Guyatt, 2001) This approach preserves a comparison of groups as 
randomised, and in the presence of perfect adherence also provides an unbiased comparison of 
treatment efficacy (performance of the treatment under ideal circumstances), while in the 
presence of imperfect adherence it provides an unbiased estimate of offering treatment. 
0 New treatment worse than comparator  New treatment better than comparator
Inconclusive (no evidence of superiority)
Superiority
Superior
Inconclusive (no evidence of equivalence)
Equivalence
Equivalent
Inferior
Non-inferiority
Not inferior
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6.2.3 Traditional methods for estimating treatment efficacy in RCTs 
As described above, under certain circumstances an ITT analysis can be used to estimate 
treatment efficacy in RCTs. However, non-adherence to medication is an issue that pervades 
many RCTs, and in the presence of non-adherence (or departures from randomised treatment), 
efficacy based on an ITT analysis may provide an estimate that is biased towards demonstrating 
no differences between treatments. While this is deemed conservative for a trial aiming to 
determine whether or not there is a difference between treatments (and, in conjunction with its 
randomisation-respecting nature, why it is considered the gold standard approach for the analysis 
of these designs (Moher et al., 2010)), for a non-inferiority trial this is anticonservative, as it is 
desirable for treatment groups to be as similar as possible. (Jones et al., 1998 and ICH Steering 
Committee, 1998) 
The most common approach to assessing treatment efficacy in an RCT that accounts for 
treatment non-adherence is to conduct a per-protocol (PP) analysis. This analysis excludes 
participants who have not adhered to their randomised treatment (Figure 6.4). However, this 
approach fails to maintain a comparison of groups as randomised, and is therefore prone to 
selection bias (a phenomenon whereby individuals’ membership in a group is not determined at 
random). While selection bias is thought to be minimised in trials with blinding, and modified 
definitions of these populations that adjust for observed confounders can be used (a confounder 
being a variable that is correlated with both exposure and outcome), selection bias can never be 
completely discounted from any analyses that make post-randomisation exclusions or 
manipulations. Nevertheless, PP analyses are commonly reported alongside ITT analyses in 
publications of RCT findings (see Chapter 2). Indeed, due to the anticonservative nature of ITT 
analysis in non-inferiority trials, it is recommended to conduct a PP analysis alongside an ITT 
analysis and only conclude non-inferiority if indicated in both analyses. (Lesaffre, 2008) 
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Figure 6.4: Illustration of a per-protocol analysis 
 
 
To estimate treatment efficacy in RCTs, the ideal analytical method would be based on 
participants who received the treatment to which they were allocated, whilst maintaining a 
comparison of groups as randomised. This approach would avoid selection bias, while also 
yielding an estimate of the causal effect of receiving treatment. 
6.2.4 Randomisation-based efficacy estimators 
Randomisation-based efficacy estimators (RBEEs) compare outcomes between groups of 
participants who were allocated to and received treatment with groups not allocated to treatment, 
but who would have received treatment had they been allocated to the treatment group. (White, 
2005) By taking a potential outcomes framework perspective on causal modelling, and 
recognising that at the beginning of a trial all participants have two potential outcomes – one if 
they are treated and one if they are not, a RBEE relates average outcomes in treated participants 
to their (potentially counterfactual) outcomes that would have been observed had they received 
no treatment (i.e. their treatment-free outcome). (Frangakis and Rubin, 2002) 
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Inferring causal treatment effects from RBEEs relies on the following core assumptions (Angrist 
and Imbens, 1996): 
 For binary adherence (adhered / did not adhere) adherence-type is a latent trait, a 
baseline characteristic that is independent of randomisation. One way to think of RBEEs 
is as the ITT effect in the sub-group of participants who would always adhere to treatment 
(Figure 6.5). 
 An individual’s outcome is unaffected by the treatment received by another individual. 
 Due to randomisation, the expected proportion of non-adherers will be the same in each 
group. 
 In the absence of treatment, randomisation in and of itself has no effect on outcome. 
This assumption is often referred to as the exclusion restriction. 
Figure 6.5: Illustration of randomisation-based efficacy estimator (green ticks correspond to those 
who would adhere to treatment if allocated to it) 
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By treating randomisation as an instrument (i.e. assuming that it is independent of both observed 
and unobserved confounders, and only effects outcome through its effect on exposure to 
treatment), the observed data on exposure to treatment can be used to obtain estimates of the 
effect of taking treatment that avoids selection bias (Figure 6.6). RBEEs can be estimated using 
Structural Mean Models (SMM), whereby a value of the treatment effect is found such that 
balance is achieved between groups on the outcome in participants who were not treated (i.e. the 
treatment-free outcome). 
Figure 6.6: Causal Directed Acyclic Graph (DAG) illustrating the use of randomisation as an 
instrument to derive a randomisation-respecting estimate of treatment efficacy 
 
6.2.4.1 RBEEs in active control trials 
The methodological approach described above relies on a comparison between an active 
treatment and no treatment (or placebo). In trials comparing two active treatments, a common 
feature of non-inferiority trials, there is no observed outcome on which to base the potential 
outcome in the untreated/treatment-free group, and therefore the method cannot readily be 
applied. 
Following Fischer et al. (2011), for a two-arm trial where n participants are allocated to one of 
two active treatments, we can define the structural mean models for treatments A and B as: 
𝐸[𝑌𝑖
𝐴 − 𝛾 𝐴(𝐶𝑖
𝐴, 𝑋𝑖; Ψ
𝐴)|𝐶𝑖
𝐴, 𝑋𝑖] = 𝐸[𝑌𝑖
0|𝐶𝑖
𝐴, 𝑋𝑖]  and 
𝐸[𝑌𝑖
𝐵 − 𝛾𝐵(𝐶𝑖
𝐵, 𝑋𝑖; Ψ
𝐵)|𝐶𝑖
𝐵, 𝑋𝑖] = 𝐸[𝑌𝑖
0|𝐶𝑖
𝐵, 𝑋𝑖],  
Randomisation Exposure
Confounders
Outcome
188 
 
where 𝑖 = 1, … , 𝑛, 𝑌𝑖
𝐴, 𝑌𝑖
𝐵
  are (potential) outcomes under assignment to A or B respectively, 
𝑌𝑖
0
 is the potential treatment-free outcome, 𝐶𝑖
𝐴, 𝐶𝑖
𝐵
 are (potential) vectors of treatment 
adherence summaries observed under assignment to A or B respectively, 𝑋𝑖 is a vector of 
baseline covariates,   𝑅𝑖
𝐴, 𝑅𝑖
𝐵
  are randomisation indicators with value 1 when a participants is 
allocated to A (B, respectively) and 0 otherwise (and where the observed outcome, 𝑌𝑖 =
𝑌𝑖
𝐴𝑅𝑖
𝐴 + 𝑌𝑖
𝐵𝑅𝑖
𝐵
), and assumes that the average effects of allocation to A and B are known 
functions 𝛾 𝐴 and 𝛾𝐵 of adherence, baseline characteristics and unknown parameter vectors Ψ𝐴 
or Ψ𝐵, respectively. (Goetghebeur and Lapp, 1997) The exclusion restrictions 𝛾 𝐴(0, 𝑋𝑖; Ψ
𝐴) =
0 and 𝛾𝐵(0, 𝑋𝑖; Ψ
𝐵) = 0 state that if no active treatment is received, the expected outcome 
equals the expected treatment-free outcome. However, as the distribution of the potential 
treatment-free outcome is not observed for trials with two active treatments, this estimator is not 
directly applicable. 
One approach that attempts to address this issue is based on identifying baseline covariates that 
are differentially associated with exposure to treatment (or treatment adherence) for each of the 
treatments. The method enables distinct causal estimators to be derived, from which a contrast 
can be made (the contrast between the two treatments generally being of primary interest). These 
baseline covariates must also be independent of outcome, therefore allowing separate sets of 
instruments to be derived for each treatment and a potential treatment-free response to be 
estimated (Figure 6.7). 
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Figure 6.7: Causal DAG illustrating the IV approach to deriving randomisation-respecting 
treatment efficacy with two active treatments 
 
When the main interest is in comparing the use (efficacy) of two active treatments, identifying 
distinct causal parameters that can then be contrasted is of greatest interest. However, in practice 
it is not always possible to identify baseline covariates that differentially predict treatment 
adherence while remaining independent of outcome. When this is the case, it is still possible to 
derive the following: 
 An estimate of treatment efficacy in the subpopulation who would always adhere to their 
allocated treatment at a fixed level (that is, if we were to intervene and fix adherence levels 
the same in both treatment arms) 
 Estimates of treatment efficacy at varying levels of adherence (by performing a series of 
sensitivity analyses that involves varying adherence parameters) 
 An estimate of treatment efficacy at varying levels of exposure to the experimental 
treatment compared to being assigned to the standard treatment, regardless of adherence 
levels in this group (by fitting standard structural mean models and treating the standard 
treatment as the treatment-free/placebo group) 
Randomisation
Exposure to treatment 1
Confounders
Outcome
Baseline predictors 
of exposure to 
treatment 1
Exposure to treatment 2
Baseline predictors 
of exposure to 
treatment 2
Confounders
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6.2.5 Modelling RBEEs in a two-arm placebo-controlled superiority trial 
Data from the GRACE WP10a trial was used to produce adherence-adjusted estimates of the 
benefits and harms of amoxicillin for adults consulting in primary care with an acute 
uncomplicated LRTI, whilst preserving a comparison of groups as randomised. 
As reported in previous Chapters, adherence was measured in three ways during this trial: using 
self-reported diaries, via tablet counts, and over the telephone (usually for participants who did 
not return a diary). In Chapter 4 it was shown that while agreement between different types of 
measures was generally good, some discrepancies did occur. During this Chapter, where multiple 
types of measure are available, the minimum reported adherence value was used for analysis. 
Randomised participants were prescribed 42 tablets. Adherence to study medication was defined 
as the percentage of the correct number of tablets taken during the first seven days of the follow-
up period (i.e. the period for which the medication was prescribed). Three binary definitions of 
adherence were also constructed in order to provide sensitivity analyses around the 
continuous/quantitative definition. The three binary definitions were full (100%) adherence 
versus not full adherence, at least the equivalent of a five-day course (approx. 71.4%) versus less 
and at least one tablet versus no tablets (i.e. initiated/did not initiate). 
To demonstrate the benefits and harms of taking amoxicillin in this population, the analysis 
focused on the following three clinical outcomes. The first was the mean clinician-rated symptom 
severity between days two and four after initial presentation. The second was the development 
of new or worsening symptoms, defined as returning to the clinician with new or worsening 
symptoms, new signs or an illness requiring admission to hospital within the four week follow-up 
period. The third outcome was the presence of any non-respiratory symptoms (diarrhoea, skin 
rash or vomiting) during the four week follow-up period. These specific symptoms were recorded 
as they are known side effects of amoxicillin. The first two outcomes were used to demonstrate 
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the clinical benefits of amoxicillin for patients with an acute uncomplicated LRTI in primary 
care, with the third used to demonstrate harms. 
Two-stage instrumental variables regression was used to fit SMMs to the above outcomes. 
(Fischer-Lapp and Goetghebeur, 1999) This procedure involved regressing the exposure variable 
onto the instrument/s during the first stage, saving the predicted values from this regression, and 
then, in the second stage, regressing the outcome onto the predicted values. A correction is made 
during the second stage in order to obtain correct standard errors. The between-group mean 
difference in symptom severity on days two to four was estimated using a two-stage least squares 
instrumental variables regression model. To compare the odds of developing new or worsening 
symptoms and reporting any non-respiratory symptoms, a generalised linear (double logistic) 
SMM was estimated via a generalised method of moments procedure. The double logistic SMM 
involves an additional stage, whereby the association between outcome (development of new or 
worsening symptoms or reporting of side effects), trial arm and adherence was modelled first, 
with estimates from this model used in the SMM in order to obtain correct standard errors (and 
hence correct 95% confidence intervals). (Vansteelandt and Goetghebeur, 2003) As the main 
adherence measure is on a scale ranging from 0 to 100 (i.e. the percentage of the correct number 
of tablets taken during the first seven days of the follow-up period), the coefficient from the 
SMMs are interpreted as the effect per percentage point increase in adherence. These effects are 
then multiplied by 100 to give an interpretation for those who completely adhere to study 
medication. See Box 6.1 for an outline and further description of the syntax used for these 
models. 
6.2.6 Modelling RBEEs in non-inferiority trials with two active 
treatments 
Data from the CODA and ZICE trials were used to illustrate how RBEEs can be fitted for non-
inferiority trials with two active treatments, including their utility and limitations. These trials 
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differed in terms of the nature of the interventions being compared, with CODA comparing the 
same treatment prescribed with different regimens, and ZICE comparing two different 
treatments with different modes of administration. These examples, while contrasting, are typical 
of the types of non-inferiority trials conducted, and will therefore provide useful insight into the 
methods proposed. 
As described in Chapter 5, adherence to study medication in the original CODA trial analysis 
was defined as participants consuming at least 75% of their issued medication. This definition 
will also be used for the analysis presented in this Chapter. For the ZICE trial, adherence will be 
based on the combined summary measure, also described in Chapter 5. 
For the CODA trial, the outcome of interest was the proportion of participants relapsing during 
the 12 month study period. The OD regimen was considered to be non-inferior to the TDS 
regimen as long as the lower bound of the 95% confidence interval of the difference in the 
proportion of participants in each arm relapsing (OD minus TDS) did not include minus 0.1 
(i.e. the difference in the proportion of participants relapsing, between participants allocated to 
OD compared to those allocated to TDS, had to be less than 10 percentage points). For the 
ZICE trial, the outcome of interest for this analysis was the proportion of participants 
experiencing a skeletal-related event (SRE) during the first 12 months of the study. This is a 
simplified version of the primary outcome from the main trial analysis (which was based on the 
time and frequency of SREs and analysed using an Andersen-Gill model (Andersen and Gill, 
1982)), and used for illustration purposes only. There was therefore no pre-specified non-
inferiority margin for this outcome. 
Deriving distinct causal estimators for each treatment arm relied on identifying baseline variables 
that predicted adherence to treatment differently in each arm, whilst not predicting clinical 
outcome (that is, they are used as instruments for the separate treatments). Determining these 
predictors involved two main steps. First, multivariable logistic regression was used to determine 
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the factors that predicted clinical outcome. Variables that were identified univariably at the 20% 
significance level were entered into the multivariable model, with backward selection used to 
retain variables independently associated at the 10% significance level. Following this, 
multivariable logistic regression was used, with the binary adherence variable as the outcome of 
interest. Predictors of adherence were entered one-by-one into a regression model that included 
trial arm, and interaction between candidate predictor and trial arm, and the predictors of clinical 
outcome that were identified during the previous step. Any variables that were associated with 
adherence at the 20% significance level, as either a main effect or as an interaction with trial arm, 
were retained in the multivariable regression model. Predictors that remained associated at the 
10% significance level were then retained in the final regression model. 
For the CODA trial, the candidate baseline predictors used in the outcome and adherence 
models were age (<65, ≥65), age at diagnosis (≤25, 26-45, 46-64, ≥65), gender, length of remission 
(<12 months, ≥12 months), calprotectin concentration (<60mg/kg stool, ≥60 mg/kg stool), 
smoking status (never smoker, current smoker, ex-smoker), employment status (unemployed, 
employed), maximum documented extent of colitis (extensive, left-sided or sigmoid, proctitis), 
disease duration (≤10 years, 11 to 20 years, >20years), number of relapses during the past two 
years (1, 2, 3, ≥4), and endoscopy findings (normal, not normal). 
For the ZICE trial, the candidate predictors were age, gender, Body Mass Index (BMI), the 
modified Brief Pain Inventory severity score, Quality of Life (EORTC QLQ-C30 score version 
3.0 (Fayers et al., 2001)), SRE within the previous three months, previous use of 
bisphosphonates, treatments being received (including painkilling drugs, chemotherapy, 
hormone therapy, and trastuzumab). 
The SMM models were fitted using a two-stage least squares instrumental variables regression 
approach. Using this procedure, the trial arm (the instrument), predictors of outcome, and 
differential predictors of adherence were used to estimate values of the adherence variables in 
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the first stage. These values were then regressed onto the outcome in the second stage. The 
Huber-White robust standard error, with additional correction for small-samples, was used in 
order to make correct inferences about the differences in proportions. (Cheung, 2007) Box 6.2 
provides sample syntax using Stata. 
Box 6.1: Stata syntax for the structural mean models used for RBEEs in the GRACE WP10a 
trial 
Structural mean model for the between-group difference in the mean clinician-rated symptom 
severity between days two and four after initial presentation using two-stage least squares 
instrumental variables regression 
ivregress 2sls y c (x=z) 
In the syntax above, y = outcome, c = covariate, x = exposure, and z = randomisation indicator 
Generalised linear (double logistic) structural mean model for the between-group ratio of the 
odds of developing new or worsening symptoms and reporting any non-respiratory symptoms 
using generalised method of moments 
logit y x z 
matrix from = e(b) 
predict xblog, xb 
gmm (invlogit(xblog - x*{psi})-ey0), instruments(z) 
matrix from = (from, e(b)) 
gmm (y - invlogit({xb: x z} + {b0})) (invlogit({xb:} + {b0} - x*{psi}) - ey0), instruments(1:x z) 
instruments(2:z) winitial(unadjusted, independent) from(from) 
lincom[psi]_cons, eform 
estat overid 
In the syntax above, y = outcome, x = exposure, z = randomisation indicator, ey0 = mean 
exposure-free potential outcome (to stabilise the model, this has been fixed as the proportion of 
people with positive outcomes in the control group. It can however be directly estimated from 
the model). This model requires an additional stage (an associational model) because collapsing 
the logistic SMM over observed exposure (z) depends on the distribution of z. It is therefore not 
possible to derive causal odds ratios in a single stage. The stages are first run individually to obtain 
initial values for the joint estimation. The stages are then run jointly to produce standard errors 
that correctly incorporate the error from the first stage of the model. 
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Box 6.2: Stata syntax for modelling RBEEs in the CODA and ZICE trials 
Structural mean model for the between-group difference in proportion of participants relapsing 
during the 12-month follow-up period using two-stage least squares instrumental variables 
regression 
ivregress 2sls y (x=z), vce(robust) 
In the syntax above, y = outcome, x = exposure, and z = randomisation indicator. The use of the 
robust standard error is indicated by vce(robust). 
Structural mean model for the between-group difference in proportion of participants 
experiencing a skeletal-related event during the first 12 months of the study using two-stage least 
squares instrumental variables regression 
ivregress 2sls y c1 c2 (x1 x0 = z c1 z*c1 c2 z*c2), vce(robust) 
lincom[<<Experimental treatment arm effect>> - <<Standard treatment arm effect>>] 
In the syntax above, y = outcome, c1 = predictors of outcome, c2 = predictors of adherence, x1 
= exposure in the experimental arm, x2 = exposure in the standard arm, and z = randomisation 
indicator. An interaction is denoted by a *. The use of the robust standard error is indicated by 
vce(robust). The lincom command allows for a linear comparison between two estimates from a 
previously run model. 
For the CODA trial, the adherence indicator was one variable that was 1 if the participant was 
allocated to the OD arm (experimental intervention) and adhered, 0 if they were allocated to the 
OD arm and did not adhere, and also 0 if they were allocated to the TDS arm (standard care). 
For the ZICE trial, as distinct causal parameters were identifiable, each arm had its own variable 
to denote adherence. This variable was 1 if the participant was allocated to the arm and adhered, 
0 if they were allocated to the arm and did not adhere, and 0 if they were allocated to the other 
arm. 
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6.3 Results 
6.3.1 RBEEs in superiority trials: analysis of the GRACE WP10a trial 
2061 participants were recruited and randomised to either the amoxicillin group (1038) or 
placebo (1023) (Figure 6.8). The groups were well matched on baseline characteristics (Table 
6.1). 
Figure 6.8: CONSORT flow diagram for participants in the GRACE WP10a trial 
 
As reported in Chapter 4, adherence data were available for 1854 participants (90.0% of all 
randomised participants), and the majority of participants had multiple types of measure 
recorded (1214, or 58.9% of all randomised). Taking the minimum value, when more than one 
type of adherence measure was available, adherence to study medication was similar between 
trial arms and relatively high and negatively skewed overall (Table 6.2). Translating adherence 
from a percentage score into an equivalent number of days of amoxicillin consumed (assuming 
42 tablets were prescribed and six tablets were meant to be taken per day for seven days, so one 
day equals 100*[6/42] = 14.3%) Figure 6.9 illustrates the high percentage of participants who fully 
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adhered to study medication (72.3%), took at least five days’ worth of medication (84.5%), and 
initiated medication (96.2%). 
Table 6.1: Baseline characteristics of GRACE WP10a trial participants 
Baseline characteristic Amoxicillin Placebo 
Women 624/1038 (60.1%) 600/1023 (58.7%) 
Age (years) 48.6 (16.7) 49.3 (16.4) 
Non-smoker (past or 
present) 
477/1037 (46.0%) 483/1022 (47.3%) 
Illness duration before index 
consultation (days) 
9.5 (8.0) 9.3 (7.2) 
Respiratory rate (breaths per 
minute) 
16.9 (3.3) 16.9 (3.3) 
Body temperature (℃) 36.7 (3.3) 36.8 (3.3) 
Lung disease* 163/1037 (15.7%) 147/1023 (14.4%) 
Mean severity score (all 
symptoms)
†
 
2.1 (0.5) 2.1 (0.5) 
Mean severity score (cough)
†
 3.1 (0.7) 3.2 (0.7) 
Sputum production 814/1036 (78.6%) 824/1021 (80.7%) 
Discoloured sputum
‡
 481/968 (49.7%) 468/957 (48.9%) 
Data are n/N (%) or mean (SD). *Chronic obstructive pulmonary disease or asthma. †Severity 
of symptoms: 1=no problem; 2=mild problem; 3=moderate problem; 4=severe problem. 
‡Green, yellow or blood-stained. 
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Table 6.2: Levels of adherence to study medication used for statistical analyses (with the 
minimum value reported when participants had more than one type of measure)  
 
Amoxicillin 
(n = 930) 
Placebo 
(n = 924) 
Overall 
(n = 1854) 
Mean 
(SD) 
88.0  
(25.8) 
86.6 
(27.2) 
87.3 
(26.5) 
Median 
(IQR) 
100.0 
(95.2 to 100.0) 
100.0 
(85.7 to 100) 
100.0 
(90.5 to 100.0) 
Min to Max 0.0 to 100.0 0.0 to 100.0 0.0 to 100.0 
 
Figure 6.9: Proportion of participants at each adherence level (with the minimum value reported 
when participants had more than one type of measure) 
 
Table 6.3 provides descriptive statistics for each of the three clinical outcomes. As reported in 
the original paper, the adjusted between-group mean difference in symptom severity score on 
days two to four was slightly lower in the amoxicillin group than the placebo group (adjusted 
mean difference of -0.07, 95% C.I. -0.15 to 0.01). Being allocated to the amoxicillin arm (i.e. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Placebo (n=924)
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Total (n=1854)
Percentage of participants
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being prescribed amoxicillin) was associated with decreased odds of developing new or worsening 
symptoms in the four weeks post-randomisation follow-up period. The odds of developing new 
or worsening symptoms were 21% lower for participants who were prescribed amoxicillin than 
for those prescribed a matched placebo (OR = 0.79, 95% C.I. 0.63 to 0.99). When the 
effectiveness analyses were only performed on participants for whom both outcome and 
adherence data were available, there was a 19% decrease in the odds of developing new or 
worsening symptoms in participants prescribed amoxicillin (OR = 0.81, 95% C.I. 0.64 to 1.03). 
Being prescribed amoxicillin was associated with a 28% increase in the odds of reporting non-
respiratory symptoms (side effects) in the four weeks post-randomisation (OR = 1.28, 95% C.I. 
1.03 to 1.59). 
Table 6.3: Descriptive statistics of the three outcome measures 
Outcome Amoxicillin Placebo 
Mean symptom severity 
between days 2 and 4 post-
randomisation* 
1.6 (0.8) 1.7 (0.8) 
Development of new or 
worsening symptoms in the 4 
weeks post-randomisation 
162/1021 (15.9) 194/1006 (19.3) 
Reported non-respiratory 
symptoms/side effects in the 
4 weeks post-randomisation 
249/867 (28.7) 206/860 (24.0) 
Data are n/N (%) or Mean (SD). * Each symptom was scored from 0 to 6 (0=no problem, 1=very 
little problem, 2=slight problem, 3=moderately bad, 4=bad, 5=very bad, 6=as bad as it could be).  
 
Adjusting for adherence using the SMM, the between-group mean difference in symptom 
severity score for participants who complete their course of amoxicillin increased by a small 
amount, compared to the ITT estimate (mean difference for 100% adherence -0.08, 95% C.I. -
0.17 to 0.01). For the symptom severity outcome, Figure 6.10 provides a graphical illustration of 
the SMM and how it relates to the original effectiveness analysis. The treatment efficacy when 
adherence is 0% is 0 (an illustration of the exclusion restriction), the ITT (effectiveness) is 
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illustrated by the diamonds (positioned at an adherence level of 88% - the patient-average), and 
the maximum efficacy when adherence is 100% (circles). 
The odds of developing new or worsening symptoms remained lower in participants who took 
their full course of amoxicillin (OR for 100% adherence to amoxicillin = 0.81, 95% C.I. 0.66 to 
0.98). A small increase in the odds of reporting non-respiratory symptoms was found when 
adjusting for adherence (OR for 100% adherence = 1.32, 95% C.I. 1.12 to 1.57) (Table 6.4).
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Figure 6.10: Graphical illustration of the effectiveness and efficacy of amoxicillin on mean symptom severity on days two to four 
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Refitting the above efficacy analyses with binary definitions of adherence, the results 
remained largely similar and did not alter the conclusions drawn by either the efficacy or 
indeed the effectiveness analyses. The most extreme definition of adherence (full vs. not) 
yielded the largest between group differences and the least extreme (at least one tablet vs. 
none) yielded the smallest (Table 6.5). 
Table 6.4: Comparison of effectiveness and efficacy of amoxicillin for acute uncomplicated 
LRTI in primary care 
Outcome 
Effectiveness* 
 
Effectiveness 
for whom 
adherence 
data were 
also 
available
†
 
Efficacy per 
10% increase 
in adherence
†
 
Maximum 
efficacy (100% 
adherence)
†
 
Adjusted 
between-group 
mean difference 
in symptom 
severity between 
days 2 and 4 
post-
randomisation 
-0.07 
(-0.15 to 0.01) 
-0.07 
(-0.15 to 
0.01) 
-0.008  
(-0.017 to 
0.001) 
-0.08  
(-0.17 to 0.01) 
Odds ratio for 
developing new 
or worsening 
symptoms in the 
4 weeks post-
randomisation 
0.79  
(0.63 to 0.99) 
0.81 
(0.64 to 
1.03) 
0.978 
(0.960 to 
0.998) 
0.81 
(0.66 to 0.98) 
Odds ratio for 
reporting non-
respiratory 
symptoms/side 
effects in the 4 
weeks post-
randomisation 
1.28 
(1.03 to 1.59) 
1.28 
(1.04 to 
1.59) 
1.028 
(1.011 to 
1.046) 
1.32 
(1.12 to 1.57) 
* Analysis based on 1789, 2027 and 1727 participants for the symptom severity, new 
symptoms and side effect outcomes respectively. † Analysis based on 1787, 1923 and 1725 
participants for the symptom severity, new symptoms and side effect outcomes respectively. 
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Table 6.5: Efficacy analyses with binary definitions of adherence (for sensitivity) 
Outcome 
Efficacy with binary 
definition of 
adherence 
(full vs. not full) 
Efficacy with binary 
definition of 
adherence 
(at least five day 
course vs. less than 
five day course) 
Efficacy with binary 
definition of 
adherence 
(at least one tablet 
vs. no tablets) 
Adjusted between-
group mean 
difference in 
symptom severity 
between days 2 and 
4 post-
randomisation 
-0.10 
(-0.20 to 0.01) 
-0.08 
(-0.18 to 0.01) 
-0.07 
(-0.15 to 0.01) 
Odds ratio for 
developing new or 
worsening 
symptoms in the 4 
weeks post-
randomisation 
0.78 
(0.62 to 0.98) 
0.80 
(0.65 to 0.98) 
0.82 
(0.69 to 0.98) 
Odds ratio for 
reporting non-
respiratory 
symptoms/side 
effects in the 4 
weeks post-
randomisation 
1.43 
(1.15 to 1.79) 
1.35 
(1.26 to 1.62) 
1.29 
(1.11 to 1.50) 
 
When the data used to estimate adherence are missing, there may remain some residual 
bias in these efficacy analyses. To understand how severe this bias could be (particularly, 
how low the odds ratio for new or worsening symptoms could be), further sensitivity 
analyses were conducted. Table 6.6 provides the findings of these additional sensitivity 
analyses where participants with missing adherence data are assumed to have not taken any 
study medication (i.e. their adherence level is 0%). The findings demonstrate that making 
this most extreme assumption about missing adherence data did not alter the clinical 
conclusions that were drawn from the analyses. 
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Table 6.6: Efficacy analysis with missing adherence data imputed as 0% 
Outcome 
Effectivene
ss* 
 
Effectiven
ess for 
whom 
adherence 
data were 
also 
available
†
 
Efficacy 
per 10% 
increase 
in 
adheren
ce
†
 
Maximu
m 
efficacy 
(100% 
adherenc
e)
†
 
Efficacy 
per 10% 
increase 
in 
adherenc
e*
§
 
Maximum 
efficacy 
(100% 
adherence
)*
§
 
Adjusted 
between-
group mean 
difference 
in symptom 
severity 
between 
days 2 and 
4 post-
randomisati
on 
-0.07 
(-0.15 to 
0.01) 
-0.07 
(-0.15 to 
0.01) 
-0.008  
(-0.017 
to 0.001) 
-0.08  
(-0.17 to 
0.01) 
-0.008 
(-0.017 to 
0.001) 
-0.08  
(-0.17 to 
0.01) 
Odds ratio 
for 
developing 
new or 
worsening 
symptoms 
in the 4 
weeks post-
randomisati
on 
0.79  
(0.63 to 
0.99) 
0.81 
(0.64 to 
1.03) 
0.978 
(0.960 to 
0.998) 
0.81 
(0.66 to 
0.98) 
0.973 
(0.954 to 
0.994) 
0.76 
(0.62 to 
0.94) 
Odds ratio 
for 
reporting 
non-
respiratory 
symptoms/s
ide effects 
in the 4 
weeks post-
randomisati
on 
1.28 
(1.03 to 
1.59) 
1.28 
(1.04 to 
1.59) 
1.028 
(1.011 to 
1.046) 
1.32 
(1.12 to 
1.57) 
1.028 
(1.011 to 
1.046) 
1.32 
(1.11 to 
1.56) 
*Analysis based on 1789, 2027 and 1727 participants for the symptom severity, new 
symptoms and side effect outcomes respectively. † Analysis based on 1787, 1923 and 1725 
participants for the symptom severity, new symptoms and side effect outcomes respectively. 
§ Assuming those participants with missing adherence data did not take any medication 
(i.e. their adherence level is 0%). 
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6.3.2 RBEEs in non-inferiority / active control trials 
6.3.2.1 Analysis of the CODA trial 
The analysis using data from the CODA trial was based on 188 randomised participants 
with outcome data. 
In total, 174 participants adhered to their study medication (92.6%), with these making up 
the per-protocol population (Figure 6.11). The percentage of participants adhering to study 
medication was higher in those randomised to the intervention arm compared to the active 
control arm (95.7% and 89.4% respectively). 
Overall, 56 participants relapsed within the 12 month follow-up period (29.8% of all 
participants). The percentage of participants who relapsed was lower in the intervention 
arm compared to the active control arm (24.5% and 35.1% respectively). The main trial 
analysis based on complete cases demonstrated that the relapse rate was 10.6 percentage 
points higher in those randomised to the TDS arm compared to in the OD (95% 
confidence interval (CI): -2.5 to 23.8 percentage points). As the lower limit of the 95% CI 
did not include -10%, and this was also found in the PP analysis, the findings confirmed the 
non-inferiority of the OD regimen compared to the TDS regimen. 
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Figure 6.11: Flow diagram describing data available for each type of analysis in the CODA 
trial 
 
Predictors of relapse were age (participants aged 65 or older had decreased odds of 
relapsing during the follow-up period), length of remission (participants in remission for at 
least 12 months had decreased odds of relapsing during the follow-up period), and 
endoscopy findings at baseline (participants with non-normal endoscopy findings at 
baseline had increased odds of relapsing during the follow-up period) (Table 6.7). 
When conditioning on the predictors of relapse, smoking status at baseline was the only 
variable that remained independently associated with participants adhering to their study 
medication at the 10% significance level (Table 6.8). Compared to non-smokers, the odds 
of participants adhering to their study medication was higher in those who were ex-smokers. 
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However, smoking status did not differentially predict adherence across the two arms (i.e. 
the interaction between smoking status and trial arm was not statistically significant). 
 
Table 6.7: Multivariable determinants of relapse in the CODA trial (odds of relapsing 
during the 12 follow-up period) 
Variable 
Adjusted 
odds ratio 
95% Confidence Interval 
p-value 
Lower Upper 
Age at baseline (≥65 compared to 
<65 years)  
0.30 0.10 0.88 0.028 
Length of remission (≥12 compared 
to <12 months) 
0.34 0.14 0.81 0.014 
Endoscopy findings at baseline 
(non-normal compared to normal) 
4.14 2.04 8.39 <0.001 
 
It was not possible to derive two distinct causal parameters based on observed data, as there 
were no baseline variables differentially associated with adherence for each of the arms. 
Given that the definition of adherence was binary, the only sensible analysis was to consider 
the standard treatment (active control) as the “placebo” group and use standard SMM 
methods. 
The SMM analysis found that after adjusting for adherence, the relapse rate was 11.1 
percentage points higher in those randomised to intervention. The 95% CI did not contain 
-10% (95% CI: -2.5 to 24.7 percentage points), and non-inferiority could be confirmed 
based on this analysis (Figure 6.12). 
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Table 6.8: Multivariable determinants of adhering to medication in the CODA trial 
Purpose Variable 
Adjusted 
odds ratio 
95% Confidence Interval 
p-value 
Lower Upper 
Associated 
with disease 
status at 12 
months 
(relapsed/still 
in remission) 
Intervention 
(OD arm 
compared to 
TDS arm) 
2.61 0.75 9.03 0.131 
Age at 
baseline (≥65 
years 
compared to 
<65 years) 
2.42 0.27 21.70 0.430 
Length of 
remission 
(≥12 months 
compared to 
<12 months) 
1.05 0.29 3.75 0.940 
Endoscopy 
findings at 
baseline 
(non-normal 
compared to 
normal) 
0.31 0.10 1.01 0.053 
Associated 
with 
adherence to 
study 
medication 
Smoking 
status at 
baseline 
(current 
smoker 
compared to 
non-smoker) 
1.31 0.25 6.79 
0.076 
Smoking 
status at 
baseline (ex-
smoker 
compared to 
non-smoker) 
11.46 1.40 94.01 
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Figure 6.12: Forest plot of the difference in relapse rates in the CODA trial for various 
analysis sets 
 
6.3.2.2 Analysis of the ZICE trial 
The analysis is based on 1037 randomised participants with SRE data. In total, 621 of 915 
participants with adherence data adhered to their study medication (67.9%), with these 
making up the per-protocol population. The percentage of participants adhering to study 
medication was higher in those randomised to the OIA arm compared to the IZA arm 
(77.4% and 60.7% respectively). Baseline covariate data were available for 796 participants. 
This made up the SMM population (Figure 6.13). 
Overall, 382 participants experienced an SRE within the 12 month follow-up period (36.8% 
of all participants). The percentage of participants who experienced an SRE was higher in 
the OIA arm compared to the IZA arm (38.3% and 35.4% respectively). The trial analysis 
based on complete cases (and the full study period) demonstrated that the SRE rate was 
3.0 percentage points higher in those randomised to the OIA arm compared to in the IZA 
(95% confidence interval (CI): -2.9 to 8.8 percentage points) and concluded that OIA was 
inferior to IZA. 
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Figure 6.13: Flow diagram describing data available for each type of analysis in the ZICE 
trial 
 
The odds of experiencing an SRE within the first 12 months of the study were higher in 
participants with higher BMI scores, in participants who had poor role functioning, worse 
nausea/vomiting symptoms, had experienced an SRE in the three months prior to the study, 
or had recently used pain medication. The odds of experiencing an SRE within the first 12 
months of the study were lower in females than in males, in participants with higher overall 
general health, and in participants with increasing dyspnoea (Table 6.9). 
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Table 6.9: Multivariable determinants of outcome in the ZICE trial (odds of experiencing 
a skeletal-related event during the first 12 months) 
Variable 
Adjusted 
odds ratio 
95% Confidence 
Interval p-
value 
Lower Upper 
Gender (female compared to male) 0.23 0.06 0.88 0.032 
18.5kg/m
2 < BMI ≤ 25kg/m2 (normal/healthy 
weight) compared to ≤ 18.5kg/m2 
(underweight) 
6.16 0.75 50.65 
<0.001 
25kg/m
2 < BMI ≤ 30kg/m2 (overweight) 
compared to ≤ 18.5kg/m2 (underweight) 
6.85 0.84 56.13 
30kg/m
2 < BMI ≤ 35kg/m2 (moderately 
obese) compared to ≤ 18.5kg/m2 
(underweight) 
13.17 1.59 108.81 
35kg/m
2 < BMI ≤ 40kg/m2 (severely obese) 
compared to ≤ 18.5kg/m2 (underweight) 
6.99 0.81 60.39 
BMI > 40kg/m
2 
(very severely obese) 
compared to ≤ 18.5kg/m2 (underweight) 
13.11 1.44 119.65 
QLQ-C30 global health domain (per unit 
increase) 
0.98 0.98 0.99 0.001 
QLQ-C30 role functioning domain (per unit 
increase) 
1.01 1.00 1.02 0.005 
QLQ-C30 nausea / vomiting domain (per 
unit increase) 
1.01 1.01 1.02 <0.001 
QLQ-C30 dyspnoea domain (per unit 
increase) 
0.99 0.99 1.00 0.056 
SRE within the three months prior to 
baseline compared to no SRE within three 
months prior to baseline 
1.56 1.14 2.13 0.006 
Recent use of pain medication at baseline 
compared to no recent use of pain 
medication 
1.63 1.08 2.46 0.019 
 
After conditioning on the above, both cognitive functioning and use of chemotherapy were 
independently associated with adhering to study medication differently in the two arms 
(Table 6.10). The results from the model suggest that the odds of adhering to study 
medication are: 
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 Higher for participants allocated to the OIA arm, with the lowest levels of cognitive 
functioning, and not undergoing chemotherapy at baseline 
 Higher as cognitive functioning increases for participants allocated to the IZA arm 
 Lower as cognitive functioning increases for participants allocated to the OIA arm 
 Higher for participants undergoing chemotherapy at baseline and allocated to the 
IZA arm 
 Lower for participants undergoing chemotherapy at baseline and allocated to the 
OIA arm 
Distinct causal parameters could be estimated using the ZICE data, and therefore the 
difference between the two arms could be calculated. After adjusting for treatment 
adherence, the proportion with SRE in the first 12 months was no different in either of the 
arms (difference in proportions 0.0, 95% CI: -13.9 to 13.8 percentage points). While the 
point estimate from the SMM was closer to no difference, the width of the confidence 
interval was wide and crossed any non-inferiority margin that could be justified (Figure 
6.14). 
As for the analysis of the GRACE WP10a trial, missing data posed a potential problem in 
deriving RBEEs for the ZICE trial. Applying a basic imputation method meant that the 
predictors originally found were no longer statistically significant. The SMM method could 
therefore not be applied as it had been originally. Another approach I explored involved 
restricting the ITT and PP analysis to those who also feature in the SMM analysis. However, 
this changed the point estimates as well as widening the confidence intervals slightly (Figure 
6.15).  
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Table 6.10: Multivariable determinants of adhering to medication in the ZICE trial 
Purpose Variable 
Adjusted  
odds 
ratio 
95% 
Confidence 
Interval 
p-
value 
Lower Upper 
Associated 
with the 
development 
of a SRE 
within 12 
months 
Gender (female compared to 
male) 
1.29 0.36 4.55 0.697 
18.5kg/m
2 < BMI ≤ 25kg/m2 
(normal/healthy weight) 
compared to ≤ 18.5kg/m2 
(underweight) 
2.19 0.74 6.47 
<0.001 
25kg/m
2 < BMI ≤ 30kg/m2 
(overweight) compared to ≤ 
18.5kg/m
2 
(underweight) 
2.05 0.70 6.00 
30kg/m
2 < BMI ≤ 35kg/m2 
(moderately obese) compared to 
≤ 18.5kg/m2 (underweight) 
2.35 0.79 7.03 
35kg/m
2 
< BMI ≤ 40kg/m2 
(severely obese) compared to ≤ 
18.5kg/m
2 
(underweight) 
3.07 0.95 9.95 
BMI > 40kg/m
2 
(very severely 
obese) compared to ≤ 18.5kg/m2 
(underweight) 
3.90 1.06 14.31 
QLQ-C30 global health domain 
(per unit increase) 
1.00 1.00 1.01 0.358 
QLQ-C30 role functioning 
domain (per unit increase) 
1.00 1.00 1.01 0.300 
QLQ-C30 nausea / vomiting 
domain (per unit increase) 
1.01 1.01 1.02 0.000 
QLQ-C30 dyspnoea domain (per 
unit increase) 
1.00 0.99 1.00 0.547 
SRE within the three months 
prior to baseline compared to no 
SRE within three months prior to 
baseline 
1.07 0.79 1.46 0.660 
Recent use of pain medication at 
baseline compared to no recent 
use of pain medication 
0.65 0.45 0.94 0.021 
Differentially  
associated 
with  
Oral ibandronic acid arm (main 
effect) 
5.77 2.05 16.26 0.001 
QLQ-C30 cognitive functioning 
(main effect) 
1.01 1.00 1.02 0.005 
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Purpose Variable 
Adjusted  
odds 
ratio 
95% 
Confidence 
Interval 
p-
value 
Lower Upper 
adherence 
by  
trial arm 
Oral ibandronic acid arm * 
QLQ-C30 cognitive functioning 
(interaction)  
0.99 0.98 1.00 0.061 
Use of chemotherapy at baseline 
(main effect) 
2.12 1.28 3.53 0.004 
Oral ibandronic acid arm * Use 
of chemotherapy at baseline 
(interaction) 
0.47 0.22 1.02 0.057 
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Figure 6.14: Forest plot of the difference in the proportion with SRE in the first 12 months 
in the ZICE trial for various analysis sets 
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Figure 6.15 Impact of missing data on the interpretation of the SMM analysis 
 
*Intention-to-treat n = 1037; Per-protocol n = 621; Structural mean model n = 796 
†Analysis performed in participants who were included in the structural mean model analysis. 
Intention-to-treat n = 796; Per-protocol n = 536.  
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6.4 Discussion 
6.4.1 Summary 
In this Chapter, the feasibility of implementing RBEEs to adjust findings of RCTs for 
medication non-adherence was explored using data from three clinical trials. Several design 
considerations were investigated, including whether the trial was designed to investigate the 
superiority or non-inferiority of one treatment to a comparator, whether a placebo or active 
treatment was used as a comparator, and what the comparison of interest was (e.g. 
difference in means, difference in proportions, odds ratio). Sensitivity analyses were also 
conducted to examine the robustness of the methods under a various assumptions, 
including assumptions related to missing adherence and outcome data. 
6.4.2 Learning points 
1. Clinically: 
a. The findings from the GRACE WP10a trial suggest that taking amoxicillin 
improved (i.e. further reduced) symptom severity on days 2-4 (compared to 
the effect of it merely being prescribed, regardless of the extent to which 
participants adhered to treatment), further decreased the odds of 
developing new or worsening symptoms, and further increased the odds of 
reporting side effects. Nevertheless, due to the high levels of adherence to 
study medication, the findings of the original effectiveness analyses were 
reasonably robust to departures from randomised treatment. 
b. In the CODA trial, it was not possible to derive distinct estimators, and 
standard SMM methods were applied instead, treating the active control 
arm in the same way that a placebo arm would be treated. This analysis was 
consistent with the ITT and PP findings (i.e. there was evidence to suggest 
that OD was not inferior to TDS in terms of preventing relapse). The 
218 
 
reasons for this are likely threefold: (1) a limited set of baseline predictors 
that were not selected with the different treatment regimens in mind; (2) a 
small sample size, limiting the probability of detecting differences where 
they exist (i.e. power); (3) the lack of an adherence measure on all 
participants that adequately captured patterns in adherence, rather than just 
overall consumption. As the two treatments being compared were identical, 
and the only difference was their prescribed regimen, it would be difficult 
to find discernible differences between arms (as already indicated during 
Chapters 4 and 5).  
c. In the ZICE trial, it was possible to derive distinct estimators, and when 
comparing the arms the point estimate implied no difference in SRE rates 
between the arms, but the confidence intervals were considerably wider than 
the intention-to-treat and per-protocol analyses. 
2. Methodologically, the use of SMMs to adjust trial findings for non-adherence is 
attractive, as it allows for a comparison of groups that is independent of measured 
and unmeasured confounders. It is also straightforward to apply these techniques 
with minimal programming skills, and I have created a graph to depict a linear SMM 
– something that illustrates the technique, its assumptions, and how the efficacy 
estimate relates to effectiveness. However, for these approaches to be valid, they 
rely on the key assumption that for participants who were categorised as non-
adherers, merely being allocated to receive treatment had no effect on outcome (the 
so-called ‘exclusion restriction’). While this was likely to be a valid assumption for 
the GRACE WP10a trial, as participants and clinicians were blinded to allocation, 
this is less likely to be valid for non-blinded studies (for example, a two-arm 
randomised controlled trial of a weight loss intervention (versus no intervention), 
where participants are aware that the focus is on bodyweight). 
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3. Treating adherence as a continuous measure in the GRACE WP10a trial (and 
generally) made the exclusion restriction more plausible, as the lowest level of 
adherence could be defined as receiving no treatment, a level at which being 
allocated to either treatment group should really have no effect on outcome. 
However, this approach made the additional assumption that the effect of receiving 
an increasing amount of treatment on outcome increased linearly, which for a trial 
involving medication is unlikely to be true. Sensitivity analyses were conducted using 
various binary definitions of adherence, ranging from one or more tablets (versus 
no tablets) to full course (versus less than full course). While the former increased 
the plausibility of the exclusion restriction, the estimated treatment efficacy was too 
conservative. The latter analysis combined participants who would have taken 99% 
of their medication with participants who would have taken no medication and 
considered them all as not adhering (and therefore assumed they would have 
received no benefit from being allocated to the amoxicillin arm). This clearly 
violated the exclusion restriction. However, the findings from the sensitivity analyses 
largely agreed with the main findings (where adherence was measured 
continuously), adding further strength to the conclusions drawn in this Chapter. 
Similar issues were present in the CODA and ZICE trials. 
4. While these methods are particularly desirable for NI trials, as neither of ITT or 
PP analysis provide both a conservative and unbiased comparison of treatments, 
this work highlights the increase in variance when fitting these models, something 
that can only be reduced when the models include strong predictors of adherence 
and outcome. Use of the method is more accurate in terms of reducing selection 
bias, but the reduced precision necessitates the collection of relevant and complete 
baseline variables. To do this, the research team must have a good understanding 
of the predictors of outcome, and also the barriers and facilitators to adhering to 
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the randomised treatments. Studies with feasibility or pilot stages could explore 
these aspects, as well as how best to capture this data, before progressing onto more 
definitive studies. The significance thresholds for inclusion of variables in this paper 
were higher than current practice. Future studies that collect strong baseline 
predictors of adherence need not use such high significance levels. 
5. By modelling the determinants of differential adherence in the different treatment 
arms, researchers will also gain an understanding of the circumstances under which 
the treatments will be better received by patients, and therefore more likely to work. 
For example, in the ZICE study, we were able to demonstrate that for participants 
allocated to the intravenous zoledronic acid arm, adherence was higher for patients 
with higher cognitive function and for those receiving chemotherapy at baseline, 
whereas for those allocated to the oral ibandronic acid arm adherence was lower 
for patients with lower cognitive function and for those receiving chemotherapy at 
baseline. One explanation for this could be that patients with low cognitive function 
could have their medicines dispensed by a care giver, which is likely to reduce 
forgetfulness and increase adherence. Patients receiving chemotherapy at baseline 
will be attending hospital regularly for these visits, and the delivery of IZA often 
coincided with other hospital visits for cancer therapy, thereby increasing their 
chances of receiving IZA treatment. The implications of this, regardless of the 
comparative efficacy of the treatments themselves, could be that IZA should be 
offered to those undergoing additional cancer treatments (or any other treatments 
that require regular hospital visits). OIA could be offered along with an additional 
intervention to increase adherence (e.g. a reminder or monitoring system), or in 
instances where patients were not in control of their own medication dispensing 
(e.g. elderly nursing home residents). 
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6. Despite the fact that incomplete outcome and adherence data were minimal, their 
impact on findings remains unknown. However, for the GRACE WP10a trial, as 
the condition under investigation is generally self-limiting, and outcome data 
included worsening of illness (a composite outcome collected from medical notes 
that included hospitalisation), we do not believe that the small amount of missing 
data would have severely impacted on the findings or conclusions drawn from this 
study. Indeed, the further sensitivity analyses conducted, where missing data were 
taken into account, demonstrated that clinical conclusions remained largely 
unaltered, even when taking an extreme assumption about missing adherence data. 
Similarly for the ZICE trial, an assessment of the impact of missing data on the 
interpretation of the SMM analysis was performed as a sensitivity analysis with 
conclusions remaining largely the same. 
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CHAPTER 7: Discussion 
7.1 Summary and interpretation of findings 
The aim of this thesis was to investigate various methodological challenges encountered 
when studying medication adherence in clinical research, generating new evidence that 
would advance the field, and indicating areas in which further developments are warranted. 
During my literature review in Chapter 2, I identified gaps and deficiencies in knowledge 
pertaining to the measurement of medication adherence, modelling of electronic 
monitoring data over time, considerations when multiple types of measure are used (and 
disagree), approaches to modelling determinants of medication adherence, and the 
feasibility of implementing randomisation-based efficacy estimators in randomised trials 
with non-adherence. 
I explored these areas using data from three studies, described in detail in Chapter 3. These 
studies were chosen as they encompassed contrasting clinical conditions (ranging from short 
to long-term conditions), study designs (randomised controlled trials and observational 
studies), had multiple types of measures (self-report, tablet counts, electronic monitoring), 
and the randomised controlled trials varied in their comparators (placebo, same drug but 
different regimen, and different drug and different route of administration). Substantive, as 
opposed to synthetic data were used, as the new evidence generated would be of clinical 
relevance, and it was my intention to demonstrate the utility and limitations that can be 
encountered when investigating these methods in practice. 
In Chapter 4, I compared several types of methods used to measure adherence to 
medication in clinical research, using a variety of correlational and agreement approaches. 
I explored the use of advanced modelling techniques to maximise the utility of electronic 
monitoring data collected over a 12-month time period. I also considered other ways in 
which studies could make use of adherence data when captured via multiple routes, namely 
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the development of prediction models for disagreement, and several approaches to creating 
a calibrated adherence measure. I used generalised linear mixed models, accounting for 
the correlated nature of repeated observations within individuals, and modelled non-linear 
time effects using splines, to investigate patterns in adherence over time using electronic 
monitoring data. This made better use of the data, compared to summarising adherence 
over the study period, as it enabled differences between and within individuals to be 
described, and allowed behavioural patterns to be investigated (e.g. white coat adherence 
and different patterns during the week compared to at weekends). I found that, according 
to electronic monitors, patients on more complex dosing regimens adhered less well, and 
were considerably more variable, than those on simpler regimens. Nevertheless, for both 
regimens, adherence decreased over time similarly (on average). This may reflect treatment 
fatigue (patients struggling to maintain the constant routine of taking medication over a long 
time period) or perhaps treatment optimisation (patients developing an understanding on 
what works for them in terms of how they take their medication). There was evidence to 
suggest adherence improved around clinic visit dates, a hypothesised indicator of white coat 
adherence. In addition, there was evidence to suggest that adherence was worse on 
weekends than on weekdays. This comparison was chosen as, for the majority of people, 
routines tend to be different during weekdays than during weekends, largely down to 
patterns in work (e.g. the Monday to Friday 9-5 routine). It was therefore suggested that this 
break in routine may impact on levels of adherence. This was also found in the seminal 
paper by Vrijens et al., 2008. The absence of differential effects by regimen for these two 
behavioural patterns adds weight to these being naturally occurring behaviours, rather than 
artefacts of the regimen a person was on. 
I found that, like other method comparison research, correlations can provide misleading 
evidence of the performance of two measures that aim to measure the same phenomena. 
Analytical approaches for measuring agreement exist, and depending on whether 
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adherence can be summarised as a binary or continuous scale different approaches can 
provide information on the extent and nature of disagreement. Where agreement was a 
focal point in the previously identified literature, most relied on taking an arbitrary cut-off 
of adherence and reporting kappa statistics. My thesis aimed to move beyond that, 
providing visual and quantitative representations of agreement, using both binary and 
continuous measures. Bangdiwala observed agreement plots provided this for binary 
adherence measures. I considered ways of enhancing these plots, for example by overlaying 
them with reference lines to indicate agreement that would be expected by chance (akin to 
a visual representation of a kappa statistics). Bland-Altman plots and limits of agreement in 
particular can provide a wealth of information about the level of agreement between two 
types of adherence measures, provided they can both be summarised on a continuous scale. 
I identified a nuance with the Bland-Altman approach that, to my knowledge, has not been 
remarked upon previously. When plotted on its full scale (i.e. both axes spanning the entire 
range of possible values), the data points are bounded within a restricted space. For 
example, when comparing two measures, both on a scale from 0 to 100, they can be as 
extreme as [50, -100], but nothing beyond this (e.g. they cannot be [60, -100] or [20, 100]). 
This may have implications for the 95% confidence intervals and limits of agreement 
around the bias (e.g. it may be more appropriate to fit non-linear confidence intervals or 
limits of agreement to these data). Clinically, I found that when comparing adherence as 
measured via tablet counts and electronic monitoring, disagreement largely occurred for 
participants on the three times daily dosing regimen, with adherence consistently higher 
when measured by tablet counts than when measured by electronic monitoring. There is a 
wealth of literature devoted to describing the biases that may occur from measuring 
medication adherence using tablet counts (e.g. so-called “pill dumping”). However, the fact 
that this disagreement is overwhelmingly seen in patients on the three times daily regimen 
is intriguing. One plausible explanation for this finding is that patients opened their 
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container once and took all three tablets out (for example, so they did not have to carry the 
medication bottle with them throughout the day). If this were true, it would highlight a 
deficiency in the use of electronic monitoring for patients on complex regimens, on the 
grounds of both validity and acceptability. In practice, using several types of adherence 
measures implies a lack of trust of any one type of measure. 
While the vast majority of work to date correlates or assesses agreement between the 
different measures, I felt it was important to exploit this even further, and explore different 
ways of predicting disagreement and deriving calibrated adherence measures. I used several 
regression models to investigate predictors of disagreement. Each model provided different 
information (predicting agreement or disagreement, direction of disagreement, and 
direction and extent of disagreement), and while different contexts could mean any of the 
models could be beneficial, in the context used in this thesis, I found that while certain 
variables predicted disagreement and the direction of disagreement, the extent of 
disagreement (and arguably the importance of the disagreement) was minimal. A 
description of the predictors of disagreement will be described in more detail later on in 
the Chapter. The different calibration approaches I explored made only minor differences 
to reported summary measures of adherence. However, this will not be the case in all 
instances. Using a calibrated adherence measure allows a researcher to maximise the 
amount of adherence data available and/or report a measure that has some correction for 
potential misreporting, depending on the approach used and purposes of using the 
adherence estimate. 
In Chapter 5, I investigated various methods for modelling the determinants of adherence. 
The determinants of adherence were compared across different types of methods used to 
measure adherence within the same study, different clinical conditions (acute lower-
respiratory-tract infection, ulcerative colitis, and breast cancer with bone metastases), 
different study designs (observational study and RCT), and using different 
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conceptualisations of adherence (a single summary measure or as distinct processes). I 
found that different types of adherence measures can have an influence on the determinants 
that can be found. This strengthens the importance of considering appropriate adherence 
measures prior to conducting a study. For example, in a trial of two different dosing 
regimens (but where participants in both groups were expected to consume the same 
quantity of tablets), tablet count data will provide a measure of consumption, but will not 
be able to provide particularly sensitive data on patterns of adherence. This work has led 
me to consider adherence more in line with the general framework around the 
development and validation of outcome measures. This is something I will write about in 
more detail later on in this Chapter. 
The complexity of the treatment was one determinant that was consistently associated with 
adherence across all clinical conditions. Other determinants found to be associated with 
adherence, but not consistently across conditions, were age, gender, social functioning (the 
ability to interact with others in a normal way in society), days waited prior to consulting, 
clinical signs (both for the acute condition), as well as some country or structural 
determinants (countries in which a sick certification is required for missing fewer than seven 
days of work or in which single-handed practices (i.e. one clinician treating all patients) were 
widespread). Through the use of multilevel analysis, I was also able to quantify the extent 
to which the treating clinician influenced whether a patient adhered to their treatment. This 
is a determinant of medication adherence often reported in the literature, but only using 
qualitative data. The approach I have taken is novel and important, as it goes further than 
an acknowledgement that clinicians can influence medication taking behaviour and 
provides estimates of the extent to which they do influence this behaviour. I also 
demonstrated that separating adherence out into distinct processes is not only useful when 
summarising the extent to which patients took their medicine, but also for investigating the 
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determinants of adherence. Indeed, I found different determinants for each of the 
processes. I will provide further detail of the implications of this later in this Chapter. 
While initiation and implementation are vital processes for all medication taking (both 
short and long-term treatments), my investigations left me unconvinced of the necessity of 
investigating the determinants of time from initiation to discontinuation for short-term 
conditions. This is not necessarily a process that would become a target for improvements, 
particularly for treatments such as antibiotics where sub-optimal implementation, for a 
prolonged period of time, could heighten the risk of carrying antibiotic resistant organisms. 
Despite this, depending on the type of adherence measure available, time from initiation 
to discontinuation may be the only metric that can be reliably estimated. Determinants were 
grouped into five dimensions, following the framework laid out in Sabaté, 2003. What 
became clear when looking at the variables available in my datasets, and grouping them into 
these dimensions, was that while factors related to patients, conditions, and therapies were 
often available, factors related to social/economic or healthcare professionals/systems were 
rarely present. This may be due to a perception that they are likely to be less associated 
with clinical outcomes than other dimensions and due to a balance between measuring 
everything that is of interest and minimising response burden. Nevertheless, where a 
treatment is efficacious, poor adherence will have an impact on clinical outcomes 
(adherence is clearly on the causal pathway to clinical outcome), so a consideration of 
variables to collect that are related to both adherence and outcomes is needed. I make 
recommendations based on this at the end of this Chapter.  
An interesting observation is that there was considerable overlap when comparing the 
determinants of adherence in Chapter 5 and the determinants of disagreement between 
different types of adherence measures in Chapter 4 (Table 7.1). The three determinants 
that were found to be associated in both Chapters all went in the same direction. That is, 
participants were more likely to provide adherence measures that agreed and more likely 
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to adhere to their treatment. This may be suggestive of a link between the two, though 
whether this link is purely a function of the measures (high adherence is high adherence, 
no matter how it is measured) or whether this could be linked to any behavioural theories 
(e.g. participants who adhere poorly may be found to be more likely to provide measures 
that disagree due to the inherent social desirability of being seen to be someone adhering 
to their treatment), is an area that requires further investigation.  
Table 7.1: Overlap between determinants of adherence and determinants of disagreement 
between different types of adherence measures for participants in the GRACE studies 
Determinant 
Agreement between types of 
adherence measures 
Adherence 
Age 
Older participants more likely to 
agree 
Older participants more likely 
to adhere 
Auscultation 
abnormality 
Those with an auscultation 
abnormality more likely to agree 
Those with an auscultation 
abnormality more likely to 
adhere 
Days waited 
prior to 
consulting 
The longer participants waited 
prior to consulting, the more 
likely they were to agree 
The longer participants waited 
prior to consulting, the more 
likely they were to adhere 
 
Finally, during Chapter 6, I established the feasibility of calculating randomisation-based 
efficacy estimators in RCTs with non-adherence, scrutinising the implementation of these 
approaches under a variety of circumstances commonly encountered in RCTs. The specific 
circumstances I considered were where binary and/or continuous measures of adherence 
are available, where binary and/or continuous outcome variables are of interest, where 
outcome data are missing, and where the trial compares two active treatments. It is rare to 
see these analytical approaches described outside of methodological journal articles, and it 
was my intention to explore their use in practice and indicate considerations that are 
important in the design, conduct, analysis, and reporting of RCTs in which non-adherence 
is likely. I found that the techniques can be readily applied in most instances using standard 
statistical software, and minimal programming. However, while randomisation-based 
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efficacy estimators are an attractive prospect, in terms of their ability to eliminate selection 
bias, this generally comes at a cost of increased variance (i.e. less precision around 
estimates), and additional assumptions that may not always be possible to satisfy. For 
example, one of the core assumptions (the exclusion restriction), relies on there being no 
benefit gained from being allocated to receive treatment for non-adherers. When 
adherence is all-or-nothing (e.g. a single tablet), this assumption is rather plausible. 
However, when adherence is not all-or-nothing (e.g. two tablets, three times a day, for seven 
days), how you summarise the measure of adherence influences the plausibility of this 
assumption. Taking a cut-off at 100% for example (i.e. all medication consumed as 
prescribed), makes the assumption that anyone who would adhere less than this (anywhere 
between no medication consumed to 99% of medication consumed accurately) would 
receive no benefit from being allocated to receive treatment. Options I explored to 
circumvent this issue involved creating different cut-offs (initiated treatment versus not; 
adhered for the first five days versus not) and treating adherence as a continuous measure, 
the latter of which relied on the additional assumption that the effect of treatment was 
linearly related to the level of adherence, an assumption that is also unlikely to be plausible, 
given that log dose-response curves are generally sigmoidal.  
I constructed a graph of a randomisation-based efficacy estimator that used a continuous 
adherence measure, illustrating the increasing efficacy as adherence increased, and how 
these estimates related to the original effectiveness estimates. Under the assumption of 
linearity, this is a valuable way of presenting the findings from this analysis, as it shows the 
exclusion restriction assumption clearly (at the co-ordinate [0, 0]), the increase in efficacy 
as adherence increases, the effectiveness estimate (at the level of adherence achieved during 
the trial), and the potential effect of treatment in those who fully adhered (Figure 7.1). 
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Figure 7.1: Graphical illustration of the effectiveness and efficacy of amoxicillin on mean 
symptom severity on days two to four 
 
I made a case for randomisation-based efficacy estimators to be used when analysing non-
inferiority trials. However, these trials generally involve the comparison of two active 
treatments, and thus the derivation of these estimators relies on identifying pre-
randomisation variables that are differentially associated with adherence to the different 
treatments, while remaining independent of outcome. For the data available and used in 
my thesis, I found I was unable to identify such variables in one study, and while I identified 
some in another study, they were rather weak which meant it was difficult to draw any 
conclusions based on the confidence intervals (though the impact the adjustment had on 
the point estimate was still of use). Nevertheless, by modelling the differential determinants 
of adherence for each of the treatment groups, I was able to provide some indication of the 
types of patients who may benefit differently from the different treatments (e.g. the 
convenience of giving intravenous medication to someone already attending hospital for 
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another reason). In addition, I considered the impact of missing adherence data on these 
analytical methods, conducting several sensitivity analyses to explore the impact of varying 
assumptions regarding missing mechanisms on the findings.  
7.2 Novel aspects of this work 
The work presented in this thesis is both clinically and methodologically novel. 
Methodologically, I have demonstrated an approach to modelling and graphically 
illustrating electronic monitoring data of daily medication adherence that is innovative. 
Certainly, plotting the predicted probability of adherence curves for each individual and 
overlaying this with their raw data is something rather unique. When investigating 
agreement, I have considered a useful extension to the Bangdiwala observer agreement 
plots by overlaying these with reference domains that indicate chance agreement. I have 
identified bounded regions within the Bland-Altman plots that may have implications for 
how confidence intervals and limits of agreement are constructed in future method 
comparison studies. I have produced a graphical illustration of the randomisation-based 
efficacy estimator, when adherence is treated as a continuous measure. This is a convenient 
way of illustrating a concept that is difficult to grasp for both applied researchers and 
clinicians alike. I have also implemented randomisation-based efficacy estimators in non-
inferiority trials, critically considering the uses and limitations of these methods on real 
world data. To date, this is something that has only been considered in theory, so the work 
presented in this thesis is the first of its kind. 
Clinically, I have reported on the first study to electronically monitor medication adherence 
in adults in remission with ulcerative colitis. Adherence is a major concern for this 
condition, hence the move to evaluating simplified dosing regimens. By modelling 
adherence in patients over time and considering behaviour patterns of non-adherence, this 
study provided significant advances in this clinical area. I have also conducted the first study 
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that separately investigated the determinants of initiation, implementation, and 
discontinuation of antibiotic treatment. Within this work, I have also provided estimates of 
variation in initiation and implementation that is attributable to differences between 
clinicians (and countries / healthcare settings). That is, a quantitative (rather than qualitative) 
estimate of the amount influence clinicians / healthcare settings have on an individual’s 
propensity to initiate treatment or implement their treatment correctly on a given day. This 
work is not only of clinical importance, but also provides a framework for future studies 
aiming to measure this quantitatively. 
The findings presented in Chapters 4, 5, and 6 of this thesis have formed the basis of four 
publications, each of which have been published in peer-reviewed journals (Inflammatory 
Bowel Diseases, BMJ Open, BMC Trials, and Patient Preference and Adherence). This 
adds further strength to this body of work, demonstrating that the contributions I have made 
are of importance and value to the scientific community. See Appendix IV for the papers, 
as well as a diagram illustrating how they link to Chapters 4, 5, and 6. In addition, I have 
presented work related to my PhD at various national and international conferences, in 
order to increase awareness of the medication adherence field more generally (but 
specifically the methodological challenges herein). See Appendix V for more details. 
Alongside this, I have also discussed and piloted some of these ideas with colleagues in the 
Centre for Trials Research. The feedback I have received to date has been positive, with 
the figures seen as useful visualisations of either complex or abstract methodological topics. 
For example, the variability displayed by the spaghetti plot (Figure 4.8 in Section 4.3.3) was 
something not immediately apparent when reading the parameter estimates from the 
preceding Table (Table 4.5). This plot therefore enhanced the understanding of the 
findings from merely a difference between regimens for the fixed effects (averaged across 
participants) to also a higher degree of variability for participants allocated to the TDS 
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regimen, something that would be an important consideration for a prescriber / healthcare 
professional. 
7.3 Limitations 
While I discussed the rationale for using real world data earlier in this Chapter, there are 
some limitations to taking this approach. Being limited by the sample size of the original 
study meant that extra care was required when interpreting a lack of evidence of any 
association examined. This could indeed imply there was no (or limited) association, or 
could be due to a lack of power to detect an association. As the data used throughout this 
thesis came from previously conducted studies, I had no influence on the variables that 
were collected, or types of adherence measures used, at the time I began my studies. There 
are several examples of these limitations.  
In the CODA study, an OD regimen was compared against a TDS regimen, with the TDS 
regimen chosen as the comparator, as it was deemed the most logical way to divide 3 tablets 
over the course of the day and is still used by a substantial number of gastroenterologists. 
(Sandborn et al., 2010) Although there is evidence of medication adherence issues for TDS 
regimens, less pronounced differences have been shown when comparing OD regimens 
with BD regimens. (Eisen et al., 1990)  
In the GRACE studies, the analysis of determinants focused on adherence to amoxicillin 
prescriptions for immediate use only. While this reduces the potential number of 
participants (other antibiotics were prescribed and delayed prescriptions were given in the 
included observational studies), it allowed for the investigation of the impact of the dose, 
frequency, and duration without being confounded by type of antibiotic prescribed. Since 
Amoxicillin is the most commonly prescribed and recommended antibiotic for acute 
respiratory infections across Europe, (Butler et al., 2009, Wood et al., 2011) the results 
retain wide applicability. Advice regarding delayed prescriptions, while also recommended 
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for this condition, (Francis et al., 2012) are often vague (for example, “here is a prescription 
if you get any worse”), and may have been issued with the intention that the patient would 
never actually take antibiotic treatment. The work presented in this thesis assumes that 
amoxicillin was prescribed for immediate use by a clinician with the intention that it would 
be taken as prescribed.  
I used a simplified version of the original primary outcome in the ZICE study in order to 
illustrate the use of randomisation-based efficacy estimators in non-inferiority trials. One 
consequence of this is that while a non-inferiority margin was defined for the original 
primary outcome, one was not defined for the simplified version. While this could have 
limited the interpretation of this analysis, the confidence intervals were too wide for any NI 
margin to be justified, even post hoc (given that the original trial analysis suggested 
inferiority, this was a simplified outcome that would have had lower power than a recurrent 
event outcome, and the confidence interval of the SMM analysis was over twice as wide as 
the ITT and PP analyses).  
In terms of the types of adherence measures that were used, although self-reports are 
simple, cheap, and convenient to implement, particularly when regular follow-up visits are 
scheduled and the study runs over a long time period, recall is not always perfect, and 
participants are not always accurate. A participant who forgot to take his medication may 
have had no conscious recollection that he forgot his medication. (Cramer and Spilker, 
1991) The use of a validated questionnaire to capture self-reported adherence may have 
also provided a greater level of understanding of the circumstances around any non-
adherence (e.g. intentional or unintentional) than the self-report questions that were asked 
in these studies. (Horne and Weinman, 2002) In the GRACE studies, adherence was 
primarily measured using prospective self-report diaries. While this type of measure 
remains prone to similar biases, collecting these data prospectively and frequently may 
improve recall biases and hence be an improvement over retrospectively collected self-
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report data with a longer recall period (Lu et al., 2008) where unintentional non-adherence 
is an issue. However, questions in the diary only asked about daily use of treatment. We 
have therefore had to assume that if a participant reported that they consumed amoxicillin 
on a given day, they consumed the correct number of doses and these doses were spread 
evenly throughout the day – an assumption that could have been checked with a measure 
such as electronic monitoring. Similarly, adherence measured through tablet counts is 
simple, cheap, and convenient. However, mistakes in counting, intentional increases in 
medication around follow-up visits (so-called “white coat” adherence), and intentional tablet 
misrepresentation (e.g., by not bringing all medication to follow-up visits) (Vermeire et al., 
2001) may have distorted the true number of tablets taken. There may have been social 
desirability factors that influenced participants to intentionally misrepresent their level of 
adherence. (Farmer, 1999) Electronically monitored adherence yields data that have a high 
level of granularity, though it remains difficult to determine whether the correct numbers 
of tablets are removed and ingested at each dosing event. (Kenna et al., 2005) Coupled with 
the increased bulk of the bottle (compared to a standard bottle), there remains 
disadvantages to their implementation, particularly for patients taking several doses of 
medication a day. Variables that might have been important to capture were omitted from 
the studies considered. For example, social / economic determinants were missing from 
most of the studies, as were structural determinants. No study collected data on 
medication/illness concerns, beliefs, or preferences prior to being prescribed medication. 
This has been shown to be a powerful predictor of intentional non-adherence. (Horne and 
Weinman, 1999, Benedetti et al., 2011) Without simulated data, and hence knowledge 
about the truth (in our case, the real adherence level of a participant), it is difficult to assess 
the performance of some of the methods used during the thesis. Finally, use of real world 
data means that it is difficult to generalise some of these findings beyond the clinical setting 
in which the studies were conducted, or indeed specific type of measure that was used (e.g. 
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it would be difficult to extrapolate the findings based on prospective self-report diaries to 
other forms of self-report, such as retrospective validates self-report questionnaires). 
However, while this is true for the specific clinical findings (for example: prospective self-
report diaries and tablet count adherence data had high levels of agreement, clinicians 
accounted for approximately 20% of the total variation in whether a patient initiated their 
amoxicillin, fully adhering to a seven-day prescription of amoxicillin lowers your odds of 
developing new or worsening symptoms within four weeks, but increases your odds of 
reporting non-respiratory symptoms also), the general principles that I have discussed in 
detail throughout this Chapter can be generalised. 
Throughout my thesis, multivariable regression models have been built using a single 
standardised approach. That is, first by considering candidate predictors and whether they 
had a sound basis for consideration, second by screening chosen variables in univariable 
analyses, and then, depending on the outcome of these, building a multivariable model 
using a backward selection process. While this approach is criticised for overfitting (that is, 
yielding estimates that do not reflect the overall population), there is no universally agreed 
approach to selecting variables in a multivariable regression model. The rationale behind 
the approach I have taken is that I wanted to develop simple models, with unnecessary 
predictors removed, in order to reduce the risk of finding spurious relationships to random 
error. Other approaches exist for selecting variables (e.g. forward selection, ridge 
regression, lasso, etc.). However, when developing these models, the purpose was to 
develop a set of predictors that succinctly described the relationship they had with the 
outcome of interest (usually a measure of adherence), rather than to compare the 
performance of different variable selection methods. Overfitting is an ever-present concern 
when developing and generalising the findings from a model beyond the data in which it 
was developed. The associations found in the models developed throughout my thesis 
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require further understanding (and validating on external data). This is something I also 
indicate in the next section. 
7.4 Comparisons to existing literature 
Levels of medication adherence in the CODA study were generally high, as found in other 
trials measuring adherence in UC. (Farup et al., 2001, Prantera et al., 2005) Indeed, 
adherence levels were higher than those reported in prospective community-based studies 
of patients with UC, (Kane et al., 2001) which is to be expected given both the increased 
motivation and monitoring generally seen in participants in clinical trials. Similarly, 
adherence to amoxicillin in the GRACE trial was considerably higher than that reported in 
the GRACE observational studies, despite the participants recruited into the trial appearing 
reasonably similar to those recruited into the aforementioned observational study in terms 
of their baseline characteristics. (Butler et al., 2009, Francis et al., 2012) 
The finding in the CODA study that adherence deteriorated over the 12-month study 
period is also consistent with previous literature. Indeed, a study conducted in Canada 
found a 1-year persistence rate of 50% for people diagnosed with UC, (Lachaine et al., 
2013) with another study conducted in the USA finding that 55% of participants continued 
to take their UC medication. (Kane et al., 2009) 
Instances of poor agreement between the adherence measures, with more traditional 
methods providing higher estimates than those provided by the MEMS, particularly when 
adherence was poor, is consistent with the findings of a study conducted in young patients 
with inflammatory bowel disease. (Greenley et al., 2012) This pattern has also been found 
in other settings. (Daniels et al., 2011) 
An inverse relationship between the complexity of a dosing regimen and the adherence has 
long been established. (Cockburn et al., 1987, Claxton et al., 2001, Pechère et al., 2007, 
D’inca et al., 2008, Saini et al., 2009, Llor et al., 2009) However, the less frequent dosing 
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of intravenous bisphosphonates (compared to a daily oral regimen) has previously been 
cited as contributing to improved levels of adherence. (Conte and Guarneri, 2004) 
Females having lower odds of adhering to maintenance treatment for ulcerative colitis 
concurs with the findings of Lachine et al., 2014, but other studies have found the opposite 
relationship. (Kane et al., 2001) 
Approaches for adjusting treatment effects for non-adherence while preserving 
randomisation have been in existence for approximately 20 years. (Angrist et al., 1996) 
However, they have largely been consigned to specialist methodological journals, rarely 
used in practice and when used, generally focussed on non-pharmacological treatments. 
(Dunn et al., 2003) 
A recently published paper investigating the comparative efficacy of two different 
antidepressants was the first to demonstrate the practical implementation of the SMM 
approach as outlined by Fischer et al. (Wiles et al., 2014) One other study has reportedly 
implemented this approach on a non-inferiority trial. (Taylor et al,. 2012) However, as this 
was a placebo-controlled trial, and the paper detail of the approach was lacking, it was 
unclear whether they applied standard SMM methodology or the extended work described 
by Fischer et al. 
7.5 Methodological and clinical implications 
There are several implications arising from this work, primarily for researchers and applied 
statisticians working in clinical areas, but also for healthcare professionals who monitor 
medication adherence in their patients. 
We, as researchers, should always strive to use the data we have collected to its maximum 
potential. Often in research, we are too quick to take a set of data and summarise it as a 
single value that, on the surface, has face value, but when considered more critically does 
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not provide much useful information. This point is exemplified in two places in my thesis. 
First, where I took adherence collected via electronic monitors in participants over a 12-
month period and modelled daily adherence within individuals. This allowed me to 
describe adherence patterns over time, variation between and within individuals, and 
explore behavioural patterns. Had I combined these data into a single summary measure, 
none of this would have been possible. Second, where I investigated the determinants of 
different elements of adherence (i.e. initiation, implementation, and discontinuation). 
Traditional approaches to investigating factors associated with adherence/non-adherence 
involved regressing onto a single summary measure (e.g. adhered/did not adhere, an 
adherence ‘score’). By investigating factors for different adherence processes, I was able to 
uncover certain characteristics that were more associated with these different processes (e.g. 
initiation but not implementation, or vice versa). This again is something that would have 
(and indeed was) missed when condensing adherence into a single summary measure.  
In terms of implications for healthcare professionals, these findings indicate that for patients 
on long-term treatments adherence may decline over time, and behaviour may change 
around clinic visit dates/during breaks in an individual’s normal routine. The former point 
requires further exploration into why this is occurring. As discussed earlier in this Chapter, 
this could be down to treatment fatigue or treatment optimisation. It should be 
acknowledged that patient behaviour may change around clinic visits (both before and 
afterwards), and this should be taken into account if monitoring adherence. Gaining an 
understanding of an individual’s daily routine, how much it varies day-to-day, and whether 
it is generally consistent or there are distinct disruptions (such as at weekends) would seem 
important when it comes to understanding how to integrate medication into an individual’s 
life. Where disruptions in routine are present, alternative strategies may be required, and 
these should be devised in advance of commencing treatment. 
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The work presented in Chapters 4 and 5 has led me to conclude that when considering 
methods for measuring medication adherence in clinical research, this should be 
approached in a way analogous to the selection of appropriate outcome measures. There 
needs to be an understanding of the phenomena that is of importance. This will be context-
specific. For example, when interest lies in the extent to which patients take their medication 
as prescribed, and two different dosing regimens are compared (where the same amount 
of medication is consumed, but the regimen differs), using tablet counts as your primary 
means of describing medication adherence would not be recommended. Electronic 
monitoring is better suited for this purpose, as dose patterns and timings can be collected. 
For this reason, it is a more valid means of measuring adherence in this situation. This does 
not mean that tablet count data should be discarded however, even in the scenario 
described. Assessing agreement between tablet counts and electronic monitoring during 
Chapter 4, I suggested that for patients on complex dosing regimens, electronic monitoring 
may not necessarily be an acceptable or reliable way of measuring adherence. Tablet count 
data could provide a useful reliability check in this instance. The ability for a measure to 
detect change (i.e. responsiveness), is a related and another desirable property of an 
adherence measure. During Chapter 5 I demonstrated that adherence as measured using 
self-reported data and electronic monitors were able to distinguish between regimens, 
whereas tablet counts were not. In addition, understanding the types of people or 
circumstances that are likely to result in disagreement between measures could aid in 
choosing appropriate adherence measures in future research, or even tailoring types of 
adherence measures (certain types or single/multiple types for certain individuals). 
It is difficult to interpret the determinants found during Chapter 5, and further work would 
still be required prior to implementing any interventions to improve adherence in reaction 
to these determinants. That said, the general lack of consistency across setting would imply 
that adherence to treatment is context-specific, and this context is likely to entail the types 
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of patients being treated and types of treatment being given. The types of determinants 
found to be associated with adherence suggest, however, that addressing cultural 
perceptions of illness and medication taking behaviour could be a pathway to improving 
adherence. The therapeutic alliance between treating clinician and patient is acknowledged 
as vital for achieving good clinical outcomes, and this would indeed appear to be the case 
if they influence the extent to which a patient takes their medication as prescribed. Different 
determinants were associated with different adherence processes. The implication of this is 
that depending on where the adherence problem lies for a specific condition (i.e. people 
are not initiating, or are initiating but not implementing correctly, or initiation is sufficient 
to achieve positive clinical outcomes, or what matters most is the length of time you’re on 
treatment, regardless of how well you take it, so time to discontinuation is important) the 
intervention to improve this (with the ultimate goal of improving clinical outcomes), may 
differ. 
The drawbacks of using randomisation-based efficacy estimators in RCTs with non-
adherence can be largely addressed by ensuring studies are designed to appropriately 
answer the question of treatment efficacy from the start. Retrofitting randomisation-based 
efficacy estimators to studies is fraught with compromises that are likely to lead to imprecise 
estimates and/or the employment of questionable assumptions that are difficult to verify. 
Considering the use of these analytical approaches from the outset requires building non-
adherence into the sample size calculation, thinking about how adherence will be defined, 
the type or types of measures that will be used, and ensuring that variables that are likely to 
be associated with adherence (in both arms, if there are two active treatments) are collected. 
When determining the type of measure (or measures) to monitor adherence, the findings 
and implications from the work I carried out during Chapter 4 will be particularly relevant. 
The dimensions described in Chapter 5 can be used as a framework for deciding on 
important variables to measure for this work. 
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The increase in variance that is observed when fitting randomisation-based efficacy 
estimators might be seen unacceptable when the key question of interest is related to the 
effectiveness (or population-level) effect of treatment. However, this increase in variance 
represents real uncertainty, and therefore where the question of treatment efficacy is of 
interest, this needs considering during the design phase. A simple sample size adjustment 
would inflate for the reciprocal of the proportion of participants estimated to adhere to 
treatment, but may also increase the effect size, as there would be an expectation that an 
efficacy effect (effect in participants who take their treatment) would be larger than an 
effectiveness effect (effect in participants regardless of whether or not they take treatment). 
Finally, a theme running throughout my work has been that adherence is more difficult for 
patients on complex treatments. The natural reaction to this is to simplify treatments. For 
example, prescribe treatment for a shorter duration, have patients take all medication at 
one point during a day, or let patients have treatments they can take at home rather than 
having to travel to hospital for each dose. While to a large degree I agree with this idea, 
what is often overlooked is the consequence of non-adherence and how this can be 
exacerbated for patients on simple regimens (compared to them being on more complex 
regimens). For example, one of the studies I focused on during my thesis comprised two 
groups of patients: both groups were prescribed three tablets a day, but one group were 
told to take all three tablets at the same time and the other were told to take the tablets in 
three divided doses throughout the day. An individual was defined as having not adhered 
to their regimen on a given day if they did not take the correct number of doses. An 
individual in one group could be described as not adhering to their regimen even if they 
took two out of the three tablets, whereas if an individual in the other group did not adhere 
this was because they took no tablets on that day. For individuals on a treatment for a long 
time period, several instances of non-adherence could amount to a considerable lack of 
treatment in one group and could potentially be quite clinically harmful, whereas an 
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individual could be perceived to be as non-adherent to a more complex regimen, but at a 
reduced risk of harm due to them still consuming some medication. This insight leads to 
the implication that it is not as straightforward as simplifying treatment regimens in all 
circumstances. There will be instances where complex regimens remain the only safe 
option while non-adherence is still a possibility. 
7.6 Further areas for research 
There are various strands of work that can be taken forward, following the work presented 
in my thesis. These are summarised below: 
1. Joint modelling of electronic monitoring data and pharmacology data (e.g. data 
from pharmacokinetic / pharmacodynamic studies): By combining these rich data 
sources, models could be developed that described patterns in adherence, and how 
they related to treatment response. These models could then be used to refine 
medication use (for example, they could be used to determine the number of doses 
a patient could safely miss, and this could be built into their prescribing strategy to 
minimise side effects caused by taking medication for a prolonged duration). One 
area in which this may be important is in the prescribing of antibiotics, as the risk 
that poor adherence poses is not just clinical failure, but also development of 
antibiotic resistant organisms, and this would be a concern at a society-level (rather 
than purely a problem for the individual).  
2. Calibration techniques: Extensions could be made to the hierarchy calibration 
technique I explored during Chapter 4. This technique could be improved by 
accounting for the different variances associated with the different types of measures 
considered, or even the number of measures considered. More complex calibration 
techniques, for example using latent variable approaches (e.g. structural equation 
modelling), are also worthy of further investigation. The use of nested study designs 
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for informing calibrated measures may be provide an efficient way of carrying out 
research in this area. Another approach to calibrating could also be to use one 
measure that captures overall consumption (e.g. tablet counts), use another that 
captures patterns (e.g. prospective self-report diaries or electronic monitoring) and 
calibrate the patterned data with the overall consumption data. 
3. Further exploration of the limits of agreement and confidence intervals around 
them are needed for bounded measures such as the ones encountered when 
measuring adherence. 
4. Development of a model that incorporates all adherence processes without 
amalgamating them as a single summary measure: This is the natural progression 
from separating the elements out, and attempts I have made at combining them (for 
example, using hurdle models). The utility of such a model, however, will depend 
on the approach or approaches used to monitor adherence. 
5. Further extensions to randomisation-based efficacy estimators: deficiencies in the 
application of these approaches on real datasets has been described throughout my 
thesis. Methodological work in this area that would be of immediate practical 
importance, focuses on the extension of these techniques to more complex 
outcomes (for example, recurrent events that are usually modelled using the 
Anderson-Gill Cox regression model), empirical guidance on situations when 
assuming a linear relationship between adherence and treatment effect or the 
exclusion restriction is most appropriate, and, following on from this, methods to 
account for non-linear relationships between adherence and treatment effects. 
6. Finally, the development of standardised approaches when a key goal of research is 
to study medication adherence. The work presented throughout my thesis, but 
particularly in Chapters 5 and 6, highlight the need for the development of core 
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measure sets for research where adherence is the focus. These sets may be generic, 
condition-specific, perhaps only separate for short and long-term treatments, but 
would contain guidance on items that are vitally important to collect when 
medication adherence is a focus (primary or key secondary) during a study. This 
might lead to a requirement to collect more data in a study, something that on the 
surface may seem to conflict with other initiatives (such as Trial Forge (Treweek et 
al., 2015)), however for studies that plan to focus on medication adherence, this 
additional data will be important. 
7.7 Concluding remarks 
I have investigated various methodological challenges that are encountered when studying 
medication adherence in clinical research. The new evidence I have generated will advance 
the field, and I have indicated areas in which further developments are warranted. 
It is my hope that this work and recommendations herein will be seized upon by applied 
medical researchers, and that moving forward medication adherence will be a key 
consideration during the design, conduct, analysis, and reporting of all research where the 
use of medication is being investigated. 
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Appendices 
Appendix I – Description of variables collected as part of the 
GRACE studies 
I. GRACE WP8 CRF 
  
  
  
  
 
  
  
 
  
  
 
  
  
 
  
  
II. GRACE WP8 Diary 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
III. GRACE WP9 and WP10a CRF 
  
  
  
  
 
  
  
IV: GRACE WP9 and WP10a Diary 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
Appendix II – Description of variables collected as part of the 
CODA study 
 
 
CODA Study 
 
Colitis: Once Daily Asacol  
 
A Randomized, Multicentre, Parallel Group Single-
Blind Study to Assess the Efficacy and Safety of 
Dosing Mesalazine 800mg Tablets (Asacol®) at 2.4g 
Once Daily versus Divided Doses Three Times Daily 
for 12 months in the Maintenance of Remission of 
Ulcerative Colitis 
 
Case Report Form 
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CODA Study Colitis: Once Daily Asacol                                                                                           SCREENING 
                                            
Patient initials __ __ __         Randomisation No. __ __ __ __  
 
SCREENING ASSESSMENT:       Visit date: __ __ /__ __ __/ __ __ __ __      
                              d d     m  m  m   y   y   y   y 
 
NOTE: You can combine screening and baseline visits. Take U&E, CRP and test urine 
immediately – once results are confirmed to be within normal range, patient can be 
randomised 
 
Procedures to be carried out at this visit: 
 
 Consent  
            To be obtained prior to undertaking any study procedure 
 Demographics, disease history & disease assessment 
 Rigid or flexible sigmoidoscopy (biopsy not required) 
 Concomitant medication 
 Blood for U & E, CRP  
 Urine dipstick 
 Inclusion & exclusion criteria 
 Document details of visit in medical notes 
 
   
1     Patient details: 
 
1.1   Date of Birth:  __ __ /__ __ __/ __ __ __ __   
    d d     m  m  m   y   y   y   y 
  
1.2   Sex:  Male  □ Female  □   
 
 
2     Disease history:  
 
2.1   Date UC diagnosed: __ __ __/ __ __ __ __   
   
CODA Study Colitis: Once Daily Asacol                                                                                           SCREENING 
                                            
Patient initials __ __ __         Randomisation No. __ __ __ __  
    m  m  m   y   y   y   y 
 
2.2   Maximum Documented Extent of UC: 
        Extensive □     Left-sided or sigmoid □ Proctitis □ 
 
 
 
3     Relapse history: 
Patient must be in remission, and have had a relapse in the past two years - Relapse definition: 
symptoms of colitis requiring treatment  
 
 
3.1   When did the patient finish treatment for the last episode of active colitis? 
 
       __ __ /__ __ __/ __ __ __ __   
        d d     m  m  m   y   y   y   y 
 
3.2   How many relapses has the patient had in the past two years? ___ ___ 
 
4     Which 5-ASA containing drug is currently being used: 
This will be stopped when trial medication is started 
 
Drug name Dose Frequency Route Date 
started 
(year only) 
 
 
    
 
 
5     Other Current Drug Therapy for Ulcerative Colitis: 
   
CODA Study Colitis: Once Daily Asacol                                                                                           SCREENING 
                                            
Patient initials __ __ __         Randomisation No. __ __ __ __  
Complete medication documentation on page 30 
 
 
6     Blood and urine sample: 
Take blood for urea & electrolytes and CRP, carry out dipstick urinalysis (send blood to local lab 
& use local dipsticks). Record results on laboratory samples page 32 
  
 
7      Other Medical Conditions: 
Condition 
Tick either active or inactive for each condition 
Currently active Inactive 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
7.1   Has the patient had appendicectomy? 
        Yes □          No □          Don’t know □   
 
8     Usual Stool Frequency: 
 
8.1   What is the normal stool frequency for this patient when in remission? 
  
   
CODA Study Colitis: Once Daily Asacol                                                                                           SCREENING 
                                            
Patient initials __ __ __         Randomisation No. __ __ __ __  
        _____ stools / day 
 
9     Current disease status: 
Perform sigmoidoscopy – no biopsy required 
 
10     Mayo Clinic Score: 
 
Score symptoms according to the past 3 days Subscore 
Stool frequency 
0=Normal no. of stools for this subject 
1= 1-2 stools/day more than normal  
2= 3-4 stools/day more than normal 
3= >5 stools/day more than normal 
 
Rectal bleeding 
0= No blood seen 
1= Streaks of blood with <50% of stools 
2= Obvious blood seen with >50% of stools 
3= Blood alone passed 
 
Physician’s global assessment 
0= Normal (ie inactive) 
1= Mild disease 
2= Moderate disease 
3= Severe disease 
 
Findings on Sigmoidoscopy * 
0= Normal  
1= Mild disease (erythema, decreased vascular pattern, mild friability). 
No contact bleeding. 
2= Moderate disease (marked erythema, absent vascular pattern, 
friability, erosions) 
3= Severe disease (spontaneous bleeding, ulceration) 
 
  
Total score 
 
 
* For this trial the sigmoidoscopic score will be equivalent to the modified Baron score: - i.e. 
contact bleeding will be classed as grade 2 and spontaneous bleeding as grade 3  
   
CODA Study Colitis: Once Daily Asacol                                                                                           SCREENING 
                                            
Patient initials __ __ __         Randomisation No. __ __ __ __  
 
11 Inclusion Criteria 
 
Tick  to confirm the following applies to the patient:- 
 
Tick 
Diagnosis of ulcerative colitis confirmed histologically in the past  
Colitis in clinical remission for 4 weeks or longer   
Has undergone rigid or flexible sigmoidoscopy at this visit showing mucosal 
appearance of    grade 0 or 1 (modified Baron score)  
Has had symptomatic relapse of UC within past 2 years  
Has a current Mayo score of  ≤ 2  
Currently taking mesalazine, sulphasalazine, balsalazide, olsalazine or other 
drug containing 5-aminosalicylic acid, for 4 weeks or longer  
Aged over 18   
If female, must be (as documented in patient notes): 
 
 postmenopausal (at least 1 year without spontaneous menses), or 
 surgically sterile (tubal ligation or hysterectomy at least 6 months prior 
to enrolment), or 
 using acceptable contraception (e.g., oral, intramuscular, or implanted 
hormonal contraception) at least 3 months prior to enrolment, or 
 have a sexual partner with non-reversed vasectomy (with confirmed 
azoospermia), or 
 be using 1 barrier method (e.g., condom, diaphragm, spermicide, or 
intra-uterine device) 
 
Has given written informed consent  
 
  
   
CODA Study Colitis: Once Daily Asacol                                                                                           SCREENING 
                                            
Patient initials __ __ __         Randomisation No. __ __ __ __  
 
 
12 Exclusion Criteria 
 
Tick to confirm there is no evidence of :- 
 
Tick 
Crohn’s disease  
 
 
Symptoms of active colitis 
 
 
Modified Baron sigmoidoscopy score of 2 or 3 
 
 
Use of oral, enema, intravenous or suppository preparations of 
corticosteroids, oral or intravenous ciclosporin, mesalazine enemas or 
suppositories within the past four weeks. 
 
Altered dose or commencement of azathioprine or 6-mercaptopurine within 
the past three months, (these drugs permitted in stable dose during the 
study).  
 
Intolerance to Asacol 400 mg or mesalazine.  
 
 
Women who are pregnant or lactating. 
 
 
Known HIV infection  
 
 
Known hepatic disease with significant elevation of liver enzymes (more than 
twice upper limit of normal)  
 
 
Renal impairment (creatinine above local reference range), or with positive 
urine dipstick test to blood or protein  
 
 
Other serious medical or psychiatric illness that in the opinion of the 
investigator would possibly compromise the study  
 
   
CODA Study Colitis: Once Daily Asacol                                                                                           SCREENING 
                                            
Patient initials __ __ __         Randomisation No. __ __ __ __  
Problem alcohol excess or drug abuse that in the opinion of the investigator 
would possibly compromise the study 
 
 
 
This patients fits the study criteria and is suitable for inclusion      Yes □              No □ 
If no, please retain screening documents 
 
 
Signature: _____________________________   Date __ __ /__ __ __/ __ __ __ __   
                  d d     m  m  m   y   y   y   y 
 
Name:  
(in capitals) ___________________________     Designation_____________________ 
 
 
  
   
CODA Study Colitis: Once Daily Asacol                                                                                           SCREENING 
                                            
Patient initials __ __ __         Randomisation No. __ __ __ __  
Screening checklist 
 
Have the following been completed? Tick 
Consent 
 
 
Sigmoidoscopy 
 
 
Blood for U & E, CRP 
 
 
Urine dipstick 
 
 
Record concomitant medication 
 
 
Document visit in medical notes 
 
 
Arrange baseline visit (must be within 10 days of screening):  date: __ 
__/__ __ __/__ __ __ __ 
         d d   m  m  m    y   y   y   y 
or  
complete baseline visit today if blood and urine results are available to 
confirm eligibility 
 
 
  
   
CODA Study Colitis: Once Daily Asacol                                                                                              BASELINE 
                                            
Patient initials __ __ __         Randomisation No. __ __ __ __ 
 
BASELINE ASSESSMENT:        Visit date: __ __ /__ __ __/ __ __ __ __   
                                   d d     m  m  m   y   y   y   y 
 
 
Procedures to be carried out at this visit: 
 
 Randomisation 
 Dispense medication 
 Faecal calprotectin 
 Other medical history 
 Document details of visit in medical notes 
 Fax Clinical Trial Coordinator to inform of recruitment 
 Send GP letter 
 
 
1 Extra-intestinal Complications (current or previous) 
Tick all that apply 
 
Tick 
Arthritis (swollen or deformed joints) 
 
 
Arthralgia 
 
 
Sacro-iliitis 
 
 
Ankylosing spondylitis 
 
 
Pyoderma gangrenosum 
 
 
   
CODA Study Colitis: Once Daily Asacol                                                                                              BASELINE 
                                            
Patient initials __ __ __         Randomisation No. __ __ __ __ 
 
Erythema nodosum 
 
 
Aphthous ulcers or stomatitis 
 
 
Primary sclerosing cholangitis 
 
 
Auto-immune hepatitis 
 
 
Uveitis or iritis 
 
 
None of the above 
 
 
   
CODA Study Colitis: Once Daily Asacol                                                                                              BASELINE 
                                            
Patient initials __ __ __         Randomisation No. __ __ __ __ 
 
 
2     Smoking status: 
2.1   Is the patient a current smoker? Yes   □      No □(If no go to part 2.5 ) 
2.2   Does the patient smoke  daily □        occasionally □ 
2.3   Does the patient smoke:       cigarettes □            pipe □                   cigars □ 
2.4   How many per day:                      <10 □                   ≥10 □    ounces tobacco □     
2.5   Is the patient an ex-smoker? Yes   □      No □(If no go to part 2.7 ) 
  
2.6   Date gave up __ __ __ __   
                               y   y   y   y 
 
2.7   Do you use nicotine in any other form (e.g. chewing gum, patches)? Yes □ No □ 
If yes, please specify ___________________________________________________ 
 
   
3     Ethnicity: 
White    □ African or Afrocaribbean □ 
South Asian (Indian subcontinent) □ Other  (give detail): __________________
    
 
 
4 Employment 
please tick all that apply 
 
Tick 
Full-time education   
   
CODA Study Colitis: Once Daily Asacol                                                                                              BASELINE 
                                            
Patient initials __ __ __         Randomisation No. __ __ __ __ 
 
    
Part-time education 
      
 
Full-time employment   
    
 
Part-time employment  
 
 
Homemaker or not in paid employment 
  
 
Unemployed or seeking work   
   
 
Not working due to disability  
   
 
Retired 
        
 
 
  
   
CODA Study Colitis: Once Daily Asacol                                                                                              BASELINE 
                                            
Patient initials __ __ __         Randomisation No. __ __ __ __ 
 
5     Faecal calprotectin: 
Collect stool sample for faecal calprotectin as per instructions on enclosed sheet 
 
5.1 Was the stool sample obtained:  at this visit □  or     pot given to patient □ 
 
6     Study medication: 
Complete prescription for study medication. Remind patient not to open a new bottle of 
medication until the opened one is empty and to return unused medication and empty bottles 
at next visit.  
Obtain randomisation number from pharmacy, once the patient has collected their trial 
medication. 
 
 
  
   
CODA Study Colitis: Once Daily Asacol                                                                                              BASELINE 
                                            
Patient initials __ __ __         Randomisation No. __ __ __ __ 
 
Baseline  checklist 
 
Have the following been completed? Tick 
Randomisation - Pharmacy will assign the randomisation number. You need 
to obtain the number from pharmacy (or the patient) to complete the CRF 
and calprotectin sample documents 
 
 
Dispense medication 
 
 
Faecal calprotectin sample 
 
 
Document details of visit in medical notes 
 
 
Give patient trial card 
 
 
Write to GP – trial participation 
 
 
Fax Clinical Trial Coordinator to inform of recruitment 
 
 
Arrange next visit (6 weeks +/-1 week) date __ __/__ __ __/__ __ __ __ 
                                                                        d  d   m  m  m  y   y  y   y 
 
Remind patient to bring remaining study medication & empty bottles to next 
visit 
 
 
  
   
CODA Study Colitis: Once Daily Asacol                                                                                                   WEEK 6 
                                            
Patient initials __ __ __         Randomisation No. __ __ __ __ 
 
WEEK 6 ASSESSMENT:        Visit date: __ __ /__ __ __/ __ __ __ __   
                                                                 d d     m  m  m   y   y   y   y 
 
 
Procedures to be carried out at this visit: 
 
 Tablet count & give tablets back to patient 
 Disease assessment 
 Concomitant medication 
 Blood for U & E, CRP 
 Urine dipstick 
 Record any adverse events 
 Document details of visit in medical notes 
 
1     Disease status: 
 
1.1   Has the patient received treatment for a flare up of ulcerative colitis? 
        Yes □              No □ 
Note: It is a violation of the protocol for patients to receive treatment for flare up whilst in the 
study. If patient has received treatment for UC flare up withdraw them from trial and complete 
relapse assessment – page 26. Do not complete any further questions for this visit. 
 
1.2   Bowel frequency (past 3 days) ___ / day 
 
1.3   Rectal bleeding (past 3 days)        None                                                     □  
                                                               Streaks of blood with <50% of stools  □ 
                                                               Obvious blood with >50% of stools     □ 
                                                               Blood alone passed                               □ 
 
1.4   Is it possible that the patient has relapsed?    Yes □              No □ 
   
CODA Study Colitis: Once Daily Asacol                                                                                                   WEEK 6 
                                            
Patient initials __ __ __         Randomisation No. __ __ __ __ 
 
If yes, do not complete any further questions for this visit. Complete relapse assessment page 
26 and withdraw from study if relapse confirmed 
 
 
2     Trial medication: 
Remind patient not to open a new bottle of medication until the opened one is empty and to 
return unused medication and empty bottles at next visit 
 
2.1   Record how many trial tablets are left in the medication pack: ________ 
There are 180 tablets in an unopened bottle. 
 
2.2   According to the patient have they taken their study tablets as prescribed?  
        Yes (≥ 90% of the time)□              No (< 90% of the time)□ 
 
2.3   According to the patient how easy was it remembering to take the trial  tablets: 
        Very easy □    Fairly easy □     Fairly difficult □     Very difficult □ 
 
 
3     Concomitant medication: 
 
3.1   Have there been any changes in medication?  
        Yes □              No □  
 
Record any changes on the changes to concomitant medication page 31 
 
 
4     Adverse events: 
 
4.1   Has the patient experienced any adverse events since the last visit? 
     Yes □              No □ 
If yes, complete adverse events page 33 
 
 
5     Blood and urine sample: 
Take blood for urea & electrolytes and CRP, carry out dipstick urinalysis (send blood to local lab 
& use local dipsticks). Record results on laboratory samples page 32 
  
   
CODA Study Colitis: Once Daily Asacol                                                                                                   WEEK 6 
                                            
Patient initials __ __ __         Randomisation No. __ __ __ __ 
 
Week 6 Checklist 
 
Have the following been completed? Tick 
Tablet count & give tablets back to patient 
 
 
Changes to medication check 
 
 
Symptom assessment 
 
 
Blood for U & E, CRP 
 
 
Urine dipstick 
 
 
Record any adverse events 
 
 
Remind patient to bring remaining study medication & empty bottles to next 
visit 
 
 
Document visit in medical notes 
 
 
Date in diary for 3 month telephone contact: __ __/__ __ __/__ __ __ __ 
                                                                         d d   m  m  m    y   y   y   y 
 
 
Arrange 6 month visit (max 6 months/- 2 weeks): date:                                              
                                                                           __ __/__ __ __/__ __ __ __ 
                                                                           d d   m  m  m    y   y   y   y                                                                                                                              
 
 
  
    
  
CODA Study Colitis: Once Daily Asacol                                                                                              3 MONTH     
                                                                                                                                                            TELEPHONE  
Patient initials __ __ __         Randomisation No. __ __ __ __ 
THREE MONTH TEL. CONTACT: Contact date: __ __/__ __ __/__ __ __ 
__    
                                  d  d   m  m  m   y   y   y   y  
1     Disease status: 
1.1   Has the patient received treatment for a flare up of ulcerative colitis? 
        Yes □              No □ 
Note: It is a violation of the protocol for patients to receive treatment for flare up whilst in the 
study. If patient has received treatment for UC flare up withdraw them from trial & arrange 
relapse assessment visit as soon as possible. Do not complete any further questions for this visit. 
 
1.2   Bowel frequency (past 3 days) ___ / day 
 
1.3   Rectal bleeding (past 3 days)        None                                                     □  
                                                               Streaks of blood with <50% of stools  □ 
                                                               Obvious blood with >50% of stools     □ 
                                                               Blood alone passed                               □ 
 
1.4   Is possible that the patient has relapsed?    Yes □              No □ 
If yes, arrange relapse assessment visit as soon as possible 
 
2     Trial medication: 
2.1   According to the patient have they taken their study tablets as prescribed?  
        Yes (≥ 90% of the time)□              No (< 90% of the time)□ 
 
2.2   According to the patient how easy was it remembering to take the trial  tablets: 
        Very easy □    Fairly easy □     Fairly difficult □     Very difficult □ 
 
3     Concomitant medication: 
3.1   Have there been any changes in medication?  
        Yes □              No □  
Record any changes on the changes to concomitant medication page 31 
 
4     Adverse events: 
4.1   Has the patient experienced any adverse events since the last visit? 
       Yes □              No □ 
If yes, complete adverse events page 33 
 
    
  
CODA Study Colitis: Once Daily Asacol                                                                                              3 MONTH     
                                                                                                                                                            TELEPHONE  
Patient initials __ __ __         Randomisation No. __ __ __ __ 
Confirm date of next visit and remind patient to bring remaining study medication with 
them.  
 
SIX MONTH ASSESSMENT:              Visit date: __ __ /__ __ __/ __ __ __ __   
                                                                 d d     m  m  m   y   y   y   y 
 
 
Procedures to be carried out at this visit: 
 
 Tablet count & return empty bottles and unused tablets to pharmacy 
 Dispense medication 
 Disease assessment 
 Concomitant medication 
 Blood for U & E, CRP 
 Urine dipstick 
 Record any adverse events 
 Document details of visit in medical notes 
 
1     Disease status: 
 
1.1   Has the patient received treatment for a flare up of ulcerative colitis? 
        Yes □              No □ 
Note: It is a violation of the protocol for patients to receive treatment for flare up whilst in the 
study. If patient has received treatment for UC flare up withdraw them from trial and complete 
relapse assessment – page 26. Do not complete any further questions for this visit.  
 
1.2   Bowel frequency (past 3 days) ___ / day 
 
1.3   Rectal bleeding (past 3 days)        None                                                     □  
                                                               Streaks of blood with <50% of stools  □ 
                                                               Obvious blood with >50% of stools     □ 
                                                               Blood alone passed                               □ 
 
    
  
CODA Study Colitis: Once Daily Asacol                                                                                                6 MONTH     
                                                                                                                      
Patient initials __ __ __         Randomisation No. __ __ __ __ 
1.4   Is it possible that the patient has relapsed?    Yes □              No □ 
If yes, do not complete any further questions for this visit. Complete relapse assessment pages 
26 and withdraw from study if relapse confirmed 
 
2     Trial medication: 
Complete prescription for study medication. Remind patient not to open a new bottle of 
medication until the opened one is empty and to return unused medication and empty bottles 
at next visit 
 
2.1   Record how many trial tablets are left in the medication pack: ________ 
There are 180 tablets in an unopened bottle 
 
2.2   According to the patient have they taken their study tablets as prescribed?  
        Yes (≥ 90% of the time)□              No (< 90% of the time)□ 
 
2.3   According to the patient how easy was it remembering to take the trial  tablets: 
        Very easy □    Fairly easy □     Fairly difficult □     Very difficult □ 
 
 
3     Concomitant medication: 
 
3.1   Have there been any changes in medication?  
        Yes □              No □  
 
Record any changes on the changes to concomitant medication page 31 
 
 
4     Adverse events: 
 
4.1   Has the patient experienced any adverse events since the last visit? 
     Yes □              No □ 
If yes, complete adverse events page 33 
 
 
5     Blood and urine sample: 
Take blood for urea & electrolytes and CRP, carry out dipstick urinalysis (send blood to local lab 
& use local dipsticks). Record results on laboratory samples page 31 
 
 
 
 
    
  
CODA Study Colitis: Once Daily Asacol                                                                                                6 MONTH     
                                                                                                                      
Patient initials __ __ __         Randomisation No. __ __ __ __ 
Six  month checklist 
 
Have the following been completed? Tick 
Tablet count & return unused tablets and empty bottles to pharmacy 
 
 
Changes to medication check 
 
 
Symptom assessment 
 
 
Blood for U & E, CRP 
 
 
Urine dipstick 
 
 
Record any adverse events 
 
 
Prescribe study medication 
 
 
Remind patient to bring remaining study medication & empty bottles to next 
visit 
 
 
Document visit in medical notes 
 
 
Date in diary for 9 month telephone contact: __ __/__ __ __/__ __ __ __ 
                                                                          d d   m  m  m    y   y   y   y 
 
 
Arrange 12 month visit (max 12 months/- 2 weeks): date:                                  
                                                                      __ __/__ __ __/__ __ __ __                        
                                                                       d d   m  m  m    y   y   y   y    
Sigmoidoscopy required at 12 month visit   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
  
CODA Study Colitis: Once Daily Asacol                                                                                             9 MONTH     
                                                                                                                                                            TELEPHONE Patient initials __ __ 
__         Randomisation No. __ __ __ __ 
NINE MONTH TEL. CONTACT: Contact date: __ __/__ __ __/__ __ __ 
__    
                             d  d   m  m  m   y   y   y   y  
1     Disease status: 
1.1   Has the patient received treatment for a flare up of ulcerative colitis? 
        Yes □              No □ 
Note: It is a violation of the protocol for patients to receive treatment for flare up whilst in the 
study. If patient has received treatment for UC flare up withdraw them from trial & arrange 
relapse assessment visit as soon as possible. Do not complete any further questions for this visit. 
 
1.2   Bowel frequency (past 3 days) ___ / day 
 
1.3   Rectal bleeding (past 3 days)        None                                                     □  
                                                               Streaks of blood with <50% of stools  □ 
                                                               Obvious blood with >50% of stools     □ 
                                                               Blood alone passed                               □ 
 
1.4   Is possible that the patient has relapsed?    Yes □              No □ 
If yes, arrange relapse assessment visit as soon as possible 
 
2     Trial medication: 
2.1   According to the patient have they taken their study tablets as prescribed?  
        Yes (≥ 90% of the time)□              No (< 90% of the time)□ 
 
2.2   According to the patient how easy was it remembering to take the trial  tablets: 
        Very easy □    Fairly easy □     Fairly difficult □     Very difficult □ 
 
3     Concomitant medication: 
3.1   Have there been any changes in medication?  
        Yes □              No □  
Record any changes on the changes to concomitant medication page 31 
 
4     Adverse events: 
4.1   Has the patient experienced any adverse events since the last visit? 
       Yes □              No □ 
If yes, complete adverse events page 33 
 
    
  
CODA Study Colitis: Once Daily Asacol                                                                                             9 MONTH     
                                                                                                                                                            TELEPHONE Patient initials __ __ 
__         Randomisation No. __ __ __ __ 
Confirm date of next visit and remind patient to bring remaining study medication with 
them.  
 
TWELVE MONTH ASSESSMENT:   Visit date: __ __ /__ __ __/ __ __ __ __   
                                                                 d d     m  m  m   y   y   y   y 
 
  
Procedures to be carried out at this visit: 
 
 Tablet count and stop study drug – return unused medication and empty bottles to 
pharmacy 
 Rigid or flexible sigmoidoscopy (biopsy not required) 
 Disease assessment 
 Concomitant medication 
 Blood for U & E, CRP 
 Urine dipstick 
 Record any adverse events 
 Prescription for future treatment  
 Write to GP – trial completion 
 Document details of visit in medical notes 
 Arrange routine hospital follow up 
 Thank patient for participating 
 
 
 
1     Disease status: 
 
1.1   Has the patient received treatment for a flare up of ulcerative colitis? 
        Yes □              No □ 
Note: It is a violation of the protocol for patients to receive treatment for flare up whilst in the 
study. If patient has received treatment for UC flare up withdraw them from trial and complete 
relapse assessment – page 26. Do not complete any further questions for this visit. 
 
  
 
  
CODA Study Colitis: Once Daily Asacol                                                                                              12 MONTH     
                                                                                                                      
Patient initials __ __ __         Randomisation No. __ __ __ __  
 
1.2   Bowel frequency (past 3 days) ___ / day 
 
 
1.3   Rectal bleeding (past 3 days)        None                                                     □  
                                                               Streaks of blood with <50% of stools  □ 
                                                               Obvious blood with >50% of stools     □ 
                                                               Blood alone passed                               □ 
1.4   Is possible that the patient has relapsed?    Yes □              No □ 
If yes, do not complete any further questions for this visit. Complete relapse assessment pages 
26 and withdraw from study if relapse confirmed 
 
1.5   Mayo Clinic Score  
 
Score symptoms according to the past 3 days Subscore 
Stool frequency 
0=Normal no. of stools for this subject 
1= 1-2 stools/day more than normal  
2= 3-4 stools/day more than normal 
3= >5 stools/day more than normal 
 
Rectal bleeding 
0= No blood seen 
1= Streaks of blood with <50% of stools 
2= Obvious blood seen with >50% of stools 
3= Blood alone passed 
 
Physician’s global assessment 
0= Normal (ie inactive) 
1= Mild disease 
2= Moderate disease 
3= Severe disease 
 
Findings on Sigmoidoscopy * 
0= Normal  
1= Mild disease (erythema, decreased vascular pattern, mild friability). 
No contact bleeding 
2= Moderate disease (marked erythema, absent vascular pattern, 
friability, erosions) 
3= Severe disease (spontaneous bleeding, ulceration) 
 
* For this trial the sigmoidoscopic score will be equivalent to the modified Baron score: - i.e. 
contact bleeding will be classed as grade 2 and spontaneous bleeding as grade 3 
 
 
2     Trial medication: 
  
 
  
CODA Study Colitis: Once Daily Asacol                                                                                              12 MONTH     
                                                                                                                      
Patient initials __ __ __         Randomisation No. __ __ __ __  
 
2.1   Record how many trial tablets are left in the medication pack: ________ 
There are 180 tablets in an unopened bottle 
 
 
2.2   According to the patient have they taken their study tablets as prescribed?  
        Yes (≥ 90% of the time)□              No (< 90% of the time)□ 
 
2.3   According to the patient how easy was it remembering to take the trial  tablets: 
        Very easy □    Fairly easy □     Fairly difficult □     Very difficult □ 
 
 
3     Concomitant medication: 
 
3.1   Have there been any changes in medication?  
        Yes □              No □  
 
Record any changes on the changes to concomitant medication page 31 
 
 
4     Adverse events: 
 
4.1   Has the patient experienced any adverse events since the last visit? 
        Yes □              No □ 
If yes, complete adverse events page 33 
 
 
6 Blood and urine sample: 
Take blood for urea & electrolytes and CRP, carry out dipstick urinalysis (send blood to local lab 
& use local dipsticks). Record results on laboratory samples page 32 
 
 
7 Trial completion: 
Date patient completed trial treatment:                                 __ __ /__ __ __/ __ __ __ __      
                             d d     m  m  m   y   y   y   y 
 
Complete end of study form page 29 
 
 
 
 
  
 
  
CODA Study Colitis: Once Daily Asacol                                                                                              12 MONTH     
                                                                                                                      
Patient initials __ __ __         Randomisation No. __ __ __ __  
Twelve month checklist 
 
Have the following been completed? Tick 
Tablet count & return unused medication and empty bottles to pharmacy 
 
 
Changes to medication check 
 
 
Symptom assessment 
 
 
Sigmoidoscopy 
 
 
Blood for U & E, CRP 
 
 
Urinalysis 
 
 
Record any adverse events 
 
 
Complete end of study form 
 
 
Discuss dose of mesalazine to be used by patient and prescribe if required 
 
 
Document details of visit in medical notes 
 
 
Thank patient for participation in study 
 
 
Write to GP – trial completion 
 
 
Arrange routine hospital follow up 
 
 
 
 
This patient has completed the study according to the protocol & remained in remission 
 
Signature: _______________________________ Date __ __ /__ __ __/ __ __ __ __   
                d d     m  m  m   y   y   y   y 
Name:  
(in capitals) __________________________      Designation_____________________ 
  
   
CODA Study Colitis: Once Daily Asacol                                                                                    UNSCHEDULED     
                                                                                                                      
Patient initials __ __ __         Randomisation No. __ __ __ __   
 
UNSCHEDULED ASSESSMENT:       Visit date: __ __ /__ __ __/ __ __ __ __      
                   d d     m  m  m   y   y   y   y 
 
 
Procedures to be carried out at this visit: 
 
 Tablet count 
 Disease assessment 
 Concomitant medication 
 Record any adverse events 
 Document details of visit in medical notes 
 
 
1     Reason for visit:     
 
NOTE: 
a)     If the reason for this visit is suspected relapse do not complete these pages, go to relapse 
assessment page 26  
b)    If unscheduled visit falls within time window of routine visits, do not complete these pages, 
complete relevant visit pages 
 
1.1   State reason for visit: _________________________________________________                                   
                                            
 
2     Disease status: 
 
2.1   Bowel frequency (past 3 days) ___ / day 
 
2.2   Rectal bleeding (past 3 days)        None                                                     □  
                                                               Streaks of blood with <50% of stools  □ 
                                                               Obvious blood with >50% of stools     □ 
                                                               Blood alone passed                               □ 
 
2.3   Is the patient still in remission?     Yes □              No □ 
   
CODA Study Colitis: Once Daily Asacol                                                                                    UNSCHEDULED     
                                                                                                                      
Patient initials __ __ __         Randomisation No. __ __ __ __   
 
If no, do not complete any further questions for this visit. Complete relapse assessment page 26 
and withdraw from study if relapse confirmed 
 
 
3     Trial medication: 
Remind patient not to open a new bottle of medication until the opened one is empty and to 
return unused medication and empty bottles at next visit 
 
3.1   Record how many trial tablets are left in the medication pack: ________ 
There are 180 tablets in an unopened bottle 
 
3.2   According to the patient have they taken their study tablets as prescribed?  
        Yes (≥ 90% of the time)□              No (< 90% of the time)□ 
 
3.3   According to the patient how easy was it remembering to take the trial  tablets: 
        Very easy □    Fairly easy □     Fairly difficult □     Very difficult □ 
 
 
4     Concomitant medication: 
 
4.1   Have there been any changes in medication?  
        Yes □              No □  
Record any changes on the changes to concomitant medication page 31 
 
 
5     Adverse events: 
 
5.1   Has the patient experienced any adverse events since the last visit? 
       Yes □              No □ 
If yes, complete adverse events page 33 
 
 
  
   
CODA Study Colitis: Once Daily Asacol                                                                                    UNSCHEDULED     
                                                                                                                      
Patient initials __ __ __         Randomisation No. __ __ __ __   
 
Unscheduled checklist  
 
Have the following been completed? Tick 
Tablet count 
 
 
Changes to medication check 
 
 
Symptom assessment  
 
 
Record any adverse events 
 
 
Document details of visit in medical notes 
 
 
Continue trial and arrange next visit date: __ __/__ __ __/__ __ __ __ 
                                                                     d d   m  m  m    y   y   y   y 
 
 
 
  
   
CODA Study Colitis: Once Daily Asacol                                                                  RELAPSE ASSESSMENT     
                                                                                                                      
Patient initials __ __ __         Randomisation No. __ __ __ __   
 
RELAPSE ASSESSMENT         DATE: __ __ /__ __ __/ __ __ __ __      
                  d d     m  m  m   y   y   y   y 
      
1     Disease status: 
 
1.1 Has the patient received treatment for flare up of UC? 
        Yes □              No □ if no, go to part 1.3 
 
1.2   If yes, what date did the treatment for flare up start? 
        
        __ __ /__ __ __/ __ __ __ __  go to part 3 
         d d     m  m  m    y   y   y   y 
 
Note: It is a violation of the protocol for patients to receive treatment for flare up whilst in the 
study. If patient has received treatment for UC flare up withdraw them from trial. 
 
 
1.3   Has the patient got symptoms of active disease? 
 
Symptoms of relapse are defined as: 
 
 Bloody diarrhoea or rectal bleeding lasting 3 days or more 
 Non-bloody diarrhoea or increase in stool frequency lasting 3 days or more 
 Other symptoms the patient associates with relapse of his/her ulcerative colitis 
       Yes □              No □ If no, go to section 3 - patient continues in trial.  
 
1.4   Perform sigmoidoscopy  
         
        Date of sigmoidoscopy:   __ __ /__ __ __/ __ __ __ __  
      d d     m  m  m    y   y   y   y 
 
  
   
CODA Study Colitis: Once Daily Asacol                                                                  RELAPSE ASSESSMENT     
                                                                                                                      
Patient initials __ __ __         Randomisation No. __ __ __ __   
 
1.5   Mayo Clinic Score  
 
Score symptoms according to the past 3 days Subscore 
Stool frequency 
0=Normal no. of stools for this subject 
1= 1-2 stools/day more than normal  
2= 3-4 stools/day more than normal 
3= >5 stools/day more than normal 
 
Rectal bleeding 
0= No blood seen 
1= Streaks of blood with <50% of stools 
2= Obvious blood seen with >50% of stools 
3= Blood alone passed 
 
Physician’s global assessment 
0= Normal (ie inactive) 
1= Mild disease 
2= Moderate disease 
3= Severe disease 
 
Findings on Sigmoidoscopy * 
0= Normal  
1= Mild disease (erythema, decreased vascular pattern, mild 
friability).No contact bleeding 
2= Moderate disease (marked erythema, absent vascular pattern, 
friability, erosions) 
3= Severe disease (spontaneous bleeding, ulceration) 
 
* For this trial the sigmoidoscopic score will be equivalent to the modified Baron score: - i.e. 
contact bleeding will be classed as grade 2 and spontaneous bleeding as grade 3 
 
1.6   In the opinion of the investigator has the patient relapsed? 
Relapse is defined as symptoms of active disease with grade 2 or 3 changes on sigmoidoscopy 
        Yes □              No □  
 
 
3     Trial medication: 
 
3.1   Record how many trial tablets are left in the medication pack: ________ 
There are 180 tablets in an unopened bottle 
 
3.2   According to the patient have they taken their study tablets as prescribed?  
        Yes (≥ 90% of the time)□              No (< 90% of the time)□ 
 
3.3   According to the patient how easy was it remembering to take the trial  tablets: 
        Very easy □    Fairly easy □     Fairly difficult □     Very difficult □ 
   
CODA Study Colitis: Once Daily Asacol                                                                  RELAPSE ASSESSMENT     
                                                                                                                      
Patient initials __ __ __         Randomisation No. __ __ __ __   
 
 
 
4     Concomitant medication: 
 
4.1 Have there been any changes in medication? Include any treatment for flare up 
        Yes □              No □  
 
Record any changes on the changes to concomitant medication page 31 
 
 
 
 
5     Adverse events: 
 
5.1   Has the patient experienced any adverse events since the last visit? 
     Yes □              No □ 
If yes, complete adverse events page 33 
 
 
6     Blood and urine sample: 
Take blood for urea & electrolytes and CRP, carry out dipstick urinalysis (send blood to local lab 
& use local dipsticks). Record results on laboratory samples page 32 
 
If patient has relapsed or started treatment for a flare up complete end of study form on page 
29. Patient is withdrawn from the study and offered routine treatment for relapse. 
 
  
   
CODA Study Colitis: Once Daily Asacol                                                                  RELAPSE ASSESSMENT     
                                                                                                                      
Patient initials __ __ __         Randomisation No. __ __ __ __   
 
Relapse assessment checklist 
 
Have the following been completed? Tick 
Tablet count 
 
 
Changes to medication check 
 
 
Symptom assessment and Mayo clinic score 
Not required if patient has already started treatment for flare up 
 
Sigmoidoscopy 
Not required if patient has already started treatment for flare up 
 
Blood for U & E, CRP 
 
 
Urine dipstick 
 
 
Record any adverse events 
 
 
Document details of visit in medical notes 
 
 
 
If relapse confirmed:                                                       If no 
relapse:   
 
- Withdraw patient from study                                -   Confirm date of next visit: 
  (complete end of study page 29)                                __ __/__ __ __/__ __ __ __ 
                                                                                      d d   m  m  m    y   y   y   y  
- Discuss further treatment and prescribe 
  if required 
 
- Thank patient for participation in study 
 
- Write to GP – re: withdrawal  
 
- Arrange routine hospital follow up 
 
  
   
CODA Study Colitis: Once Daily Asacol                                                                                   END OF STUDY 
                                                                                                                      
Patient initials __ __ __         Randomisation No. __ __ __ __   
 
END OF STUDY:                                                         
 
 
1     What date did the patient stop taking trial treatment:   __ __ /__ __ __/ __ __ __ __   
                 d d     m  m  m    y   y   y   y 
  
 
2     Did the patient complete the 12 month trial period in remission: 
         Yes □              No □ 
If yes go to part 4 
 
 
3     Withdrawal: 
 
3.1   Was the patient withdrawn from the study during the trial period? 
        Yes □              No □ 
 
3.2   What was the principal reason for withdrawal from trial treatment? 
 
Relapse of colitis    □  
                                        
Drug side-effects    □  
 
Patient preference   □   
 
Other                      □  please state: ___________________________   
 
 
 
4     Signature: _________________________    Date __ __ /__ __ __/ __ __ __ __   
                d d     m  m  m    y   y   y   y 
 
Name:  
(in capitals) __________________________    Designation_____________________ 
 
  
 
  
CODA Study Colitis: Once Daily Asacol                                                                                CONCOMITANT     
                                                                                                                                                    MEDICATION                                                                      
Patient initials __ __ __         Randomisation No. __ __ __ __  
Please ensure that data entered into CRF is complete and 
accurate. Remove the top copy of each page and post a 
complete copy of the CRF to the Trial Co-ordinator.  
All pages must be sent even if data has not been entered on them. 
 
Concomitant medication at start of trial 
 
Drug treatment for ulcerative colitis 
 
Name 
 
Dose & route Frequency & 
time of day 
taken 
Start date – only required if 
started  in last 3 months 
(dd/mmm/yyyy) 
 
 
   
 
 
 
   
 
 
 
   
 
 
   
 
 
Other Current Drug Therapy 
 
Name 
 
Dose Frequency & time 
of day taken 
Route 
 
 
   
 
 
   
  
 
  
CODA Study Colitis: Once Daily Asacol                                                                                CONCOMITANT     
                                                                                                                                                    MEDICATION                                                                      
Patient initials __ __ __         Randomisation No. __ __ __ __  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
  
 
  
CODA Study Colitis: Once Daily Asacol                                                                                     MEDICATION                                                                                                                                                              
CHANGES                                                                               
Patient initials __ __ __         Randomisation No. __ __ __ __  
Changes to Concomitant Medication during trial 
(including study drug if stopped) 
 
Drug Date of change 
(dd/mmm/yyyy) 
Dose & 
route 
Frequency & 
time of day 
taken 
Date stopped - leave 
blank if ongoing 
 
 
 
    
 
 
 
    
 
 
 
    
 
 
 
    
 
 
 
    
 
 
 
    
   
 
 
  
 
 
 
    
 
 
 
    
 
 
 
    
 
 
 
    
 
 
 
    
 
 
 
    
 
 
 
    
 
  
 
  
CODA Study Colitis: Once Daily Asacol                                                                                    LAB RESULTS 
 
Patient initials __ __ __         Randomisation No. __ __ __ __  
Laboratory Results 
 
Please enter normal range for your laboratory 
 
 Normal 
range 
Screening 6 weeks 6 months 12 months Unscheduled 
Visit date 
 
 
 
 
     
Urea 
 
      
Creatinine 
 
      
Sodium 
 
      
Potassium 
 
      
CRP 
 
      
 
Urine 
protein 
(dipstick) 
      
Urine blood 
(dipstick) 
      
 
 
Record urinalysis results as: nil; trace; +1; +2; +3 etc.
   
Adverse events 
 
DEFINITIONS: 
 
Adverse event:  
Any untoward medical occurrence in a patient or clinical trial subject which does not necessarily 
have a causal relationship with this treatment. This includes “any unfavourable and unintended 
sign (including an abnormal laboratory finding), symptom or disease temporally associated with 
the study drug”. This may include, for example, a cold, or an accident.  
 
Serious adverse event:  
Any untoward medical occurrence or effect that at any dose:  
 results in death  
 is life-threatening, requires  inpatient hospitalisation or prolongation of existing 
hospitalisation  
 results in persistent or significant disability/incapacity  
 is a congenital anomaly/birth defect  
 
Note: Do not record Serious Adverse Events on this page. Complete SAE 
form on page 36 
 
 
Detail all adverse events here. This includes drug side-effects and deterioration of UC or UC-related 
symptoms, whether or not they are drug related. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date started: _ _/ _ _ _/ _ _ _ _  Date resolved: _ _/ _ _ _/ _ _ _ _  
 
Describe adverse event: ____________________________________________________________________ 
 
Severity: Action taken: 
         
  
  
   
  hospitalization prolonged 
      (complete SAE form)   
   
Change in Severity: 
Date changed: _ _/ _ _ _/ _ _ _ _   Date changed: _ _/ _ _ _/ _ _ _ _    
       
      
Relationship to     
* Please give details 
Additional Notes: 
   
Adverse events 
Detail all adverse events here. This includes drug side-effects and deterioration of UC or UC-related 
symptoms, whether or not they are drug related. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date started: _ _/ _ _ _/ _ _ _ _  Date resolved: _ _/ _ _ _/ _ _ _ _  
 
Describe adverse event: ____________________________________________________________________ 
 
Severity: Action taken: 
         
  
  
   
  lized or hospitalization prolonged 
      (complete SAE form)   
   
Change in Severity: 
Date changed: _ _/ _ _ _/ _ _ _ _   Date changed: _ _/ _ _ _/ _ _ _ _    
       
      
Relationship to     
trial treatment:  Outcome: 
     
    
    
       Effect 
    
 
* Please give details 
Additional Notes: 
Date started: _ _/ _ _ _/ _ _ _ _  Date resolved: _ _/ _ _ _/ _ _ _ _  
 
Describe adverse event: ____________________________________________________________________ 
 
Severity: Action taken: 
        
  
 Study medication dose changed* 
  
   
      (complete SAE form)   
   
Change in Severity: 
Date changed: _ _/ _ _ _/ _ _ _ _   Date changed: _ _/ _ _ _/ _ _ _ _    
       
      
Relationship to     
trial treatment:  Outcome: 
     
* Please give details 
Additional Notes: 
   
Adverse events 
Detail all adverse events here. This includes drug side-effects and deterioration of UC or UC-related 
symptoms, whether or not they are drug related. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date started: _ _/ _ _ _/ _ _ _ _  Date resolved: _ _/ _ _ _/ _ _ _ _  
 
Describe adverse event: ____________________________________________________________________ 
 
Severity: Action taken: 
         
  
 Study medication dose changed* 
   
   
      (complete SAE form)   
   
Change in Severity: 
Date changed: _ _/ _ _ _/ _ _ _ _   Date changed: _ _/ _ _ _/ _ _ _ _    
       
      
Relationship to     
trial treatment:  Outcome: 
     
    
    
       Effect 
    
 
 
* Please give details 
Additional Notes: 
Date started: _ _/ _ _ _/ _ _ _ _  Date resolved: _ _/ _ _ _/ _ _ _ _  
 
Describe adverse event: ____________________________________________________________________ 
 
Severity: Action taken: 
        
  
  
  
  
      (complete SAE form)   
   
Change in Severity: 
Date changed: _ _/ _ _ _/ _ _ _ _   Date changed: _ _/ _ _ _/ _ _ _ _    
       
      
Relationship to     
trial treatment:  Outcome: 
     
* Please give details 
Additional Notes: 
  
 
SERIOUS ADVERSE EVENT 
 
  
Action Taken: 
Relationship of the event to Asacol treatment 
None: clearly due to other causes (clinical state, environment, other medication) 
Unlikely: no temporal relationship to treatment, not an anticipated response to Asacol, more 
likely to be caused by patient’s clinical state or other medication 
Possible: temporal relationship to Asacol treatment, may be an anticipated response to Asacol 
but may be caused by clinical state or other medication 
Probably: temporal relationship to Asacol treatment, an anticipated response to Asacol, not 
reasonably explained by clinical state or other medication 
Definite: an anticipated response to Asacol that stops on withdrawal of Asacol and restarts on 
reintroduction, not explained by other factors. 
Ongoing 
Permanent 
Residual Effect 
Death 
None 
Symptomatic treatment* 
Asacol dose altered* 
Asacol discontinued 
Hospitalisation 
Other* 
An event that resulted in 
death 
An event that is life-
threatening 
An event that requires 
hospitalisation 
An event that has prolonged 
hospitalisation 
An event that results in persistent 
or significant disability or incapacity 
An event that is a congenital anomaly or 
birth defect 
Person reporting Adverse Event 
Name: …………………………………………………   Telephone: …………………………………………………….. 
 
Outcome 
Start Date: 
End Date: 
Resolved 
* Provide further details of action here, including any additional medication or 
altered dose levels: 
Account of Adverse Event: 
Serious adverse event events must be reported to the Trial Co-ordinator at the University Hospital of 
Wales within 24 hours.  Please complete this page with all available details and fax to 029 20742108 
  
 
Appendix III – Description of variables collected as part of the ZICE 
study 
Registration: 
doreg Registration Date  
rptini Patient Initials 
rdob Date of Birth 
rpatid Patient Trial No  
 
  
  
 
Screening: 
ptini Patient Initials 
dob Date of Birth 
patid Patient Trial No 
doinf Date of Informed Consent 
dovis Date of Visit 
dovis Date of Visit 
sex Gender 
wt Weight 
ht Height 
secog ECOG 
screat Serum Creatinine 
doscrt Date of Sample 
doscrt Date of Sample 
ecreat Estd Creatinine Clearance 
doecrt Date of Sample 
doecrt Date of Sample 
albu Albumin 
doalbu Date of Sample 
doalbu Date of Sample 
corcal Corrected Calcium 
docrcl Date of Sample 
docrcl Date of Sample 
serbil Serum Bilirubin 
dosrbl Date of Sample 
dosrbl Date of Sample 
ast AST 
astlvl AST Level 
doast Date of Sample 
doast Date of Sample 
alt ALT 
  
 
altlvl ALT Level 
doalt Date of Sample 
doalt Date of Sample 
qlq Quality of life 
reqlq Reason 
bpi BPI 
rebpi Reason  
bis Any Bisphosphonate treatment prior to Rando? 
dobis Last dose date 
dobis Last dose date 
  
  
 
Randomisation: 
dor Randomisation Date 
centno Centre No 
hosp Hospital 
ptini Patient Initials 
dob Date of Birth 
hosno Hospital Number 
chemo Chemotherapy 
hormone Hormone Therapy 
sre SRE 
ageok Over 18 years 
mets Newly Dignosed with Mets 
dodiag Diagnosis Date 
diatime Time since diagnosis (days)                   [Derived] 
suit Suitable for Bisphosphonate treatment 
clindec Clinician decision to treat with bisphosphonates 
dodec Date of clinical decision 
isoscn ISO scan conducted? 
doiso ISO Scan date 
isotime ISO Time (days)                                      [Derived] 
inf Informed Consent obtained? 
ecogok ECOG 0,1 or 2 
mcntnv Central Nervous System Mets 
dent Current active Dental problems 
jaw Planned dental or Jaw Surgery 
peptic Peptic Ulcer 
preg Pregnant or Lactating 
ckgult Cockcroft-Gault 
astalt AST or ALT Levels 
pbis Previous Bisphosphonate Treatment 
dopbis Prev. Bis treatment ending date 
  
 
dopbis Prev. Bis treatment ending date 
pbistime Prv.Bis.treatment ending time (days)      [Derived] 
uncomp Unable to comply with instructions to study med 
hypbis Hypersensitivity to bisphosphonates 
patid Patient Trial No 
treat Treatment allocated 
  
  
 
Baseline and disease history: 
patid Patient Trial No 
dobrst Date of diagnosis of Breast Cancer 
dobrst Date of diagnosis of Breast Cancer 
dobrst Date of diagnosis of Breast Cancer 
erstat ER Status 
prstat PR Status 
herstat HER-2 Status 
menstat Current menstrual status 
ajchmo Adjuvant chemotherapy 
ajendo Adjuvant endocrine therapy 
ajtras Adjuvant Trastuzumab 
locrec Local recurrence 
recsite If Yes, first site 
recspec Specify 
dorec Date of diagnosis 
pmets Previous history of mets 
dopmet Date of Diagnosis 
dopmet Date of Diagnosis 
frsite First Site(s)                                                [Repeated] 
othsite Specify                                                       [Repeated] 
metcur Current Bone Mets                                  [Repeated] 
metoth Specify                                                      [Repeated] 
bassre Any SRE(s) in previous 3 months 
radpln Previous or planned radiotherapy for bone mets 
ortsur Orthopaedic surgery for bone mets 
symfrac Symptomatic vertebral fracture 
patfrac Pathological non-vertebral fracture 
spicom Spinal cord compression 
hyper Hypercalcaemia 
dothxy Date of Thoracic Spine Xray 
  
 
dothxy Date of Thoracic Spine Xray 
thles Mets lesion in Thoracic Spine 
thtype Type of Lesion in Thoracic Spine 
thfrac Fracture/Vertabal collapse visible -Thoracic Spine 
dolmxy Date of Lumbar spine Xray 
dolmxy Date of Lumbar spine Xray 
lumles Mets lesion - Lumbar spine 
lumtype Type of Lesion in Lumbar Spine 
lumfrac Fracture/Vertabal collapse visible -Lumbar Spine 
radioot Other - specify                                            [Repeated] 
doot Date of  Xray                                              [Repeated] 
doot Date of  Xray                                             [Repeated] 
otles Mets lesion                                                [Repeated] 
ottype Type of Lesion                                          [Repeated] 
othfrac Fracture/Vertabal collapse visible        [Repeated] 
pain Painkilling Drugs 
drug Drug Name (painkiller)                            [Repeated] 
cat Category (Painkiller)                               [Repeated] 
lstday No of days in last 7                                 [Repeated] 
bchmo Chemotherapy 
bchspc Specify 
dobchm Start Date 
bhorm Hormone   Therapy 
bhrmspc Specify 
dobhorm Start Date 
btrast Trastuzumab 
btstspc Specify 
dobtrst Start Date 
bother Other 
bothspc Specify 
doboth Start Date 
  
 
otdrug Patient on any other medication inc antiemetics 
bdrug Drug Name                                                 [Repeated] 
dobdrug Start Date                                                  [Repeated] 
  
  
 
Interims: 
patid Patient Trial No 
attend Did patient attend 
doyvis Visit date 
donvis Date last known to be alive 
revis Reason for not attending 
revis Reason for not attending 
visoth other 
dosttrt Medication start date 
dosttrt Medication start date 
bpi BPI been completed 
rebpi No, reason 
sched Study Medication administered as prescribed 
resched Reason if no 
schedot Specify 
iban Ibandronate only patient tablet amount 
pain Any Painkilling Drugs taken in last 7 days 
drug Drug Name (painkiller)                                     [Repeated] 
cat Category (Painkiller)                                        [Repeated] 
lstday No of days in last 7                                          [Repeated] 
bis Any Bisphosphonates been given since last visit 
bisnme BIS drug Name                                                 [Repeated] 
cont Continuing                                                        [Repeated] 
dostrt start date                                                          [Repeated] 
dostp stop date                                                          [Repeated] 
vits Vitamin D and Calcium 
medchg Has there been any other changes to medications 
mednme Other medication drug name                           [Repeated] 
medcat Category                                                            [Repeated] 
dostmed Start date                                                          [Repeated] 
medcont Continuing                                                         [Repeated] 
  
 
dospmed Stop date                                                          [Repeated] 
sre Any SRE's since last visit 
bscan Any bone scans or X rays performed 
srerel Related to SRE's 
srerel Related to SRE's 
screat Serum Creatinine 
doscrt Date of Sample 
doscrt Date of Sample 
wt Weight  
ecreat Estd Creatinine Clearance 
conhlh Patient Consultations since last visit 
hthpro Health Provider                                                 [Repeated] 
locat Home or Surgery                                              [Repeated] 
visnum Number of visits                                              [Repeated] 
rehvis Reason for visit                                               [Repeated] 
travel How did they travel to clinic 
accomp Who accompanied patient 
tmeoff Involve time of work 
cost Cost of visit 
dist Mileage/Distance 
dent Current active Dental problems 
otprob Other problems (toxicity) 
toxic Toxicity                                                              [Repeated] 
toxgrd Toxicity Grade                                                  [Repeated] 
toxot Toxicity other                                                   [Repeated] 
  
  
 
12 weekly assessments: 
ptini Patient Initials 
dob Date of Birth 
patid Patient Trial No 
attend Did patient attend 
doyvis Visit date 
donvis Date last known to be alive 
ecog ECOG 
revis Reason for not attending 
visoth other 
sched Study Medication administered as prescribed 
resched Reason if no 
schedot Specify 
iban Ibandronate only patient tablet amount 
qlbp Qual of life and BPI Questionnaire been completed 
reqlbp Reason if no 
pain Painkilling Drugs in the past 7 days 
drug Drug Name (painkiller)                                                                [Repeated] 
cat Category (Painkiller)                                                               [Repeated] 
lstday No of days in last 7                                                                            [Repeated] 
bis Any Bisphosphonates other than study   drug been given since last visit 
bisnme BIS drug Name                                                                         [Repeated] 
cont Continuing                                                                                         [Repeated] 
dostrt start date                                                                                         [Repeated] 
dostp stop date                                                                                  [Repeated] 
vits Vitamin D and Calcium been taken 
medchg Has there been any other changes to medications 
mednme Other medication drug name                                                               [Repeated] 
medcat Category                                                                                   [Repeated] 
dostmed Start date                                                                         [Repeated] 
medcont Continuing                                                                                          [Repeated] 
  
 
dospmed Stop date                                                                                           [Repeated] 
sre Any SRE's since last visit 
bscan Any bone scans or X rays performed 
srerel Related to SRE's 
screat Serum Creatinine 
doscrt Date of Sample 
doscrt Date of Sample 
wt Weight  
ecreat Estd Creatinine Clearance 
conhlh Patient Consultations since last visit 
hthpro Health Provider                                                                                   [Repeated] 
locat Home or Surgery                                                                                 [Repeated] 
visnum Number of visits                                                                                  [Repeated] 
rehvis Reason for visit                                                                                   [Repeated] 
travel How did they travel to clinic 
accomp Who accompanied patient 
tmeoff Involve time of work 
cost Cost of visit 
dist Mileage/Distance 
dent Current active Dental problems 
otprob Other problems (toxicity) 
toxic Toxicity                                                                                       [Repeated] 
toxgrd Toxicity Grade                                                                                [Repeated]  
toxot Toxicity other                                                                                [Repeated] 
 
  
  
 
Annual follow-up: 
ptini Patient Initials 
dob Date of Birth 
patid Patient Trial No 
point Follow up time point 
doass Date of Assessment 
fustat Status 
dostat Date last known to be alive 
osteo Osteonecrosis of the Jaw 
doosteo Date of diagnosis 
 
  
  
 
Withdrawal 
ptini Patient Initials 
dob Date of Birth 
patid Patient Trial No 
rewith Level of withdrawal 
dowith Date of withdrawal 
intol Intolerance to treatment 
patcho Patient choice 
clidec Clinicians Decision 
nocomp Non Compliance 
withot other, specify 
 
  
  
 
SRE: 
ptini Patient Initials 
dob Date of Birth 
patid Patient Trial No 
dosre Date of visit 
fracnum Fractures since last visit 
sreste Site                                                      [Repeated] 
sreoth Specify                                                [Repeated] 
doid Date Identified                                      [Repeated] 
disrel Disease related/traumatic                    [Repeated] 
sresym Symptomatic/asymptomatic                 [Repeated] 
xrysre Radiotherapy since last visit 
xryste Site                                                      [Repeated] 
xryoth Specify                                                [Repeated] 
doxry Start Date                                            [Repeated] 
hypmal Hypercalcemia of Malignancy 
srco value                                                   [Repeated] 
dosrco Onset Date                                          [Repeated] 
ortsurg Orthopaedic surgery since last visit 
ortste Site                                                      [Repeated] 
ortoth Specify                                                [Repeated] 
doort Date of surgery                                   [Repeated] 
spi Spinal Cord compression since last visit 
spilvl Level                                                    [Repeated] 
desrel Disease related/traumatic                    [Repeated] 
dospi Date of diagnosis                                [Repeated] 
spimtd Method                                                [Repeated] 
spioth Specify                                               [Repeated] 
 
  
  
 
SAE: 
ptini Patient Initials 
dob Date of Birth 
patid Patient Trial No 
dorep Report date 
reptyp Report Type 
sex Sex 
saeser Why was the event serious 
saedes Description of SAE 
saenme SAE Name (CTACE)              [Repeated] 
saegrd Grade (CTCAE)                     [Repeated] 
dosae Onset Date                            [Repeated] 
dspsae Resolved Date                       [Repeated] 
saestat SAE Status                            [Repeated] 
saerel SAE Relationship                   [Repeated] 
saeexp Expectedness                       [Repeated] 
saetrt Trial Drug 
dose Total Daily Dose 
dodose Start date 
condse Ongoing Therapy 
dostdse End date 
actn Action taken 
clin Reporting Clinicians Name 
clintl Contact Telephone No. 
doclin Date completed 
 
  
  
 
End of treatment: 
patid Patient Trial No 
dob Date of Birth 
ptini Patient Initials 
doass Date of Assessment 
ht Height 
dothxy Date of Thoracic Spine Xray 
thles Mets lesion in Thoracic Spine 
thtype Type of Lesion in Thoracic Spine 
thfrac Fracture/Vertabal collapse visible -Thoracic Spine 
dolmxy Date of Lumbar spine Xray 
lumles Mets lesion - Lumbar spine 
lumtype Type of Lesion in Lumbar Spine 
lumfrac Fracture/Vertabal collapse visible -Lumbar Spine 
radioot Other - specify                                        [Repeated] 
doot Date of  Xray                                           [Repeated] 
otles Mets lesion                                              [Repeated] 
ottype Type of Lesion other                              [Repeated] 
othfrac Fracture/Vertabal collapse visible          [Repeated] 
  
  
 
Death: 
ptini Patient Initials 
dob Date of Birth 
patid Patient Trial No 
dod Date of death 
cause Primary Cause of death 
cseoth Specify 
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ORIGINAL ARTICLE
Electronic Monitoring of Medication Adherence in a 1-year Clinical
Study of 2 Dosing Regimens of Mesalazine for Adults in Remission
with Ulcerative Colitis
David Gillespie, BSc,* Kerenza Hood, PhD,* Daniel Farewell, PhD,† Rachel Stenson, MSc,‡
Christopher Probert, MD,§ and A. Barney Hawthorne, DM¶
Background: Adherence to medication is an issue of great importance for patients with ulcerative colitis. Once daily mesalazine seems to be no worse
than divided doses in preventing relapse in remitting patients. Although this has been attributed to improved adherence, detailed measures of adherence
have been lacking from previous studies.
Methods: A 1-year substudy was conducted alongside a trial that compared 2 different dosing regimens (once daily versus three times daily) of
mesalazine for patients in remission with ulcerative colitis. Participants in the substudy had their adherence monitored electronically using the medication
event monitoring system, self-report, and tablet counts. We compared measures, determined factors associated with adherence and associations between
adherence and relapse, modeled adherence over time, and explored behavioral aspects.
Results: We included 58 participants. Adherence was high across all measures (89.3% self-report, 96.7% tablet counts, and 89.2% medication event
monitoring system). Agreement between the measures was poor at times. Adherence according to the medication event monitoring system best
distinguished between the participants who relapsed (71.4%) and those who remained in remission (93.4%), although this difference was not statistically
discernible at the 5% level. Adherence deteriorated over the study period, with three times daily participants generally less adherent than once-daily
participants (odds ratio, 0.03; 95% conﬁdence interval, 0.01–0.08). Adherence was higher on weekdays (odds ratio, 1.47; 95% conﬁdence interval,
1.31–1.65) and around clinic visit dates (odds ratio, 1.43; 95% conﬁdence interval, 1.18–1.72).
Conclusions: Simple dosing regimens are preferable to multiple daily dosing regimens. Electronic monitoring of adherence should be used more often
in clinical studies. Self-reported adherence and tablet counts may underestimate adherence. Adherence declined over time, and adherence was generally
lower and more varied for those allocated to the three times daily regimen.
(Inﬂamm Bowel Dis 2014;20:82–91)
Key Words: medication adherence, ulcerative colitis, MEMS, mesalazine, clinical trial
A dherence to medication has long been recognized as a topic ofgreat importance, concern, and complexity, particularly for
patients with long-term chronic conditions.1 Poor adherence to
medication has been demonstrated to be associated with reduced
effectiveness of pharmacological treatments. In some areas, poor
adherence has been shown to lead to the development of more
severe life-threatening illnesses.2,3 In addition to being a major
public health concern, poor adherence to medication places a sub-
stantial ﬁnancial burden on healthcare systems, both through the
prescription of medication that is not taken and through medica-
tion adherence-related hospital admissions.3–7
Coated formulations of mesalazine (Asacol) have been
demonstrated in many trials to prevent relapses in patients who
have achieved remission of ulcerative colitis (UC).8,9 Treatment is
often prescribed in divided daily doses (e.g., two or three times
daily dosing schedules [TDS]),10 with adherence and treatment
success suffering as a result.11,12 There has been an increasing
interest in evaluating once-daily (OD) dosing of mesalazine.3,13–15
The Colitis Once-Daily Asacol study assessed the efﬁcacy
and safety of OD dosing with mesalazine versus TDS dosing over
a 12-month period for patients in remission with UC. The study
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found that the OD regimen was no worse than TDS in terms of
clinical relapse.16 Although this was attributed to better adher-
ence, the measures used (self-report and tablet counts at clinic
visits) have several known limitations,17 with detailed measures
of adherence lacking from both the main trial and from previous
studies in the UC ﬁeld. Foreseeing this as a problem, a substudy
was run alongside the main study. The aim of the substudy was to
evaluate the impact of OD dosing on treatment adherence, using
a more intensive monitoring process to capture adherence than
that had been used previously. Using this substudy, the aim of this
article was to investigate the use of the electronic monitoring
device for assessing medication adherence, comparing this
method with those used in the main trial, and exploring patterns
in adherence over time.
MATERIALS AND METHODS
Study Design
The original study was an investigator-blind multicenter
randomized trial comparing OD Asacol given as three 800 mg
tablets (OD group), with one 800 mg Asacol tablet given TDS as
a maintenance therapy over a 12-month period or until relapse of UC.
Participants attended trial follow-up visits at 6 weeks, 6 months, and
12 months after randomization, or in the event of a suspected relapse.
In addition, participants were also contacted through telephone at
3 and 9 months. A subgroup of participants was invited to participate
in a substudy, with a separate consent process, where they were given
a bottle cap that recorded the date and time of bottle openings
throughout the study. Details of the randomization and data collection
methods are described elsewhere.16 Further analyses were undertaken
on this subgroup of participants to explore our study questions.
Participants
Participants were recruited into the main trial with UC in
remission on maintenance therapy with mesalazine, sulfasalazine,
olsalazine, or balsalazide for at least 4 weeks, but who had
experienced at least 1 relapse within the previous 2 years.
Participants had to be aged older than 18 years, if female to be
taking adequate contraception, and able to give informed consent.
Participants were excluded if they had Crohn’s disease, symptoms
of active colitis, a modiﬁed Baron score at sigmoidoscopy of 2 or 3,
used enema or suppository therapy for UC in the past 4 weeks, had
started or altered the dose of azathioprine or 6-mercaptopurine in
the past 3 months, had intolerance to mesalazine, known HIV
infection, signiﬁcant renal or hepatic impairment, or other medical
or psychiatric disorder that in the opinion of the investigator would
affect participation in the study, or women if pregnant or lactating.
Further participant details are described elsewhere.16 Five of the 32
centers that recruited participants into the main trial were also asked
to recruit participants into the substudy.
Measures of Medication Adherence
Medication adherence was monitored through self-report
and tablet counts at the trial follow-up visits (6 weeks, 6 months,
and 12 months postrandomization, or at point of relapse) and
electronically via the medication event monitoring system
(MEMS). These methods will now be discussed in turn.
Self-report
Participants were asked about their perceived adherence
levels (i.e., whether or not they had taken their study tablets as
prescribed at least 90% of the time), and the ease of medication
taking (very easy, fairly easy, fairly difﬁcult, or very difﬁcult to
remember to take their medication). For analysis purposes, we
assumed that participants reported their levels of adherence
honestly and had perfect recall in the time under consideration.
Tablet Count
Tablet counts were performed by trained research nurses at
each trial follow-up visit. We assumed that the difference between
the number of tablets participants started with and the amount
remaining at each follow-up visit equated to the amount taken
during the time interval. For the purposes of reporting, adherence
measured using tablet counts was reported as the number of tablets
taken expressed as the percentage of correct number of tablets taken.
Tablet counts provide a measure of consumption over a deﬁned
period rather than adherence patterns over a deﬁned period.
Electronic Monitoring
The date and time of bottle cap openings were electroni-
cally recorded using the MEMS, with data uploaded onto the
study database at each trial follow-up visit. Use of the MEMS
assumes that the correct number of tablets is removed and
consumed each time the bottle is opened. Adherence was reported
as the percentage of days that a participant was adherent (i.e., the
percentage of days that a participant opened their bottle the
correct number of times).
Statistical Methods
Medication adherence measures were reported as detailed
above and compared using nonparametric methods, correlation
coefﬁcients, and scatter plots. For the comparison between tablet
count and MEMS adherence, a Bland–Altman plot was con-
structed to illustrate the level of agreement between the 2 meas-
ures,18 where perfect agreement would be illustrated by all data
points lying along the line y ¼ 0, with symmetric random scatter
above and below the line an indication of no systematic biases in
either of the measures.
Factors associated with varying levels of medication adher-
ence and the association between medication adherence and clinical
relapse were determined using appropriate statistical models.
Using the data obtained from the MEMS caps, medication
adherence was modeled over time by ﬁtting a 2-level generalized
linear (logistic) mixed-effects model, with daily adherence indica-
tors nested within participants. A participant was assumed to be
adherent on a given day if they opened their cap the required
number of times (once for the OD group and 3 times for the TDS
group). Nonlinear patterns of adherence over time were accounted
for using B-splines.19 The model also accounted for different
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participant adherence patterns by ﬁtting B-spline estimates of a
time-varying mean with random coefﬁcients, thereby allowing each
participant to have their own individual curve that was not
restricted by the overall ﬁxed effect curve. Trial arm (dosing reg-
imen) was included in the model as an explanatory variable to
describe the difference in adherence patterns between the regimens.
The interaction between trial arm and time was also explored.
To explore any potential differences in adherence during
the week compared with the weekend, the above model was
extended by the addition of an indicator that distinguished
whether a day fell on a weekday or weekend. Its interaction with
trial arm was also explored to determine whether these differences
were larger for participants allocated to a particular dosing
regimen. Similarly, the model was also extended to explore any
potential differences in adherence at clinic visit dates (deﬁned as
the date of a scheduled clinic visit and 1 week either side of this
date). Model ﬁt was assessed using Akaike’s Information Crite-
rion.20 Results are presented as odds ratios (OR) with associated
95% conﬁdence intervals (CIs) and P values.
The term “statistically discernible” will be used in place of
“statistically signiﬁcant” throughout the article, as the authors
believe it is a more meaningful descriptor of the results arising
from hypothesis testing.
Data management and descriptive statistics were performed
using IBM SPSS Statistics20,21 with the generalized linear mixed-
effect modeling implemented in R.22,23
ETHICAL CONSIDERATIONS
Ethical approval was received for this study (REC reference
number: 05/Q2502/156). Written informed consent was obtained
from each participant. The study was registered at ClinicalTrials.
gov (NCT00708656).
Role of Funding Source
The funding sources had no roles in data collection,
analysis, or interpretation; report writing; or submission.
D. Gillespie had full access to all the data in the study and takes
responsibility for the integrity and the accuracy of the data
analysis. All authors had responsibility for the ﬁnal decision to
submit for publication.
Role of Study Sponsor
Cardiff and Vale University Health Board, as trial sponsor
was responsible for the scientiﬁc quality of the study, monitoring,
and management to ensure quality and accuracy of the data, and
the safety and well-being of participants.
RESULTS
Participants
In total, 579 participants were assessed for eligibility in the
main Colitis Once-Daily Asacol trial, with a total of 213
randomized from 32 centers. Of these participants, 71 from
5 centers were approached to take part in the substudy. Ten
participants declined to take part, with the most common reason for
nonparticipation being the unwillingness to carry around the
MEMS bottles during the daytime (e.g., because of work commit-
ments). Three participants did not provide any MEMS cap data
because of faulty caps, leaving 58 participants who took part in the
substudy and provided data. Participants were approximately
equally split between the trial arms (Fig. 1). The average age at study
entry was 49.4 years (standard deviation, 15.72 years) and 55.2%
were male. Overall, 29.8% of participants had extensive colitis,
50.9% left-sided colitis or proctosigmoiditis, and 19.9% had proctitis
at study entry. The percentage of participants who classiﬁed them-
selves as current smokers was 10.3%, 44.8% classiﬁed themselves as
nonsmokers with the remaining 44.8% ex-smokers. The median
duration of remission before study entry was 6 months (interquartile
range [IQR], 3.0–12.0 months) (Table 1). Participants were mostly
representative of those in the main trial.16
Medication Adherence
Self-reported adherence data was available for 56 participants
(96.6% of all sub-study participants). At the ﬁnal follow-up visit
(12 months or relapse if before 12 months), 50 participants believed
that they had taken their medication at least 90% of the time
throughout the study period (89.3%). The remaining 6 stated that
they had taken their medication,90% of the time. In total, 45 of the
50 participants who reported being adherent found it fairly or very
easy to remember to take their medication (90.0%). Of the 6 partic-
ipants who reported not being adherent, 5 stated that they found it
difﬁcult (fairly or very) to remember to take their medication. Figure,
Supplemental Digital Content 1, http://links.lww.com/IBD/A379,
describes self-reported adherence longitudinally (at each of the
follow-up visits). Adherence data based on tablet counts was avail-
able for 49 participants (84.5% of all sub-study participants). The
median percentage of correct number of tablets taken, conducted at
the ﬁnal follow-up visit, was 96.7% (IQR, 89.0%–99.2%). The
median percentage of adherent days, collected using the MEMS,
was 89.2% (IQR, 52.3%–96.7%).
Comparison of Measures
Participants who reported that they had taken their medica-
tion as prescribed had a median percentage of correct number of
tablets taken, according to tablet counts, of 97.6% (IQR, 92.3%–
99.4%). Similarly, their median percentage of adherent days
according to the MEMS was 92.9% (IQR, 63.1%–97.3%). Those
that believed that their adherence was ,90% had considerably
lower median adherence levels according to these 2 measures, with
tablet count median 76.6% (IQR, 74.3%–83.4%) and MEMS
median 34.1% (IQR, 14.0%–45.8%). Both differences were statis-
tically discernible, with both P # 0.001.
Adherence measured by tablet counts was strongly corre-
lated with adherence measured by the MEMS, with a coefﬁcient
of 0.756 (Fig. 2). Although this suggests a strong relationship
between the 2 measures, Figure 3 demonstrates that there is a dis-
tinct lack of agreement between the 2, with adherence measured
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using the MEMS consistently lower than adherence measured
using tablet counts, particularly for participants with low levels
of adherence.
Factors Associated with
Medication Adherence
We found no statistically discernible associations
between medication adherence and demographic variables
(age, gender, smoking, or employment status). The trial arm
(i.e., prescribed dosing regimen) that participants were ran-
domly assigned to was the only variable that was consistently
different for the 3 adherence measures. Of the participants
randomized to OD, 26/27 (96.3%) described themselves as at
least 90% adherent compared with 24/29 (82.8%) randomized
to TDS. By tablet counts, the median percentage of correct
number of tablets taken for OD participants was 98.9% (IQR,
94.8%–99.6%) compared with 94.2% for TDS participants
(IQR, 83.4%–97.4%). MEMS cap data show that the median
percentage of adherent days for OD participants was 96.6%
(IQR, 92.7%–98.0%) compared with 54.9% for TDS partici-
pants (IQR, 34.4%–85.7%). The differences observed for the
tablet count and MEMS adherence measures were statistically
discernible (P ¼ 0.005 and P , 0.001, respectively), whereas
the self-report adherence measure was not (P value based on
the exact test was 0.195), although there were only a few
participants who described themselves as ,90% adherent
(Table 2).
Medication Adherence and Relapse
In total, 16 participants included in the substudy relapsed
during the study period (27.6%). The median number of days that
relapsing participants were in the study was 216.5 (IQR, 65.5–262.0).
All 16 participants who relapsed described themselves as at
least 90% adherent, whereas 85.0% of participants who remained in
remission described themselves as at least 90% adherent (34/40).
The median percentage of correct number of tablets taken
for participants who relapsed was 96.0% (IQR, 83.7–97.4) com-
pared with a median percentage of 97.7% for those who remained
in remission (IQR, 89.3–99.4).
According to the MEMS, the median percentage of
adherent days for participants who relapsed was 71.4% (IQR,
39.8–93.0) compared with a median percentage of 93.4% for
those who remained in remission (IQR, 60.5–97.3).
The association between medication adherence and clinical
relapse was not statistically discernible at the 5% level for any of
the adherence measures.
FIGURE 1. Participant ﬂow diagram.
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Medication Adherence over Study Period
There was a small but statistically discernible decrease in
medication adherence over time. As illustrated by Figure 4, there
is an initial decrease in adherence followed by a period of stabi-
lization, with some further reduction in adherence towards the end
of the study. There was a marked difference between the 2 dosing
regimens (OR for TDS regimen, 0.03; 95% CI, 0.01–0.08; P ,
0.001). As is also evident in Figure 4, there was considerably
more variation in individual adherence patterns over time for
TDS participants than for OD participants. There was no discern-
ible interaction between dosing regimen and time (all P $ 0.124),
indicating that although medication adherence was generally
higher for participants allocated to the OD regimen, the adherence
in both the groups decreased over time at a similar rate.
Behavioral Aspects of Medication Adherence
Comparison Between Weekday and Weekend
Medication Adherence
As demonstrated by Figure 5, medication adherence was
generally lower on weekends than it was on weekdays, with the
difference larger for participants allocated to the TDS dosing reg-
imen than for those allocated to OD. There was a small but
statistically discernible difference in adherence on weekdays com-
pared with adherence at weekends, with odds of being adherent
47% higher on weekdays compared with weekends (OR for week-
day, 1.47; 95% CI, 1.31–1.65; P, 0.001). The interaction between
time of the week and dosing regimen was not discernible at the 5%
level (P ¼ 0.111).
Medication Adherence Around Clinic
Visit Dates
Similarly, there was a small but discernible difference
between adherence around clinic visit times and nonclinic visit
times, with the odds of being adherent around clinic visit times
43% higher compared with nonclinic visit times (OR for clinic
visit times, 1.43; 95% CI, 1.18–1.72; P , 0.001). The interaction
between time of visit and dosing regimen was not discernible at
the 5% level (P ¼ 0.429).
DISCUSSION
Summary of Key Findings
This study found that medication adherence, as measured
by self-report, tablet counts, and the MEMS, was generally high.
Although self-reported adherence produced estimates consistent
with the other 2 measures, there were noticeable disparities,
particularly between tablet counts and the MEMS. The MEMS
provided estimates of adherence lower than those provided by
tablet counts. Although the relationship between MEMS adher-
ence and relapse was not statistically discernible at the 5% level,
compared with the other measures it best distinguished between
TABLE 1. Participant Characteristics at Study Entry
Variable
Substudy Participants
(n ¼ 58)
Age at study entry* 49.4 (15.72)
Gender (male)† 32 (55.2)
Maximum documented extent of UC
Extensive† 17 (29.8)
Left-sided or sigmoid† 29 (50.9)
Proctitis† 11 (19.9)
Smoking status
Nonsmoker† 26 (44.8)
Current smoker† 6 (10.3)
Ex-smoker† 26 (44.8)
Employment status
In full-time employment† 32 (55.2)
Not in full-time employment† 26 (44.8)
Disease duration, yrs‡ 6.0 (2.0–12.0)
Number of relapses in past 2 years‡ 1.0 (1.0–2.0)
Duration of remission, mo‡ 6.0 (3.0–12.0)
Calprotectin concentration, mg/kg stool‡ 46.3 (19.5–112.3)
Baseline sigmoidoscopy score
Normal† 42 (72.4)
Not normal† 16 (27.6)
*Mean (standard deviation).
†Number (%).
‡Median (IQR).
FIGURE 2. Scatter plot comparing tablet counts to MEMS adherence.
One participant had a reported tablet count adherence level of 244%
and were adherent for 40% of the days that they were participating in
the trial (according to the MEMS). This was viewed as an outlier, and
the participant had their tablet count recoded assuming that they did
not return an unopened pack of 180 tablets (reducing their tablet
count adherence to 94.2%). This increased the size of the correlation
coefﬁcient from 0.681 to 0.756. Removing the outlier entirely
increased the coefﬁcient to 0.757.
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the participants who relapsed and those who remained in
remission, suggesting that this may be the most useful method
for measuring medication adherence in clinical studies of patients
with long-term chronic conditions. There was a small but
statistically discernible decrease in medication adherence over
the 12-month study period, and while adherence levels were
largely inﬂuenced by the dosing regimen to which participants
were randomized, there was no evidence of different rates of
decreases for these regimens. Finally, adherence to medication
was slightly better on weekdays than it was at weekends and
slightly better around clinic visit times than at other times.
Strengths and Limitations
This is the ﬁrst study to electronically monitor medication
adherence in adults in remission with UC. Participants were
monitored for up to 12 months (or until point of relapse), which
allowed for both a rich description of adherence over a long time
period and for the exploration of various behavioral aspects of
medication adherence. However, although the study collected and
analyzed adherence data for almost 15,000 participant days, this
only equated to a total of 58 participants. Therefore, there is
substantial uncertainty around some of the estimates.
Adherence was measured over the study period using self-
report, tablet counts, and electronic measures. This allowed for
a direct comparison of measures within the same individuals, and
enabled a greater understanding of the utility of each of the
measures. However, all adherence measures used in the study were
indirect, relying on various assumptions that were difﬁcult to test.
Although measuring adherence using self-reports was simple, cheap,
and convenient to implement, particularly in the case of our study,
as regular follow-up visits were a necessary feature, recall is not
always perfect, and participants are not always accurate. A
participant who forgot to take his medication may have had no
conscious recollection that he forgot his medication.24 The use of
a validated questionnaire to capture self-reported adherence may
have also provided a greater level of understanding than the self-
report questions that were asked in this study.25 Adherence mea-
sured through tablet counts was similarly simple, cheap, and con-
venient. However, mistakes in counting, intentional increases in
medication around follow-up visits (so-called “white coat” adher-
ence), and intentional tablet misrepresentation (e.g., by not bringing
all medication to follow-up visits)1 may have distorted the true
number of tablets taken. There may have been social desirability
factors that inﬂuenced participants to intentionally misrepresent their
FIGURE 3. Bland-Altman plot comparing the agreement between tablet counts and MEMS adherence.
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TABLE 2. Factors Associated with Medication Adherence Across all 3 Measures
Variable
Medication Adherence According To:
Self-report: Yes (n ¼ 50) Self-report: No (n ¼ 6) P Tablet Counts (n ¼ 49) P MEMS (n ¼ 58) P
Age at baseline* 52.0 (39–60) 50.0 (32.0–57.0) 0.853 0.20 0.169 0.14 0.284
Gender†
Male 28 (56.0) 2 (33.3) 0.401 97.4 (92.4–99.3) 0.252 92.4 (77.5–96.7) 0.217
Female 22 (44.0) 4 (66.7) 94.9 (84.3–99.1) 72.7 (44.6–97.2)
Maximum documented extent of UC†‡
Extensive 13 (26.0) 2 (40.0) 0.280 95.7 (85.1–98.7) 0.254 89.6 (41.2–95.8) 0.142
Left-sided or sigmoid 28 (56.0) 1 (20.0) 98.0 (94.0–99.2) 93.2 (80.8–97.3)
Proctitis 9 (18.0) 2 (40.0) 92.4 (77.7–97.9) 57.1 (42.9–92.3)
Smoking status†
Nonsmoker 23 (46.0) 3 (50.0) 0.664 96.4 (90.2–99.1) 0.971 93.3 (54.0–96.7) 0.710
Current smoker 6 (12.0) 0 (0.0) 96.2 (94.2–98.9) 70.2 (40.0–96.6)
Ex-smoker 21 (42.0) 3 (50.0) 97.4 (83.4–99.4) 88.7 (52.3–97.2)
Employment status†
In full-time employment 28 (56.0) 3 (50.0) 1.000 96.7 (91.6–99.0) 0.809 93.3 (57.7–97.3) 0.325
Not in full-time employment 22 (44.0) 3 (50.0) 96.0 (84.3–99.2) 84.5 (47.4–95.8)
Disease duration, yrs* 17.0 (5.0–21.0) 5.5 (2.0–10.0) 0.108 0.001 0.992 20.18 0.177
Number of relapses in the past 2 years* 1.0 (1.0–2.0) 1.0 (1.0–2.0) 0.892 20.02 0.914 0.11 0.393
Duration of remission, mo* 6.5 (3.0–13.0) 5.0 (3.0–11.0) 0.690 0.08 0.571 20.09 0.487
Calprotectin concentration, mg/kg stool* 40.6 (19.5–106.6) 97.8 (19.5–199.0) 0.451 20.10 0.498 20.03 0.819
Baseline sigmoidoscopy†
Normal 35 (70.0) 5 (83.3) 0.662 95.7 (86.6–99.2) 0.318 90.3 (45.8–96.7) 0.281
Not normal 15 (30.0) 1 (16.7) 97.7 (95.6–99.1) 89.2 (77.5–98.3)
Allocated dosing regimen (trial arm)†
OD regimen 26 (52.0) 1 (16.7) 0.195 98.9 (94.8–99.6) 0.005 96.6 (92.7–98.0) ,0.001
TDS regimen 24 (48.0) 5 (83.3) 94.2 (83.4–97.4) 54.9 (34.4–85.7)
*Median (IQR) for self-report, Spearman’s correlation coefﬁcient for tablet counts and MEMS.
†Number (%) for self-report, median (IQR) for tablet counts and MEMS.
‡There was 1 missing value of maximum documented extent of UC.
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level of adherence.26 The use of an electronic monitoring device
such as the MEMS was deemed advantageous, as it could provide
detailed insights into patterns of adherence over an entire study
period. Consequently, it is viewed by some to be the current gold
standard for measuring medication adherence.27 However, with this
additional level of detail comes an increase in cost. It was also
difﬁcult to determine whether the correct numbers of tablets were
removed (and ingested) at each dosing event.17 In addition, the
MEMS cap is bulky, and signiﬁcantly disadvantages patients ob-
liged to carry a large bottle and cap with them during the day, if on
a TDS dosing regimen.
The study compared an OD regimen against a TDS
regimen, with the TDS regimen chosen as the comparator, as it
was deemed the most logical way to divide 3 tablets over the
course of the day and is still used by a substantial number of
gastroenterologists.28 Although there is evidence of medication
adherence issues for TDS regimens, less pronounced differences
have been shown when comparing OD regimens with BD
regimens.29
Comparisons with Other Studies
Levels of medication adherence in our study were generally
high, as found in other trials measuring adherence in UC.30,31 Our
study found medication adherence levels higher than those re-
ported in prospective community-based studies of patients with
UC,32 which is to be expected given both the increased motivation
and monitoring generally seen in participants in clinical trials.
The ﬁnding of occasional poor agreement between the
adherence measures, with more traditional methods providing
higher estimates than those provided by the MEMS, particularly
when adherence was poor, is consistent with the ﬁndings of
a study conducted in young patients with inﬂammatory bowel
disease.33
An inverse relationship between the complexity of a dosing
regimen and the adherence has long been established.27,34 Our
ﬁndings are consistent with this work and, given the association
seen in previous work between the levels of adherence and
adverse clinical outcomes,35,36 support the use of a OD dosing
regimen.
The ﬁnding that adherence deteriorated over the 12-month
study period is also consistent with previous literature. Indeed,
a recent study conducted in Canada found a 1-year persistence
rate ,50% for people diagnosed with UC,37 with an older study
conducted in the USA ﬁnding that 55% of participants continued
to take their UC medication.38 The ﬁnding also coincides with
those reported for other chronic conditions.39
FIGURE 4. Estimated medication adherence probabilities over time (using the MEMS cap data). The bold black lines represent the overall esti-
mated adherence probabilities derived from the ﬁxed effects of the Generalized Linear Mixed-effects Mode, with the grayed area representing the
95% conﬁdence bands around these probabilities. All other curves are estimated individual adherence probabilities, derived from the random
effects of the Generalized Linear Mixed-effects Mode, for each participant in the study. Color-coded indicators are attached to each individual
curve to represent days that a participant adhered to or did not adhere to their medication (blue and red, respectively). There were 2 instances of
individuals having MEMS caps that malfunctioned for a small period during the study, with no data collected during this time. These periods are
marked as gray on the corresponding individual curves.
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White-coat adherence is a phenomenon that has been
previously documented, with 2 recent studies of chronic con-
ditions in particular demonstrating improved adherence around
clinic visit dates.40,41 The ﬁnding that adherence is better during
weekdays is comparable to the ﬁndings of a study of antipsychotic
medication adherence in people with schizophrenia, which found
that dose omissions were more likely to occur on weekends.42
Interpretation and Implications
This study has demonstrated that ongoing electronic
monitoring of medication adherence in clinical research provides
a level of information that is not possible with standard methods.
It is likely that self-reported adherence and tablet counts may
signiﬁcantly underestimate adherence.
For patients with chronic conditions, required to take long-
term medication, simple single dosing regimens are preferable
over more complex ones. Therefore, in clinical studies involving
patients with long-term chronic conditions, researchers should
strongly consider collecting medication adherence data electron-
ically, particularly where patients are given complex dosing
regimens to follow. There was a general decline in medication
adherence over time. Further research is needed to develop and
evaluate interventions aimed at improving adherence to medica-
tion for long-term chronic conditions.
ACKNOWLEDGMENTS
We would like to acknowledge all investigators and
participants who were involved in the CODA study. This study
would not have been possible without the tremendous effort given
by these 2 groups. D. Farewell would also like to acknowledge the
support of an MRC Methodology Fellowship.
Author contributions: All authors contributed to the con-
ception, design, acquisition, or interpretation of data. D. Gillespie
analyzed the data and drafted the article. All authors critically
revised draft versions of the article. All authors approved the ﬁnal
version of the article.
REFERENCES
1. Vermeire E, Hearnshaw H, Van Royen P, et al. Patient adherence to
treatment: three decades of research. A comprehensive review. J Clin
Pharm Ther. 2002;26:331–342.
2. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly
active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:
1181–1183.
3. Kane SV. Systematic review: adherence issues in the treatment of ulcer-
ative colitis. Aliment Pharmacol Ther. 2006;23:577–585.
4. McDonnell PJ, Jacobs MR. Hospital admissions resulting from prevent-
able adverse drug reactions. Ann Pharmacother. 2002;36:1331–1336.
5. Berg JS, Dischler J, Wagner DJ, et al. Medication Compliance: A Health-
care Problem. Harvey Whitney Books Company; 1993:27.
6. Aliotta SL, Vlasnik JJ, DeLor B. Enhancing adherence to long-term med-
ical therapy: a new approach to assessing and treating patients. Adv Ther.
2004;21:214–231.
7. Nunes V, Neilson J, O’Flynn N, et al. Clinical Guidelines and Evidence
Review for Medicines Adherence: Involving Patients in Decisions about Pre-
scribed Medicines and Supporting Adherence. London, United Kingdom:
National Collaborating Centre for Primary Care and Royal College of
General Practitioners; 2009:364.
8. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of
inﬂammatory bowel disease in adults. Gut. 2011;60:571–607.
9. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of
remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;2.
FIGURE 5. Comparison of percentage of adherent days by day of the week (using the MEMS cap data).
Gillespie et al Inﬂamm Bowel Dis  Volume 20, Number 1, January 2014
90 | www.ibdjournal.org
Copyright © 2013 Crohn’s & Colitis Foundation of America, Inc. Unauthorized reproduction of this article is prohibited.
10. Joint Formulary Committee. British National Formulary (Online). London,
United Kingdom: BMJ Group and Pharmaceutical Press; 2013. Available
at: http://www.medicinescomplete.com. Accessed March 21, 2013.
11. D’IncÀ R, Bertomoro P, Mazzocco K, et al. Risk factors for non‐adherence
to medication in inﬂammatory bowel disease patients. Aliment Pharmacol
Ther. 2008;27:166–172.
12. Shale MJ, Riley SA. Studies of compliance with delayed‐release mesala-
zine therapy in patients with inﬂammatory bowel disease. Aliment Phar-
macol Ther. 2003;18:191–198.
13. Flourié B, Hagège H, Tucat G, et al. Randomised clinical trial: once‐vs.
twice‐daily prolonged‐release mesalazine for active ulcerative colitis. Ali-
ment Pharmacol Ther. 2013;37:767–775.
14. Gandia P, Idier I, Houin G. Is once‐daily mesalazine equivalent to the
currently used twice‐daily regimen? A study performed in 30 healthy
volunteers. J Clin Pharmacol. 2007;47:334–342.
15. Hussain FN, Ajjan RA, Kapur K, et al. Once versus divided daily dosing
with delayed‐release mesalazine: a study of tissue drug concentrations and
standard pharmacokinetic parameters. Aliment Pharmacol Ther. 2001;15:
53–62.
16. Hawthorne AB, Stenson R, Gillespie D, et al. One‐year investigator‐blind
randomized multicenter trial comparing asacol 2.4 g once daily with
800 mg three times daily for maintenance of remission in ulcerative
colitis. Inﬂamm Bowel Dis. 2012;18:1885–1893.
17. Kenna LA, Labbé L, Barrett JS, et al. Modeling and simulation of
adherence: approaches and applications in therapeutics. AAPS J. 2005;7:
E390–E407.
18. Bland MJ, Altman DG. Statistical methods for assessing agreement between
two methods of clinical measurement. Lancet. 1986;327:307–310.
19. Harre FE, Lee KL, Pollock BG. Regression models in clinical studies:
determining relationships between predictors and response. J Natl Cancer
Inst. 1988;80:1198–1202.
20. Akaike H. A new look at the statistical model identiﬁcation. IEEE Trans-
actions on Automatic Control. 1974;19:716–723.
21. IBM Corp. IBM SPSS Statistics for Windows. 20.0 ed. Armonk, NY:
IBM Corp. 2011.
22. R Core Team. R: A Language and Environment for Statistical Computing.
Vienna, Austria: R Foundation for Statistical Computing, 2012.
23. Bates D, Maechler M, Bolker B, et al. lme4: linear mixed-effects models
using S4 classes. R package version 0.999999-0. Available at: http://
CRAN.R-project.org/package¼lme4.
24. Cramer JA, Spilker B. Patient Compliance in Medical Practice and Clin-
ical Trials: New York, NY: Raven Press; 1991.
25. Horne R, Weinman J. Self-regulation and self-management in asthma:
exploring the role of illness perceptions and treatment beliefs in explain-
ing non-adherence to preventer medication. Psychol Health. 2002;17:
17–32.
26. Farmer KC. Methods for measuring and monitoring medication regimen adher-
ence in clinical trials and clinical practice. Clin Ther. 1999;21:1074–1090.
27. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations
between dose regimens and medication compliance. Clin Ther. 2001;23:
1296–1310.
28. Sandborn WJ, Korzenik J, Lashner B, et al. Once-daily dosing of delayed-
release oral mesalamine (400-mg tablet) is as effective as twice-daily
dosing for maintenance of remission of ulcerative colitis. Gastroenterol-
ogy. 2010;138:1286–1296.e3.
29. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily
dose frequency on patient medication compliance. Arch Intern Med. 1990;
150:1881–1884.
30. Farup PG, Hinterleitner TA, Lukás M, et al. Mesalazine 4 g daily given as
prolonged‐release granules twice daily and four times daily is at least as
effective as prolonged‐release tablets four times daily in patients with
ulcerative colitis. Inﬂamm Bowel Dis. 2001;7:237–242.
31. Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for
5‐ASA: preliminary clinical ﬁndings for MMx. Inﬂamm Bowel Dis. 2005;
11:421–427.
32. Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with
maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroen-
terol. 2001;96:2929–2933.
33. Greenley RN, Kunz JH, Biank V, et al. Identifying youth nonadherence in
clinical settings: data‐based recommendations for children and adolescents
with inﬂammatory bowel disease. Inﬂamm Bowel Dis. 2012;18:1254–
1259. doi: 10.002/ibd.21859.
34. Saini SD, Schoenfeld P, Kaulback K, et al. Effect of medication dosing
frequency on adherence in chronic diseases. Am J Manag Care. 2009;15:
e22–e33.
35. Bresci G, Parisi G, Bertoni M, et al. Long-term maintenance treatment in
ulcerative colitis: a 10-year follow-up. Dig Liver Dis. 2002;34:419–423.
36. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes
of patients with quiescent ulcerative colitis. Am J Med. 2003;114:39–43.
37. Lachaine J, Yen L, Beauchemin C, et al. Medication adherence and per-
sistence in the treatment of Canadian ulcerative colitis patients: analyses
with the RAMQ database. BMC Gastroenterol. 2013;13:23.
38. Kane SV, Accortt NA, Magowan S, et al. Predictors of persistence with
5‐aminosalicylic acid therapy for ulcerative colitis. Aliment Pharmacol
Ther. 2009;29:855–862.
39. Evon DM, Esserman DA, Bonner JE, et al. Adherence to PEG/ribavirin
treatment for chronic hepatitis C: prevalence, patterns, and predictors of
missed doses and nonpersistence. J Viral Hepat. 2013;20:536–549.
40. Feldman SR, Camacho FT, Krejci-Manwaring J, et al. Adherence to
topical therapy increases around the time of ofﬁce visits. J Am Acad
Dermatol. 2007;57:81–83.
41. Modi AC, Ingerski LM, Rausch JR, et al. White coat adherence over the
ﬁrst year of therapy in pediatric epilepsy. J Pediatr. 2012;161:695–699.
42. Acosta FJ, Ramallo-Fariña Y, Bosch E, et al. Antipsychotic treatment
dosing proﬁle in patients with schizophrenia evaluated with electronic
monitoring (MEMS). Schizophr Res. 2013;146:196–200.
Inﬂamm Bowel Dis  Volume 20, Number 1, January 2014 Electronic Monitoring of Medication Adherence
www.ibdjournal.org | 91
Copyright © 2013 Crohn’s & Colitis Foundation of America, Inc. Unauthorized reproduction of this article is prohibited.
Adherence-adjusted estimates of
beneﬁts and harms from treatment with
amoxicillin for LRTI: secondary analysis
of a 12-country randomised placebo-
controlled trial using randomisation-
based efﬁcacy estimators
David Gillespie,1 Kerenza Hood,1 Daniel Farewell,2 Christopher C Butler,2,3
Theo Verheij,4 Herman Goossens,5 Beth Stuart,6 Mark Mullee,6 Paul Little,7
On behalf of the GRACE consortium
To cite: Gillespie D, Hood K,
Farewell D, et al. Adherence-
adjusted estimates of benefits
and harms from treatment
with amoxicillin for LRTI:
secondary analysis of a 12-
country randomised placebo-
controlled trial using
randomisation-based efficacy
estimators. BMJ Open
2015;5:e006160.
doi:10.1136/bmjopen-2014-
006160
▸ Prepublication history and
additional material is
available. To view please visit
the journal (http://dx.doi.org/
10.1136/bmjopen-2014-
006160).
Received 18 July 2014
Revised 27 January 2015
Accepted 28 January 2015
For numbered affiliations see
end of article.
Correspondence to
David Gillespie;
gillespied1@cardiff.ac.uk
ABSTRACT
Objectives: Estimate the efficacy of amoxicillin for acute
uncomplicated lower-respiratory-tract infection (LRTI) in
primary care and demonstrate the use of randomisation-
based efficacy estimators.
Design: Secondary analysis of a two-arm individually-
randomised placebo-controlled trial.
Setting: Primary care practices in 12 European
countries.
Participants: Patients aged 18 or older consulting with
an acute LRTI in whom pneumonia was not suspected by
the clinician.
Interventions: Amoxicillin (two 500 mg tablets three
times a day for 7 days) or matched placebo.
Main outcome measures: Clinician-rated symptom
severity between days 2–4; new/worsening symptoms
and presence of side effects at 4-weeks. Adherence was
captured using self-report and tablet counts.
Results: 2061 participants were randomised to the
amoxicillin or placebo group. On average, 88% of the
prescribed amoxicillin was taken. The original analysis
demonstrated small increases in both benefits and harms
from amoxicillin. Minor improvements in the benefits of
amoxicillin were observed when an adjustments for
adherence were made (mean difference in symptom
severity −0.08, 95% CI −0.17 to 0.01, OR for new/
worsening symptoms 0.81, 95% CI 0.66 to 0.98) as well
as minor increases in harms (OR for side effects 1.32,
95% CI 1.12 to 1.57).
Conclusions: Adherence to amoxicillin was high, and
the findings from the original analysis were robust to
non-adherence. Participants consulting to primary care
with an acute uncomplicated LRTI can on average expect
minor improvements in outcome from taking amoxicillin.
However, they are also at an increased risk of
experiencing side effects.
Trial registration numbers: Eudract-CT 2007-001586-
15 and ISRCTN52261229.
The trial was registered at EudraCT in 2007 due to an
administrative misunderstanding that EudraCT was a
suitable registry—which it was not in 2007, but has
become since. On discovery of this error, the trial was
also registered at ISRCTN ( January 2009). Trial
procedures did not change between the two registrations.
INTRODUCTION
Acute uncomplicated lower-respiratory-tract
infection (LRTI) is one of the most common
reasons for patients consulting in primary
care.1 2 Antibiotics are prescribed to the
majority of consulting patients, with amoxicil-
lin being the most common across Europe.3
Evidence for the beneﬁts and harms of anti-
biotic treatment has been unclear, primarily
Strengths and limitations of this study
▪ This is the largest randomised placebo-controlled
trial evaluating amoxicillin for acute, uncomplicated
lower-respiratory-tract infection in primary care to
date.
▪ Consideration of the benefits and harms of
amoxicillin allowed for a balanced assessment of
this treatment.
▪ Multiple types of adherence measures meant that
agreement between measures could be assessed.
▪ As is often the case in research, indirect measures
of medication adherence were collected. These rely
heavily on their inherent assumptions (eg, accurate
patient recall, returning of all unused medication).
Direct measures (eg, direct observation) are prefer-
able, but often not feasible in practice.
▪ Structural mean models enabled an adjustment
for treatment non-adherence while maintaining a
comparison of groups as randomised.
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due to underpowered and inappropriately designed
studies.4 With antibiotic resistance becoming a growing
problem worldwide, the need for clear evidence for the
beneﬁts and harms of antibiotics for this condition has
never been more of a priority.5 6
A recently published trial of amoxicillin for acute
uncomplicated LRTI in primary care concluded that
amoxicillin provides little clinical beneﬁt and causes slight
harms.7 The ﬁndings of this trial were based on a compari-
son of participants in the arm to which they were originally
randomised (ie, using the intention to treat (ITT) prin-
ciple). While an ITT analysis is an important part of the
analysis of any trial, as it reﬂects the design of the trial and
uses randomisation to avoid selection bias,8 this approach
does not take into account deviations that occur following
randomisation, such as lack of adherence to treatment.
Adherence to antibiotic treatment in primary care is
poor.9 Less than 60% of patients prescribed an antibiotic
for an acute cough/LRTI in primary care initiated their
treatment, and less than half took the full course.10 Poor
levels of adherence to antibiotics wastes healthcare
resources, could negatively impact on clinical outcomes
and could increase the selective pressures for antibiotic
resistance. When issues with adherence are present in a
trial, analysis based on the ITT principle underestimates
treatment effects, and can only provide an unbiased esti-
mate of the effect of prescribing treatment (effectiveness),
rather than the effect of treatment itself (efﬁcacy).11
Two traditional approaches to estimating treatment
efﬁcacy include per-protocol analysis, where participants
who do not adhere to their allocated treatment are
excluded from analyses, and on-treatment analysis,
where participants are analysed in the group corre-
sponding to the treatment they took (regardless of the
group they were allocated to).12 Both methods make the
implicit assumption that the groups of participants are
equivalent with respect to observed and unobserved vari-
ables, something that is implausible in practice.13
Approaches to estimating efﬁcacy without making this
key assumption exist, and are becoming increasingly
popular.14 15 However, these approaches are generally
reported in specialist methodological journals, rather
than the general medical literature and as such there
still remains a reliance on more traditional and arguably
inadequate methods.
The aim of this paper is to use the data set from the
largest placebo-controlled trial of amoxicillin for acute
uncomplicated LRTI in primary care to produce
adherence-adjusted estimates of the beneﬁts and harms
from amoxicillin for adults consulting in primary care
with an acute uncomplicated LRTI, while preserving a
comparison of groups as randomised.
METHODS
Study design and participants
A two-arm individually-randomised placebo-controlled
trial was conducted between November 2007 and
April 2010. Patients were recruited consecutively from
primary care practices from 12 European countries
(Belgium, England, France, Germany, Italy, the
Netherlands, Poland, Slovakia, Slovenia, Spain,
Sweden and Wales).
The trial has previously been described in detail else-
where.7 A brief description about recruitment, random-
isation, blinding, the interventions, data collection and
follow-up are given below. Further analyses were per-
formed in order to investigate our study question.
Recruitment, randomisation, blinding and interventions
Participants were eligible for inclusion if they were aged
18 years or older and consulting for the ﬁrst time with
either an acute cough (≤28 days’ duration) as their
main symptom, for which non-infective diagnoses were
judged very unlikely, or an illness in which cough was
not the most prominent symptom but the clinician
thought acute LRTI the most probable diagnosis.
Participants were deemed ineligible if their initial
diagnosis was community-acquired pneumonia (ie, com-
plicated LRTI) on the basis of focal chest signs (focal
crepitations, bronchial breathing) and systemic features
(high fever, vomiting, severe diarrhoea). Participants
were also ineligible if their working diagnosis was cough
of a non-infective cause (eg, pulmonary embolus, left
ventricular failure, oesophageal reﬂux, allergy), they
had used antibiotics in the previous month, were unable
to provide informed consent or complete the diary
(eg, they had dementia, psychosis or severe depression),
were pregnant, allergic to penicillin or had immuno-
logical deﬁciencies.
Participants were allocated to groups on a 1:1 basis
using block randomisation. As this was a double-blinded
trial, clinicians and participants were blinded to the ran-
domisation sequence and allocation. All outcome data
were also collected without prior knowledge of the
group to which participants were allocated.
Randomised participants received a prescription for
amoxicillin, to be taken as two 500 mg tablets three
times a day for 7 days, or a placebo identical in appear-
ance, taste and texture.
Data collection and participant follow-up
Consenting participants had their comorbidities, clinical
signs and symptoms recorded by the recruiting clinician.
Following recruitment, consent and randomisation,
participants were given a daily symptom diary to com-
plete for up to 28 days. The diary recorded the duration
and severity of 12 symptoms (cough, phlegm, shortness
of breath, wheeze, blocked or runny nose, chest pain,
muscle aches, headaches, disturbed sleep, general feeling
of being unwell, fever and interference with normal activ-
ities). Severity was scored on a scale from 0 to 6 (0=no
problem, 1=very little problem, 2=slight problem, 3=mod-
erately bad, 4=bad, 5=very bad, 6=as bad as it could be).
Patients also recorded non-respiratory symptoms, such as
diarrhoea, skin rash and vomiting.
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Members of the research team telephoned partici-
pants after 4 days to offer support and answer questions
about the completion of the diary. If the diary was not
returned after 4 weeks, brief information was collected
about symptom duration and severity. This information
was collected with either a short questionnaire or a stan-
dardised telephone call.
Measures of adherence
Using their daily symptom diary, participants recorded
whether or not they took their study medication on a
given day, and whether they took their study medication
according to the instructions. Where it was indicated
that participants did not take their study medication
according to the instructions, space was given to provide
more detail. Participants for whom a diary was not
returned were asked to state the number of days that
they took their study medication. This information was
collected using the short questionnaire/telephone call
described in the previous section. Participants were also
instructed to return their study medication bottles, com-
plete with any unused medication, at the end of the
trial. The number of tablets returned was recorded by
members of the research team.
Randomised participants were prescribed 42 tablets.
Adherence to study medication was deﬁned as the per-
centage of the correct number of tablets taken during
the ﬁrst 7 days of the follow-up period (ie, the period
for which the medication was prescribed). Three binary
deﬁnitions of adherence were also constructed in order
to provide sensitivity analyses around the continuous def-
inition. The three binary deﬁnitions were full (100%)
adherence versus not full adherence, at least the equiva-
lent of a 5-day course (approximately 71.4%) versus less
and at least one tablet versus no tablets.
Where participants indicated that they had taken
medication on a particular day, in the absence of infor-
mation to the contrary (eg, stating that they only took
one tablet three times a day instead of two tablets), the
assumption was made that a participant consumed all
study medication as instructed. Where medication
bottles were returned, it was assumed that the difference
between the number of tablets prescribed and the
number returned equated to the number of tablets con-
sumed. We also assumed that all tablets were consumed
during the ﬁrst 7 days of the follow-up period. Where a
short questionnaire or telephone call was conducted, it
was assumed that the correct numbers of tablets
were taken for the number of days medication was
reportedly taken.
Where multiple types of adherence measures were
available for a participant the agreement between mea-
sures, and the assumptions inherent in our deﬁnition of
adherence, were investigated.
Outcomes
To demonstrate the beneﬁts and harms of amoxicillin
in this population, and to illustrate the use of
randomisation-based efﬁcacy estimators, the paper con-
centrates on three of the outcomes described in the ori-
ginal paper. The ﬁrst was the mean clinician-rated
symptom severity between days 2 and 4 after initial pres-
entation. The second outcome was the development of
new or worsening symptoms, deﬁned as returning to the
clinician with new or worsening symptoms, new signs or
an illness requiring admission to hospital within the
4-week follow-up period. The third outcome was the
presence of any non-respiratory symptoms (diarrhoea,
skin rash or vomiting) during the 4-week follow-up
period. These speciﬁc symptoms were recorded as they
are known side effects of amoxicillin. The ﬁrst two out-
comes were used to demonstrate the clinical beneﬁts of
amoxicillin for patients with an acute uncomplicated
LRTI in primary care, with the third used to demon-
strate harms. The decision to exclude the outcome
“time to resolution of moderately bad symptoms” from
the analysis was made for two reasons. First, in order to
reduce the number of assumptions made when deriving
the deﬁnition of adherence (we have not made any
assumptions about adherence on individual days, but
would have to make this additional assumption to
perform analysis on this outcome). The second reason
was that standard techniques for adjusting time-to-event
outcomes for non-adherence rely on ﬁtting an acceler-
ated failure time model. The original outcome was ana-
lysed using a Cox proportional hazards model, and
therefore the outcome would initially require reanalys-
ing using an accelerated failure time model before an
adjustment could be made. As the results from this ana-
lysis cannot be directly compared with the ﬁndings from
the main paper, the decision to exclude this outcome
from consideration was made.
Statistical analysis
Participants and their adherence to study medication
were described using means (SDs), medians (IQRs) and
percentages as appropriate.
Participants for whom more than one measure of
adherence was available had their agreement between
measures compared using Bland and Altman limits of
agreement.16 Bland and Altman plots are presented with
jittering and semitransparency to highlight overlapping
data points. Where multiple types of adherence measures
were reported and there was disagreement between
values, the minimum value was used for analysis.
The between-group mean difference in symptom
severity on days 2 to 4 postrandomisation was estimated
using linear regression. The mean clinician-rated
symptom severity at baseline was controlled for as a cov-
ariate. The between-group odds of developing new or
worsening symptoms and of reporting any non-
respiratory symptoms in the 4 weeks following random-
isation were compared using logistic regression without
covariates. These analyses included participants on an
intention-to-treat basis. That is, they did not adjust for
deviations following randomisation. The analyses
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therefore provide an estimate of the effectiveness of
amoxicillin for patients with an acute uncomplicated
LRTI in primary care, and as an estimate of efﬁcacy, are
viewed as being biased towards the null.
To determine efﬁcacy in a way that preserves random-
isation (ie, provides a comparison of groups ie, inde-
pendent of observed and, importantly, unobserved
confounders), and is not biased towards the null, struc-
tural mean models (SMM) were used to compare the
between-group differences in the aforementioned out-
comes. By recognising that at the beginning of a trial, all
participants have two potential outcomes—one if they
are treated and one if they are not, a SMM relates a
treated participant’s observed outcome to their poten-
tially counterfactual outcome that would have been
observed had they received no treatment. Standard
approaches to ﬁtting a SMM rely on using observed
levels of exposure, and treating randomisation as an
instrument (ie, assuming that it is independent of both
observed and unobserved confounders and only effects
outcome through its effect on exposure). Estimation
procedures therefore rely on ﬁnding a value of the treat-
ment effect such that balance is achieved between
groups on the outcome (or potential outcome) in parti-
cipants who were not treated. The between-group mean
difference in symptom severity on days 2 to 4 was esti-
mated using a two-stage least squares instrumental vari-
ables regression model.17 To compare the odds of
developing new or worsening symptoms and reporting
any non-respiratory symptoms, a generalised linear
(double logistic) SMM was estimated via a generalised
method of moments procedure.18 The double logistic
SMM involved a two-step process whereby the association
between outcome (development of new or worsening
symptoms or reporting of side effects), trial arm and
adherence was modelled ﬁrst, with estimates from this
model used in the SMM in order to obtain correct SEs
(and hence correct 95% CIs). For more information on
the use of randomisation-based efﬁcacy estimators and
their core assumptions, including the Stata syntax used
to implement the SMMs, please see the online supple-
mentary appendices 1 and 2.
Results from the linear regression model are pre-
sented as adjusted mean differences with associated
95% CIs. Results from the logistic regression models are
presented as ORs with associated 95% CIs. For the SMM
(double logistic SMM), results are presented as both the
adjusted mean difference (OR) per % increase in adher-
ence and per 100% adherence, the latter of which can
be interpreted as the maximum possible efﬁcacy.
Additional analyses using the three binary deﬁnitions
of adherence were performed to investigate the sensitiv-
ity of the main efﬁcacy analyses to departures from the
assumed linear relationship between adherence and
outcome.
Data management and descriptive statistics were per-
formed using IBM SPSS Statistics V.20.19 All other ana-
lyses were performed using Stata V.13.20
RESULTS
Participants
In total, 2061 participants were recruited and rando-
mised to either the amoxicillin group (1038) or placebo
(1023; ﬁgure 1). The groups were well matched on base-
line characteristics (table 1).
Adherence to study medication
Adherence data were available for 1854 participants
(90% of all randomised participants). The majority of
participants had multiple types of measure recorded
(1214, or 58.9% of all randomised; ﬁgure 2).
Adherence to study medication was similar between
trial arms and relatively high overall. Average levels of
adherence were highest for responses obtained from
self-reported diaries and lowest for responses from self-
reported telephone. Adherence data were highly skewed
for all three measures and spanned the entire range of
possible responses (table 2).
Agreement between adherence measures
Where multiple types of adherence measures were avail-
able, self-reports (diary and telephone formats) provided
slightly higher estimates of adherence on average com-
pared to tablet counts (mean differences of 1.7 and 2.6
percentage points, respectively). The limits of agreement
when comparing diary and tablet count adherence
ranged from −26.8 (self-reported diary adherence was
calculated as 26.8 percentage points lower than tablet
count adherence) to 30.2 (self-reported diary adherence
was calculated as 30.2 percentage points higher than
tablet count adherence) and when comparing tele-
phone and tablet count from −21.8 to 26.9 (table 3).
Figure 3A, B provide an illustration of the level of agree-
ment between different types of measures. What is clear
from these ﬁgures is that adherence was high and was
generally good (most data points on both plots are clus-
tered around the coordinate (100, 0), indicating full
adherence and no difference between measures). For
the comparison of diary to tablet count adherence, 7%
of participants were outside the limits of agreement; for
the comparison of telephone to tablet count adherence,
5% of participants were outside the limits of agreement.
Taking the minimum reported adherence value
(where multiple values were reported), adherence to
study medication remained high and negatively skewed
(table 4 and ﬁgure 4).
Outcomes
Table 5 provides descriptive statistics for each of the
three clinical outcomes.
Effectiveness
Table 6 compares the effectiveness and efﬁcacy of
amoxicillin with respect to the various outcomes below.
As reported in the original paper, the adjusted
between-group mean difference in symptom severity
score on days 2 to 4 was slightly lower in the amoxicillin
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group than the placebo group (adjusted mean differ-
ence of −0.07, 95% CI −0.15 to 0.01).
Being allocated to the amoxicillin arm (ie, being pre-
scribed amoxicillin) was associated with decreased odds
of developing new or worsening symptoms in the 4 weeks
postrandomisation follow-up period. The odds of devel-
oping new or worsening symptoms were 21% lower for
participants who were prescribed amoxicillin than for
those prescribed a matched placebo (OR=0.79, 95% CI
0.63 to 0.99). When the effectiveness analyses were only
performed on participants for whom outcome and
adherence data were available, there was a 19% decrease
in the odds of developing new or worsening symptoms in
participants prescribed amoxicillin (OR=0.81, 95% CI
0.64 to 1.03).
Being prescribed amoxicillin was associated with a
28% increase in the odds of reporting non-respiratory
symptoms (side effects) in the 4 weeks postrandomisa-
tion (OR=1.28, 95% CI 1.03 to 1.59).
Efficacy
Adjusting for adherence using the SMM, a small
increase in the between-group mean difference in
symptom severity score for participants who complete
their course of amoxicillin was found (−0.08, 95% CI
−0.17 to 0.01).
Figure 1 CONSORT flow diagram.
Table 1 Baseline characteristics of trial participants
Baseline characteristic Amoxicillin Placebo
Women 624/1038 (60.1%) 600/1023 (58.7%)
Age (years) 48.6 (16.7) 49.3 (16.4)
Non-smoker (past or present) 477/1037 (46.0%) 483/1022 (47.3%)
Illness duration before index consultation (days) 9.5 (8.0) 9.3 (7.2)
Respiratory rate (breaths per minute) 16.9 (3.3) 16.9 (3.3)
Body temperature (°C) 36.7 (3.3) 36.8 (3.3)
Lung disease* 163/1037 (15.7%) 147/1023 (14.4%)
Mean severity score (all symptoms)† 2.1 (0.5) 2.1 (0.5)
Mean severity score (cough)† 3.1 (0.7) 3.2 (0.7)
Sputum production 814/1036 (78.6%) 824/1021 (80.7%)
Discoloured sputum‡ 481/968 (49.7%) 468/957 (48.9%)
Data are n/N (%) or mean (SD).
*Chronic obstructive pulmonary disease or asthma.
†Severity of symptoms: 1=no problem; 2=mild problem; 3=moderate problem; 4=severe problem.
‡Green, yellow or blood stained.
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Figure 5 provides an illustration of the effectiveness
and efﬁcacy of amoxicillin for the above outcome. The
treatment efﬁcacy when adherence is 0% is 0, the ITT
(effectiveness) is illustrated by the diamonds (positioned
at an adherence level of 88%—the patient-average), and
the maximum efﬁcacy when adherence is 100%.
The odds of developing new or worsening symptoms
remained lower in participants who took their full
course of amoxicillin (OR for 100% adherence to
amoxicillin=0.81, 95% CI 0.66 to 0.98).
A small increase in the odds of reporting non-respiratory
symptoms was found when adjusting for adherence (OR
for 100% adherence=1.32, 95% CI 1.12 to 1.57).
Sensitivity analyses
Reﬁtting the above efﬁcacy analyses with binary deﬁni-
tions of adherence, the results remained largely similar
and did not alter the conclusions drawn by either the
efﬁcacy or indeed the effectiveness analyses. The most
extreme deﬁnition of adherence (full vs not) yielded
the largest between group differences and the least
extreme (at least one tablet vs none) yielded the smal-
lest (table 7).
DISCUSSION
Principal findings
In this 12-country randomised placebo-controlled trial of
amoxicillin for acute uncomplicated LRTI in primary
care, reported levels of adherence to study medication
was very high. Prescribing amoxicillin in this setting was
shown to have modest improvements in symptom sever-
ity on days 2–4, and a decrease in the odds of develop-
ing new or worsening symptoms in the 4 weeks following
index consultation. However, this has to be balanced
with the odds of reporting non-respiratory symptoms
(side effects) in the 4 weeks following index consult-
ation, which also increased. Adjusting these ﬁndings for
Figure 2 Availability of different types of adherence data for
all 2061 randomised participants.
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adherence, the effect of taking amoxicillin in this setting
largely agreed with the effect of prescribing described
above. Given the high level of adherence reported in
the trial, the adjustments made were minor, though in
the expected direction. Compared to the effect of pre-
scribing amoxicillin (ie, including participants who may
take their medication to a varying degree), taking
amoxicillin was shown to further improve symptom
severity on days 2–4, further decrease the odds of devel-
oping new or worsening symptoms and further increase
the odds of reporting side effects.
Strengths and weaknesses
To date, this remains the largest randomised placebo-
controlled trial evaluating amoxicillin for acute, uncom-
plicated LRTI in primary care. By maintaining a broad
inclusion criteria, recruiting across a range of different
countries, and recruiting participants similar in nature
to previously conducted observational studies in this
setting,3 the ﬁndings of this study are likely to be widely
applicable.
This paper demonstrated that the ﬁndings of main
effectiveness analysis were robust to non-adherence to
treatment, and did so using a method of analysis that
was not prone to the usual selection biases that arise
when ITT ﬁndings are adjusted for treatment adherence
traditionally (eg, per-protocol analysis).
By considering the beneﬁts and harms, the study pro-
vided a comprehensive account of the consequences of
taking amoxicillin for an acute uncomplicated LRTI in
primary care.
Adherence to medication was assessed using self-report
and tablet count data, and while both only provided
indirect measures of medication adherence, relying
heavily on various assumptions (eg, accurate participant
recall, returning of all unused medication), both mea-
sures were often available for the same individual, allow-
ing for the assessment of agreement between measures.
Agreement was good, with adherence calculated as 100%
for both measures for the majority of participants.
The use of SMMs to adjust trial ﬁndings for non-
adherence was attractive as it allowed for a comparison
of groups that was independent of measured and
unmeasured confounders. However, for this comparison
to be valid, it relied on the key assumption that for parti-
cipants who were categorised as non-adherers, merely
being allocated to receive treatment had no effect on
outcome (the so-called exclusion restriction).21 While
this was likely to be a valid assumption for this study, as
participants and clinicians were blinded to allocation,
this is less likely to be valid for non-blinded studies.
Table 3 Difference between adherence measures and limits of agreement
Difference between
adherence measures
Self-reported diary adherence minus
tablet count adherence (n=1135)
Self-reported telephone adherence
minus tablet count adherence (n=80)
Mean 1.7 2.6
SD 14.5 12.4
Lower 95% limit of agreement −26.8 −21.8
Upper 95% limit of agreement 30.2 26.9
Figure 3 (A and B) Bland and Altman plots illustrating the
agreement between the self-reported (diary (A) and telephone
(B)) and tablet count adherence measures. Red solid line
represents perfect agreement between measures. Black solid
line represents the mean difference (bias) between measures.
Black dashed lines are the 95% limits of agreement. Where
data points took the same value (ie, when more than one
participant had both the same average and difference in
adherence), semitransparency and jittering effects were
applied to provide an illustration of the number of overlapping
data points. There were a large number of data points at (100,
0), and this is illustrated by the large cluster of jittered points
around this coordinate.
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Deﬁning adherence as a continuous measure made the
exclusion restriction more plausible, as the lowest level of
adherence could be deﬁned as receiving no treatment, a
level at which being allocated to either treatment group
should really have no effect on outcome. However, this
approach made the additional assumption that the effect
of receiving an increasing amount of treatment on
outcome increased linearly,22 which for a trial involving
medication is unlikely to be true. Sensitivity analyses were
conducted using various binary deﬁnitions of adherence,
ranging from one or more tablets (vs no tablets) to full
course (vs less than full course). While the former
increased the plausibility of the exclusion restriction, the
estimated treatment efﬁcacy was too conservative. The
latter analysis combined participants who would have
taken 99% of their medication with participants who
would have taken no medication and considered them all
as not adhering (and therefore assumed they would have
received no beneﬁt from being allocated to the amoxicil-
lin arm). This clearly violated the exclusion restriction.
However, the ﬁndings from the sensitivity analyses largely
agreed with the main ﬁndings (where adherence was
measured continuously), adding further strength to the
conclusions of the paper.
Despite the fact that incomplete outcome and adher-
ence data were minimal, their impact on ﬁndings
remains unknown. However, as the condition under
investigation is generally self-limiting, and outcome data
included worsening of illness (a composite outcome col-
lected from medical notes that included hospitalisation),
we do not believe that the small amount of missing data
would have severely impacted on the ﬁndings or conclu-
sions drawn from this study. Indeed, sensitivity analyses
demonstrate that clinical conclusions remain largely
unaltered even when taking an extreme assumption
about missing adherence data (see online supplemen-
tary appendix 3 for further details).
Comparison to existing literature
The ﬁndings from this study concur with those reported
in the main ﬁndings paper,7 both of which are consist-
ent with a recently published Cochrane review of anti-
biotics for acute bronchitis.3
Adherence to amoxicillin in this study was consider-
ably higher than that reported in an observational study
of antibiotics for adults with acute cough/LRTI in
primary care.10 However, the participants recruited into
this trial were similar to those recruited into the afore-
mentioned observational study in terms of their baseline
characteristics.3
Approaches for adjusting treatment effects for non-
adherence while preserving randomisation have been in
existence for approximately 20 years.21 However, they
have largely been consigned to specialist methodological
journals, rarely used in practice and when used, gener-
ally focussed on non-pharmacological treatments.23
A recent publication using the same SMM approach as
this paper on a clinical trial involving patients with
depression demonstrates further that these methods are
becoming more mainstream and should be reported
alongside standard ITT estimates of treatment effective-
ness, when there is also interest in knowing the efﬁcacy
of treatment.24
Implications
The slight beneﬁts gained from taking amoxicillin in
adults consulting to primary care with acute uncompli-
cated LRTI must be balanced against the slight harms
that amoxicillin causes in terms of side effects, as well as
the associated contribution to antibiotic resistance.
While estimating the effectiveness of treatment using
the ITT principle remains the gold standard in clinical
trials, an ITT analysis only tells us the population-average
effect that prescribing treatment has. The analysis there-
fore provides the answer to a question that is of primary
interest to clinicians and policymakers (“What are the
effects when this drug is prescribed?”). However, to a
patient, the analysis may not be as informative (“What are
the effects when I take this drug as prescribed?”). Some
of these prescriptions will not be taken in their entirety,
others not at all. In general, an ITT analysis does not esti-
mate how good the medication is at treating the illness
Table 4 Levels of adherence to study medication used for statistical analyses (with the minimum value reported when
participants had more than one type of measure)
Amoxicillin (n=930) Placebo (n=924) Overall (n=1854)
Mean (SD) 88.0 (25.8) 86.6 (27.2) 87.3 (26.5)
Median (IQR) 100.0 (95.2–100.0) 100.0 (85.7–100) 100.0 (90.5–100.0)
Minimum–maximum 0.0–100.0 0.0–100.0 0.0–100.0
Figure 4 Proportion of participants at each adherence level
(with the minimum value reported when participants had more
than one type of measure).
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Table 6 Comparison of effectiveness and efficacy of amoxicillin for acute uncomplicated LRTI in primary care
Outcome Effectiveness*
Effectiveness for
whom adherence data
were also available†
Efficacy per 10%
increase in adherence†
Maximum efficacy
(100% adherence)†
Adjusted between-
group mean difference
in symptom severity
between days 2 and 4
postrandomisation
−0.07 (−0.15 to 0.01) −0.07 (−0.15 to 0.01) −0.008 (−0.017 to 0.001) −0.08 (−0.17 to 0.01)
OR for developing new
or worsening symptoms
in the 4 weeks
postrandomisation
0.79 (0.63 to 0.99) 0.81 (0.64 to 1.03) 0.978 (0.960 to 0.998) 0.81 (0.66 to 0.98)
OR for reporting
non-respiratory
symptoms/side effects
in the 4 weeks
postrandomisation
1.28 (1.03 to 1.59) 1.28 (1.04 to 1.59) 1.028 (1.011 to 1.046) 1.32 (1.12 to 1.57)
*Analysis based on 1789, 2027 and 1727 participants for the symptom severity, new symptoms and side effect outcomes, respectively.
†Analysis based on 1787, 1923 and 1725 participants for the symptom severity, new symptoms and side effect outcomes, respectively.
LRTI, lower-respiratory-tract infection.
Table 5 Descriptive statistics of the three outcome measures
Outcome Amoxicillin Placebo
Mean symptom severity between days 2 and 4 postrandomisation* 1.6 (0.8) 1.7 (0.8)
Development of new or worsening symptoms in the 4 weeks postrandomisation 162/1021 (15.9) 194/1006 (19.3)
Reported non-respiratory symptoms/side effects in the 4 weeks postrandomisation 249/867 (28.7) 206/860 (24.0)
Data are n/N (%) or mean (SD).
*Each symptom was scored from 0–6 (0=no problem, 1=very little problem, 2=slight problem, 3=moderately bad, 4=bad, 5=very bad, 6=as
bad as it could be).
Figure 5 Graphical illustration of the effectiveness and efficacy of amoxicillin on mean symptom severity on days 2–4.
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under consideration. Adjusting for adherence does allow
for the estimation of this. If an ITT analysis shows little
evidence of beneﬁt, but an adherence-adjusted analysis
demonstrates beneﬁt, then the attention of policymakers
should turn to ensuring that patients take their treatment
properly. Estimating efﬁcacy can provide additional
insight into the potential beneﬁt from treatment, and
can indicate whether additional resources need to be
allocated to the improvement of adherence to medica-
tion for speciﬁc conditions.
As was seen in this paper, if an ITT analysis ﬁnds little
evidence of any beneﬁt, and these conclusions are not
affected by an adherence-adjusted analysis, it can be con-
cluded that the intervention does not work in practice or
principle.
Estimating efﬁcacy in clinical trials while preserving the
random allocation of participants to treatment groups is
vital for inferring causal treatment effects. Standard soft-
ware is available for implementing methods such as the
SMM, and should become more widely used and
reported in the medical literature.
Future research
While the main ﬁndings paper reported that a subgroup
of older participants (aged 60 years or older) received
no differential effect of treatment, investigating the efﬁ-
cacy of amoxicillin in this subgroup may be beneﬁcial.
The SMM as presented in this paper relies on the
assumption of a linear relationship between adherence
(dose) and treatment efﬁcacy. The incorporation of
non-linear dose–response relationships into SMMs may
increase the applicability of these methods in clinical
trials, and is something that needs further attention.
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Appendices 
Appendix 1. Summary of concepts and motivation for randomisation-based efficacy estimators 
1. The importance of randomisation when inferring causal treatment effects 
 One of the key reasons we perform experiments is to determine the effect that a treatment 
has on some outcome of interest – the causal effect. 
 In general, we would like to infer these causal effects to the level of individuals. However, 
without simultaneously observing the effect of both giving and not giving treatment, we will 
never be able to calculate a true individual-level treatment effect. 
Figure 1: Illustration of an individual-level treatment effect 
 
 Instead, we calculate population-level (or average) treatment effects, where the average 
outcomes of individuals in the treated group are compared to those in the untreated group 
and we use this calculation as an estimate for the individual-level effects (that we only ever 
partially observe). 
 For this estimate to be valid, the choice to be in the treated / untreated group must be made 
at random. 
o If the choice is not made at random, the estimate is likely to be biased unless the 
decision to choose one group over the other (i.e. the selection mechanism) is fully 
measured and adjusted for. However, this is very unlikely to be the case in practice, 
where typically some variables that contribute to the selection mechanism are likely 
to remain unmeasured. 
Figure 2: Illustration of a population-level (average) treatment effect from a randomised experiment 
  
2. What does an Intention to Treat (ITT) analysis allow and what does it not allow? 
 ITT analysis allows for a comparison of groups as randomised, independent of both observed 
and (most importantly) unobserved confounders. It reflects the design of the trial and uses 
randomisation to avoid selection bias. To preserve randomisation, deviations following 
randomisation (such as lack of adherence to allocated treatment) are not adjusted for. 
 When all participants receive their allocated medication as intended, an ITT analysis 
provides an unbiased estimate of the effect of both prescribing and taking treatment. 
 When some participants do not receive their treatment as intended, an ITT analysis can only 
be guaranteed to provide an unbiased estimate of the effect of prescribing treatment. 
3. What is a per-protocol analysis and why is it usually inappropriate to perform in an RCT? 
 A per-protocol analysis generally only includes participants who followed study protocol as 
intended. Examples of protocol deviations could be: 
o Participant was incorrectly randomised 
o Being in the treatment arm and not taking treatment 
o Being in the control arm and taking treatment 
o Not providing follow-up data 
 A per-protocol analysis makes the assumption that analysed participants are equivalent to 
excluded participants (i.e. that the choice to deviate from protocol is made completely at 
random, or, if there is a selection mechanism, that it has been fully measured and adjusted 
for).  
 However, these exclusions occur post-randomisation, and as illustrated in Point 1, selection 
mechanisms that are not based on randomisation are likely to yield biased estimates of 
treatment effects. Therefore using a per-protocol population to estimate treatment effects 
in RCTs should usually be avoided. 
Figure 3: Illustration of per protocol analysis 
 
 
 
 
 
  
4. What are randomisation-based efficacy estimators and why are they generally a better approach? 
 Randomisation-based efficacy estimators (RBEE) compare the effect of treatment in those 
who were allocated to and adhered to treatment with those allocated to control who would 
have adhered to treatment (if allocated to the treatment arm). 
 Dependent on data type, there are many ways of calculating a RBEE, but most methods rely 
on the following core assumptions: 
1. Participants’ adherence/compliance-type is a latent trait, a baseline characteristic 
that is independent of randomisation. One way to think of RBEEs is as the ITT effect 
in the sub-group of participants who would always adhere to treatment. 
2. Due to randomisation, the proportion of participants classed as non-adherers will be 
the same in each group. 
3. In the absence of treatment, randomisation in and of itself has no effect on 
outcome. 
 By making these assumptions, observed adherence data can be used to classify individuals 
and obtain estimates of the effect of receiving treatment on outcome that are not prone to 
the selection bias commonly seen in traditional efficacy analyses. 
 While a binary definition of adherence is often used, this can either make the third core 
assumption implausible (by including participants in the non-adherent group that may have 
received some treatment and may therefore benefit from it) or involve a restrictive 
definition of adherence (e.g. took at least one tablet). 
 A continuous definition of adherence makes this third assumption plausible, as zero can 
represent those who received no treatment. However, the use of a continuous definition 
implies the additional assumption of a linear relationship between adherence and treatment 
effect, which is likely to have varying degrees of plausibility depending on setting. 
Figure 4: Illustration of randomisation-based efficacy estimator 
 
Appendix 2: Stata syntax for the structural mean models 
Structural mean model for “mean clinician-rated symptom severity between days two and four 
after initial presentation” outcome using two-stage least squares instrumental variables 
regression 
ivregress 2sls y c (x=z) 
In the syntax above, y = outcome, c = covariate, x = exposure, and z = randomisation indicator 
Generalised linear (double logistic) structural mean model for “development of new or worsening 
symptoms” and “presence of any non-respiratory symptoms” outcomes using generalised method 
of moments 
logit y x z 
matrix from = e(b) 
predict xblog, xb 
gmm (invlogit(xblog - x*{psi})-ey0), instruments(z) 
matrix from = (from, e(b)) 
gmm (y - invlogit({xb: x z} + {b0})) (invlogit({xb:} + {b0} - x*{psi}) - ey0), instruments(1:x z) 
instruments(2:z) winitial(unadjusted, independent) from(from) 
lincom[psi]_cons, eform 
estat overid 
In the syntax above, y = outcome, x = exposure, z = randomisation indicator, ey0 = mean exposure-
free potential outcome (to stabilise the model, this has been fixed as the proportion of people with 
positive outcomes in the control group. It can however be directly estimated from the model). This 
model requires an additional stage (an associational model) because collapsing the logistic SMM 
over observed exposure (z) depends on the distribution of z. It is therefore not possible to derive 
causal odds ratios in a single stage. The stages are first run individually to obtain initial values for the 
joint estimation. The stages are then run jointly to produce standard errors that correctly 
incorporate the error from the first stage of the model. 
  
Appendix 3: Additional sensitivity analysis with missing adherence data imputed 
The aim of this paper was to demonstrate how randomisation-based efficacy estimators can be used 
to produce unbiased adherence-adjusted estimates of benefits and harms from treatment with 
amoxicillin for patients consulting with an LRTI. The main effectiveness findings (reference 7 in the 
main manuscript) were used as the reference results. However, two participants did not have 
adherence data available for the symptom severity between days 2 and 4 post-randomisation and 
non-respiratory symptoms/side effects in the 4 weeks post-randomisation outcomes. A total of 104 
participants did not have adherence data available for the new or worsening symptoms in the 4 
weeks post-randomisation outcome. While the two former outcomes were collected via symptom 
diaries, the latter was collected from patient notes, and was consequently available for more 
participants. Table 2 in the manuscript suggests that the level of adherence in participants without 
self-reported diary or tablet count data was considerably lower (self-reported telephone data was 
primarily collected in those who did not return diaries). In the presence of missing adherence data, 
there may remain some residual bias. To understand how severe this bias could be (particularly, how 
low the odds ratio for new or worsening symptoms could be), Table 9 provides the findings of 
additional sensitivity analyses where participants with missing adherence data are assumed to have 
not taken any study medication (i.e. their adherence level is 0%). The findings demonstrate that 
making this most extreme assumption about missing adherence data did not alter the clinical 
conclusions that were drawn from the analyses. 
Table 9: Efficacy analysis with missing adherence data imputed as 0% 
Outcome 
Effectiveness* 
 
Effectiveness 
for whom 
adherence 
data were 
also 
available
†
 
Efficacy 
per 10% 
increase in 
adherence
†
 
Maximum 
efficacy 
(100% 
adherence)
†
 
Efficacy per 
10% 
increase in 
adherence*
§
 
Maximum 
efficacy 
(100% 
adherence)*
§
 
Adjusted 
between-group 
mean difference 
in symptom 
severity 
between days 2 
and 4 post-
randomisation 
-0.07 
(-0.15 to 0.01) 
-0.07 
(-0.15 to 
0.01) 
-0.008  
(-0.017 to 
0.001) 
-0.08  
(-0.17 to 
0.01) 
-0.008 
(-0.017 to 
0.001) 
-0.08  
(-0.17 to 
0.01) 
Odds ratio for 
developing new 
or worsening 
symptoms in 
the 4 weeks 
post-
randomisation 
0.79  
(0.63 to 0.99) 
0.81 
(0.64 to 
1.03) 
0.978 
(0.960 to 
0.998) 
0.81 
(0.66 to 
0.98) 
0.973 
(0.954 to 
0.994) 
0.76 
(0.62 to 0.94) 
Odds ratio for 
reporting non-
respiratory 
symptoms/side 
effects in the 4 
weeks post-
randomisation 
1.28 
(1.03 to 1.59) 
1.28 
(1.04 to 
1.59) 
1.028 
(1.011 to 
1.046) 
1.32 
(1.12 to 
1.57) 
1.028 
(1.011 to 
1.046) 
1.32 
(1.11 to 1.56) 
* Analysis based on 1789, 2027 and 1727 participants for the symptom severity, new symptoms and side effect outcomes 
respectively. † Analysis based on 1787, 1923 and 1725 participants for the symptom severity, new symptoms and side 
effect outcomes respectively. § Assuming those participants with missing adherence data did not take any medication (i.e. 
their adherence level is 0%). 
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Background
In the majority of randomised controlled trials (RCTs),
the primary goal is to investigate the superiority of one
treatment over another [1]. However, in some instances,
it can be sufficient to demonstrate that a treatment is no
worse than another on some outcome of interest. This is
particularly true where a standard treatment is already
in place (a so-called ‘active control’), and the new treat-
ment could offer substantial benefits on non-primary
outcomes such as reduce side effects, reduced costs,
simpler dosing regimen, etc. This is the purpose of a
non-inferiority (NI) trial, where the aim is to demon-
strate that a new treatment is no worse than a standard
treatment by more than an acceptable amount [2].
The ‘gold standard’ approach to analysis in a superior-
ity trial is based on the intention-to-treat (ITT)
principle, where participants are analysed in the groups
to which they were originally randomised [3]. This ap-
proach is favoured as it preserves randomisation and, in
the case of departures from randomised treatment,
makes treatment groups appear more similar; therefore,
producing a conservative estimate of treatment effect.
However, in a NI trial it is desirable for treatment groups
to be as similar as possible, and therefore an ITT
analysis is viewed as anti-conservative in this situation
[4, 5]. Current recommendations are that a per-protocol
(PP) analysis should be conducted alongside an ITT ana-
lysis for NI trials [6]. A PP analysis excludes participants
with departures from randomised treatment, but as-
sumes that the group of participants who are excluded
are similar to those who are included on both observed
and unobserved variables; an assumption that is usually
deemed implausible [7]. The ideal analytical method
would be based on participants who received the treat-
ment to which they were allocated, while maintaining a
comparison of groups as randomised (and thus not
prone to the selection biases that are common with a PP
analysis).
Randomisation-based efficacy estimators (RBEEs),
such as Structural Mean Models (SMMs), compare the
effect of treatment in the group of participants who were
allocated to and adhered to treatment with the group al-
located to receive control (or standard treatment) but
who would have adhered to treatment (had they been al-
located to the treatment group) [8]. The approach allows
for treatment non-adherence [9] while maintaining a
comparison of randomised groups. Fischer et al. have
developed an approach for estimating treatment efficacy
in randomised trials with two active treatments, a com-
mon feature of NI trials [10].
The aim of this paper is to demonstrate the use of
RBEEs in NI trials using the methods outlined by
Fischer et al., and to appraise the feasibility of these
estimators as the primary analysis in NI trials. A brief
introduction to randomisation-based efficacy estima-
tors will be given in ‘Methods section’, specifically
where the estimators are used in trials with two ac-
tive interventions. This section will also highlight gen-
eral steps to fitting these models using standard
statistical software, before concluding with a descrip-
tion of the studies used as examples in this paper.
‘Results section’ will present worked examples using
data from the studies described in ‘Methods section’,
while ‘Discussion section’ will summarise the work of
the previous sections and highlight the implications
of using these methods in practice.
Methods
Traditional approaches to deriving efficacy in RCTs
An ITT analysis is used to determine treatment effect-
iveness in RCTs [11, 12]. Under certain circumstances
(e.g. all participants receive all of the treatment to which
they were randomised), an ITT analysis can also be used
to estimate treatment efficacy. However, in the presence
of non-adherence, or departures from randomised treat-
ment, the most common approach to assessing treat-
ment efficacy in an RCT is to conduct a PP analysis.
This analysis excludes participants who are determined
to have not adhered to their randomised treatment.
However, it fails to maintain a comparison of groups as
randomised, and is therefore prone to selection bias
[11]. While selection bias is thought to be minimised in
trials with blinding, and modified definitions of these
populations that adjust for observed confounders can be
used, selection bias can never be completely discounted
from any analyses that make postrandomisation exclu-
sions or manipulations.
Structural Mean Models to derive randomisation-based
efficacy estimators
By recognising that at the beginning of a trial all partici-
pants have two potential outcomes – one if they are
treated and one if they are not, a SMM relates a treated
participant’s observed outcome to their (potentially
counterfactual) outcome that would have been observed
had they received no treatment [13]. Standard ap-
proaches to fitting a SMM rely on using observed expos-
ure, treating randomisation as an instrument (i.e.
assuming that it is independent of both observed and
unobserved confounders and only effects outcome
through its effect on exposure), and finding a value of
the treatment effect such that balance is achieved be-
tween groups on the outcome in participants who were
not treated [14].
By doing this it becomes possible to derive an estimate
of treatment efficacy (the effect that receiving treatment
has on outcome) that is not prone to the usual selection
biases usually found in traditional methods (Fig. 1).
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SMMs with two active treatments
Conventional SMM methodology is based on trials com-
paring an active treatment to no treatment (or a
placebo). However, in non-inferiority trials it is common
to just compare two active treatments – one experimen-
tal and one standard. This complicates matters, as with-
out a no-treatment group there is no observed outcome
on which to base the potential outcome in the untreated,
and therefore the method described above cannot be
readily applied.
By identifying baseline covariates that are differentially
associated with treatment adherence for each of the
treatments, the methodology developed by Fischer et al.
allows for the estimation of two distinct causal parame-
ters, from which a contrast can then be made. Identify-
ing baseline covariates that are differentially associated
with treatment adherence for each of the treatments,
but independent of outcome, allows separate sets of in-
struments to be derived for each treatment, and allows a
potential treatment-free response to be estimated [10].
If suitable baseline covariates are not identified, two
distinct causal parameters cannot be estimated. Despite
this, a linear contrast can still be made and the following
approaches can be taken:
 Fix adherence levels as the same in both arms, and
estimate the treatment efficacy in the subpopulation
that would always adhere to their treatment at that
given level
 Perform sensitivity analyses that vary adherence
parameters to explore the impact that differential
adherence levels has on outcomes
 Use standard SMM methods and consider the
standard treatment as the ‘placebo’ group. This will
allow for the comparison of average outcomes at
varying levels of the experimental treatment to the
average outcome if assigned to the standard
treatment (regardless of adherence levels to that
standard treatment)
Example studies
Two non-inferiority trials, whose data were available to
the authors, were used to illustrate the proposed
methods and its uses and limitations. Beyond the avail-
ability of data, the two studies described below were
chosen as they were both two-arm non-inferiority trials,
with two active treatments involving patients with long-
term conditions whose medication use was monitored
throughout the trial. The trials differ in terms of the na-
ture of the interventions being compared, with Colitis
Once Daily Asacol (CODA) comparing the same treat-
ment prescribed with different regimens, and Zoledronate
versus Ibandronate Comparative Evaluation (ZICE) com-
paring two different treatments with different modes of
administration. These examples, while contrasting, are
typical of the types of non-inferiority trials conducted and
will, therefore, provide useful insight into the methods
proposed.
The Colitis Once Daily Asacol (CODA) trial
The CODA trial was designed to assess the efficacy and
safety of once daily dosing (OD) versus three times daily
dosing (TDS) of mesalazine over a 12-month period for
patients in remission with ulcerative colitis. The study
concluded that the OD regimen was no worse than (non-
inferior to) the TDS regimen in terms of clinical relapse
using both an ITT and a PP analysis [15]. Research nurses
counted the number of tablets returned at each study visit,
and deducting this from the number of tablets issued de-
termined the number consumed during the study period.
Adherence to study medication in the original trial was
defined as participants consuming at least 75% of their is-
sued medication. A subset of participants also had their
medication adherence recorded using the Medication
Event Monitoring System (MEMS), an electronic monitor
that records the date and time of each bottle cap opening.
This substudy demonstrated that adherence to study
medication was generally lower and more varied for par-
ticipants allocated to the TDS regimen. However, as this
type of measure was not used for all trial participants, it
will not be considered further in this paper [16].
The Zoledronate versus Ibandronate Comparative
Evaluation (ZICE) trial
The ZICE trial was designed to assess whether orally ad-
ministered ibandronic acid (OIA) was non-inferior to
intravenously administered zoledronic acid (IZA) in pre-
venting skeletal-related events (SREs) in patients with
bone metastases from breast cancer. The study con-
cluded that orally administered ibandronic acid was in-
ferior to intravenously administered zoledronic acid in
both ITT and PP populations [17].
Adherence to study medication was noted by the treat-
ing clinician at interim and 12-weekly visits. Participants
were defined as having adhered to their allocated treat-
ment if the clinician recorded that study medication had
been administered as prescribed during all scheduled
visits. See Additional file 1 for more detail.
Fig. 1 Causal Directed Acyclic Graph (DAG) illustrating using
randomisation as an instrument to derive a randomisation-based
efficacy estimate
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Statistical methods
Outcomes
For the CODA trial, the outcome of interest was the pro-
portion of participants relapsing during the 12-month
study period. The OD regimen was considered to be non-
inferior to the TDS regimen as long as the lower bound of
the 95% confidence interval of the difference in the pro-
portion of participants in each arm relapsing (OD minus
TDS) did not include −0.1.
For the ZICE trial, the outcome of interest for this
paper was the proportion of participants experiencing a
SRE during the first 12 months of the study. This is a
simplified version of the primary outcome from the
main paper (time and frequency of SREs), and used for
illustration purposes only. There was, therefore, no pre-
specified non-inferiority margin for this outcome.
Modelling approach
Determining baseline covariates that differentially
predict adherence Deriving distinct causal estimators
for each treatment arm relied on identifying baseline
variables that predicted adherence to treatment differ-
ently in each arm, while not predicting clinical outcome.
Determining these predictors involved two main steps.
First, multivariable logistic regression was used to deter-
mine the factors that predicted clinical outcome. Vari-
ables that were identified univariably at the 20%
significance level were entered into the multivariable
model, with backward selection used to retain variables
independently associated at the 10% significance level.
Following this, multivariable logistic regression was
used, with the binary adherence variable as the outcome.
Predictors of adherence were entered one-by-one into a
regression model that included trial arm, and interaction
between candidate predictor and trial arm, and the pre-
dictors of clinical outcome that were identified during
the previous step. Any variables that were associated
with adherence at the 20% significance level, as either a
main effect or as an interaction with trial arm, were
retained in the multivariable regression model. Predic-
tors that remained associated at the 10% significance
level were then retained in the final regression model.
For the CODA trial, the candidate baseline predictors
used in the outcome and adherence models were age
(<65, ≥65 years), age at diagnosis (≤25, 26–45, 46–64,
≥65 years), gender, length of remission (<12 months,
≥12 months), calprotectin concentration (<60 mg/kg stool,
≥60 mg/kg stool), smoking status (never smoker, current
smoker, ex-smoker), employment status (unemployed,
employed), maximum documented extent of colitis
(extensive, left-sided or sigmoid, proctitis), disease
duration (≤10 years, 11 to 20 years, >20 years), num-
ber of relapses during the past 2 years (1, 2, 3, ≥4),
and endoscopy findings (normal, not normal).
For the ZICE trial, the predictors were age, gender,
Body Mass Index (BMI), the modified Brief Pain
Inventory severity score, quality of life (EORTC QLQ-
C30 score version 3.0), SRE within the previous
3 months, previous use of bisphosphonates, treatments
being received (including painkilling drugs, chemother-
apy, hormone therapy, and trastuzumab).
Variables that were included in the models were
checked for notable deviations from linearity. While the
relationship between age and outcome in the CODA
trial was considered non-linear, this was not the case for
the ZICE trial. A cut-off of 65 years was chosen to distin-
guish between elderly/non-elderly participants (see http://
www.who.int/healthinfo/survey/ageingdefnolder/en/).
Fitting the structural mean model The SMM models
were fitted using a two-stage, least squares, instrumental
variables regression approach. Using this procedure, the
trial arm (the instrument), predictors of outcome, and dif-
ferential predictors of adherence were used to estimate
values of the adherence variables in the first stage. These
values were then regressed onto the outcome in the sec-
ond stage. These regressions were fitted simultaneously in
order to avoid standard errors that were artificially large.
The Huber-White robust standard error, with additional
correction for small samples, was used in order to make
correct inferences about the differences in proportions
[18]. Table 1 provides sample syntax using Stata (v13.0).
Table 1 Sample Stata (v13.0) syntax of the structural mean
models described in ‘Methods section’ and fitted in ‘Results
section’
The Colitis Once Daily Asacol (CODA) trial
ivregress 2sls < <Outcome> > (<<Adherence indicator> > = < <Trial arm
indicator>>), vce(robust)
The Zoledronate versus Ibandronate Comparative Evaluation (ZICE) trial
ivregress 2sls < <Outcome> > <<Predictors of outcome> > <<Predictors
of adherence> > (<<Adherence in experimental arm> > <<Adherence in
standard treatment arm> > = < <Trial arm indicator> > <<Predictors of
outcome> > <<Trial arm * Predictors of outcome interactions> >
<<Predictors of adherence> > <<Trial arm * Predictors of adherence
interaction>>), vce(robust)
lincom[<<Experimental treatment arm effect> > - < <Standard treatment
arm effect>>]
For the CODA trial, the adherence indicator was one variable that was
1 if the participant was allocated to the OD arm (experimental
intervention) and adhered, 0 if they were allocated to the OD arm and
did not adhere, and also 0 if they were allocated to the TDS arm
(standard care).
For the ZICE trial, as distinct causal parameters were identifiable, each
arm had its own variable to denote adherence. This variable was 1 if
the participant was allocated to the arm and adhered, 0 if they were
allocated to the arm and did not adhere, and 0 if they were allocated to
the other arm.
OD once daily, TDS three times daily
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Results
The CODA trial
The analysis is based on 188 randomised participants
with outcome data. In total, 174 participants adhered to
their study medication (92.6%), with these making up
the PP population (Fig. 2). The percentage of partici-
pants adhering to study medication was higher in those
randomised to the intervention arm compared to the ac-
tive control arm (95.7% and 89.4%, respectively).
Overall, 56 participants relapsed within the 12-month
follow-up period (29.8% of all participants). The percent-
age of participants who relapsed was lower in the inter-
vention arm compared to the active control arm (24.5%
and 35.1%, respectively). The main trial analysis based
on complete cases demonstrated that the relapse rate
was 10.6 percentage points higher in those randomised
to the TDS arm compared to in the OD (95% confidence
interval (CI): −2.5 to 23.8 percentage points). As the
lower limit of the 95% CI did not include −10%, and this
was also confirmed in the PP analysis, the findings con-
firmed the non-inferiority of the OD regimen compared
to the TDS regimen.
Predictors of outcome
Predictors of relapse were age (participants aged 65 years
or older had decreased odds of relapsing during the
follow-up period), length of remission (participants in
remission for at least 12 months had decreased odds of
relapsing during the follow-up period), and endoscopy
findings at baseline (participants with non-normal en-
doscopy findings at baseline had increased odds of re-
lapsing during the follow-up period) (Table 2).
Predictors of adherence
When conditioning on the above variables, smoking sta-
tus at baseline was the only variable that remained inde-
pendently associated with participants adhering to their
study medication at the 10% significance level (Table 3).
Compared to non-smokers, the odds of participants ad-
hering to their study medication was higher in those
who were ex-smokers. However, smoking status did not
differentially predict adherence across the two arms (i.e.
the interaction between smoking status and trial arm
was not statistically significant).
Structural mean model
It was not possible to derive two distinct causal parame-
ters based on observed data, as there were no baseline
variables differentially associated with adherence for
each of the arms. Given that the definition of adherence
was binary, the only sensible analysis was to consider the
standard treatment (active control) as the ‘placebo’
group and use standard SMM methods.
Fig. 2 Flow diagram describing data available for each type of analysis in the Colitis Once Daily Asacol (CODA) trial
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The SMM analysis found that after adjusting for ad-
herence, the relapse rate was 11.1 percentage points
higher in those randomised to intervention. The 95% CI
did not contain −10% (95% CI −2.5 to 24.7 percentage
points), and non-inferiority could be confirmed based on
this analysis (Fig. 3).
The ZICE trial
The analysis is based on 1037 randomised participants
with outcome data. In total, 621 of 915 participants with
adherence data adhered to their study medication
(67.9%), with these making up the PP population. The
percentage of participants adhering to study medication
was higher in those randomised to the OIA arm com-
pared to the IZA arm (77.4% and 60.7%, respectively).
Baseline covariate data were available for 796 partici-
pants. This made up the SMM population (Fig. 4).
Overall, 382 participants experienced an SRE within
the 12-month follow-up period (36.8% of all partici-
pants). The percentage of participants who experienced
an SRE was higher in the OIA arm compared to the IZA
arm (38.3% and 35.4%, respectively). The trial analysis
based on complete cases demonstrated that the SRE rate
was 3.0 percentage points higher in those randomised to
the OIA arm compared to in the IZA (95% confidence
interval (CI) −2.9 to 8.8 percentage points) and con-
cluded that OIA was inferior to IZA.
Predictors of outcome
The odds of experiencing an SRE within the first
12 months of the study were higher in participants with
higher BMI scores, in participants who had poor role
functioning, worse nausea/vomiting symptoms, had ex-
perienced an SRE in the 3 months prior to the study, or
had recently used pain medication. The odds of experi-
encing an SRE within the first 12 months of the study
were lower in women than in men, in participants with
higher overall general health, and in participants with in-
creasing dyspnoea (Table 4).
Predictors of adherence
After conditioning on the above, both cognitive func-
tioning and use of chemotherapy were independently
associated with adhering to study medication differ-
ently in the two arms (Table 5). The results from the
model suggest that the odds of adhering to study
medication are:
 Higher for participants allocated to the OIA arm,
with the lowest levels of cognitive functioning, and
not undergoing chemotherapy at baseline
 Higher as cognitive functioning increases for
participants allocated to the IZA arm
 Lower as cognitive functioning increases for
participants allocated to the OIA arm
 Higher for participants undergoing chemotherapy at
baseline and allocated to the IZA arm
 Lower for participants undergoing chemotherapy at
baseline and allocated to the OIA arm
 BMI Body Mass Index, IZA Intravenously
administered zoledronic acid, OIA Orally
administered ibandronic acid OIA, QLQ-C30
EORTC QLQ-C30 score version 3.0, SRE Skeletal-
related event,
Table 2 Multivariable determinants of outcome in the Colitis Once Daily Asacol (CODA) trial (odds of relapsing during the 12-month
follow-up period)
Variable Adjusted odds
ratio
95% Confidence interval p value
Lower Upper
Age at baseline (≥65 compared to <65 years) 0.30 0.10 0.88 0.028
Length of remission (≥12 compared to <12 months) 0.34 0.14 0.81 0.014
Endoscopy findings at baseline (non-normal compared to normal) 4.14 2.04 8.39 <0.001
Table 3 Multivariable determinants of adhering to medication in the Colitis Once Daily Asacol (CODA) trial
Purpose Variable Adjusted odds
ratio
95% Confidence
interval
p value
Lower Upper
Associated with disease status at
12 months (relapsed/still in remission)
Intervention (OD arm compared to TDS arm) 2.61 0.75 9.03 0.131
Age at baseline (≥65 years compared to <65 years) 2.42 0.27 21.70 0.430
Length of remission (≥12 months compared to <12 months) 1.05 0.29 3.75 0.940
Endoscopy findings at baseline (non-normal compared to normal) 0.31 0.10 1.01 0.053
Associated with adherence to study
medication
Smoking status at baseline (current smoker compared to non-smoker) 1.31 0.25 6.79 0.076
Smoking status at baseline (ex-smoker compared to non-smoker) 11.46 1.40 94.01
OD once daily, TDS three times daily
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Structural mean model
Distinct causal parameters could be estimated using the
ZICE data, and therefore the difference between the two
arms could be calculated. After adjusting for treatment
adherence, the proportion with SRE in the first
12 months was no different in either of the arms (differ-
ence in proportions 0.0, 95% CI −13.9 to 13.8 percentage
points). While the point estimate from the SMM was
closer to no difference, the width of the confidence
interval contains any non-inferiority margin that could
be justified (Fig. 5).
Discussion
Summary of paper
This paper investigated the use of randomisation-based
efficacy estimators in non-inferiority trials. Structural
mean models were fitted using a method proposed by
Fischer et al., where baseline variables that predicted ad-
herence differentially were sought to derive causal esti-
mators in each treatment arm. This method was applied
to two datasets from clinical trials involving patients in
remission with ulcerative colitis (CODA) and breast can-
cer with bone metastases (ZICE) using standard statis-
tical software. In the CODA trial, it was not possible to
derive distinct estimators, and standard SMM methods
were applied instead, treating the active control arm in
the same way that a placebo arm would be treated. This
analysis was consistent with the ITT and PP findings (i.e.
there was evidence to suggest that OD was not inferior
to TDS in terms of preventing relapse). In the ZICE trial
it was possible to derive distinct estimators, and when
comparing the arms the point estimate implied no dif-
ference in SRE rates between the arms, but the confi-
dence intervals were considerably wider than the ITT
and PP analyses.
Strengths and weaknesses of the approach
To our knowledge, this is the first paper to demon-
strate the potential use of randomisation-based efficacy
Fig. 3 Forest plot of the difference in relapse rates in the Colitis
Once Daily Asacol (CODA) trial for various analysis sets
Fig. 4 Flow diagram describing data available for each type of analysis in the Zoledronate versus Ibandronate Comparative Evaluation (ZICE) trial
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Table 4 Multivariable determinants of outcome in the Zoledronate versus Ibandronate Comparative Evaluation (ZICE) trial (odds of
experiencing a skeletal-related event during the first 12 months)
Variable Adjusted odds
ratio
95% Confidence
interval
p value
Lower Upper
Gender (female compared to male) 0.23 0.06 0.88 0.032
18.5 kg/m2 < BMI≤ 25 kg/m2 (normal/healthy weight) compared to≤ 18.5 kg/m2 (underweight) 6.16 0.75 50.65 <0.001
25 kg/m2 < BMI≤ 30 kg/m2 (overweight) compared to≤ 18.5 kg/m2 (underweight) 6.85 0.84 56.13
30 kg/m2 < BMI≤ 35 kg/m2 (moderately obese) compared to≤ 18.5 kg/m2 (underweight) 13.17 1.59 108.81
35 kg/m2 < BMI≤ 40 kg/m2 (severely obese) compared to≤ 18.5 kg/m2 (underweight) 6.99 0.81 60.39
BMI > 40 kg/m2 (very severely obese) compared to≤ 18.5 kg/m2 (underweight) 13.11 1.44 119.65
QLQ-C30 global health domain (per unit increase) 0.98 0.98 0.99 0.001
QLQ-C30 role functioning domain (per unit increase) 1.01 1.00 1.02 0.005
QLQ-C30 nausea / vomiting domain (per unit increase) 1.01 1.01 1.02 <0.001
QLQ-C30 dyspnoea domain (per unit increase) 0.99 0.99 1.00 0.056
SRE within the three months prior to baseline compared to no SRE within three months prior to baseline 1.56 1.14 2.13 0.006
Recent use of pain medication at baseline compared to no recent use of pain medication 1.63 1.08 2.46 0.019
Table 5 Multivariable determinants of adhering to medication in the Zoledronate versus Ibandronate Comparative Evaluation (ZICE) trial
Purpose Variable Adjusted odds
ratio
95% confidence
interval
p value
Lower Upper
Associated with the development of a
SRE within 12 months
Gender (female compared to male) 1.29 0.36 4.55 0.697
18.5 kg/m2 < BMI≤ 25 kg/m2 (normal/healthy weight) compared
to≤ 18.5 kg/m2 (underweight)
2.19 0.74 6.47 <0.001
25 kg/m2 < BMI≤ 30 kg/m2 (overweight) compared to
≤ 18.5 kg/m2 (underweight)
2.05 0.70 6.00
30 kg/m2 < BMI≤ 35 kg/m2 (moderately obese) compared to
≤ 18.5 kg/m2 (underweight)
2.35 0.79 7.03
35 kg/m2 < BMI≤ 40 kg/m2 (severely obese) compared to
≤ 18.5 kg/m2 (underweight)
3.07 0.95 9.95
BMI > 40 kg/m2 (very severely obese) compared to≤ 18.5 kg/m2
(underweight)
3.90 1.06 14.31
QLQ-C30 global health domain (per unit increase) 1.00 1.00 1.01 0.358
QLQ-C30 role functioning domain (per unit increase) 1.00 1.00 1.01 0.300
QLQ-C30 nausea/vomiting domain (per unit increase) 1.01 1.01 1.02 0.000
QLQ-C30 dyspnoea domain (per unit increase) 1.00 0.99 1.00 0.547
SRE within the 3 months prior to baseline compared to no SRE
within 3 months prior to baseline
1.07 0.79 1.46 0.660
Recent use of pain medication at baseline compared to no
recent use of pain medication
0.65 0.45 0.94 0.021
Differentially associated with adherence
by trial arm
Orally administered ibandronic acid arm (main effect) 5.77 2.05 16.26 0.001
QLQ-C30 cognitive functioning (main effect) 1.01 1.00 1.02 0.005
Orally administered ibandronic acid arm x QLQ-C30 cognitive
functioning (interaction)
0.99 0.98 1.00 0.061
Use of chemotherapy at baseline (main effect) 2.12 1.28 3.53 0.004
Orally administered ibandronic acid arm x Use of chemotherapy
at baseline (interaction)
0.47 0.22 1.02 0.057
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estimators as a primary analysis in non-inferiority trials.
Data from two non-inferiority trials were used, and the
strengths and limitations of RBEEs and SMMs using the
method proposed by Fischer et al. when applied to real-
world data were established.
Both studies captured adherence to treatment differ-
ently. In the CODA trial, adherence was captured using
tablet counts and in the ZICE trial adherence was cap-
tured using self-report and hospital attendance data.
These methods have been demonstrated to over-
estimate adherence in certain circumstances, [19–21]
but they are methods that are cheap and easy to apply in
large-scale randomised controlled trials, so are likely to
reflect the type of data obtained in other settings (as op-
posed to more direct methods or electronic monitoring).
The ZICE trial used a simplified version of the original
primary outcome in order to illustrate the use of these
methods. One consequence of this is that while a non-
inferiority margin was defined for the original primary
outcome, one was not defined for the simplified version.
While this could have limited the interpretation of this
analysis, the confidence intervals were too wide for any
NI margin to be justified, even post hoc (given that the
original trial analysis suggested inferiority, this was a
simplified outcome that would have had lower power
than a recurrent event outcome, and the confidence
interval of the SMM analysis was over twice as wide as
the ITT and PP analyses).
Both studies took adherence as a quantitative measure
and dichotomised it. While this was necessary for defin-
ing the analysis set, it was an approach that meant a loss
of information with regards to the extent to which par-
ticipants adhered to treatment. Using a binary definition
of adherence (≥75%/<75% for the CODA trial and full
versus not full for the ZICE trial) meant that the exclu-
sion restriction was less likely to be plausible [14]. How-
ever, choosing an arbitrary lower threshold would have
yielded estimates that were difficult to interpret, and
treating adherence as a quantitative measure would have
meant the additional assumption of a linear relationship
between treatment adherence and treatment effect [22].
Participants with missing outcome or adherence data
may have induced some selection bias in the findings
presented. However, adjustments for missing data (e.g.
with multiple imputation) tend to be used as secondary/
sensitivity analysis in trials [23], and the purpose of this
paper was to demonstrate the use of RBEEs as the main
analysis in NI trials. An assessment of the impact of
missing data on the interpretation of the SMM analysis
can be seen in Additional file 1. Additionally, other vari-
ables that were not recorded in sufficient detail that may
have influenced adherence to trial treatments, clinical
outcomes, and/or dropout include the use of rescue
medication and other medication that was added to a
patient’s treatment plan part way through the study.
It was also decided to present an approach that could
be adopted more readily, hence the use of modified least
squares (MLS) for a binary outcome, rather than deriv-
ing estimates using a generalised method of moments
approach [24].
Comparisons to existing trials literature
A recently published paper investigating the comparative
efficacy of two different antidepressants was the first to
demonstrate the practical implementation of the SMM
approach as outlined by Fischer et al. [25]. However, this
approach is particularly appropriate for non-inferiority
trials (as indicated in the abovementioned paper), and
thus our publication complements this work by imple-
menting this SMM approach in two non-inferiority tri-
als. One other study has reportedly implemented this
approach on a non-inferiority trial [26]. However, as this
was a placebo-controlled trial, and the paper detail of
the approach was lacking, it was unclear whether they
applied standard SMM methodology or the extended
work described by Fischer et al. Therefore, to our know-
ledge, this is the first publication to demonstrate how
this approach works in practice for non-inferiority trials
with two active interventions.
Implications for researchers
Structural mean models could replace traditional efficacy
analyses that are often reported alongside an ITT ana-
lysis in non-inferiority trials. However, this paper high-
lights the increase in variance experienced when fitting
these models, something that can only be reduced when
the models include strong predictors of adherence and
outcome. Use of the method is more accurate in terms
of reducing selection bias, but is likely to be less precise,
and increases the importance of collecting relevant and
complete baseline variables. To do this, the research
team must have a good understanding of the predictors
of outcome, and also the barriers/facilitators to adhering
Fig. 5 Forest plot of the difference in the proportion with skeletal-
related event (SRE) in the first 12 months in the Zoledronate versus
Ibandronate Comparative Evaluation (ZICE) trial for various analysis sets
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to the randomised treatments. Studies with feasibility/
pilot stages could explore these aspects, as well as how
best to capture this data, before progressing onto more
definitive studies. The significance thresholds for inclusion
of variables in this paper were higher than current prac-
tice. Future studies that collect strong baseline predictors
of adherence need not use such high significance levels.
Estimating efficacy in randomised trials is valuable, as
it answers a more patient-centred question than can be
answered by an estimate of effectiveness. That is, “what
is the effect if I take this treatment?”, rather than the
more health care professional-centred question “what is
the effect if I offer this treatment?” Both questions are
useful, but for a patient trying to understand the effect
of a treatment, the more pertinent of the two questions
relates to efficacy rather than effectiveness.
By modelling the determinants of differential adher-
ence in the different treatment arms, researchers will
also gain an understanding of the circumstances under
which the treatments will be better received by patients
and, therefore, more likely to work. For example, in the
ZICE study, we were able to demonstrate that for partic-
ipants allocated to the intravenously administered zole-
dronic acid arm, adherence was higher for patients with
higher cognitive function and for those receiving chemo-
therapy at baseline. Whereas for those allocated to the
orally administered ibandronic acid arm adherence was
lower for patients with lower cognitive function and for
those receiving chemotherapy at baseline. One explan-
ation for this could be that patients with low cognitive
function could have their medicines dispensed by a care
giver, which is likely to reduce forgetfulness and increase
adherence. Patients receiving chemotherapy at baseline
will be attending hospital regularly for these visits, and
the delivery of IZA often coincided with other hospital
visits for cancer therapy, thereby increasing their
chances of receiving IZA treatment. The implications of
this, regardless of the comparative efficacy of the treat-
ments themselves, could be that IZA should be offered
to those undergoing additional cancer treatments (or
any other treatments that require regular hospital visits).
OIA could be offered along with an additional interven-
tion to increase adherence (e.g. a reminder or monitor-
ing system), or in instances where patients were not in
control of their own medication dispensing (e.g. elderly
residents of nursing homes).
Potential extensions and future work
By extending this methodology to allow for different
types of outcome (e.g. binary, count, survival), this
approach could be more widely used. For example, the
primary analysis in the ZICE trial was based on an
Anderson-Gill model (survival model with recurrent
events) [27].
While not as necessary here, as a binary definition of
treatment receipt is required to define an analysis set,
methods of RBEEs that allow for non-linear relationships
between an increase in adherence and treatment effects
would be useful for capturing the complexity of some
dose-response relationships more accurately.
Finally, further work is needed in order to incorporate
necessary adjustments into sample size calculations for
the design of trials that wish to use these methods as
more than an exploratory analysis. Adjustments will
likely depend on the proportion of non-adherence, as
well as the number and strength of baseline predictors/
instruments that are likely to be identified.
Conclusions
In NI trials, RBEEs can provide a randomisation-
respecting estimate of treatment efficacy that accounts
for treatment adherence, addressing the deficiencies of
both ITT and PP analysis for this study design. For NI
trials involving two active treatments, RBEEs can also be
modelled, remain straightforward to implement using
standard statistical software, but require thorough plan-
ning during the design stage of the study to ensure that
strong baseline predictors of treatment are captured.
Additional file
Additional file 1: Data assumptions made for the ZICE trial. Descriptions
of how the adherence and outcome data were derived for the ZICE
study. Sensitivity analysis exploring the impact of missing data on the
interpretation of the SMM analysis in the ZICE trial. (DOCX 20 kb)
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Additional material: 1 
1. Full description of determining medication adherence in the ZICE study 2 
Questions about adherence to study medication were asked at three initial interim visits, and then 3 
subsequently at 12-weekly visits. 4 
Missing visit patterns were inspected, with the view to calculate adherence levels only in those with 5 
complete visit data up until the point of an event, withdrawal, death, or the end of the first 12 months.  6 
For participants allocated to intravenous zoledronic acid: 7 
 Adherence to intravenous zoledronic acid was based on interim and 12-weekly visit data, as 8 
participants were required to attend to receive intravenous medication. It was assumed that 9 
participants did not adhere to study medication if they either did not attend a scheduled visit, 10 
or attended but were noted as not receiving study medication as prescribed during at least 11 
one visit. 12 
For participants allocated to oral ibandronic acid: 13 
 Interim visits were primarily arranged so that participants allocated to intravenous zoledronic 14 
acid could receive their medication. Participants in the oral ibandronic acid arm were also 15 
invited to attend interim visits to minimise the likelihood that an increase in clinical contact in 16 
one arm could impact on trial findings. However, as it was not necessary for participants in 17 
this arm to attend visits to receive medication, and non-attendance at one or more interim 18 
visit was high, adherence to oral ibandronic acid was based on 12-weekly visit data only. It 19 
was assumed that participants did not adhere to study medication if they were noted as not 20 
receiving study medication as prescribed during at least one visit. 21 
Adherence data were available for 1164 participants. 22 
 23 
2. Full description of determining outcome (a skeletal-related event within the first 12 months) in 24 
the ZICE study 25 
The outcome used for the ZICE study in this paper is the occurrence of a skeletal-related event (SRE) 26 
by the end of the 12 month post-randomisation follow-up period. Based on the available data (up to 27 
the end of the trial), participants were classed as one of the following: 28 
 Reported an SRE within the first 12 months (YES) 29 
 Reported an SRE after the first 12 months (NO) 30 
 Alive at the end of the follow up period, no SRE reported (NO) 31 
 Died after the end of the 12 month follow-up period, did not report an SRE in the first 12 32 
months (NO) 33 
 Died before the end of the 12 month follow-up period, no SRE reported (MISSING) 34 
 Withdrew after the end of the 12 month follow-up period, did not report an SRE in the first 35 
12 months (NO) 36 
 Withdrew before the end of the 12 month follow-up period, no SRE reported (MISSING) 37 
SRE outcome data were available for 1037 participants. 38 
 39 
 40 
 41 
 42 
 43 
 44 
 45 
 46 
3. Impact of missing data on the interpretation of the SMM analysis 47 
Applying a basic imputation method meant that the predictors I had originally found were no longer 48 
statistically significant. I was therefore unable to apply the SMM method as I had originally. Another 49 
approach I took, was to restrict the ITT and PP analysis to those who also feature in the SMM analysis. 50 
However, this changes the point estimates as well as widening the confidence intervals slightly 51 
(Additional Figure 1). 52 
 53 
Additional Figure 1: Impact of missing data on the interpretation of the SMM analysis 54 
 55 
*Intention-to-treat n = 1037; Per-protocol n = 621; Structural mean model n = 796 56 
†Analysis performed in participants who were included in the structural mean model analysis. 57 
Intention-to-treat n = 796; Per-protocol n = 536 58 
-15 -10 -5 0 5 10 15
Per-protocol†
Intention-to-treat†
Structural mean model*
Per-protocol*
Intention-to-treat*
Higher rate in IZA arm            Higher rate in OIA arm
Difference in SRE rates after 12 months
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Aim: To investigate the determinants of adherence to amoxicillin in patients with acute lower 
respiratory tract infection.
Materials and methods: Three European data sets were used. Adherence data were collected 
using self-reported diaries. Candidate determinants included factors relating to patient, condition, 
therapy, health care system/provider, and the study in which the patient participated. Logistic 
and Cox regression models were used to investigate the determinants of initiation, implementa-
tion, and discontinuation of amoxicillin.
Results: Although initiation differed across samples, implementation and discontinuation 
were similar. Determinants of initiation were days waited before consulting, duration of 
prescription, and being in a country where a doctor-issued sick certificate is required for being 
off work for ,7 days. Implementation was higher for older participants or those with abnormal 
auscultation. Implementation was lower for those prescribed longer courses of amoxicillin 
($8 days). Time from initiation to discontinuation was longer for longer prescriptions and 
shorter for those from countries where single-handed practices were widespread.
Conclusion: Nonadherence to amoxicillin was largely driven by noninitiation. Differing sets of 
determinants were found for initiation, implementation, and discontinuation. There is a need to 
further understand the reasons for these determinants, the impact of poor adherence to antibiotics 
on outcomes, and to develop interventions to improve antibiotic use when prescribed.
Keywords: adherence, antibiotics, general practice, determinants
Introduction
Lower respiratory tract infections (LRTIs), characterized by acute cough, account 
for approximately one-fifth of all consultations in primary care, and the majority of 
patients who consult are prescribed antibiotics.1,2 However, adherence to antibiotics 
in primary care is often poor.3,4 This wastes health care resources,5,6 could nega-
tively impact on clinical outcomes,7 and could result in infecting bacteria being 
exposed to sub-optimal levels of treatment; creating an environment that promotes 
antibiotic resistance.8
With concerns growing about the consequences of increasing levels of antimicrobial 
resistance,9 interventions that effectively promote the appropriate use of antibiotics 
are important. Although most antibiotic stewardship programs have focused on 
reducing antibiotic use,10,11 less attention has been paid to ensuring that antibiotics are 
appropriately used when prescribed. Interventions for improving adherence are likely 
to be most effective if they are informed by an understanding of the determinants of 
sub-optimal adherence. These determinants may operate on multiple levels to impact 
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on whether a patient adheres to a prescribed treatment, and 
therefore large, detailed data sets are required to accurately 
quantify these influences.
Adherence may be defined as “the process by which 
patients take their medicine as prescribed”.12 Traditionally, 
this has been represented quantitatively as a single variable 
(eg, percentage of medicine taken as prescribed and a binary 
taken as prescribed or not). However, recent work in this 
field encourages the use of the distinct processes involved 
in taking medicine, namely, initiation, implementation, and 
discontinuation.13 Each individual process may have its own 
determinants and influences on outcomes. Therefore, dif-
ferent interventions may be required to address each of the 
adherence processes.
In this paper, we aim to investigate the determinants of 
initiation, implementation, and discontinuation of amoxi-
cillin by adults consulting with an acute LRTI in European 
primary care.
Materials and methods
studies, patients, settings, and inclusion 
criteria for analysis
Data were used from three studies conducted as part of 
the Genomics to combat Resistance against Antibiotics in 
Community-acquired LRTI in Europe (GRACE) Network 
of Excellence research program.14 All three studies recruited 
adult patients aged $18 years consulting with an acute 
LRTI/cough in primary care and are described in detail 
elsewhere. In brief, Study 1 was a prospective cohort 
study conducted in 13 European countries between 2006 
and 2007;1 Study 2 was an observational study on the 
etiology, diagnosis, and prognosis of LRTI conducted in 
12 European countries between 2007 and 2010;15 and Study 3 
was a placebo-controlled trial of amoxicillin nested within 
Study 2.16 Following an initial consultation with a clinician, 
participants in all three studies were given a diary that 
recorded symptoms, medication use, and health care contacts. 
Participants were asked to complete their diary for 28 days. 
All three studies collected data using similar case report 
forms (CRFs) and patient diaries. Study participants were 
included in analysis if they were prescribed amoxicillin 
for immediate use at their initial consultation (defined as 
being prescribed amoxicillin and not advised to delay, as 
recorded on the CRF) and it was possible to ascertain adher-
ence measures using self-reported diary data. The present 
study focuses on the use of amoxicillin only, as this is the 
recommended first-line antibiotic for LRTI in the European 
Union.17 In Studies 1 and 2, participants who were prescribed 
antibiotics other than amoxicillin were excluded. In Study 3 
(the trial), amoxicillin was the only antibiotic prescribed.
Definition of adherence elements
initiation
Participants were defined as having initiated their amoxicillin 
if they indicated in their diary that they took amoxicillin at 
least once during the 28 day follow-up period.
implementation
In participants who initiated their amoxicillin, implementa-
tion describes the extent to which the prescription was taken 
as prescribed among those who initiated their amoxicillin. 
For the purpose of this paper, it is defined as the proportion 
of amoxicillin reportedly taken during the prescribed period. 
For example, if a participant was prescribed amoxicillin for 
5 days and only reported taking it for 4 days during the first 
5 days of the follow-up period, their implementation score 
would be 0.8 (ie, they initiated their amoxicillin course and 
took 80% of it during the prescribing period).
Discontinuation
Participants were defined as having discontinued their 
amoxicillin prescription if they initiated their prescription and 
subsequently reported a full week of not taking their medicine. 
A gap of 1 week was deemed appropriate in distinguishing 
between patients who stopped and restarted their medicine 
and those who were prescribed a new course of amoxicillin. 
The first day of that 1-week gap was defined as the day they 
discontinued, and the time to discontinuation was calculated 
as the difference in days between the day of discontinuation 
and the day of initiation. For example, if a participant was 
prescribed a 7-day course of amoxicillin, initiated their 
amoxicillin on day 3, and days 10–17 were the first full week 
where no amoxicillin was reportedly taken, they would be 
defined as having discontinued on day 10, and their time from 
initiation to discontinuation would be 7 days.
candidate determinants
Determinants related to the patient, illness, prescription, 
and health care setting were investigated. A full description 
of the candidate determinants is given in the online supple-
mentary materials.
statistical analysis
Descriptive statistics were reported as numbers and 
percentages, means and standard deviations (SDs), or 
medians and interquartile ranges (IQRs), as appropriate. 
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
1.
25
1.
25
4.
15
0 
on
 3
0-
M
ar
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Patient Preference and Adherence 2017:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
563
Determinants of adherence to amoxicillin in patients with acute cough
Findings in all descriptive tables are presented both overall 
and separately for each study.
A three-level logistic regression model was fitted to 
investigate the determinants of initiation, with participants 
nested within clinicians nested within countries.
To investigate the determinants of implementation, a 
multilevel logistic regression model was fitted to participants 
who had initiated amoxicillin. The model allowed for 
clustering at four levels, specifically, days nested within 
participants nested within clinicians nested within countries. 
This approach, therefore, modeled implementation as the 
probability of correctly implementing on a given day.
A Cox proportional hazards model18 was fitted to investi-
gate the determinants of time from initiation to discontinua-
tion. The standard errors from this model were corrected for 
the clustering of participants within clinicians.
Throughout, results are presented in terms of odds ratios 
(ORs), hazard ratios (HRs), and associated 95% confidence 
intervals (CIs), as appropriate. Variables were entered into a 
univariable model and retained if they were significant at the 
P,0.1 level. Variables in the multivariable model that were 
not significant at the P,0.05 level were removed sequentially, 
from largest to smallest P-value, until a final multivariable 
model was attained. The study from which a participant pro-
vided data was used in all models (both univariable and mul-
tivariable) to ensure that any association was not confounded 
by the characteristics of participants from different studies.
For initiation and implementation, the clinician and 
country-level intracluster correlation coefficients (ICCs) 
were calculated to demonstrate the proportion of variation in 
initiation/implementation that was attributable to differences 
between clinicians and countries. Some clinicians partici-
pated in more than one of the three studies, and where this 
was the case their identifier was linked across studies.
Data management and descriptive statistics were con-
ducted using Statistical Package for the Social Sciences, 
version 20 (IBM Corporation, Armonk, NY, USA).19 All 
other analyses used Stata version 13.20
ethical approval
The original studies were approved by ethics committees 
in all participating countries. The work carried out in this 
paper remains sufficiently within the remit of those origi-
nal approvals.
Results
Descriptive statistics
number of participants, clinicians, and primary care 
networks
In total, data were available for 1,346 participants prescribed 
amoxicillin for immediate use and for whom self-reported 
follow-up diary data were available (Study 3, the placebo-
controlled trial, n=848; Study 1, the prospective observational 
study, n=306; and Study 2, the observational study within 
which the trial was nested, n=192).
Overall, participants were recruited by 322 clinicians who 
were based in 15 different countries across Europe (Figure 1).
Participant characteristics
Participants were aged between 18 and 88 years (median 51, 
IQR: 38–62). Although the age distributions in Studies 1 and 3 
were similar, those recruited into Study 2 tended to be slightly 
?????? ???????????????????????????????????????????
?????????????????????????????????
???????????????????????????? ??????????????????
????????????????????????????????????????? ?????????????????????????????????????????
????????????????????????????????????
?????????????????????????????????????????
???????????????????????????? ?????????????????? ???????????????????????????? ????????????????????
????????????????????????????????? ?????????????????????????????????
?????? ????????????????????????????????????????????
?????? ??????????????????????????????????????????????????????????????????????????
Figure 1 Study flow diagram.
Abbreviations: grAce, genomics to combat resistance against Antibiotics in community-acquired lrTi in europe; lrTi, lower respiratory tract infection.
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older (median 58, IQR: 45–65). Overall, 540 participants 
were men (40.1%) and 372 participants had at least one 
of the listed co-morbidities (27.7%). Study 2 contained 
a higher percentage of participants with co-morbidities 
(36.5%; Table 1).
illness characteristics
Other than cough, which was part of the inclusion criteria for 
all three studies, the five most frequently reported symptoms 
were phlegm (81.3%), feeling generally unwell (79.8%), 
interference with normal activities (69.6%), disturbed 
sleep (64.5%), and shortness of breath (59.0%). Fever and 
headache were most frequently reported by participants 
in Study 1 and coryza by participants in Study 3. Phlegm, 
shortness of breath, wheeze, disturbed sleep, feeling generally 
unwell, and diarrhea were the symptoms most frequently 
reported by participants in Study 2 (Table 1).
Overall, the median clinician-rated symptom severity 
score at recruitment was 36 (IQR: 25–46), with participants 
from Study 2 reporting the highest average symptom severity 
(median =38, IQR: 26–48) and those from Study 3 the lowest 
(median =35, IQR: 25–46). Abnormal findings on ausculta-
tion examination were found in 652 participants (48.5%), 
with participants in Study 3 least likely to have abnormal 
findings (34.3%). Discolored phlegm was reported by 680 
participants (53.2%; Table 1).
Prescription characteristics
Although participants in Study 3 were prescribed a fixed dose, 
frequency, and duration of amoxicillin, it was not fixed for 
participants in the other two studies. For these participants, 
the most frequently prescribed dose was 500 mg (218, or 
44.2% of all participants were prescribed this dose), with 393 
instructed to take their medication three or more times a day 
(79.2%), and 339 prescribed a 6- or 7-day course (68.3%). 
Participants in Study 1 were more likely to be prescribed 
higher doses to be taken less frequently and for a shorter 
duration, than those in Study 2 (Table 2).
healthcare setting characteristics
Of the 15 countries included, single-handed practices were 
common in six (40.0%), campaigns around antibiotic use 
had recently been conducted in seven (46.7%), patients 
were required to pay to see a general practitioner at the point 
of delivery of care in seven (46.7%), and a doctor-issued 
sick certificate was required for certifying people off work 
Table 1 Participant and illness characteristics by study
Participant/illness characteristics Study 1 (n=306) Study 2 (n=192) Study 3 (n=848) Overall (n=1,346)
Agea 49 (37–62) 58 (45–65) 50 (37–61) 51 (38–62)
Maleb 124 (40.5) 75 (39.1) 341 (40.2) 540 (40.1)
Femaleb 182 (59.5) 117 (60.9) 507 (59.8) 806 (59.9)
At least one co-morbidityb 77 (25.2) 70 (36.5) 225 (26.6) 372 (27.7)
clinician-rated symptom severitya 36 (26–48) 38 (26–48) 35 (25–46) 36 (25–46)
Phlegmb 255 (83.6) 173 (90.1) 665 (78.5) 1,093 (81.3)
shortness of breathb 198 (64.7) 143 (74.5) 452 (53.4) 793 (59.0)
Wheezeb 175 (57.2) 125 (65.1) 344 (40.6) 644 (47.9)
coryzab 204 (66.9) 134 (69.8) 635 (75.0) 973 (72.4)
Feverb 183 (59.8) 79 (41.1) 290 (34.3) 552 (41.1)
chest painb 157 (51.3) 100 (52.1) 372 (44.0) 629 (46.8)
Muscle achingb 179 (58.5) 108 (56.2) 421 (49.7) 708 (52.6)
headacheb 199 (65.0) 104 (54.2) 467 (55.1) 770 (57.2)
Disturbed sleepb 213 (69.8) 145 (75.9) 508 (60.0) 866 (64.5)
Feeling generally unwellb 269 (88.2) 174 (90.6) 629 (74.3) 1,072 (79.8)
interference with normal activitiesb 242 (79.3) 143 (74.5) 551 (65.1) 936 (69.6)
confusion/disorientationb 23 (7.5) 11 (5.7) 23 (2.7) 57 (4.2)
Diarrheab 23 (7.5) 19 (9.9) 53 (6.3) 95 (7.1)
Abnormal auscultation findingb,c 220 (71.9) 142 (74.3) 290 (34.3) 652 (48.5)
no phlegmb,d 50 (16.5) 17 (9.1) 133 (16.9) 200 (15.6)
normal colored phlegmb,d 71 (23.4) 60 (32.1) 268 (34.0) 399 (31.2)
Discolored phlegmb,d 182 (60.1) 110 (58.8) 388 (49.2) 680 (53.2)
Waited 7 days or fewer prior to consultingb 212 (70.4) 123 (65.4) 524 (62.7) 859 (64.8)
Waited 8–14 days prior to consultingb 68 (22.6) 43 (22.9) 192 (23.0) 303 (22.9)
Waited 15 days or more prior to consultingb 21 (7.0) 22 (11.7) 120 (14.4) 163 (12.3)
Notes: aMedian (iQr). bn (%). cAt least one of the following: diminished vesicular breathing, wheeze, crackles, or rhonchi. dnormal colored phlegm = clear or white, discolored 
phlegm = yellow, green, or bloodstained. study 1: prospective cohort study conducted in 13 european countries between 2006 and 2007.1 study 2: observational study on the 
etiology, diagnosis, and prognosis of lrTi conducted in 12 european countries between 2007 and 2010.15 study 3: placebo-controlled trial of amoxicillin nested within study 2.16
Abbreviations: iQr, interquartile range; lrTi, lower respiratory tract infection.
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for ,7 days in three (20.0%). Amoxicillin was the first-line 
choice of antibiotic in the national guidelines of six of the 
countries (40.0%), and antibiotic prescribing rates ranged 
from 11.2 defined daily doses per 1,000 inhabitants/day 
(the Netherlands) to 28.6 defined daily doses per 1,000 inhab-
itants/day (France), with six countries categorized as low 
prescribers (the Netherlands, Sweden, Germany, Slovenia, 
Norway, and Hungary), five as moderate (England, Wales, 
Finland, Spain, and Poland), and four as high prescribers 
(Slovakia, Belgium, Italy, and France) (Table 3).
Analysis
initiation
While overall, a high proportion of participants initiated their 
amoxicillin (1,057 or 78.5% of participants), this was largely 
driven by the almost-complete initiation of amoxicillin seen 
in Study 3 (97.6%). Initiation in participants from Study 1 
and Study 2 was considerably lower (51.0% and 38.0%, 
respectively). When initiation occurred, it was mostly on 
the day of prescription (91.5% of participants who initiated 
did so on day 1).
Compared to those who had waited #7 days, partici-
pants who had waited $15 days prior to consulting had 
higher odds of initiating their amoxicillin (OR =2.77, 95% 
CI: 1.35–5.67). There was some evidence that the duration 
of the prescription was also associated with amoxicillin 
initiation. Participants who were prescribed amoxicillin 
for $8 days had higher odds of initiating their amoxicillin 
than those prescribed for #5 days, although this was not 
statistically significant at the 5% level (OR =2.29, 95% CI: 
0.97–5.42). Participants in countries where a sick certifi-
cate was required for taking ,7 days off work had higher 
odds of initiating their amoxicillin (OR =2.15, 95% CI: 
1.27–3.64) (Table 4).
The ICC from the final multivariable model indicated 
that 17% of the total variation in initiation was attributable 
to differences between clinicians. The country-level ICC 
was negligible.
Table 3 health care setting characteristics
Country Widespread 
availability of 
single-handed 
practicesa
Recent public 
campaigns 
around 
antibiotic usea
Payment 
required to 
see general 
practitionera
Sick certification 
required for less 
than 7 days off 
worka
Amoxicillin first-
line choice for a 
respiratory infection 
in primary carea
Antibiotic 
prescribing 
rateb
Belgium      27.1 (25.2–28.2)
england   17.4 (16.5–18.7)
Finland  18.1 (17.8–18.5)
France    28.6 (28.1–29.6)
germany   14.6 (14.5–14.9)
hungary  15.6 (15.2–16.0)
italy  28.1 (27.6–28.7)
the netherlands    11.2 (11.1–11.4)
norway  15.5 (15.2–15.8)
Poland   21.9 (20.8–23.6)
slovakia   23.9 (23.2–24.8)
slovenia  14.9 (14.3–15.9)
spain   19.9 (19.7–20.3)
sweden   14.6 (14.1–15.5)
Wales  17.4 (16.5–18.7)
Notes: aObtained from interview data as part of the grAce project.14 bObtained from the Antimicrobial consumption interactive database (ESAC-Net),30 and defined as the defined 
daily dose per 1,000 inhabitants per day. rate averaged across years 2007–2010 (min and max values in brackets). United Kingdom rates used for england and Wales.
Abbreviations: grAce, genomics to combat resistance against Antibiotics in community-acquired lrTi in europe; lrTi, lower respiratory tract infection; max, maximum; 
min, minimum.
Table 2 Amoxicillin prescription characteristics by study
Prescription 
characteristic
Study 1 
(n=306)
Study 2 
(n=192)
Study 3 
(n=848)
Overall 
(n=1,346)
Dose (mg)
,500 23 (12.3) 52 (17.0) 0 (0.0) 75 (5.6)
500 99 (52.9) 119 (38.9) 0 (0.0) 218 (16.3)
$500 to ,1,000 
(not inclusive)
8 (4.3) 34 (11.1) 0 (0.0) 42 (3.1)
$1,000 57 (30.5) 101 (33.0) 848 (100.0) 1,006 (75.0)
Frequency (times per day)
Twice 13 (6.8) 90 (29.4) 0 (0.0) 103 (7.7)
More than twice 177 (93.2) 216 (70.6) 848 (100.0) 1,241 (92.3)
Duration (days)
#5 14 (7.3) 59 (19.3) 0 (0.0) 73 (5.4)
6 or 7 144 (75.4) 195 (63.9) 848 (100.0) 1,187 (88.3)
$8 33 (17.3) 51 (16.7) 0 (0.0) 84 (6.2)
Notes: Data presented as n (%). study 1: prospective cohort study conducted in 13 
european countries between 2006 and 2007.1 study 2: observational study on the 
etiology, diagnosis, and prognosis of lower respiratory tract infection conducted in 
12 european countries between 2007 and 2010.15 study 3: placebo-controlled trial 
of amoxicillin nested within study 2.16
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implementation
In participants who initiated amoxicillin, implementation 
levels were high and highly skewed across all three studies. 
Full implementation was achieved by 827 participants overall 
(78.3%), with full implementation across studies ranging 
from 70.8% of participants in Study 2 (51/72) to 80.0% in 
Study 3 (662/828) (Figure 2).
The odds of implementing amoxicillin on a given day 
were higher among older participants (OR for a decade 
increase =1.21, 95% CI: 1.03–1.41), and there was some 
evidence that it was higher for participants with abnormal 
auscultation findings at their index consultation, although 
the 95% CI included 1 (OR =1.71, 95% CI: 1.00–2.91). 
The odds were lower for participants prescribed courses of 
amoxicillin lasting $8 days (OR compared to courses lasting 
up to 5 days =0.07, 95% CI: 0.01–0.42) (Table 5).
Sixty-two percent of the total variation in whether 
amoxicillin was taken on a given day was attributable to 
differences between participants. The clinician and country-
level ICCs were both 0.04.
Discontinuation
The median time from initiation to discontinuation of amoxicillin 
was 7 days across all three studies (overall IQR: 7–8 days).
Longer courses were associated with a longer time 
to discontinuation (HR for 6–7 days compared with #5 
days =0.30, 95% CI: 0.17–0.55, HR for $8 days compared 
with #5 days =0.19, 95% CI: 0.10–0.36). Participants from 
countries where single-handed practices were widespread 
were associated with a shorter time until discontinuation 
(HR =1.15, 95% CI: 1.03–1.28). The findings persisted 
when the standard errors were corrected for clustering of 
participants within countries.
Differences across studies
As indicated by the forest plots presented in the online 
supplementary materials, there was insufficient evidence to 
suggest that the determinants found in the models for initia-
tion, implementation, and discontinuation differed within 
the individual studies.
Table 4 Three-level multivariable logistic regression model 
investigating the determinants of the initiation of amoxicillin
Variablesa Odds 
ratio
95% CI P-value
Lower Upper
Waited #7 days prior to consulting reference category
Waited 8–14 days prior to consulting 1.47 0.92 2.34 0.010
Waited 15+ days prior to consulting 2.77 1.35 5.67
Prescribed amoxicillin for #5 days reference category
Prescribed amoxicillin for 6 or 7 days 0.84 0.44 1.62 0.013
Prescribed amoxicillin for 8$ days 2.29 0.97 5.42
Sick certification required for  
missing ,7 days of work
2.15 1.27 3.64 0.004
Participant from study 1 reference category
Participant from study 2 0.46 0.28 0.75 ,0.001
Participant from study 3 56.04 27.54 114.03
Notes: aThe model is based on 1,323 participants, nested within 330 clinicians, nested 
within 15 countries. The intracluster correlation coefficients from the final model 
were: clinician: 0.17; country: 0.00. study 1: prospective cohort study conducted in 
13 european countries between 2006 and 2007.1 study 2: observational study on the 
etiology, diagnosis, and prognosis of lrTi conducted in 12 european countries between 
2007 and 2010.15 study 3: placebo-controlled trial of amoxicillin nested within study 2.
Abbreviations: CI, confidence interval; LRTI, lower respiratory tract infection.
???????????????
???????????????
???????????????
?? ??? ??? ??? ??? ???
??????????????????????????
??? ??? ??? ??? ????
????????????????????????????
?????????????????????????????
?????????????????????????????
??????????????????????????
Figure 2 implementation of amoxicillin by study.
Notes: study 1: prospective cohort study conducted in 13 european countries between 2006 and 2007.1 study 2: observational study on the etiology, diagnosis, and prognosis 
of lower respiratory tract infection conducted in 12 european countries between 2007 and 2010.15 study 3: placebo-controlled trial of amoxicillin nested within study 2.16
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Discussion
Summary of key findings
In this pooled analysis of three European studies of 
amoxicillin treatment for LRTI in primary care, participants 
who had waited longer before consulting or were prescribed 
a longer course of amoxicillin were more likely to initiate 
their course. In those who did initiate amoxicillin, older 
participants, or those with abnormal chest findings were more 
likely to implement their amoxicillin correctly on a given 
day. Participants were less likely to correctly implement their 
amoxicillin on a given day if they were prescribed a longer 
course. A considerable amount of variation in initiation and 
implementation was attributable to differences between 
clinicians, and the odds of initiation were higher in countries 
where sick certificates were required for being absent from 
work for ,7 days. Course length (time from initiation to 
discontinuation) was longer in countries where single-handed 
practices were common.
strengths and limitations
This is the first study to separately investigate the deter-
minants of initiation, implementation, and discontinuation 
of antibiotic treatment and builds on previous work where 
we have described initiation, partial, and full adherence 
to antibiotics prescribed in primary care.3 In that study, 
we found that the odds of fully adhering to treatment was 
positively associated with the duration of symptoms prior to 
consulting, negatively associated with the duration of pre-
scribed treatment, and varied according to antibiotic class.
This analysis used a large amount of prospective primary 
care data from patients in diverse settings in Europe, using 
similar data collection methods and with similar inclusion 
criteria. The determinants of nonadherence to medication can 
be multifaceted.9 Four of the five World Health Organization-
defined dimensions were investigated, and it was possible 
to assess the clustering of initiation and implementation 
behavior by clinician, which gave an indication of the influ-
ence of clinician attributes on patients’ antibiotic treatment 
adherence. Characteristics of the countries from which 
patients were recruited were obtained and investigated, rather 
than estimating the differences between the countries them-
selves. This provided more useful information, as the goal 
of this study was to investigate determinants as a platform 
for intervening in the process, rather than simply to describe 
variation by country.
Our findings are consistent with previous studies of adher-
ence to antibiotic treatment and other treatments alike.21–25
Separating out adherence into distinct processes enabled 
different sets of determinants to be considered. The pro-
cesses are distinct, and indeed different determinants were 
associated with each. Had adherence been considered as a 
single variable, such nuances would have been missed. This 
approach made fuller use of the available data.
The analysis in this paper focuses on adherence to 
amoxicillin prescriptions for immediate use only. Although 
this reduces the potential number of participants (other 
antibiotics were prescribed and delayed prescriptions were 
given in the included observational studies), it allowed for 
the investigation of the impact of the dose, frequency, and 
duration without being confounded by the type of antibiotic 
prescribed. As amoxicillin is the most commonly prescribed 
and recommended antibiotic for acute respiratory infections 
across Europe,1,17 the results retain wide applicability. Advice 
regarding delayed prescriptions, while also recommended for 
this condition,26 are often vague (eg, here is a prescription 
if you get any worse), and may have been issued with the 
intention that the patient would never actually take antibiotic 
treatment. The work presented in this paper assumes that 
amoxicillin was prescribed for immediate use by a clinician 
with the intention that it would be taken as prescribed.
Our estimation of initiation, implementation, and discon-
tinuation is based on data obtained from self-reported diaries. 
Although this type of measure is prone to bias,27,28 by having 
a daily entry, these biases are likely to be minimized. This 
method is also generally more feasible on larger populations, 
compared to more precise measures (eg, electronic monitor-
ing) and provides more informative data than tablet counts, 
which can only provide an overall measure of consumption. 
However, questions in the diary only asked about daily the 
use of treatment. We have, therefore, had to assume that if 
Table 5 Four-level logistic regression model investigating the 
determinants of the implementation of amoxicillin
Variablesa Odds 
ratio
95% CI P-value
Lower Upper
Age (per decade increase) 1.21 1.03 1.41 0.019
Auscultation abnormalityb 1.71 1.00 2.91 0.050
Prescribed amoxicillin for #5 days reference category
Prescribed amoxicillin for 6 or 7 days 1.18 0.22 6.25 ,0.001
Prescribed amoxicillin for $8 days 0.07 0.01 0.42
Participant from study 1 reference category
Participant from study 2 1.23 0.42 3.64 0.909
Participant from study 3 1.18 0.48 2.88
Notes: aThe model is based on 7,421 days nested within 1,054 participants, nested 
within 281 clinicians, nested within 15 countries. The intracluster correlation 
coefficients from the final model were: participant: 0.62; clinician: 0.04; country: 
0.04. bAt least one of the following: diminished vesicular breathing, wheeze, crackles, 
or rhonchi.
Abbreviation: CI, confidence interval.
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a participant reported that they consumed amoxicillin on a 
given day, they consumed the correct number of doses and 
these doses were spread evenly throughout the day – an 
assumption that could have been checked with a measure, 
such as electronic monitoring.
To reduce any biases that may arise, from comparing 
adherence to medication in observational studies and trials, 
all analyses controlled for the study from which a patient 
participated.
implications
Clinicians may be able to improve adherence to prescribed 
antibiotics, especially in those most likely to benefit from 
antibiotic treatment, by considering which patients are unlikely 
to start or incorrectly implement their prescription.
There are no obvious, evidence-based, reasons for varia-
tion in adherence related to the determinants we identified. 
There is a need to further understand the reasons for these 
determinants and to develop interventions to improve 
antibiotic use in this setting. However, the determinants that 
were found associated with initiation and implementation 
(particularly days with symptoms prior to consulting and 
auscultation findings) may imply that an intervention that 
addresses patients’ perceptions about their illness might 
help improve adherence. Given the degree of clustering of 
initiation and implementation at the level of the responsible 
clinician, an intervention that was delivered by clinicians 
would seem most likely to be effective.
Given the theorized association between sub-optimal 
exposure to antibiotics and the development of antibiotic 
resistance, time from initiation to discontinuation (regardless 
of how correctly the medicine was implemented) does not 
seem to be a priority target for intervention. Although it is an 
element that has value in other areas (eg, medicines to be taken 
long term and for which there may not be a defined end date), 
its value for antibiotics for acute conditions is questionable.
Selection of resistance may already occur after the first 
dose of an antibiotic, and therefore initiation of antibiotic 
treatment may be the main driver of antibiotic resistance, not 
necessarily implementation or discontinuation.29 Nonadher-
ence was driven by noninitiation. Different determinants were 
found for each adherence element.
Future research
Future work should focus on establishing whether there is 
a causal relationship between noninitiation, poor imple-
mentation, and clinical outcomes (eg, patient recovery, 
hospitalizations, re-consultations, and short- and long-term 
carriage of antibiotic-resistant organisms). Should a link be 
established, the findings reported in this paper could inform 
the development of an intervention that improves initiation and 
implementation, and in turn improves clinical outcomes for 
patients with acute respiratory infections in primary care.
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Description of candidate determinants 
Patient‐related determinants included age, gender, and whether the participant had a co‐morbidity 
(at  least one of  the  following: Chronic Obstructive Pulmonary Disease  (COPD), asthma, other  lung 
disease, heart failure, ischemic heart disease, other heart disease, or diabetes). 
Illness‐related  determinants  included  presenting  symptoms  (cough,  phlegm,  shortness  of  breath, 
wheeze, coryza, fever, chest pain, muscle aching, headache, disturbed sleep, feeling generally unwell, 
interference with normal activities, confusion/disorientation, and diarrhoea), clinician‐rated symptom 
severity score (a summation of the severity of the 14 symptoms previously described scaled to range 
from 0 to 100, where 100 represented the maximum severity on all 14 symptoms and 0 represented 
no problems on any of the 14 symptoms), phlegm colour (categorised as no phlegm, normal coloured 
phlegm  (white  or  clear),  and  discoloured  phlegm  (yellow,  green,  or  bloodstained)),  whether  an 
abnormality was found when performing an auscultation examination (at least one of the following: 
diminished vesicular breathing, wheeze, crackles, or rhonchi), and the number of days of symptoms 
prior to consulting (categorised as seven days or less, eight to 14 days, or 15 days or more). 
Prescription‐related  determinants  included  the  dose  (categorised  as  less  than  500mg,  500mg, 
between 500 and 1000mg (not  inclusive), and 1000mg or more), frequency (categorised as twice a 
day or more than twice a day), and duration (categorised as five days or less, six to seven days, or eight 
or more days) of the amoxicillin prescription. For the participants in study 3 (i.e. the placebo‐controlled 
trial), this was fixed, as all participants were prescribed 1000mg of amoxicillin, three times a day for 
seven days. 
While  there  were  no  specific  healthcare  professional‐related  determinants  available  consistently 
across  all  three  datasets,  responsible  clinician  identifiers  were  available  and  could  be  used  to 
determine whether variation in adherence could be attributed to the influence of individual clinicians. 
Participants  were  recruited  from  several  European  countries  (Belgium,  England,  Finland,  France, 
Germany, Hungary,  Italy, Norway, Poland, Slovakia, Slovenia, Spain, Sweden, The Netherlands, and 
Wales), and healthcare setting‐related determinants were established from work carried out as part 
of the GRACE project (GRACE website. Available from: http://www.grace‐lrti.org/portal/en‐gb/), and 
subsequent surveys among clinicians from countries that were not represented  in this work. These 
included whether single‐handed practices were common (e.g. representing at  least a quarter of all 
practices), whether there had been public campaigns related to antibiotic use, whether patients had 
to pay to see a general practitioner, whether clinicians were required to certify sickness for less than 
seven days of absence  from work, whether amoxicillin was  the  first‐line  choice of antibiotic  for a 
respiratory infection in primary care, and the country‐level antibiotic prescribing rate. The prescribing 
rate was obtained  from  the European  Surveillance of Antimicrobial Consumption Network  (ESAC) 
antimicrobial  consumption  interactive  database  (ESAC‐Net.  Available  from: 
http://ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/esac‐net‐
database/Pages/overview‐country‐consumption.aspx.), defined as the Defined Daily Dose (DDD) per 
1000 inhabitants per day, averaged across the years 2007 to 2010. 
Finally, the study  in which the patient participated was evaluated as a potential determinant  in all 
analyses. 
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Appendix V – List of conference presentations given as part of my 
thesis 
Title Format Conference Date 
Medication adherence for long term 
chronic conditions: results from a 12 
month trial of patients in remission with 
Ulcerative Colitis 
Oral 
Young Statisticians’ Meeting 
(YSM), London 
July  
2013 
Determining the Efficacy of 
Amoxicillin for Acute Uncomplicated 
Lower-Respiratory-Tract Infection in 
Primary Care 
Oral 
General Practitioners’ 
Research in Infections 
Network (GRIN) annual 
meeting, Nice 
October 
2013 
1. Efficacy of amoxicillin for acute 
uncomplicated lower-respiratory-tract 
infection in primary care: findings from 
a 12-country randomised placebo-
controlled trial  
2. Factors associated with adherence to 
prescribed antibiotics: a comparison of 
findings from an observational study 
and a randomised clinical trial  
1. Elevator 
pitch 
2. Poster 
South West Society for 
Academic Primary Care 
(SWSAPC) annual meeting, 
Bristol 
March 
2014 
Factors associated with adherence to 
prescribed antibiotics: a comparison of 
findings from an observational study 
and a randomised clinical trial 
Oral 
GRIN annual meeting, 
Antwerp 
October 
2014 
Adherence to antibiotics in primary 
care and the impact of non-adherence 
on clinical outcomes 
Oral 
Postgraduate Research Day, 
Cardiff 
December 
2014 
Adherence-Adjusted Estimates Of 
Benefits And Harms From Treatment 
With Amoxicillin For LRTI: 
Secondary Analysis Of A 12-Country 
Randomised Placebo-Controlled Trial 
Using Randomisation-Based Efficacy 
Estimators 
Poster 
Society for Clinical Trials 
annual meeting, Washington 
DC 
May  
2015 
Determinants of initiation, 
implementation, and completion of 
amoxicillin for adults with an acute 
cough in primary care: pooled analysis 
of three international datasets 
Oral 
GRIN annual meeting, 
Galway 
October 
2015 
Determinants of initiation, 
implementation, and completion of 
amoxicillin for adults with an acute 
cough in primary care: pooled analysis 
of three international datasets 
Oral 
European Society for Patient 
Adherence, Compliance, and 
Persistence (ESPACOMP) 
annual meeting, Prague 
November 
2015 
The use of randomisation-based 
efficacy estimators in non-inferiority 
trials 
Poster 
International Clinical Trials 
Methodology Conference bi-
annual meeting, Glasgow 
November 
2015 
 
 
